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In-vivo Assessment Of A Novel Ventricular Systole-synchronized,
Intraventricular Propelling, Left Ventricular Assist Device For Advanced
Heart Failure
Laurent Barandon, MD, PhD1, Karine Nubret, MD2,
Mohammad Haddadi, PhD3, Stephane Garrigue, MD, PhD4; 1Cardiac
Surgery, University of Bordeaux, Pessac, France, 2Heart Transplant,
University of Bordeaux, Pessac, France, 3Fluid Mechanics, FineHeart,
Pessac, France, 4St-Augustin Heart Center, Bordeaux, France

Optimizing LVAD Speed And Speed Modulation Using Computational
Hemodynamics Modeling On A Large Patient Cohort
Dina Dragoljic, None1, Jasmine Martinez, None1,
Gavin Loera, None2, Michael Aldape, None2,
Jennifer Beckman, MSN, ARNP3, Song Li, MD3,
Claudius Mahr, DO3, Alberto Aliseda, PhD4,
Venkat Keshav Chivukula, PhD1; 1Biomedical and Chemical Engineering
and Sciences, Florida Institute of Technology, Melbourne, FL, USA,
2
Biomedical Engineering, University of North Texas, Denton, TX, USA,
3
Cardiology, University of Washington Medical Center, Seattle, WA, USA,
4
Mechanical Engineering, University of Washington, seattle, WA, USA

Study: Current left ventricular assist device (LVAD) designs are not synchronized to the cardiac cycle and are not designed for totally implantable wireless operation, design features that are believed to enhance
performance and adoption of durable LVAD therapy. We performed
in-vivo animal testing of a novel ventricular systole-synchronized, intraventricular propelling pump.
Methods: Pump performance was assessed in 6 calves for acute studies
with induced severe heart failure and 10 sane calves for chronic safety
studies. The LVAD system was implanted via a beating heart minimallyinvasive left thoracotomy surgical approach without cardiopulmonary
bypass. Animals were sacrificed after 7 (n=4), 21 (n=2), and 30 (n=4) days
of device support.
Results: In all animals, echocardiography demonstrated optimal pump
positioning (pump outlet 1-2cm below the aortic valve) with use of an
adjustable fixation system. No mitral valve dysfunction nor suction were
observed. Hemodynamic data are shown in the table. D-Dimers remained
in the normal range. At sacrifice and necropsy, no clots were identified on
the pump impeller, no injury to the aortic or mitral valves were observed
nor embolic infarcts in the brain or kidneys, except for one calf (one
minimal kidney infarct at Day-7). A novel totally-implantable, wireless
operating, intraventricular propelling LVAD system has demonstrated reliable operation in an in-vivo model out to 30 days. These findings support
continued development and consideration for first-in-human studies.

Study: This study investigates the interplay between LVAD speeds, speed
modulation waveforms, and MAP management to assess their effect on
cardiovascular system hemodynamics for optimal performance for a large
patient cohort (n=61).
Methods: A custom-designed computational hemodynamic lumped
parameter model (CHLPM) of the entire human circulatory network that
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simulates HF with complete LVAD support and incorporates the LVAD’s
H-Q relationships at various operating speeds was developed and utilized.
The model was personalized for each patient according to their measured
hemodynamic data using algorithms designed in-house. For each patientspecific model, hemodynamic optimization was performed using virtual
MAP management optimization to meet a prescribed MAP target of 70
mmHg. Further, several speed modulation waveforms (such as linear
ramp up/down, sinusoidal variation, etc) were investigated to encourage intermittent aortic valve (AV) flow, and to evaluate dependence on
synchronization with native cardiac cycle.
Results: After performing virtual MAP management for all patients
keeping LVAD speed unchanged, 84% (51 patients) overshot the CO
target of 5 L/min, while keeping LVAD speed unchanged. Speed modulation enabled the AV to open intermittently, based on preload and
afterload. Abrupt changes in LVAD speed such as square waves resulted
in a sudden drop in flow through the LVAD, which can be detrimental
to hemodynamic performance. A gradual change in the LVAD speed
(sinusoidal or linear ramp up/down waveforms) resulted in smoother
variations in hemodynamic metrics, indicating the benefit of such waveforms. Flow conditions were strongly influenced when abrupt speed
changes occurred during peak systole, indicating a complex interplay
between LVAD speed modulation and native cardiac cycle synchronization. Utilizing customized cardiovascular flow models can help optimize
LVAD speed as well as speed modulation to improve hemodynamic
performance.

Influence Of Patient Weight On Vad Outcomes In Pediatric And Young
Adult Patients With Dilated Cardiomyopathy - An Analysis Of The Action
Registry
David Kwiatkowski, MD, MS1, Farhan Zafar, MBBS, MPH2,
Aliessa Barnes, MD3, Michelle Ploutz, MD, MPH4,
Sabrina Law, MD5, Muhammad Shezad, MD2,
David Morales, MD2, Matthew O’Connor, MD6; 1Pediatric - Cardiology,
Stanford University School of Medicine, Palo Alto, CA, USA, 2The Heart
Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH,
USA, 3Pediatric - Cardiology, Children’s Mercy Kansas City, Kansas City,
MO, USA, 4Pediatric - Cardiology, University of Utah Health, Salt Lake
City, UT, USA, 5Pediatric - Cardiology, Columbia University School of
Medicine, New York, NY, USA, 6Pediatric - Cardiology, Children’s Hospital of
Pennsylvania, Philadelphia, PA, USA
Study: Ventricular assist device (VAD) options vary for children in different
weight groups. This study evaluates contemporary outcomes for children
in different weight categories.
Methods: Data from the Advanced Cardiac Therapies Improving
Outcomes Network (ACTION) registry were examined for patients with
dilated cardiomyopathy (DCM) in 4 weight cohorts: <8kg (1), 8-20kg (2),
21-40kg (3) and >40kg (4) for devices implanted 3/2013 -10/2020. Device
type, adverse event rates, and rates of positive outcome (alive on device,
transplanted or ventricular recovery) were analyzed.
Results: A total of 222 DCM patients (0–29 year old; median 75 (range
1 - 1681) device days) were identified with 24% (53) in cohort 1, 23%
(50) in cohort 2, 15% (34) in cohort 3 and 38% (85) in cohort 4. Of the
272 total implants, paracorporeal pulsatile flow devices (PCPF) were
common (95%) in cohorts 1 and 2 and intracorporeal continuous flow
devices (ICCF) were common (81%) in cohorts 3 and 4. A small number
of ICCF implants (7), all HeartWare HVAD (13-20kg), were used in cohort
2 [Figure]. Stroke was noted in 19%, 12%, 6% and 4% of cohorts 1 thru
4, respectively (Cohort 1 vs 3 - p=0.04; Cohort 1 vs 4 - p=0.001; Cohorts
2 vs 4 - 0.028; all other comparisons-not significant). Major bleeding
was noted in 9%, 10%, 18% and 16% of cohorts 1 thru 4, respectively (all
comparisons - not significant). Positive outcome was noted in 91%, 94%,
97% and 91% of cohorts 1 thru 4 patients, respectively (all comparisons not significant). Conclusions: In this contemporary cohort, intracorporeal
devices in patients below 20 kg were rare. Above 20 kg, intracorporeal
devices accounted for most implants. Stroke rate was higher in smaller
cohorts, but bleeding rate was similar across groups. Positive outcomes
were attained in over 90% across all weight groups, demonstrating the
excellent outcomes that can be achieved for the diverse pediatric and
young adult population with DCM using currently available devices.
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requiring packing (n=51, 40%) and cauterization (n=19, 15%). Additionally,
72 patients (31%) had recurrent epistaxis, but rated them less severe than
the first (41 (7, 86) vs 33 (7, 61), p=0.006). Patients requiring an ED visit,
hospital admission, or blood transfusion had significantly greater reported
epistaxis severity (p<0.05 for all). We report the largest and most comprehensive survey of epistaxis in patients with LVADs to date. Further
prospective studies are required to investigate the impact on patient
outcomes of this common adverse event in patients with LVADs.

Seasonal And Regional Variations In Epistaxis Among Patients With A
Left Ventricular Assist Device: A National Multi-center Study
Umar A. Siddiqi, None1, Justin Okray, PA-C1, Jami Bennett, BSN2,
Colleen McIllvennan, PhD3, Snehal Patel, MD4,
Elizabeth Hambright, MSN5, Lilly Jackman, BSN6,
Sarah Schroeder, MSN7, Rena Lucier, MSN8, Miriam Ross, BSN9,
Krista Marz, BSN10, Angela Washenko, BSN11, Nicole Cote, MSN12,
Michael Kiernan, MD13, Robert Cole, MD14,
Valluvan Jeevanandam, MD1, Sean Pinney, MD15,
Pamela S. Combs, PhD16; 1Cardiac Surgery, University of Chicago, Chicago,
IL, USA, 2Advanced Heart Failure and Transplant Clinic, Methodist, San
Antonio, TX, USA, 3Advanced Heart Failure and Transplantation, University
of Colorado, Aurora, CO, USA, 4CT Surgery, Montefiore, Bronx, NY, USA,
5
Advanced Heart Failure and Mechanical Circulatory Support Program,
Medical University of South Carolina, Charleston, SC, USA, 6VAD, New
Mexico Heart Institute, Albuquerque, NM, USA, 7MCS, Bryan Heart,
Lincoln, NE, USA, 8Center for Circulatory Support, University of Michigan,
Ann Arbor, MI, USA, 9MCS, University of Kentucky, Lexington, KY, USA,
10
MCS, Ochsner Health, New Orleans, LA, USA, 11Heart Failure & Recovery
Program, University of Utah, Salt Lake City, UT, USA, 12Stanford Health
Care, Stanford, CA, USA, 13MCS, Tufts University Medical Center, Boston,
MA, USA, 14Cedars Sinai Smidt Heart Institute, Los Angeles, CA, USA,
15
Advanced Heart Failure and Transplantation, University of Chicago,
Chicago, IL, USA, 16Cardiac Surgery, University of Chicago Cardiac Surgery,
Chicago, IL, USA
Study: Left ventricular assist device (LVAD) implantation is a common
end-stage heart failure therapy and is associated with bleeding complications. This multicenter study investigates epistaxis occurrence within this
patient population.

Methods: An online survey was sent through Survey Monkey® from 14
centers to their patients. Responses were categorized into the following
geographical regions: Midwest, Northeast, South, Southeast and West.
Questions addressed risk factors, seasonality, incidence, and management of epistaxis.
Results: A total of 235 patients with LVADs responded to the survey. Most
(58%) experienced at least one occurrence of epistaxis. Many could not
recall seasonality of their epistaxis (n=35, 26%), but of those who could,
most reported epistaxis occurrence in the winter (n=34, 25%). Epistaxis
events occurring in the spring were rated as significantly more severe
than those in the winter (median: 77 (51, 93) vs 25 (4, 58) on a 1–100
scale, p=0.01). Patients from the West rated their epistaxis severity
significantly higher than those from the South (57 (17, 90) vs 14 (4, 39),
p=0.026). Of patients with epistaxis, 21% received emergency department (ED) care for management, 10% required admission, and 6% were
transfused. Of the 128 patients requiring treatment, 100 (78%) felt it was
effective. The majority (n=93, 73%) applied manual pressure, with some
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Utility Of Protocolized Whole-body CT Imaging Following ECMO
Cannulation For Cardiac Arrest
Robin B. Osofsky, MD1, Bryce Owen, BS2, Whitney Elks, MD1,
Jaideep Das Gupta, MD1, Ross Clark, MD1, Erik Kraai, MD3,
Mohammad Ali Rana, MD1, Jonathan Marinaro, MD4,
Sundeep Guliani, MD1; 1Department of Surgery, University of New Mexico
School of Medicine, Albuquerque, NM, USA, 2University of New Mexico
School of Medicine, Albuquerque, NM, USA, 3Department of Internal
Medicine, University of New Mexico School of Medicine, Albuquerque,
NM, USA, 4Department of Emergency Medicine, University of New Mexico
School of Medicine, Albuquerque, NM, USA

Gas Transfer Efficiency And Hemocompatibility Assessment In
Microfluidic Blood Oxygenators
Else M. Vedula, PhD1, Jose A. Santos, MS1,
Brett C. Isenberg, PhD1, WeiXuan Lai, BS1, Diana Lewis, PhD1,
David W. Sutherland, II, PhD1, Teryn R. Roberts, PhD2,
George T. Harea, PhD2, Christian E. Wells, BS1, Bryan Teece, BSME1,
Joseph Urban, None1, Thomas Risoleo, None1, Derek Solt, None3,
Sahar T. Leazer, MD4, Kevin K. Chung, MD4,
Sivaprasad Sukavaneshvar, PhD3, Andriy I. Batchinsky, MD2,
Jeffrey T. Borenstein, PhD1; 1Biomedical Engineering, Draper, Cambridge,
MA, USA, 2Autonomous Reanimation and Evacuation Program, The
Geneva Foundation, San Antonio, TX, USA, 3Thrombodyne, Inc, Salt Lake
City, UT, USA, 4Metis Foundation, San Antonio, TX, USA

Study: Evaluate the utility of whole-body computed tomography (WBCT)
imaging in detecting clinically significant findings in patients who have
undergone extracorporeal membrane oxygenation (ECMO) cannulation for cardiac arrest (extracorporeal cardiopulmonary resuscitation, or
“eCPR”).
Methods: Single-center retrospective review of 52 consecutive patients
from 2017 to 2019 who underwent eCPR and received concomitant WBCT
imaging. WBCT images were reviewed for clinically significant findings
(compression-related injuries, cannulation-related complications, etiology
of cardiac arrest, incidental findings, and evidence of hypoxic brain injury)
as well as the frequency of interventions performed as a direct result of
such findings.
Results: 38 patients met inclusion criteria for analysis. Clinically significant
WBCT findings were present in 37/38 (97%) of patients with 3.3 ± 1.7
findings per patient. An intervention as a direct result of WBCT findings
was performed in 54% (20/37) of patients with such findings. An intervention was performed as a direct result of a WBCT finding in 20/37 (54%)
of patients with significant findings. Overall there were 37 interventions
performed with a mean number of 1.0 ± 1.1 interventions per patient. Of
interventions performed, 7/37 (19%) were surgical, 9/37 (24%) were procedural, 11/37 (30%) were medical, and 10/37 (27%) received a recommendation for further investigation. Figure 1 demonstrates distribution of
significant findings and subsequent interventions performed by category.
Evidence of hypoxic brain injury on WBCT was associated with clinical
brain death as compared to those without such findings (10/15 [67%] vs
1/22 [4%], p< 0.001), respectively.In conclusion, whole-body CT (WBCT)
scan following eCPR frequently detects clinically significant findings which
commonly prompt an intervention directly affecting the patient’s clinical
course. We advocate for protocolized use of WBCT imaging in all eCPR
patients.

Study: Microfluidic extracorporeal lung support technologies seek to
optimize gas transfer efficiency and device hemocompatibility at clinicallyrelevant blood flow rates compared with standard lung support technologies. We have developed biomimetic microfluidic oxygenators for the
past decade, and report here on oxygen transfer efficiency and ex-vivo
hemocompatibility of a single-layer prototype (Fig. 1), scalable to larger
structures via stacking and assembly with blood distribution manifolds.
Methods: Devices were designed with biomimetic blood distribution
manifolds that maintain control over shear stress, and performance was
modeled via computational approaches. Devices were fabricated using
high precision-machined metal master molds, microreplication of silicone
layers, and a gas permeable membrane sandwiched between vascular
and oxygen layers. Oxygen transfer was evaluated by flowing 100% O2 at
100 ml/min and blood at 0 - 25 mL/min on either side of the membrane
while monitoring O2 partial pressures in the blood. In a 6 hour ex vivo
hemocompatibility test, devices (n=5) were assessed at a 25 ml/min flow
rate with heparinized swine donor blood against control circuits (n=3).
Results: Oxygen saturation increased from 65% to 95% at 25ml/min in
devices. In the ex vivo study, three microfluidic devices and all control
circuits remained patent to 6 hours. Plasma free hemoglobin did not
increase significantly in devices (BL = 24 ± 1mg/dL; 6 hrs = 56 ± 4mg/dL)
compared to controls (BL = 25±2 mg/dL; 6 hrs = 49±4 mg/dL). Platelet loss
was also comparable between the microfluidic oxygenator group (-34 ± 6
%) and control group (-26 ± 7%, p=0.466). Heparin coating of the devices
significantly decreased thrombus accumulation and stabilized pressures
over 3 hrs in vitro in two device geometries compared to uncoated
controls. Data collected suggests our microfluidic technology has the
potential to benefit future applications in extracorporeal lung support
technologies for acute lung injury.
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Outcomes In Left Ventricular Assist Device Patients With Coronavirus
Disease-19
Laura Coyle, APRN-BC1, Tracy Aicher, APRN-BC1,
Krystina Chickerillo, APRN-BC1, Colleen Gallagher, BSN1,
Katelyn Kuper, APRN-BC1, Jack Zakrzewski, BS2,
Vinh Q. Chau, MD1, Christopher Sciamanna, D.O.1,
Antone Tatooles, MD1; 1Advocate Christ Medical Center, Oak Lawn, IL,
USA, 2Univeristy of Illinois, Oak Lawn, IL, USA.

Active Circulating Blood Volume During Hemodialysis: A Bench Model
Dean Hu, MSc1, Nikolai M. Krivitski, ScD2, Fahimeh Salehpour, MSc2,
Logan Rivas, BS1, Yaadveer Chahal, BS1, Michael Aragon, MD1; 1Outset
Medical, SAN JOSE, CA, USA, 2Transonic Systems Inc, Ithaca, NY, USA
Study: Innovation in ESKD therapy has remained largely unchanged for
decades. Dialysis devices lack the precision and predictive technologies
to provide personal and participatory therapy to patients. Hypotensive
events due to excessive fluid removal are a common complication of HD.
With automated, direct quantification of Active Circulating Blood Volume
(ACBV), a fluid removal rate can be more intelligently established and
adjusted than the ‘dry weight method’ of today.
Methods: A novel bench model (Fig 1) included a central pump representing the heart and compartments/tubing to represent the central and
peripheral circulation. A 4–5% saline solution was circulated in the model.
A blood oxygenator was used to simulate lung volume and two sealed
containers represented fast and slow circulation compartments. A separate dialysis circuit with blood pump was incorporated. Vascular access
was simulated in two modes - a shunt (fistula or graft), and a central
venous catheter. Two ultrasound flow-dilution probes were located the
arterial and venous lines of the dialysis circuit. Around 50 ml of isotonic
saline was released from the saline bag into the physiological model.
ABCV was measured by comparing baseline dilution curve to the curve
as saline was circulated through the model. To evaluate the accuracy of
this technique, we investigated changing cardiac output (CO, 3-7L/min),
central venous volume (Vv, 600-1300mL), shunt flow (QS, 0.6–1.5L/min),
vascular access type and HD pump flow (Qb, 200-400mL/min).
Results: Overall percentage error (mean±SD) across all tests with variations on Vv, Qs, CO, Qb and access type (n=15 conditions, each in triplicate)
was 2.6% ± 7.4%. Accuracy of experiments using the shunt was between
-3.3% and +11.5% and that of those using CVC was between -6.5% and
7.5%. The presented bench model demonstrates the ability to accurately
measure active circulating blood volume.

Study: Patients on left ventricular assist device (LVAD) support are at
risk for severe disease and complications from coronavirus disease
2019 (COVID-19) due to older age, comorbidities, and an immunocompromised state. We examined the clinical characteristics, treatments,
and outcomes for LVAD patients diagnosed with COVID-19.
Methods: Single-center, retrospective analysis of all active LVAD
patients 9% (24/270) who presented with symptoms of COVID-19, PCR
test positive for SARs-CoV-2, and allowed for a minimum of one month
follow up. Baseline demographics, clinical markers, diagnostics, adverse
events, treatment modalities, and outcomes were studied.
Results: Twenty-four patients (83% male, 88% destination therapy)
with a median age of 65 ± 11.2 years, BMI 26.8 ± 5.9, and 2.6 years
(range, 9 days - 6.6 years) of LVAD support were included (Table 1).
Patients presented from home (67%), hospital acquired (17%), subacute rehab facilities (12%), and a long-term acute care hospital (4%).
Twenty-three patients (96%) required hospitalization; 13 to intensive
care and 10 to step-down units. Five patients (21%) required intubation and 15 (63%) supplemental oxygen. Most patients remained on
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home dose Coumadin (88%) and ASA (50%), 54% were placed on systemic
heparin. Treatment modalities included: Remdesivir (46%), Steroids (38%),
Vitamin C (33%), Zinc (29%), Azithromycin (13%), Tocilizumab (8%), and
Convalescent Plasma (4%). Median length of hospital stay was 6.5 days ±
10 (range, 1–52). In hospital COVID-19 mortality was 21%. An additional
2 patients expired at home, 9 days and 6 months after discharge; causes
of death unknown, and 1 patient expired during a readmission, 3 months
after COVID-19 from a respiratory arrest. Our cohort of LVAD patients
tended to be older, of minority ethnicity, and have numerous underlying
conditions. LVAD patients who contract COVID-19 are at a high risk of
increased morbidity and mortality, and should be closely monitored for
progression of the disease.

6
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Low Blood Flow Silicon Nanopore Membrane Hemodialysis Without
Anticoagulation In Swine
Jarrett Moyer, MD1, Jimmy Ly, PhD1,
Nathan Wright, Masters, Engineering2, David Maginnis, BA1,
Charles Blaha, BA2, Benjamin Chui, PhD1, Tariq Haniff, PhD1,
Caressa Chen, MD1, Harini Sarathy, MD3, Lynda A. Frassetto, MD3,
Shant Vartanian, MD4, William H Fissell, , MD5, Shuvo Roy, PhD1; 1Surgery,
Bioengineering, UC San Francisco, San Francisco, CA, USA, 2Silicon
Kidney, LLC., San Francisco, CA, USA, 3Nephrology, UC San Francisco, San
Francisco, CA, USA, 4Surgery, UC San Francisco, San Francisco, CA, USA,
5
Nephrology, Vanderbilt University Medical Center, Nashville, TN, USA

Biohybrid Lung Development - Extracellular Matrix Synthesis Promotes
Essential Monolayer Stability For Clinical Application
Michael Pflaum, PhD, Katherina Katsirntaki, PhD,
Marisa Mälzer, None, Claudia Hartl, None, Zlata Vukadinovic, None,
Axel Haverich, MD, PhD, Bettina Wiegmann, Jr., MD; Dpt. for
Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical
School, Hannover, Germany
Study: This project aims for biohybrid lung (BL) development based on
hollow ﬁbre membrane (HFM) technology used in ECMO. For long-lasting
BL durability, optimized bio- and haemocompatibility of all blood contacting surfaces, in particular of HFM, is needed and achieved by their endothelialisation. For this, HFM coating using fibronectin (FN) or albumin/
heparin (AH) is essential enabling monolayer confluence, but clinically
relevant flow exposure results in endothelial cell (EC) detachment. We
hypothesize, that optimized HFM seeding protocol enabling physiologic
extracellular matrix (EM) synthesis increases flow-resistance for clinical BL
application.
Methods: FN and AH coated HFM were endothelialized, cultivated
under static conditions for 2 or 6 days and exposed to flow conditions
for 24h. Quantitative cell counting after flow exposure was analyzed,
EC confluence and EM-synthesis under static and dynamic conditions
were assessed by immunofluorescence (IF) for VE-Cadherin (CD144)
and Collagen-IV (ColIV). Expression levels of EM associated genes, like
collagen-alpha-1(IV)chain (COL4A1), syndecan-2 (SDC2) Laminin-alpha4
(LAMA4), exostosin-1 (EXT1) were analyzed by qRT-PCR.
Results: Regardless of HFM coating, IF indicated confluent monolayers and time-dependent increase of ColIV. Prolonged static cultivation
resulted in higher cell numbers after flow exposure. While COL4A1
expression levels remained constant under static and dynamic conditions, EM-associated genes SDC2, LAMA4 and EXT1 were up-regulated
under flow exposure. Prolonged static cultivation promotes CollV increase
improving monolayer resistance to flow exposure, additional protein synthesis generating physiological EM requires flow stimulus. These results
are valuable to improve HFM endothelialisation protocol for optimal
EM-formation to resist clinically relevant flow conditions for long-term BL
application.

Study: Acute kidney injury can require continuous renal replacement
therapy (CRRT). However, CRRT is prone to thrombosis due to patient
hypercoagulability, low blood flow rates and a large surface-area filter not
optimized for blood flow. Systemic and local anticoagulants reduce coagulability but are associated with increased complications, complexity, and
costs. We previously prototyped and tested high flux parallel-plate silicon
nanopore membrane hemodialyzers (SNMHD) for enhanced hemocompatibility and sustained toxin clearance for up to 30 days without systemic
anticoagulation under high-flow (>700 ml/min) arteriovenous implantation. Here, we assess hemocompatibility and clearance for extracorporeal
SNMHD under low-flow (<400 ml/min) conditions.
Methods: Small-scale (25 cm2 silicon surface area) and large-scale devices
(800 cm2) were optimized for blood flow using computational fluid
dynamics (CFD). The devices were attached to a healthy minipig within a
standard dialysis circuit in order to perform 4-hour extracorporeal blood
flow sessions at 300 mL/min via hemodialysis catheters without systemic
anticoagulation. The small-scale SNMHD with 10 nm pores were used to
measure diffusive clearance with counter-current dialysate flow, while
large-scale solid-silicon devices and a conventional hollow-fiber filter
control were tested to assess hemocompatibility.
Results: Two large-scale and three small-scale devices remained patent
for 4 hours. The small-scale SNMHD demonstrated urea and creatinine
clearances of approximately 60 and 50 ml/min/m2, respectively. The hollow-fiber filter thrombosed completely after 2 hours. The minipig exhibited no adverse reactions. In sum, SNMHD can provide clinically relevant
solute clearance and may offer improved hemocompatibility compared to
hollow-fiber dialyzers without systemic anticoagulation for CRRT.
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Novel Stacked Motor In Continuous-flow Total Artificial Heart: First
Chronic In Vivo Results
Barry D. Kuban, BS, Christine Flick, BS, Chihiro Miyagi, MD, PhD,
Takuma Miyamoto, MD, PhD, Anthony Polakowski, MS,
Jamshid H. Karimov, MD, PhD, Kiyotaka Fukamachi, MD, PhD; Biomedical
Engineering, Cleveland Clinic, Cleveland, OH, USA

Assessment Of Hvad Flow Signals Under Nominal Operation
Veronica Ramos, BS, MS, Michael C. Brown, BS, MS; Medtronic, Miami
Lakes, FL, USA
Study: HVAD pump waveforms reflect real-time blood flow through
the pump and are recorded as logfiles over time. Optimized pump flow
includes targeting a pulsatility of 2 liters/minute (LPM) with a minimum
flow (trough) >2 LPM. Suction events, depicted by negative deflections in
the logfiles (Fig. 1), are often due to ventricular collapse or inflow obstruction, and if left unchecked may lead to significant drops in pump flow and
ultimately clinical events. Proper LVAD speed management is crucial to
avoid suction events. We sought to characterize the incidence of suction
events and pump flow operational conditions in HVAD patients without
adverse events to guide device management.

Study: The Cleveland Clinic continuous-flow total artificial heart (CFTAH)
features a rotating assembly that is free to move axially within its bloodlubricated hydraulic bearing. It is constrained axially by the magnetic
forces between the stator laminates and the permanent magnets within
the rotating assembly. These forces must be sufficient to prevent the
rotor from moving too far axially where it might contact the pump
volutes. When the rotor is within 0.02 inches of the axial center of the
stator, these forces are relatively weak, allowing the rotor to move freely
in response to the pressure difference between the left and right sides.
The purpose of the stacked motor is to increase the axial magnetic forces
on the rotor when it is outside of the free-motion range. Here we report
the first chronic in vivo study that was performed with a stacked motor
CFTAH.
Methods: The stacked motor CFTAH was implanted in a chronic 30-day
calf model and started at a mean speed of 3000 rpm with 15% sinusoidal speed modulation at 80 bpm. The mean speed was increased to
3,200 rpm in the Chronic Care Unit on post-operative day (POD) 1. The
beat rate was reduced from 80 to 70 bpm on POD 3. The speed modulation was reduced from 15% to 10% on POD 8 and remained at 10% for the
remainder of the study with exception of pulse studies. These changes
were made to ensure that the power dissipation in the pump stayed
below the design maximum.
Results: The pump performed as intended during the study with no
anticoagulation and an estimated mean flow of 10.1 (+/- 0.7) l/min and
a mean arterial pressure of 94.8 (+/- 14.4) mmHg. Inspection of the
pump at autopsy did not show any signs that the rotor had moved axially
beyond its design point. The stacked motor has a lower torque capability
than the non-stacked design previously used. The torque of the motor is
sufficient for normal operation, however, more care had to be taken to
prevent operation of the pump at power levels above the nominal design
points so as to not overstress the motor.

Methods: Logfiles from the ENDURANCE, ENDURANCE Supplemental,
and LATERAL clinical trials in subjects with no reported adverse events
throughout support were collected. For every data point, the logfile
suction detection algorithm was retrospectively utilized to determine the
presence or absence of suction events, classified as Suction and No Suction. Pump flow pulsatility and trough were also characterized.

Results: Analyzed pumps revealed a pump speed of 2720 ± 171 RPM
with estimated flows of 4.6 ± 1.0 LPM, flow pulsatility within 2LPM and
troughs > 2LPM (Fig. 2). Of the 754,129 unique logfiles assessed, 99% did
not indicate a suction event (Table 1).This retrospective study revealed
that logfiles in patients without reported adverse events were essentially
free of suction events and extreme low pulsatility. Visualization of this
long-term flow metric to assess pump performance may assist in optimizing pump speed and VAD therapy management.
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Hyperthermic Extracorporeal Tumor Therapy (HEATT®); Evaluation Of
New Sorbents
Roger A. Vertrees, PhD1, Jan A. Winetz, MD2, Alicia Wells, None3,
Adam Good, None3, Jonathan T. Lakey, PhD4,
Joseph B. Zwischenberger, MD5; 1Verthermia, Inc., San Jose, CA, USA,
2
Surgery, Verthermia, Inc., San Jose, CA, USA, 3University of California Irvine, Irvine, CA, USA, 4Surgery, University of Kentucky, Irvine, CA, USA,
5
Surgery, University of Kentucky, Lexington, KY, USA

Test Of The Realheart® Tah Hemodynamic Performance With A Hybrid
Cardiovascular Simulator
Libera Fresiello, PhD1, Azad Najar, MD2,
Nils Brynedal Ignell, Master of Engineering2,
Maria Rocchi, Master of Engineering1, Bart Meyns, MD, PhD1,
Ina Laura Perkins, PhD2; 1Cardiovascular Sciences, KU Leuven, Leuven,
Belgium, 2Scandinavian Real Heart AB, Västerås, Sweden.
Study: Heart disease is a leading cause of death worldwide. Due to lack of
heart donors, there is the need for alternative therapies, as total artificial
hearts (TAHs). In this study we evaluated the hemodynamic performance
of the Realheart® TAH.
Methods: The Realheart® TAH is a 4-chamber cardiac prosthesis. It has
two pumps working in series, each containing an atrium and a ventricle
separated by a valve-plane cylinder. The two pumps can work independently, with same pumping rate but stroke volume adjustable individually. Pressure sensors located in the atria are used to regulate the left/
right flow individually and the pumping rate. The Realheart® TAH was
connected to a hybrid simulator representing the entire cardiovascular
system (except ventricles) including the bronchial circulation. Tests were
conducted with the aim to assess the effectiveness of the controller in
keeping left/right flow balance under different conditions. Starting from
baseline, step changes of model parameters were imposed to reproduce:
pulmonary hypertension (5 Wood units), systemic hypertension (23.3
Wood units) and hypotension (8.3 Wood units) and hypovolemia.
Results: the Realheart® TAH adapts its left and right pump flow according
to the pressure sensed in the atria. This feature makes the device sensitive to changes of preload. For the hypovolemia test, the pumping rate
decreased of 34 bpm and the stroke volume decreased of 17 mL on the
left side and of 14 mL on the right side, so to mantain left and right atrial
pressures to positive values. For all the other tests, a steady state was
reached after the onset of a circulatory parameter change. In conclusion,
the unique feature of the Realheart® TAH allows to regulate the flow on
the left and right side independently, thus assuring left/right flow balance under a wide range of conditions. Further tests will be conducted
to assess the dynamic performance of the controller. Acknowledgement: Scandinavian Real Heart and Medtech4Health from Vinnova (N.
2020–04378).

Study: Ovarian, lung, pancreatic, and colon cancers are sensitive to 42°C
for 120 min. HEATT® combines veno-venous (VV) perfusion, dialysis, and
blood sorbent to safely raise average core temperature to 42°C. Following
two successful safety trials (advanced lung and ovarian cancer), an adult
swine study (n=9) evaluated sorbent units prior to expanded clinical
application.
Methods: REDY® dialysis (discontinued) previously balanced electrolyte
concentrations altered by hyperthermia. We compared CytoSorb® (charcoal filtration) and single-pass dialysis to the REDY®. Heating, physiology,
and chemistries were measured Q 15 min. Blood and urine samples: after
start of VV-perfusion and dialysis, after 1 and 2 hrs of target temperature,
and after cooling; blood from main perfusion blood line: pre-dialyzer, presorbent, and post-sorbent. Protein analysis and mass spectrometry were
analyzed using Mass Lynx software and multiplex cytokine array for 16
pre-selected cytokine panels. Chromatograms both pre- and post-column
filtration determined removal of small molecules.
Results: For HEATT®, all the methods resulted in stable hemodynamics,
heat transfer, and circuit dynamics. Sorbents had no effect on the heating
profile, transfer rate, or time to target temperature. Mean arterial BP,
CVP, HR; average pump blood flow rate, and percent diversion were not
different. Mass spectrometry was similar between the CytoSorb® and
charcoal column. CytoSorb® resulted in the greatest reduction of IL-2,
IL-6, IL-8, IL-10, IFNγ, and IL-1β; charcoal resulted in the greatest reduction in IL-1ra, IL -1α, TGF-β2, IL-12, IL-18, and TGF-β-1. CytoSorb® was
most efficient with electrolyte maintenance. Finally, CytoSorb® removed
the greatest number of pro-inflammatory cytokines.
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Development Of A Mock Circulation Loop To Evaluate Ventricular Assist
Device Inflow Cannula Placements Within Single Ventricle Hearts
Anne-Marie Ginn-Hedman, BS1, Staci L. Jessen, PhD1,
Bradley R. Weeks, PhD2, Fred J. Clubb, Jr., PhD1; 1Biomedical Engineering,
Texas A&M University, College Station, TX, USA, 2Veterinary Pathobiology,
Texas A&M University, College Station, TX, USA

Hydraulic Stiffness In Maglev Centrifugal Blood Pump
Tingting Wu, BS1, Thomas George Logan, PhD2, Yunpneg Wang, BS3,
Po-Lin Hsu, PhD2; 1Artificial Organ Technology Lab, School of
Mechanical and Electrical Engineering, Soochow University, Suzhou,
China, 2magAssist, Inc., Suzhou, China, 3Key Laboratory of Organic
Optoelectronics & Molecular Engineering of the Ministry of Education,
Department of Chemistry, Tsinghua University, Beijing, China.

Study: Hearts with congenital defects such as hypoplastic left heart
syndrome (HLHS) can benefit from staged surgical correction, but can
develop systolic dysfunction over time. Such patients are candidates for
ventricular assist device (VAD) implantation. However, a recent study
showed that over half of VADs are malpositioned within patient ventricles, which can lead to thrombus formation and pump failure. Therefore,
this research aims to develop a mock circulation loop to evaluate VAD
inflow cannula placements within single ventricle hearts in an effort to
minimize VAD malpositioning.
Methods: A mock circulation loop was constructed to model the physiological flow parameters of a post-Fontan HLHS adolescent patient with
systolic heart failure. The system consisted of a compliance chamber, fluid
reservoir, and ventricular duplicator as shown in the provided figure. Of
note, ventricular motion was modeled by deforming a ventricular sac
surrounded by fluid controlled by a positive displacement pump. Systolic
dysfunction and VAD conditions were tested, and multiple sacs were
prepared to evaluate various inflow cannula placements.
Results: The mock circulation loop was able to effectively mimic both
heart failure and VAD-assisted flow conditions. Furthermore, the modular
design of the system allowed easy testing of multiple VAD inflow cannula
configurations. Future work includes using particle image velocimetry to
visualize the flow patterns near the VAD inflow cannula, and compare the
bench top results to data from previous computational studies.

Study: The introduction of contactless bearing in ventricular assist devices
(VADs) gives the rotor freedom of motion, and the position of the rotor
is a balance between hydraulic forces and electromagnetic forces. We
define pump hydraulic force function as Fig1.
F is the forces acting on rotor by hydraulic system. D is the displacement
of the rotor from nominal position. Subscript x and y denote the orientation of forces and displacements. Hydraulic stiffness (Fig2) is of great
importance for maglev system controller design. Constant stiffness under
different operating conditions minimizes the variation in the transfer
function of the plant, minimizing the range of conditions that the controller needs to cope with, and thus improving its robustness.
Methods: Hydraulic radial forces in MP-EX pump head are measured by
a customized rig (Fig. 4). The impeller was driven by an external motor
via a long shaft. The shaft was connected with the motor through a
misalignment coupling, to eliminate the possible radial vibration caused
by coaxiality tolerance. Two force sensors were fixed on the shaft, radial
forces on the shaft were then measured. The hydraulic radial forces acting
on the impeller were then calculated by Fig3.
Results: All results were normalized by kxx at minimum speed and 0 L/
min flow rate. Hydraulic stiffness is related to rotational speed, but not
related to pump flow rate. The kxy is bigger than kyy and so is kyx than
kxx, which indicates the force change on orthogonal direction is bigger
than force change along displacement direction. Those phenomena are in
consistent with step response results of the controller system. The introduction of hydraulic stiffness could be beneficial for the controller design
of maglev centrifugal blood pumps.
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Manufacturing Process And Approaches In Prototyping Mechanical
Circulatory Support Systems
Anthony R. Polakowski, MEng1, David J. Horvath, MS2,
Barry D. Kuban, BS1, Christine R. Flick, BS1,
Kiyotaka Fukamachi, MD, PhD1, Jamshid H. Karimov, MD, PhD1; 1Cleveland
Clinic, Cleveland, OH, USA, 2R1 Engineering, Euclid, OH, USA

In Vitro Dynamic Thrombogenicity Testing Of Biomaterials: Animal
Versus Human Blood
Mehulkumar Patel, PhD, Megan A. Jamiolkowski, PhD,
Madelyn D. Golding, MS, Richard A. Malinauskas, PhD, Qijin Lu, PhD; U.S.
Food and Drug Administration, Silver Spring, MD, USA
Study: To determine suitable alternatives to human blood for in vitro
dynamic thrombogenicity testing, we examined the use of different animal blood species in a steady flow loop test system.
Methods: Five blood sources (Table 1), including human and animal blood
(from live donors or abattoir), were investigated. Immediately before each
dynamic loop test, the blood was recalcified and heparinized to a donorspecific concentration. The heparin level was based on a static thrombosis
pre-test with latex tubing and verified by a preliminary dynamic loop test.
For dynamic testing, whole blood was recirculated at room temperature
for 1 hr at 200 mL/min through a polyvinyl chloride (PVC) tubing loop
(Figure 1A) containing a test material. Four materials were investigated:
positive control latex, negative control polytetrafluoroethylene (PTFE), silicone, and high-density polyethylene (HDPE). Thrombus surface coverage,
thrombus weight, and platelet count reduction were measured.

Study: In the United States, 50,000 - 100,000 patients require heart
transplants or mechanical circulatory support (MCS). The Cleveland Clinic
device portfolio includes devices for ventricular assistance (VAD), left
atrial assistance (LAAD) for heart failure with preserved ejection fraction,
and continuous-flow total artificial hearts (CFTAH). Unique architecture
and design features add complexity to device manufacturability, and thus
impose specific requirements on the entire process. In this study, the
unique steps of the manufacturing, prototyping, and testing of the MCS
development process are reported.
Methods: 3D-printing of specific components, using various polymer
materials and titanium alloy (Ti-6Al-4V), has been explored for many
component types, covering our complete portfolio of devices, including
VAD, LAAD, and CFTAH. Other areas investigated include: laser welding of
rotor components to provide an impenetrable seam to prevent magnet
corrosion; finishing of impeller surfaces using a micro machining process;
testing an array of polymer liners on rotors, and; component/assembly
identification methods.
Results: With 3D-printing, our results have been encouraging. Prototype
components sometimes have a rough-looking surface finish, but when
machine-finished, the surface is satisfactory and meets our needs. Examples of 3D-printed titanium components prior to any secondary machining are shown (Fig. 1 A and 1 B). We have produced a laser-welded seam
for our rotor assemblies (Fig. 1 C), achieved mirror-like surface finishes on
impeller features, and etched serial numbers on titanium components.
The proposed validation of polymers, adhesives, and machining techniques for a titanium-polycarbonate seam successfully resulted in a seal,
which prevented blood ingress into pump components (Fig. 1 D). Many
manufacturing processes and prototyping techniques have been utilized,
resulting in MCS systems that are closer to being production-ready.

Results: All blood sources allowed differentiation between thrombogenic
and thrombo-resistant materials (Figure 1). However, donor-specific
anticoagulation levels (Table 1) and thrombosis marker sensitivity were
dependent on the animal blood source. For example, silicone exhibited
intermediate thrombogenicity only in donor ovine and bovine blood tests,
with more thrombus surface coverage and platelet reduction than PTFE
and HDPE but less than latex (P < 0.01). These results demonstrate that all
the animal blood sources tested in this study may be suitable alternatives
to human blood for thrombogenicity testing if appropriate control materials and donor-specific anticoagulation levels are used.
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Modification Of Hemocompatible Surface Coating For Extracorporeal
Artificial Graft
Inseok Jeong, MD, PhD; Chonnam National University Hospital,
GWANGJU, Korea, Republic of

Patterned Electrospinning: Distinct Fibrous Constructs Influencing Cell
Adhesion
Daniel E. Palomares, BS1, Kaitlyn R. Ammann, PhD2,
Javier Saldana Perez, BS1, Alexan Gomez, BS, MS1,
Adriana Barreda, BS1, Andrew Russell-Cheung, BS3,
Adriana Martin, MD4, Phat L. Tran, PhD5,
Sahir Hossainy, None4, Rebecca C. Slepian, BS4,
Syed F.A. Hossainy, PhD5, Marvin J. Slepian, MD4; 1Department of
Biomedical Engineering, The University of Arizona, Tucson, AZ, USA,
2
Department of Medicine, The University of Arizona, Tucson, AZ, USA,
3
Department of Biological & Biomedical Sciences, The University of
Arizona, Tucson, AZ, USA, 4Sarver Heart Center, The University of Arizona,
Tucson, AZ, USA, 5Department of Bioengineering, University of California,
Berkeley, CA, USA

Study: Development of novel surface modification still remains to be
investigated in the extracorporeal circulation technology. We evaluated both anti-thrombotic anti-bacterial properties of new developed
tube graft with novel surface coating in ex-vivo mock circulation (EVMC)
conditions.
Methods: An EVMC system was assembled using a roller pump, polyurethane (PU) tube (3/8 inch inner diameter, 50 cm length) and priming
solution (human blood 40 ml + normal saline 10 ml). We made 5 tube
grafts with novel bilaminar surface coating (base coating with acrylic
acid in inner layer and hyaluronic acid based hydrophilic coating in outer
layer). Flow cytometry (CD61b, CD62p) was used to measure the platelet
consumption and activity after 1 hours circulation and performed scanning electron microscope (SEM).

Study: In this study we manipulate the deposition of fibers to specific
regions on a collector. We took a flat conductive plate as a collector
used in electrospinning and created designs leaving non-conductive and
conductive areas on the plate. By making these gaps on the plate we were
able to create different designs for the deposition of the fibers.
Methods: The targets were designed and etched onto a copper board. A
Poly(lactic-co-glycolic) acid (PLGA) solution was prepared by mixing PLGA
in Dichloromethane (DCM) at a ratio of 0.0750 g PLGA/ 1 mL DCM. A
normal electrospinning setup was used for the novel targets 250 uL of the
solution was pumped at a fixed rate of 2.50 mL/hr at a horizontal distance
of 15 cm using 12kV on a 23 gauge needle. The collector were plastic
warped to facilitate removal of the fibers. The microfibers were removed
from the plastic and characterized by their mechanical and biocompatible
properties.
Results: Modifying collector designs led to significant differences in fiber
target coverage ranging from 300 mm2 for solid (100% of the target area)
to 217.8 mm2 for lines (72.6% of the target area). Measured fiber excess,
residual open area, and contact angle (hydrophobicity) followed the same
trend as fiber target coverage with respect to collector pattern: lines >
sinusoids > squares > zigzags > solid. Similarly, the lines design allowed
for greatest cell adhesion and retention (258 ± 31 cells), whereas solid
exhibited the lowest (150 ± 15 cells); p< 0.05. Our results demonstrate
the ability to utilize patterned collectors for modifying macroscopic and
microscopic electrospun scaffold features, which directly affect cell adhesion, and retention, offering translational utility for designing specific
tissue constructs.

Results: After 1 hours of 5 EVMC experiments, there were no thrombus
formation inside all PU tubes. No significant platelet activation and consumption were detected, based on result of flow cytometry study using
post-EVMC priming solution. On SEM, almost no platelet aggregation was
found on inner surface of PU tube. Our novel surface coating method will
be promising technology in extracorporeal circulatory device. Further
studies are needed to demonstrate the long-term durability.
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Entelon® (vitis Vinifera Seed Extract) Reduces Degenerative Changes In
Bovine Pericardium Valve Leaflet In A Dog Intravascular Implant Model
Hong Ju Shin, MD, PhD; Korea University Ansan Hospital, Ansan, Korea,
Republic of

A Computational Model Of The Hemodynamics Of ECPELLA Support
Farhan Khodaee, MSc1, Farhad Rikhtegar Nezami, PhD2,
Brooke Zampell, MSc3, Scott Corbett, PhD4,
Ahmad El Katerji, PhD4, Elazer Edelman, MD, PhD1,
Steven Keller, MD, PhD5; 1Institute of Medical Engineering & Science, MIT,
Cambridge, MA, USA, 2Department of Surgery (Cardiac Surgery), Brigham
and Women’s Hospital, Boston, MA, USA, 3École Polytechnique Fédérale
de Lausanne (EPFL), Lausanne, Switzerland, 4Abiomed, Danvers, MA,
USA, 5Department of Medicine (Pulmonary and Critical Care Medicine),
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA,
USA

Study: Inflammation and calcification are major factors responsible for
degeneration of bioprosthetic valve and other substitute heart valve
implantations. The objective of this study was to evaluate the anti-inflammatory and anti-calcification effects of Entelon150® (consisting of grapeseed extract) in a beagle dog model of intravascular bovine pericardium
implantation.
Methods: In total, 8 healthy male beagle dogs were implanted with a
bovine pericardium bilaterally in the external jugular veins and divided
into two groups. Animals in the Entelon150® group (n = 4) were treated
with 150 mg of Entelon150® twice daily for six weeks after surgery. The
negative control (NC) group (n = 4) was treated with 5 ml of saline using
the same method. After six weeks, we measured the calcium content,
performed histological examination, and performed molecular analysis.
Results: The calcium content of implanted tissue in the Entelon150®
group (0.56±0.14 mg/g) was significantly lower than that in the NC group
(1.48±0.57 mg/g) (p < 0.05). Histopathological examination showed
that infiltration of chronic inflammatory cells, such as fibroblasts and
macrophages, occurred around the graft in all groups; however, the
inflammation level of the implanted tissue in the Entelon150® group was
significantly lower than that in the NC group. Both immunohistochemical
and western blot analyses revealed that bone morphogenetic protein 2
expression was significantly attenuated in the Entelon150® group.

Study: Dual mechanical support with extracorporeal membrane oxygenation (ECMO) and the Impella percutaneous ventricular assist device,
termed ECPELLA, is an emerging modality to simultaneously maintain
perfusion and unload the left ventricle. ECPELLA hemodynamics are
unknown and may be an important determinant of clinical outcomes.
Methods: A patient-specific computational model was developed from
computerized tomography images of the aortic tree and design of the
Impella and peripheral ECMO cannula. Simulations were conducted to
analyze the hemodynamic interactions between antegrade flow from the
left ventricle and Impella and retrograde flow from the ECMO circuit using
dynamic lumped-parameter models to assign aortic exit boundary conditions. Total perfusion from all sources was 5 LPM with continuous Impella
flow of 0.5 LPM while ECMO flow was simulated at 90%, 70%, and 50% of
total flow to model profound heart failure, early heart recovery, and heart
function prior to weaning ECMO. Hemodynamics, mixing cloud dynamics,
shear stress metrics, and end-organ perfusion were compared.
Results: Increasing cardiac contractility impels the dynamic mixing cloud
caudad into the thoracic aorta and increases risk of cerebral hypoxia in
the setting of concomitant lung failure. The relative ratio of Impella to
ECMO flow determines hemodynamic patterns of ECPELLA support while
increasing ventricular contractility expands size of the mixing cloud and
changes its location over the cardiac cycle. Computational models of the
ECPELLA circulation inform effects of the relative titration of support on
end-organ perfusion and systemic hemodynamics.
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Integration Of Physicochemical Gradients Into Regenerative Vascular
Grafts To Control The Cellular Response
Maria A. Rodriguez Soto, MSc1, Natalia Suarez, MSc1,
Alejandra Riveros, BS1, Andres J. Garcia Brand, BS1,
Carolina Muñoz Camargo, PhD1, Juan C. Cruz, PhD1,
Kim Seungil, PhD2, Antonio D’amore, PhD3, William Wagner, PhD3,
Nestor Sandoval, MD4, Juan C. Briceño, PhD1; 1Department of Biomedical
Engineering, Universidad de los Andes, Bogotá, Colombia, 2McGowan
Institute of Regenerative Medicine, University of Pittsburgh, Pittsburgh,
PA, USA, 3Department of Biomedical Engineering, McGowan Institute
of Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA,
4
Fundación Cardioinfantil Instituto de Cardiología, Bogotá, Colombia.

Simulation Of Balance Between Platelet Activation, VWF Unfolding
Activity, And Surface Cleaning On Thrombus Growth In A Microfluidic
Chamber
Rodrigo Mendez Rojano, PhD, Grant W. Rowlands, MSc,
James F. Antaki, PhD; Meinig School of Biomedical Engineering, Cornell
University, Ithaca, NY, USA
Study: Thrombosis in artificial organs entails a balance between platelet
activation, deposition, and surface cleaning. These phenomena are
affected by shear stress, but to different degrees.
Methods: A multi-constituent thrombus simulation was performed in a
microfluidic channel containing a blunt obstacle “hemofoil”, which is representative of many geometries in artificial organs including VAD cannula
and impeller blades. Simulations were done at shear rates representative
of different operation regimes (Low: 100s-1 Medium: 1000s-1 and High:
5000s-1). The thrombosis model used in this study considers mechanical and chemical activation of platelets, deposition, and cleaning as a
function of wall shear stress considering the influence of von Willebrand
Factor (vWF). Open Foam was used to solve the the flow and biochemical
species conservation equations considering physiological blood constituents concentrations. The fluid was assumed as Newtonian with a constant
viscosity of 3.5 cP.
Results: In the low shear case, the central part of the hemofoil remained
clean up until 600 s due to low platelet activation levels. For the medium
case a thin film of clot formed over the obstacle at the leading edge
(~500s) that propagated downstream, in contrast, for the high shear
case the thrombus started to form in the downstream blunt edge and
propagated upstream. Thrombus deposition at the junction between the
obstacle and lateral walls is observed in all three cases due to the low
embolization rate computed at the junction. Finally, at 600s, the high
shear rate case shows increased thrombus deposition due to high vWF
activity. In conclusion, our simulations illustrated the delicate balance
between surface cleaning, platelet activation, and vWF unfolding activity
that controls thrombus growth at different levels of shear. These simulations will guide further investigations to explore a more comprehensive
set of conditions.

Study: During tissue regeneration, bioactive molecule concentration,
extracellular matrix architecture and mechanical properties guide tissue
formation. Physicochemical gradients can be useful for the rational design
of biomimetic tissue-engineered vascular grafts (TEVGs) where recovering
the complex structure of native vessels is required. Herein, we manufactured a TEVG with a physicochemical gradient based on the controlled
deposition of synthetic and natural polymers.
Methods: A multilayered scaffold was fabricated via electrospinning by
blending polyether urethane urea (PEUU) and gelatin at weight ratios of
75:25, 85:15 and 95:5. Electrospun fibers were collected over a stainless
steel mandrel. Crosslinking via glutaraldehyde was performed to preserve
gelatin structure. Scaffold mechanical properties were analyzed by
longitudinal and circumferential tensile strength tests. Surface morphology was examined via SEM. Gelatin content was analyzed with Masson
Trichrome stain. Cytocompatibility was evaluated by measuring metabolic
activity via a MTT assay. Hemocompatibility was estimated by assaying
hemolysis, and platelet aggregation, adhesion, and activation.
Results: We successfully manufactured a bioactive TEVG based on a multilayered structure of PEUU incorporating a gelatin physicochemical gradient. The scaffold has 3,1 mm internal diameter and 1 mm wall thickness.
Histology images, longitudinal and circumferential tensile strength tests
confirmed the physicochemical gradient. Mechanical properties of the
novel TEVG approach those of native non-decellularized porcine carotid
arteries. Additionally, it exhibited low cytotoxicity (below 20%) and hemolytic tendency (5%) demonstrating adequate gluraraldehyde quenching
and reduced thrombogenicity. This novel manufacturing strategy may
provide a route to improve the regeneration of the vascular walls, which
is critical to move forward in the clinical implementation of TEVGs.
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Computational Analysis And Characterization Of Inspired Therapeutics
Pediatric VAD V3
Landon H. Tompkins, PhD1, Barry N. Gellman, MS2,
Gino F. Morello, BS3, Steven R. Prina, PhD4,
Thomas Roussel, PhD1, Jonathan A. Kopechek, PhD1,
Stuart J. Williams, PhD5, Priscilla C. Petit, BS2,
Mark S. Slaughter, MD6, Kurt A. Dasse, PhD2,
Steven C. Koenig, PhD7; 1Bioengineering, University of Louisville,
Louisville, KY, USA, 2Inspired Therapuetics LLC, Merritt Island, FL, USA,
3
Veritium Research LLC, Fort Lee, NJ, USA, 4BLDC Designs LLC, Rocklin, CA,
USA, 5Mechanical Engineering, University of Louisville, Louisville, KY, USA,
6
CT Surgery, University of Louisville, Louisville, KY, USA, 7Bioengineering
and CT Surgery, University of Louisville, Louisville, KY, USA
Study: Pediatric heart failure (HF) patients are an underserved population
with few options for mechanical circulatory support (MCS) therapy as
development efforts for specific pediatric devices continue to fall behind
those for the adult population. The Inspired Therapeutics Pediatric VAD
is being developed as a pediatric specific MCS solution to provide up to
30-days of circulatory or respiratory support in a compact modular package that could allow for patient ambulation during treatment.
Methods: Hydrodynamic performance (flows, pressures), impeller/
rotor mechanical properties (torques, forces), and flow shear stress and
residence time distributions of the latest design version, Inspired Pediatric
VAD V3, were numerically predicted and investigated using computational
fluid dynamics (CFD) software (SolidWorks Flow Simulator). Transient,
time-dependent simulations were calculated using the sliding mesh
method over a range of pump rotational speeds and flow rates. Both
Newtonian and Non-Newtonian (Power Law) fluid models were employed
for result comparison.
Results: No change in flow and pressure head performance was predicted
in Inspired Pediatric VAD V3 compared to the previous device design (V2)
while meeting benchmarks based on defined pump design criteria (40
-150 mmHg at 0.5 - 3.5 L/min). VAD V3 showed an increase in predicted
impeller/rotor torques and translation forces due to changes in geometry
to accommodate MagLev motor components. At the lowest pump operating point (3000 RPM, 0.50 L/min, 75 mmHg), 79% of the pump volume
was in the shear stress range of 0 - 10 Pa with < 1% of the volume in the
critical range of 150 - 1000 Pa for blood damage. At higher speed and flow
(5000 RPM, 3.50 L/min, 176 mmHg), 65% of the volume resided in the
0 - 10 Pa range compared to 2.3% at 150 - 1000 Pa. The initial computational characterization of the Inspired Pediatric VAD V3 is encouraging and
future work will include device prototype testing in a mock circulatory
loop and acute large animal model.
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Computational Fluid Dynamic Analysis Of Three Axial Blood Pump
Designs
André C. Cavalheiro, PhD1, Diolino J. Santos Filho, PhD2,
Aron J. P. Andrade, PhD3, José R. Cardoso, PhD2; 1Mechatronics, Fundacao
Santo André, Santo Andre, Brazil, 2Mechatronics, Universidade de São
Paulo, São Paulo, Brazil, 3Bioengineer, Instituto Dante Pazzanese de
Cardiologia, São Paulo, Brazil.

Computational Fluid Dynamics Evaluation Of Hvad Sintering Transition
Mustafa E. Taskin, PhD, Daniel Tamez, BS; Medtronic LLC, Miami Lakes,
FL, USA
Study: Textured surfaces have been utilized in medical devices such as left
ventricular assist devices (LVAD) to promote tissue healing and create a
pseudo-intimal lining on the blood contacting surfaces to reduce thromboembolic events. To minimize the potential for thromboembolic events,
the HeartWare™ HVAD™ pump inflow sintering features have been modified to increase the sintered surface height (¾ of the cannula) and expose
the transition between smooth and textured surface area.
Methods: Computational fluid dynamics derived wall shear stress (WSS)
and velocities were utilized to numerically evaluate the design modifications. Sintered transition and height performance were then compared
to the commercial design. A rigid ventricle was utilized with different
ventricular wall thicknesses covering wide range of patient population.
Grid independence analysis was conducted, and steady-state simulations
were performed at different pump flow rates for diastolic and systolic
conditions. The cardiac period was represented with the combination of
these conditions.
Results: The modified exposed and higher sintered transition was
determined to be superior in both WSS and velocities in ventricular wall
thickness ranges. This improvement increased up to 62% as compared to
the commercial design for varied ventricular wall thicknesses. Higher WSS
and velocity profiles suggest that the washing potential of the modified
sintered height and transition of the HVAD may be enhanced.

Study: Studies were made to compare different axial blood pumps
geometries. These devices were submitted to real characteristics of the
human circulatory system, considering a flow rate of 5 l/min and a pump
differential pressure of 100mmHg.
Methods: The geometry of the real models were developed using the
CAD tool. To check the pressure and flow performance as a function of
rotation, Computational Fluid Dynamic (CFD) modeling of the pumps was
performed using the software Star-CCM+. In order to prove the results
obtained through the CFD simulation, In Vitro tests will be performed.
Results: The results obtained in the simulation for a rotation of 5500 RPM
and a differential pressure of 100mmHg were as follows: (i) Model 1 flow
rate of 1.2 l/min; (ii) Model 2 flow rate of 4.8 l/min; (iii) Model 3 flow
rate of 7.1 l/min. Model 1 presented a lower flow than the target flow,
model 2 close to the target value and model 3 obtained the best result as
can be seen in the graph below. The simulated models refuse both as a
function of flow and pressure when tested at different levels of rotation.
The model 3 was the best because even at low rotation, the necessary
flow was obtained. Thus the model 3 design can be a good geometry to
be used in a Ventricular Assist Device Design, thus contributing to a good
cardiovascular function
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Hemodynamic Effects Of Sinusoidal Pulsatile Support By The
Continuous-flow Total Artificial Heart During A Chronic Animal Model
Takuma Miyamoto, MD, PhD1, Chihiro Miyagi, MD1,
Anthony R. Polakowski, BS1, Barry D. Kuban, BS2,
Christine R. Flick, None1, Shiva Sale, MD3,
Jamshid Karimov, MD, PhD1, KIyotaka Fukamachi, MD, PhD4; 1Biomedical
Engineering, Cleveland Clinic, Cleveland, OH, USA, 2Biomedical
Engineering, Medical Device Solutions, Cleveland Clinic, Cleveland, OH,
USA, 3Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA,
4
Biomedical Engineering, Cleveland Clinic, Cleveland, OH, USA

Impact Of Rotor Speed Modulation On Surrogate Markers Of
Thrombogenicity In Contemporary LVADs
Andrea Boraschi, MSc1, Silvia Bozzi, PhD2, Bente Thamsen, PhD3,
Marcus Granegger, PhD4, Lena Wiegmann, PhD1,
Jonas Abeken, BS, MS1, Federico Pappalardo, MD5,
Marvin J. Slepian, MD6, Vartan Kurtcuoglu, PhD1,
Alberto Redaelli, PhD2, Filippo Consolo, PhD7,
Diane de Zélicourt, PhD1; 1Institute of Physiology, University of Zurich,
Zurich, Switzerland, 2Department of Electronics, Information and
Bioengineering, Politecnico di Milano, Milano, Italy, 3Institute for Imaging
Science and Computational Modelling in Cardiovascular Medicine,
Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Division of Cardiac
Surgery, Medical University of Vienna, Wien, Austria, 5Anesthesia and
Intensive Care, IRCCS ISMETT, Palermo, Italy, 6Sarver Heart Center,
University of Arizona, Tucson, AZ, USA, 7Università Vita Salute San Raffale,
Milano, Italy.

Study: The continuous-flow total artificial heart (CFTAH) is a novel device
that delivers a non-pulsatile flow in constant speed setting. In a pulsatile
flow mode achieved through device speed modulation, the CFTAH is
capable of adjusting the pump speed with sinusoidal shape according
to physiological need. The purpose of this study was to evaluate the
hemodynamic effects of the pulsatile mode of the CFTAH in a chronic
animal experiment. In this case, a sinusoidal waveform was used, with the
percent pulsatility describing the magnitude of the waveform and speed
adjustment.
Methods: We conducted a 30-day chronic animal experiment with a calf
(88 kg at implant). We performed five pulsatility studies (postoperative
day 13, 16, 17, 21, and 23) while the animal was sitting. We collected aortic pressure (carotid artery) and estimated pump flow while running the
CFTAH at 2,800 rpm with 0, 5, 10, 15, 20, 25, 30, and 35% pulsatility.
Results: The animal was successfully supported by the CFTAH for 30 days
without any major complications. Relationships between percent pulsatility, pulse pressures at carotid artery, and flow pulsatility are shown in
Table 1. Percent pulsatility and pulse pressure had a strong linear relationship (y = 0.44 x - 4.7, R2 = 0.98); flow pulsatility and pulse pressure also
had a strong linear relationship (y = 1.0 x - 4.6, R2 = 0.98). In conclusions,
the CFTAH had successfully created an effective pulse pressure and flow
pulsatility in a chronic animal model with a sinusoidal speed modulation
mode. Percent pulsatility and pulse pressure, and flow pulsatility and
pulse pressure, demonstrated strong linear relationships.

Study: To evaluate the impact of rotor speed modulation sequences of
contemporary LVADs on pump thrombogenicity by comparing the effects
induced by the Artificial Pulse in the HeartMate 3 (HM3, Abbott, USA) and
the Lavare Cycle in the HeartWare HVAD (Medtronic, USA).
Methods: Using computational fluid dynamics with high spatial and temporal resolution (107 elements and 2° per time step), we compared the
effect of speed modulation to a baseline case with constant speed and
pressure head in both HM3 and HVAD. Mean pump flow was 5 L/min for
all cases. Thrombotic risk was assessed via comprehensive evaluation of
i) pump washout, ii) stagnation zones, iii) fluid shear stress (FSS) exposure
on simulated platelet trajectories, and iv) platelet activation status calculated using the Platelet Activity State (PAS) model.
Results: The 95% washout time was comparable across all scenarios,
the instantaneous washout rate scaling principally with pump flow rate.
Baseline FSS were higher in the HVAD than in the HM3, resulting in 78%
of the particles exposed to high/pro-thrombotic FSS (>50Pa) vs. 52% in
the HM3 and a 67% higher median PAS. The low amplitude of the Lavare
Cycle (+/- 200 rpm) did not significantly impact FSS profiles (Fig 1) nor
PAS. In contrast, the 10-fold higher amplitude of the HM3 Artificial Pulse
(+/- 2000 rpm) drastically altered the stress-exposure profile (Fig 1),
increasing the median PAS by +124% compared to baseline. However, the
rapid acceleration from low to high speed (+4000 rpm within a few milliseconds) also reduced flow stagnation regions by up to 91% in the HM3.
This study suggests that potential benefits of speed modulation on local
washout of isolated fluid pockets warrant further exploration and should
be weighed against the need of reducing pro-thrombotic effects of strong
rotor accelerations.
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Hemodynamics Within The Penn State Failing Fontan Centrifugal Blood
Pump Under Steady And Pulsatile Conditions
Sailahari V. Ponnaluri, BS1, Emma J. Christensen, BS1,
Bryan C. Good, PhD1, Steven Deutsch, PhD1, William Weiss, PhD2,
Keefe B. Manning, PhD1; 1Department of Biomedical Engineering,
Pennsylvania State University, University Park, PA, USA, 2Department of
Surgery, Penn State Hershey Medical Center, Hershey, PA, USA

A Genetic Algorithm-based Optimization Framework For Control
Parameters Of Ventricular Assist Devices
Konstantinos Magkoutas, MSc, Marco Heim, BS,
Marianne Schmid Daners, PhD; Product Development Group, ETH Zurich,
Zurich, Switzerland.
Study: In this study, a genetic algorithm-based optimization framework
(GAOF) for control parameters of ventricular assist devices (VADs) has
been developed. The performance of the GAOF has been evaluated with
the optimization of a physiological proportional-integral-derivative (PID)
controller that relies on the pump inlet pressure.
Methods: The GAOF (Fig. 1) consists of the user inputs, the in silico environment and the genetic algorithm. Specifically, the user defines the VAD
control structure, the objective function (OF), the experiments appropriate for the evaluation, and the corresponding healthy heart data (HHD).
Each set of control parameters (individual), is fed to the controller and the
VAD-supported heart is simulated. The simulation results are compared
with the HHD and the OF is evaluated and assigned to the respective
individual as “score”. As long as the convergence criterion of the OF is not
met and the maximum number of generations (each generation includes
multiple individuals) is not achieved, the individual’s scores are fed to the
genetic algorithm. Based on those scores, the GA uses genetic operations
(elitism, replication, crossover, and mutation) to create new individuals
for the next generation. The process continues for each individual and
each generation until an optimum (or multiple) set of control parameters
has been identified. The performance of the optimized controllers is
further evaluated via dynamic tests.
Results: The GAOF converged to the optimum parameters of the PID
controller within 12 generations. The optimized controller, compared
to a benchtop proportional controller and the constant speed controller, showed a 37% and 95% reduction of the cardiac output error during
a preload variation experiment, respectively. Regardless of the control
structure, the GAOF optimizes the controller parameters aiming at the
minimization of a user-defined OF, allowing the development of VAD
controllers, which meet patient specific requirements.

Study: Approximately 1 out of every 10,000 children are born with a
single functioning ventricle, requiring the Fontan operation to bypass
the right heart by joining the inferior (IVC) and superior vena cava (SVC)
directly to the pulmonary arteries (PAs). 85% of children are surviving at
20 years post-operation but upon reaching adulthood, patients demonstrate “Fontan failure” and require heart transplantation. Due to the
limited donor hearts available, Penn State University is developing an
implantable centrifugal blood pump for failing Fontan patients. This study
aims to quantify the hemodynamics with the Penn State failing Fontan
centrifugal blood pump at both steady and pulsatile inflow conditions
using particle image velocimetry (PIV).
Methods: Using an acrylic model of the Fontan centrifugal pump, a mock
circulatory loop simulated the Fontan circulation at three steady conditions (Case 1: 4 L/min, 4000 rpm, Case 2: 5 L/min, 4000 rpm, Case 3: 5 L/
min, 5000 rpm) and a physiological pulsatile inflow condition (Case 4). PIV
quantified the velocity and turbulent stresses at three planes in the IVC,
SVC, and PA for all conditions.
Results: For steady cases, an increase in flow rate increased inlet and
outlet velocity and turbulent stresses. An increase in rotational speed
increased inlet velocity only when directly entering the pump. At the outlet, the Case 2 optimal condition produced a higher velocity than Case 3.
The physiological pulsatile condition demonstrated a velocity that varied
over the cycle and produced greater outlet turbulence than steady cases.
Flow visualization of the Fontan pump provided computational model
validation and informed pump design.
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Torque Control Mode With Left Atrial Assist Device: The Initial In Vitro
Results
Chihiro Miyagi, MD1, Barry D. Kuban, BS1,
Jamshid H. Karimov, MD, PhD1, Christine R. Flick, BS1,
Takuma Miyamoto, MD, PhD1, Shiva Sale, MD2,
Randall C. Starling, MD, MPH3,
Kiyotaka Fukamachi, MD, PhD1; 1Biomedical Engineering, Cleveland Clinic
Lerner Research Institute, Cleveland, OH, USA, 2Anesthesiology, Cleveland
Clinic, Cleveland, OH, USA, 3Cardiovascular Medicine, Cleveland Clinic,
Miller Family Heart and Vascular Institute, Cleveland, OH, USA

Kinetic And Dynamic Effects On Degradation Of Von Willebrand Factor
Choon-Sik Jhun, PhD, Lichong Xu, PhD,
Christopher A. Siedlecki, PhD, Raymond K. Newswanger, BS,
Joshua P. Cysyk, PhD, Christopher Scheib, BS,
Gerson Rosenberg, PhD; Surgery, Penn State College of Medicine,
Hershey, PA, USA
Study: Severe aortic stenosis (AS) and continuous flow left ventricular
assist devices (cf-LVADs) are often complicated by acquired von Willebrand Syndrome (AvWS) characterized by the loss of high molecular
weight multimers (HMWMs) of von Willebrand factor (vWF). It is known
that high blood shear associated with highly irregular and disorganized
blood flow in AS and cf-LVADs leads to structural changes of vWF. Interestingly, AvWS is fully corrected on the first day after surgery for AS and
quickly disappears after the removal of an implanted cf-LVAD. This suggests that high turbulent blood flow in AS and the devices is responsible
for the syndrome. This study is to understand the degradation mechanism
of HMWM in terms of exposure time and flow regime.

Study: The left atrial assist device (LAAD) is our novel device designed
to be an effective option for the treatment of heart failure with preserved ejection fraction (HFpEF). The LAAD is a mixed-flow pump that is
implanted at the mitral valve level and pumps blood from the left atrium
to the left ventricle. Although the LAAD can work in constant speed mode
like other rotary blood pumps, we have tested it in torque control (TC)
mode to improve its function as an assist device. In TC mode, the pump
speed changes during each cardiac cycle to maintain a specified torque.
We report its performance and efficacy here.
Methods: We tested the LAAD performance under four different TC settings (TC mode 0.9, 1.0, 1.25, and 1.5, Amps torque equivalent), using an
in vitro mock circulatory loop. A pneumatic mock ventricle was used as
a native left ventricle, and three diastolic heart failure (DHF) conditions
were created by adjusting the diastolic drive pressure of the pneumatic
ventricle to 0 mm Hg (mild DHF), 20 mm Hg (moderate DHF), and 40 mm
Hg (severe DHF). The pump speed, pump power, pump flow, and hemodynamics of each TC setting were recorded.
Results: With LAAD TC mode support, the cardiac output and aortic
pressure recovered to normal heart levels at TC mode 1.25 and 1.5, even
with the severe DHF condition, which was a result that was similar to the
speed control setting of the LAAD. Additionally, the dynamic head curves
in the TC mode showed steeper slopes than constant speed mode. The
lower pump speed during diastole reduced ventricular pressure, and the
increased speed during systole prevented reverse flow in TC modes 1.25
and 1.5 (Figure 1), while maintaining excellent pulsatility. These initial in
vitro results support the potential efficacy of TC mode for DHF conditions.
DHF is one of the major and typical features of HFpEF patients. Therefore, with this TC mode, the LAAD could offer a wider range of treatment
options to HFpEF patients. Further evaluation, including in vivo experiments, are required.

Methods: A custom high shear rotary device capable of creating a fully
controlled exposure time and flow regime was manufactured. The rotor
features a raised ring around its center, creating a 381 μm gap within the
stationary housing. The length of this gap and resulting flow area remain
constant so that the exposure time, texp depends only on flow rate. The
system was set so plasma flowed through at 1.75 ml/sec, 0.76 ml/sec, or
0.38 ml/sec resulting in an exposure time of 0.022 sec (n=33), 0.05 sec
(n=18), or 0.1 sec (n=33), respectively. The flow was characterized by the
Reynolds number, Re, the ratio of inertial forces to viscous forces within
flowing fluid. The device was run under 4 conditions where Re = 1500
(laminar, n=18), 3000 (transitional, n=18), 3500 (transitional, n=18), and
4500 (turbulent, n=30). After each run, a 0.5 mL sample solution was collected, frozen in dry ice immediately, and shipped to the Blood Center of
Wisconsin for multimer analysis.
Results: Destruction of HMWM at a given exposure time increases with
the Re. No destruction was observed at laminar flow at given exposure
times. The statistical analysis revealed that Re and exposure time are significant factors destroying HMWM. Interaction between Re and exposure
time, however, is not always significant (Fig 1).
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flow. The vWF level change (in percentage) measured in VPPM (Fig.2) and
patients (Fig. 3) suggested that endothelial vWF production was sensitive
to flow pulsatility and exposure to continuous flow resulted in a decrease
in endothelial vWF production. More importantly, these results suggest
that the VPPM can model the effects of loss of pulsatility seen in CF-VAD
patients accurately and serve as a valuable model to evaluate flow modulation protocols.

Effects Of Loss Of Pulsatility On Von Willerbrand Factor Availability And
Activity In Patients On Continuous Flow Ventricular Assist Device
Khanh T. Nguyen, BS1, Leslie Donoghue, BS1, Arushi Kotru, Other1,
Dori McClure, Other1, Guruprasad A. Giridharan, PhD2,
Palaniappan Sethu, PhD1; 1Biomedical Engineering, University of Alabama
at Birmingham, Birmingham, AL, USA, 2Bioengineering, University of
Louisville, Louisville, KY, USA
Study: Diminished pulsatility associated with Continuous Flow Ventricular Assisted Device (CF-VAD) is a major risk factor in the development of
acquired von Willebrand syndrome (AVWS) and non-surgical bleeding in
advanced heart failure patients. Although the exact mechanisms that contribute to AVWS remain unclear, the reduced production and excessive
degradation of endothelial von Willerbrand Factor (vWF) under continuous (non-pulsatile) flow is known to play a major role in the development
of non-surgical bleeding. To better understand this phenomenon, we
designed a comprehensive approach using in-vitro models and evaluation
of blood samples from CF-VAD patients to determine how loss of pulsatility influences the availability and activity of vWF.

Methods: In-vitro studies utilized patient-derived Human Aortic Endothelial Cells (HAEC) cultured in our Vascular Pulse Perfusion Model (VPPM),
an extensively validated vessel-on-a-chip model that can recreate both
pulsatile and continuous flow. Cell culture media perfused through VPPM
was collected after 24 hours of normal flow and after 1, 3, 5 days of
continuous flow. Patient blood samples were collected prior to CF-VAD
placement and monthly after CF-VAD implant. VPPM perfused media and
patient extracted plasma were measured for availability and activity of
endothelial vWF.

Results: The VPPM setup (Fig.1) was validated and tested in our lab to
mimic hemodynamic stresses associated with normal and continuous
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Point-of-Care Electrical Impedance Aggregometry Is Effective In
Discriminating Platelet Reactivity To Antiplatelet Drugs: The MICELI
System
Yana Roka Moiia, PhD1, Tatiana Mencarini, MS2,
Silvia Bozzi, PhD2, Alberto Redaelli, PhD2,
Marvin J. Slepian, MD1; 1Medicine, University of Arizona, Tucson, AZ, USA,
2
Department of Electronics, Information and Bioengineering, Politecnico di
Milano, Milan, Italy.

Surface Coatings Of Heparin And Hyaluronan - In Vitro And In Vivo
Studies On Anti-inflammatory Action
Thomas M. Groth, PhD, DSc1, Hala Alkhoury, PhD1,
Sanja Stojanovic, PhD2, Guoying Zhou, PhD3,
Adrian Hautmann, Master of Engineering1,
Stevo Najman, PhD, DSc2; 1Biomedical Materials, Martin Luther University
Halle-Wittenberg, Halle (Saale), Germany, 2Pharmaceutical Biology and
Pharmacology Department, University of Nis, Nis, Serbia, 3College of Life
Science, Zhejiang Chinese Medical University, Hangzhou, China.

Study: Cardiovascular therapeutic devices (CTDs) are effective clinically
yet fraught with thrombosis. Antiplatelet drugs are utilized to limit CTDrelated thrombosis. Patient response to these drugs highly varies, yet are
not measured at point-of-care (POC) largely due to bulkiness and complexity of current lab tests. To address this, we prototyped and validated
a miniature, easy-to-use, POC electrical impedance aggregometer (EIA)
termed MICELI. Here, we tested MICELI as to quantification of platelet
reactivity to antiplatelet drugs vs. light-transmission aggregometry (LTA)
as a standard.
Methods: Platelet aggregation in ACD-anticoagulated whole blood and
platelet-rich plasma of healthy donors (n=30) was evaluated. The effect
of clopidogrel, ticagrelor, cangrelor, cilostazol, and tirofiban was tested on
ADP-induced aggregation and aspirin - with arachidonic acid and collagen.
Platelet aggregation was recorded using the MICELI or BioData PAP-8E
aggregometers.
Results: MICELI EIA appropriately detected a dose-dependent decrease
in aggregation associated with a coordinate increase in drug concentration for all agents tested. Aggregation in platelet-rich plasma recorded
by LTA showed higher sensitivity to antiplatelet agents, though it did not
distinguish between different drug doses. Direct inhibitors of platelet
surface receptors (P2Y12 blockers and tirofiban) had a more distinct and
predictable inhibitory effect on platelet aggregation than inhibitors of
platelet metabolic pathways - aspirin and cilostazol. Conclusion. Platelet
aggregation in whole blood recorded by MICELI offers an advantage in
evaluation of platelet reactivity, as EIA accounts for the modulatory effect
of other blood cells on platelet hemostatic function and the pharmacodynamics of antiplatelet drugs in vivo. MICELI EIA is a promising tool for POC
monitoring of platelet function for personalized antiplatelet management
of CTD-patients.

Study: The inflammatory response to biomaterials is crucial for functional
integration of implants but also responsible for fibrosis and scarring. Glycosaminoglycans (GAG) like heparin (Hep) and hyaluronan (HA) represent
good candidates due to their immunomodulatory and anti-inflammatory
properties. Both Hep and HA were used for covalent and adsorptive
immobilization on either glass for in vitro studies or biphasic calcium
phosphate particles (BCPP) for in vivo studies in a mouse model.
Methods: Covalent immobilization was done after modification of
materials with aminopropyltriethoxysilane to obtain primary amino
groups for formation of amide bonds with carboxylic groups of both GAG.
Adsorptive immobilization was achieved by layer-by-layer technique with
chitosan as polyanion forming 5 bilayers of GAG/CHI. Physical studies
were done to study surface properties of materials. In vitro experiments
were performed with macrophages studying adhesion, formation of
multinucleated giant cells (MNGC) and IL-1beta release as measure of
pro-inflammatory response. Animal experiments were done by subcutaneous implantation of BCPP for 15 and 30 days and histochemical analysis
and RT-PCR.
Results: Both covalent and adsorptive immobilization on both substrata
glass and BCPP was successful. In vitro studies with macrophages showed
reduced adhesion of macrophages, formation of MNGC and release of
IL-1beta particularly when heparin was immobilized in multilayers (see
figure with comparison between covalent and multilayer immobilization).
Animal experiments showed particularly for HA a suppression of inflammatory response and lowered ectopic bone formation, while heparin
delayed inflammatory response. Results of this study indicate that both
GAG are potent modulators of inflammatory response with HA particularly effective in vivo indicating their potential to control tissue response
after implantation of sensors, percutaneous and other devices.
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Leveraging Platelet Zonal Analysis To Quantify Thrombogenic Risk Of
Lvad Inflow Cannula Malposition
Rachel Hillner, None1, Natalie Hill, None1,
Joshua Zhou, None2, Aaron Luong, None2,
Jennifer Beckman, MSN, ARNP3, Song Li, MD3,
Claudius Mahr, DO3, Alberto Aliseda, PhD4,
Venkat Keshav Chivukula, PhD1; 1Biomedical and Chemical Engineering
and Sciences, Florida Institute of Technology, Melbourne, FL, USA,
2
Biomedical Engineering, University of North Texas, Denton, TX, USA,
3
Cardiology, University of Washington Medical Center, Seattle, WA, USA,
4
Mechanical Engineering, University of Washington, seattle, WA, USA

Clinical Trials In Vascular Grafts: Challenges To Implement Results From
Animal Studies
Natalia A. Suárez V., BS, MS, Andrés J. García-Brand, BS,
María A. Rodríguez S., BS, MS, Alejandra Riveros, BS,
Carolina Muñoz, PhD, Juan C. Gruz, PhD,
Juan C. Briceño, PhD; Deparment of Biomedical Engineering, Universidad
de los Andes, Bogotá, Colombia
Study: Despite more than 10,000 articles and 11,000 patents under the
term tissue engineered vascular graft (TEVG), we have knowledge of
one clinically available TEVG. This indicates a barrier in the translation of
science and technology to clinical practice potentially related to the low
predictability of pre-clinical studies. However, emerging technologies with
potential to reendothelialize and reduce complications of grafts should be
tested clinically. Here, we analyzed the clinical research of TEVGs identifying technologies suitable to implement and the challenges associated
with their translation to clinical practice.
Methods: A review of clinical trials was performed querying “tissue engineered regenerative vascular graft” in ClinicalTrials.gov and within the
WHO database i.e., ANZCTR, ReBec, ChiCTR, CRiS, CTRI, RPCEC, EU-CTR,
DRKS, IRCT, ISRCTN, JPRN, LBCRT, NTR, PACTR, REPEC, SLCTR. The results
were compared to those obtained before on preclinical trials and to databases of approved and commercially available grafts

Study: In this study, we quantify the risk of platelet aggregation in the left
ventricle (LV) due to unfavorable hemodynamics caused by inflow cannula
malposition using high-fidelity Computational fluid dynamics (CFD) and
platelet-focused analysis.
Methods: CFD and Lagrangian platelet tracking was used in five virtual
patient-derived LV models to simulate blood flow patterns and platelet
behavior in the LV implanted with a generic LVAD inflow cannula (orientations ranging from ± 14° from axial alignment). Platelet trajectories for
hundreds of thousands of platelets were analyzed for each configuration
to determine important characteristics such as residence time (RT) and
shear history (SH) using rigorous statistical analysis. The LV was divided
into four zones: Zone 1 (aortic root), Zone 2 (LV central core), Zone 3
(exterior ‘donut’ peripheral region), and Zone 4 (apical region around
inflow cannula), and platelet behavior in each zone was analyzed using
rigorous statistical analysis.
Results: Preliminary analysis indicates zones 1 and 4 are stagnation zones,
confirming the risk of platelets accumulating within these zones, potentially forming a nidus of microthrombi. Platelets in zone 3 were found to
experience long RTs coupled with high SH, and were statistically significantly different from all other zones using the Wilcoxon Rank-sum Test.
High platelet RT and/or SH in the LV zones produce an unfavorable hemodynamic environment where platelet activation is more likely to occur,
increasing the risk of thrombotic complications. Through these results,
platelet clustering analysis could be utilized as a useful tool to identify
specific thrombogenic zones in the LV, such as aortic root or apical zones.
Such analysis can lead to determining optimal LVAD implantation configurations for patients based on their left ventricular morphology, thereby
reducing complications.

Results: The review of more than 120 preclinical studies on TEVG indicated
at least 30% with regeneration potential. However, only 10 studies (7
technologies) reported clinical research. Most were related to autologous
grafts in contrast with the spectrum of technologies in animal models. 5 of
these studies targeted hemodialysis access, 3 congenital cardiopathy and 2
vascular disease, while most of the animal studies were tested in peripheral
vasculature. Two technologies completed clinical phase II and have patents
and trademark, however neither reached translation. This shows a mismatch between the technologies tested preclinically and those with higher
clinical relevance. An ulterior aspect of translation, unrelated to quality,
but to scalability and industrialization might limit implementation. We put
forward the notion that the development of a translation strategy for TEVG
should correspond to a better match with the relevance of the clinical need.
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Engineering Of Stable Thermoresponsive Multilayers Based On Crosslinked PNIPAM-grafted-chitosan And Heparin For Cell Sheet Generation
Yi-Tung Lu, MSc1, Kui Zeng, MSc2, Kai Zhang, PhD2,
Bodo Fuhrmann, PhD3, Thomas Groth, PhD1; 1Department of Biomedical
Materials, Martin Luther University Halle-Wittenberg, Halle(Saale),
Germany, 2Department of Wood Technology and Wood-based
Composites, Georg-August-University of Goettingen, Göttingen, Germany,
3
Interdisciplinary Center of Material Research and Interdisciplinary
Center of Applied Research, Martin Luther University Halle-Wittenberg,
Halle(Saale), Germany

Endothelialisation Of Left Ventricular Assist Device Impeller
Hans Güntner, None, Katherina Katsirntaki, PhD,
Michael Pflaum, PhD, Jasper Haritz, None,
Axel Haverich, MD, PhD, Bettina Wiegmann, Jr., MD; Dpt. for
Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical
School, Hannover, Germany
Study: The use of left ventricular assist devices (LVAD) with its artificial
surfaces is inter alia limited by the activation of the coagulation system,
where thrombus formation results in the exchange of the system. Driven
by advances in regenerative medicine, endothelial cell (EC) seeding is considered to be an important tool to optimize hemocompatibility of artificial
materials. In order to improve hemocompatibility of LVAD, we established
EC monolayer integrity for clinical flow-resistance on the impeller using
a a new approach using magnetic forces and intracellular superparamagnetic nanoparticles (NP).
Methods: EC were incubated with different nanoparticles concentrations and coatings for various time periods. Nanoparticulate absorption
behaviour was visualized by Prussian blue staining. Batches with high
intracellular nanoparticle quantities were analysed for cell viability by
immunofluorescence staining and proliferation assay, possible cytotoxicity by flow cytometry. Cellular alignment induced by different magnetic
forces was examined and transferred to LVAD impeller endothelialisation.
Results: Concentration-, coating- and time-dependent changes in cell
viability, proliferation and cytotoxicity could be shown, indicating best
results for low concentrated sodium citrate nanoparticles, which were
used for subsequent cell migration experiments. Magnetic field sufficiently affected endothelialisation as significantly more NP loaded ECs
adhered to the impeller surface compared to the unloaded control group.
These results are promising steps towards the improved hemocompatibility of LVAD, as the LVAD itself may provide the needed magnetic field for
sufficient flow-resistant endothelialisation.

Study: Poly(N-isopropylacrylamide) (PNIPAM) exhibiting a lower critical
solution temperature (LCST) around 32 °C can enable detachment of cell
sheets from cell culture substrata by reducing the temperature below
LCST. This study focuses on the development of a thermoresponsive polyelectrolyte multilayer (PNIPAM-PEM) using layer-by-layer (LbL) technique.
It can help us to understand the physical and biological properties of the
sophisticated PEM systems containing PNIPAM.
Methods: PNIPAM with different sizes are covalently grafted onto chitosan (Chi) to obtain different degrees of substitution (DS) of PNIPAMgrafted-chitosan (PChi). Nuclear magnetic resonance spectroscopy and
dynamic light scattering are used to analyze DS and conformational
change of PChi with temperature. The PNIPAM-PEMs are built at pH4
with PChi as polycation and bioactive heparin as polyanion. Subsequently,
the systems are chemically cross-linked to stabilize the PEM. The growth
behavior, thickness, and wetting properties and temperature effects of
the PNIPAM-PEM are studied by different analytical methods. In addition,
the stability of the PEMs is tested by rinsing with PBS, pH 7.4 and DMEM.
Finally, the use of PNIPAM-PEM as cell culture substrate is examined using
multipotent mouse stem cells.
Results: PChi with higher DS and sizes show significant increase in the
diameter above LCST. They have the ability to form PNIPAM-PEM with
heparin. After rinsing with PBS and DMEM, the thickness significantly
decreases in non-cross-linked compared to negligible changes in crosslinked PEM. As the temperature changes, the PNIPAM-PEM is slightly
more hydrophobic at 37 °C than at 20 °C. Moreover, higher adhesion
and spreading of cells on cross-linked PEM are observed. Therefore, the
PNIPAM-PEMs with cross-linking provides greater stability as a cell culture
system for further investigation of cell sheet generation for engineering
of tissues.
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Fitting Studies Of A Pediatric Continuous-flow Total Artificial Heart In 32
Pediatric Patients
Chihiro Miyagi, MD1, Munir Ahmad, MD2,
Jamshid H. Karimov, MD, PhD1, Yuichiro Kado, MD, PhD1,
Raymond Dessoffy, Other1, Anthony R. Polakowski, BSME1,
Tara Karamlou, MD, MS2, Kiyotaka Fukamachi, MD, PhD1,
Hani K. Najm, MD, MS2; 1Biomedical Engineering, Cleveland Clinic Lerner
Research Institute, Cleveland, OH, USA, 2Thoracic and Cardiovascular
Surgery, Cleveland Clinic, Cleveland, OH, USA

From Benchtop To Beside: Patient-specific Outcomes Explained By Invitro Experiment
Seraina Anne Dual, PhD1, Aditi Nayak, MD, MS2,
Alanna A Morris, MD, MS2, Jennifer Cowger, MD, MS3,
Marianne Schmid Daners, PhD4; 1Stanford University, Stanford, CA, USA,
2
Emory University School of Medicine, Atlanta, GA, USA, 3Henry Ford
Hospital, Detroit, MI, USA, 4ETH Zurich, Zurich, Switzerland.
Study:
Recent analyses show that females have higher early postoperative (PO)
mortality and right ventricular failure (RVF) than males after left ventricular assist device (LVAD) implantation; and that this association is partially
mediated by smaller LV size in females. Benchtop experiments allow us
to investigate patient-specific (PS) characteristics in a reproducible way
given the fact that the PS anatomy and physiology is mimicked accurately.
With multiple heart models of varying LV size, we can directly study the
individual effects of titrating the LVAD speed and the resulting bi-ventricular volumes, shedding light on the interplay between LV and RV as well
as resulting inter-ventricular septum (IVS) positions, which may cause the
different outcomes pertaining to sex.
Methods:
In vitro, we studied the impact of the heart size to IVS position using two
smaller and two larger sized PS silicone heart phantoms derived from
clinical CT images (Fig. 1A). With ultrasound crystals that were integrated
on a placeholder inflow cannula, the IVS position was measured during LV
and RV volume changes (dV) mimicking varying ventricular loading states
(Fig. 1B).
Figure 1 A Two small (blue) and two large PS heart phantoms (orange) on
B benchtop. C Median septum curvature results. LVEDD/LVV/RVV: LV enddiastolic diameter/LV and RV volume.
Results:
Going from small to large dV, at zero curvature, the septum starts to shift
towards the left; for smaller hearts at dV = -40 mL and for larger hearts
at dV = -50 mL (Fig. 1C). This result indicates that smaller hearts are more
prone to an IVS shift to the left than larger hearts. We conclude that
smaller LV size may therefore mediate increased early PO LVAD mortality and RVF observed in females compared to males. Novel 3D silicone
printing technology enables us to study accurate, PS heart models across
a heterogeneous patient population. PS relationships can be studied
simultaneously to clinical assessments and support the decision-making
prior to LVAD implantation.

Study: The continuous-flow total artificial heart (CFTAH) is our invention
for the treatment of end-stage heart failure. Pediatric patients with complex congenital heart disease often experience severe heart failure, but
the CFTAH is too big for them. Therefore, we are developing a pediatric
CFTAH (P-CFTAH) to determine feasibility for various congenital heart
anomalies. This study was designed to evaluate the fitting of a replica of
the P-CFTAH in patients of different weights and morphologies.
Methods: The P-CFTAH pump was derived by downsizing the adult
CFTAH at a scale of 0.70 (1/3 of total volume). The 3D-printed models of
the pump (Fig. 1A) were evaluated for anatomical fit during open-heart
surgery (Fig. 1B) for a variety of congenital heart anatomies ranging from
2.9 kg to 30 kg (mean 7.1 ± 4.9 kg) of body weight (BW). The P-CFTAH
has been reviewed with a total of 32 patients so far, and the results were
divided into two groups (fit and non-fit) after the intraoperative visual
assessment of fitting. The pre-op thoracic size (mm) and heart sizes (mm)
were measured in their pre-op chest X-rays, and the differences between
the two groups and the cutoff lines were statistically analyzed.
Results: Among the 32 patients, 17 were in the fit group, and 15 in the
non-fit group. There were significant differences (p < 0.0001) between fit/
non-fit groups for BW, height (Ht), body surface area (BSA), and thoracic
and heart size (A, B, C, and D in Fig. 1C). The cutoff values of each are:
BW: 5.10 kg, Ht: 63.5 cm, BSA: 0.36 m2, A: 137.0 mm, B: 77.0 mm, C:
57.0 mm, and D: 76.0 mm. The area under the curve for all of the parameters except C were >0.93; that of C was 0.88. This study revealed the suitable range of the P-CFTAH with easily acquirable data from the pediatric
patients, and the range of proper fit was wide enough to accommodate
most of the pediatric patients. Further studies, including the evaluation of
pump performance in vivo, are required.
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Design Optimization Of The Corwave Membrane Lvad
Trevor A. Snyder, PhD, François Cornat, BS, Nicolas Jem, BS,
Rémi Pruvost, BS, MS, Eugenio Monticone, BS, MS,
Diego Marino, BS, Francesca Condemi, PhD,
Francesca Tesser, PhD, Antoine Olive, BS, MS,
Mattias Scheffler, PhD, Pierre-Yves Quenlenn, BS, MS,
Luc Polverelli, BS, MS, Michel Vernizeau, PhD,
Carl Botterbusch, MBA; Corwave, Clichy, France.

Microfluidic Artificial Lungs: A Parametric Analysis Of Capillary Height
Lindsay J. Ma, BS1, Emmanuel Akor, BS2, Alex J. Thompson, PhD1,
Joseph A. Potkay, PhD3; 1VA Ann Arbor Healthcare System, Ann Arbor,
MI, USA, 2Department of Biomedical Engineering, University of Michigan,
Ann Arbor, MI, USA, 3Department of Surgery, University of Michigan, Ann
Arbor, MI, USA
Study: Microfluidic artificial lungs (μALs) have been designed with small
artificial capillary diameters (10–40 μm) to maximize gas exchange
efficiency or with larger diameters (~100 μm) to simplify construction and
potentially minimize clotting. However, no study has directly compared
the impact of capillary diameter on μAL properties and performance,
which is the goal of this work.

Study: CorWave is developing a unique LVAD employing an undulating
membrane to propel blood. By changing the oscillation frequency and
magnitude, the membrane operation replicates a physiologic pulse. CorWave LVADs have previously completed over 40 implants in ovines with
durations up to 2 months. The present studies focused on optimization
of the device performance and hemocompatibility to advance towards
design freeze.
Methods: Pump designs were analyzed and refined using computational
fluid dynamics and fluid structure interactions. The blood flow path
was investigated by altering fluid path dimensions. The pump control
algorithm was modified from open loop to closed loop control mode.
Hydraulic testing in a mock circulatory loop and hemolysis measurements
in static and pulsatile conditions were then performed in vitro. Membrane position and oscillation during operation were quantified by laser
micrometry.
Results: In in silico simulations, increasing membrane holder skirt length
and decreasing flow channel size increased hydraulic performance until
the channel size approached the boundary layer thickness. However, to
maintain shear stresses of normal physiology (< ~9 Pa) required larger
gaps. In vitro testing confirmed that altering the gaps increased hydraulic
output by >40%, while reducing the hemolysis by >60%. Implementing
closed loop control in concert with motor optimization increased the
pump operating range, confirmed by in vitro testing and membrane visualization studies. Building on the foundation of successful animal implants
and durability studies, we conducted optimization of CorWave LVAD,
seeking to improve pump performance and efficiency, while preserving
physiologic shear stress conditions. The robust optimization and new control algorithms yielded significant hydraulic performance increase while
improving hemocompatibility. The updated designs have been integrated
into new pump designs which will be characterized and evaluated.

Methods: Murray’s law, the Hagen-Poiseuille equation, and a previouslydeveloped model of gas exchange in μALs were used to compare μAL
designs with capillary heights (Hc) between 10 and 100 μm. Designs
contained distribution channels and capillaries and were constrained to
fit on 6” silicon wafers. Rated blood flow (QR) and total pressure drop (ΔP)
were fixed at 0.8 mL/min and 60 mmHg for all designs. Three designs (Hc
= 30, 60, 100 μm) were modeled using CFD (SOLIDWORKS), implemented
via soft lithography, and tested in vitro with bovine blood to verify
performance.
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A Total Artificial Heart Based On A Single Nutating Disc Pump
Richard Wampler, MD1, Alexander Larkey, BSME2,
Dave Lancisi, Masters, Engineering3,
Robert Mastromattei, BS, MS3; 1Surgery, Oregon Health Sciences
University, Loomis, CA, USA, 2Solera, Carmichael, CA, USA, 3Sierramotion,
Loomis, CA, USA
Study: The purpose of this study is to evaluate the feasibility of using
a single nutating disc pump as a TAH. A nutating pump employs a disc
centered in a pumping chamber by means of a spherical bearing and
is caused to nutate or wobble, creating a wave action which displaces
fluid from an inlet to an outlet. Although, not currently used for
mechanical circulatory assistance, they may have better blood handling
properties since maximum velocities are less than 10% of rotary
pumps. In the 2003 ASAIO Journal (49):123–127, Yusuke Abe demonstrated good blood compatibility and complete circulatory support of
a goat for 46 days with a total artificial heart (TAH) comprised of two
nutating disc pumps.

Results: Gas exchange surface area (Ac,g) increased with capillary height
(Fig. 1) while total blood contacting surface area (Ab,c) and wall shear
stress (τw,avg) exhibited a maximum and priming volume (Vprime) exhibited
a minimum around Hc = 40 μm (Fig. 1). CFD (Fig. 2) results were within
15% of ΔP and τw,avg calculations. In vitro experiments (Fig. 3) confirmed
theoretical gas exchange, but measured pressure drop was ~45% lower
than theory.

Methods: A single nutating disc pump was converted to two parallel
pumps by changing the location of the inlets and outlets from radial
porting to axial placement such that each side of the disc is a distinct
pump as shown in the figure. In so doing, a single nutating disc pump
could be configured to simultaneously support the pulmonary and
systemic circulation. A nutating disc water meter chamber was modified
to create two parallel pumps on opposite sides of the disc. The existing
radial ports were plugged with epoxy and axial inlets and outlets were
machined. Printed ports were bonded to the modified housings as
shown in the figure. A fixture was created to drive the pump with a DC
motor.
The flow versus speed for the two sides were measured at 10 mm Hg.
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Influencing Factors Contribute To In Vitro Testing Of Extracorporeal
Membrane Oxygenation-induced Hemolysis
Chris Hoi Houng Chan, PhD1, Katrina K. Ki, PhD2,
Amelia Zhang, PhD3, Cooper Asnicar, BA2, Hwa Jin Cho, PhD4,
Carmen Ainola, BA2, Mahe Bouquet, BA2, Silver Heinsar, BA2,
Jo Pauls, PhD1, Jacky Y. Suen, PhD2, John F. Fraser, PhD2; 1School of
Engineering and Built Environment, Griffith University, Brisbane, Australia,
2
Faculty of Medicine, The University of Queensland, Brisbane, Australia,
3
School of Mechanical and Mining Engineering, University of Queensland,
Brisbane, Australia, 4School Department of Pediatrics, Chonnam National
University Children’s Hospital and Medical School, Brisbane, Korea,
Republic of
Study: In vitro hemolysis testing has been commonly used to determine
hemocompatibility of early prototypes of blood-contacting devices such
as ExtraCorporeal Membrane Oxygenation (ECMO). However, poor
reproducibility remains a challenging problem due to several unidentified influencing factors which affect the outcome of in vitro hemolysis
testing of ECMO. The present study investigated potential influencing
factors, such as flow rate, anticoagulation and gender of blood donor,
on hemolysis with a specific aim to provide benchmark values for future
ECMO development.
Methods: Four ECMO (Permanent Life Support System, Maquet) loops
were randomly tested and re-used using citrated (n = 6) or heparinized
human blood (n = 12), with two different flow rates of 4 L/min and 1.5 L/
min. Equal numbers of female and male blood donors were allocated
to each group of testing condition. All in vitro testing of ECMO were
performed at 37°C over 6 hours (consistent with ASTM F1841-97 and
F1830-97).
Results: Regardless of flow rate conditions, the level of hemolysis
remained unchanged for citrated blood, but significant increase in hemolysis was observed in heparinized blood over the 6-hour ECMO circulation. The ratio of normalized index of hemolysis (NIH) of heparinized
blood to citrated blood were 11.7-fold at 4 L/min and 16.5-fold at 1.5 L/
min. We further identified that hemolysis of heparinized blood collected
from female donors were significantly less at both flow rate conditions
compared to blood from male donors. The ratio of NIH of male blood
to female blood were 1.7-fold at 4 L/min and 2.2-fold at 1.5 L/min. The
choice of anticoagulation and blood donor gender are important influencing factors during in vitro hemolysis testing of ECMO. These factors must
be taken into consideration in order to reduce both bias and variability
between tests.

Results: The flow, speed and shaft power on shown in the table.
Occluding the outlet of one side did not cause an increase in the flow of
the non-occluded side suggesting leakage between pumps was minimal.
Limitations of the modified water meter pump precluded producing
systemic pressures.This preliminary study suggests that a single nutating
disc pump could be adapted for use as a TAH and may offer significant
improvement in blood handling compared to rotary blood pumps. Design
of a first prototype sized for human use is in progress and the feasibility of
electromagnetic actuation of the disc is being studied
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The Effects Of Outlet Boundary Conditions On Cerebral Blood Flow And
Emboli Transport During Cardiopulmonary Bypass
Bryan Good, PhD; Mechanical, Aerospace, and Biomedical Engineering,
University of Tennessee, Knoxville, TN, USA
Study: The risk of postoperative neurologic dysfunction in patients on
cardiopulmonary bypass (CPB) remains high despite improvements in
protective strategies. Primary risk factors linked to poor outcomes are
an increased risk of stroke resulting from higher micro-embolic load and
altered cerebral blood flow (CBF). Both factors are strongly influenced
by cerebral autoregulation (CAR), which allows the body to maintain
adequate CBF despite changes in CPB flow rates and perfusion pressures.
Previous studies have investigated the effects of CAR boundary conditions
in an ascending aorta model and on emboli distribution in the Circle of
Willis (CoW), but none have compared boundary conditions in a full CoW
model during CPB.
Methods: In order to accurately model cerebral hemodynamics and
the delivery of micro-emboli to the CoW during CPB, improved boundary conditions that mimic CAR are needed in a complete head-to-neck
vascular model. A 3D patient cerebral vascular model that incorporates
all branches of the aortic, arteries of the neck, and CoW was used to
perform computational fluid dynamics simulations with OpenFOAM software. Four sets of outlet boundary conditions of increasing complexity
(fixed-pressure, resistance-based, Windkessel model (WKM), and lumpedparameter CAR) were compared as to their effect on CBF distribution and
hypoperfusion. Additionally, Lagrangian particle-tracking was incorporated and particles released from the CPB cannula to mimic embolization.
Results: Under a range of perfusion pressures (50–150 mmHg), the fixedpressure, resistance-based, and WKM boundary conditions experienced
no change in CBF, while the CAR conditions led to a decrease in CBF when
pressures dropped below normal levels (<80mmHg) and an increase
when they exceeded them (>120mmHg). Micro-emboli distribution varied
as well with CBF distribution and increased to CoW branches with WKM
and CAR boundary conditions.
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Risk Factors And Outcomes Of Patients Requiring Left Ventricular
Unloading On Veno-Arterial Extracorporeal Membrane Oxygenation
Support
Bree Ann C. Young, MD, MS, Chetan Pasrija, MD,
Sari Holmes, PhD, Samantha J. Kegel, BS, Douglas Tran, MD,
Eric M. Krause, MD, Dawn M. Parsell, BS, Ronson Madathil, MD,
Nicole Hays, BS, Lauren E. Levy, BS, Joshua Finkel, BS,
Kristopher B. Deatrick, MD; Surgery, Division Cardiac Surgery, University
of Maryland, Baltimore, MD, USA
Study: Veno-arterial extracorporeal membrane oxygenation (VA ECMO)
can provide full systemic perfusion in cardiogenic shock, but does not
unload the left ventricle. Left atrial hypertension, pulmonary edema,
hemorrhage, and further LV dysfunction may result. The need for routine
unloading, however, remains controversial. We sought to identify risk factors for LV dysfunction receiving unloading and to compare outcomes of
patients who received unloading to those that did not.
Methods: Patients who underwent peripheral cannulation for VA-ECMO
for refractory cardiogenic shock from January 2015 to December 2019
were reviewed.

Results: VA ECMO patients were analyzed (N=302) and 42 (14%) required
LV unloading. Unloading strategies included Impella placement (n=13,
31%), atrial septostomy (n=27, 64%), and both (n=2, 5%). Prior CVA
(24 vs 10%, P=0.018) and S-T segment elevation myocardial infarction
(STEMI) as indication for ECMO (26 vs 3%, P<0.001) were associated with
LV unloading. Hypertension (64 vs 66%, P=0.828), dyslipidemia (50 vs
41%, P=0.289), and ECMO-CPR (eCPR) status (29 vs 24%, P=0.509) were
not risk factors for LV unloading. No significant difference was found for
age, BMI, gender, and race. ECMO duration (12 vs 6 days, P<0.001), limb
ischemia (26 vs 13%, P=0.026), and cardiac/aortic thrombus (21 vs 10%,
P=0.037) were higher in patients requiring LV unloading. ECMO mortality
was higher (50% vs 21%, P<0.001) and survival to discharge was lower (38
vs 67%, P<0.001) in patients requiring LV unloading. Patients requiring LV
unloading strategies on VA ECMO had higher incidence of ECMO mortality
and lower survival to discharge at our institution. STEMI patients requiring ECMO may be at highest risk for requiring LV unloading. These results
may help guide clinical decision-making regarding VA ECMO initiation,
support, and implementing LV unloading strategies.
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Improved Outcomes In Veno-arterial Extracorporeal Membrane
Oxygenation For Primary Graft Failure After Heart Transplantation
Aaron Guo, BS, Brandon Jocher, BS, Irene Fischer, MPH,
Kunal Kotkar, MD, Muhammad Masood, MD,
Akinobu Itoh, MD, PhD; Surgery, Washington University School of
Medicine in St. Louis, St. Louis, MO, USA

Cerebrovascular Accidents In Patients Supported With Veno-Arterial
Extra-corporeal Membrane Oxygenation—Is Duration Of Support
Important?
Sheraz Hussain, MD1, Natalia Zero, DO1, Tareq Al Saadi, MD1,
Moneeb Asghar, DO1, Muhammad Ali Khan, MD1,
Nicole Glowacki, MPH2, David Alexander, None3,
Christopher Sciamanna, DO4, Anjali Joshi, MD4,
Ambar Andrade, MD4, Muhyaldeen Dia, MD4,
Gregory Macaluso, MD4, Nikhil Narang, MD4,
Philip Alexander, MD5, Antone Tatooles, MD5,
Patroklos Pappas, MD5, William Cotts, MD4, Sunil Pauwaa, MD4; 1Internal
Medicine, University of Illinois at Chicago/Advocate Christ Medical Center,
Oak Lawn, IL, USA, 2Research, Advocate Christ Medical Center, Oak Lawn,
IL, USA, 3Advocate Christ Medical Center, Oak Lawn, IL, USA, 4Advanced
Heart Failure, Mechanical Circulatory Support and Transplant Cardiology,
Advocate Christ Medical Center, Oak Lawn, IL, USA, 5Department of
Cardiovascular and Thoracic Surgery, Advocate Christ Medical Center, Oak
Lawn, IL, USA

Study: Extracorporeal membrane oxygenation (ECMO) support is a lifesaving measure in the acute phase after heart transplant, wherein the
allograft primarily may become dysfunctional (PGD) despite maximal
pharmacologic efforts. We aimed to formally assess ECMO strategies on
outcomes at our single center over the last 8 years.
Methods: 276 heart transplant patients between 1/1/2013 and
9/30/2020 were reviewed. 41 patients were identified who required
ECMO for PGD during in-hospital recovery post-transplant. Patients
were stratified by transplant before or after January 2017, when our
center changed ECMO strategies as described here: before 1/3/2017,
we primarily used central (direct through aorta/right atrium) or direct
peripheral (percutaneous or open through femoral artery/vein) standard
cannulation techniques for VA-ECMO. After January 2017, we introduced
the use of cannulation into a chimney graft sewn to the brachiocephalic
artery, axillary artery, or aorta; percutaneous venous cannulation was
performed through the femoral vein or internal jugular vein. We aimed at
earlier extubation and mobilization of post-transplant patient even on VAECMO. Primary outcome of interest was survival to discharge. Secondary
outcomes included survival to wean from ECMO and 30-day survival from
transplant. Clinical data was collected from electronic chart review and
Society for Thoracic Surgeons (STS) database.
Results: Survival to discharge before 2017 was 45% (9/20), which
improved to 76% (16/21) after January 2017 (p=0.041). Before 2017,
median time to ECMO weaning was 4 days with 65% (13/20) survival
to weaning. This is compared to after 2017, with median time to ECMO
weaning of 5 days with 100% survival to weaning. 30-day survival
was 55% (11/20) and 90% (19/21) before and after 2017, respectively
(p=0.010). This new modified approach to ECMO after heart transplant is
associated with significantly improved outcomes.

Study: Veno-Arterial Extra-corporeal Membrane Oxygenation (VA-ECMO)
is indicated for refractory cardiac and/or respiratory failure. Adverse
events remain considerable despite best practices. We specifically aimed
to understand risk factors associated with cerebrovascular accidents
(CVA) in patients who underwent VA-ECMO support.
Methods: We retrospectively assessed all VA-ECMO patients from 2007
to 2019 at our institution. We identified those who experienced a CVA
while supported by VA-ECMO. Patients with the primary event (CVA) were
matched to controls (no CVA) based on age and sex. Comparisons were
made between groups using McNemar’s, Mantel-Haenszel, and Wilcoxon
Signed-Rank tests where appropriate.

Results: Of the 278 VA-ECMO patients in the registry, 32 patients who
experienced a CVA were identified; 24 (8.6%) ischemic and 8 (2.9%) hemorrhagic. Median age was 59.5 years (inter-quartile range: 49–65 years)
and 75% of patients were males. Hypertension, diabetes, CAD and CHF
were common co-morbidities (Table 1). Cardiogenic shock was the most
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common indication for VA-ECMO support in both cohorts, 75% in cases
and 71.9% in controls. Cannulation strategies were identified as central
or peripheral. There was a significant association of duration of VA-ECMO
support with incidence of CVA, with a p-value of 0.03. Regression analysis
showed a trend of increased risk of CVA by 4% for each additional day
on VA-ECMO, however, this was not statistically significant (Odds ratio:
1.04; confidence interval 1.00–1.08). Most common outcome was death
followed by decannulation to recovery and bridge to LVAD. Conclusion
Ischemic and hemorrhagic CVAs are not uncommon during VA-ECMO support. Our case control study shows an association of duration of VA-ECMO
support with incidence of CVA. This underscores the importance of timely
assessment and weaning or bridging of VA-ECMO patients to their next
management step.

Comparing Intraoperative Blood Product Use During Heart
Transplantation In Patients With Axillary Impella 5.5 Versus Durable Left
Ventricular Device As Bridge Therapy
Rohan M. Goswami, MD1, Alexander Heckman, MD2,
Basar Sareyyupoglu, MD3, Parag Patel, MD1, Juan Leoni, MD1,
Daniel S. Yip, MD1, Osama Haddad, MD3, Si Pham, MD3,
Kevin Landolfo, MD3; 1Department of Transplant, Mayo Clinic Florida,
Jacksonville, FL, USA, 2Department of Cardiology, Mayo Clinic Florida,
Jacksonville, FL, USA, 3Department of Cardiothoracic Surgery, Mayo Clinic
Florida, Jacksonville, FL, USA
Study: Increased intraoperative blood product transfusion can potentiate the vasodilatory phenomenon of cardiopulmonary bypass (CPB).
Furthermore, increased transfusion is also associated with worse right
ventricular function after heart transplantation (OHT). This may increase
the need for mechanical circulatory or increased vasoactive support after
OHT. As a large volume center utilizing axillary support devices for bridge
therapy (BTT) we analyzed their role in minimizing transfusion during OHT
compared to left ventricular assist device (LVAD).
Methods: We performed a retrospective single center review of patients
who underwent OHT from January 1, 2019 to December 31, 2020. All
patients with axillary Impella devices and LVAD were included. All transfused blood products, including cell saver were reviewed. Descriptive
statistical analysis was performed to assess the significance of product
transfusion, CPB, length of stay and post-bypass vasoactive inotrope score
(VIS).
Results: 82 patients underwent OHT during our study. 15 patients
underwent axillary Impella placement (13M and 2F) and 13 had durable
LVAD (8M and 5F) at the time of OHT. Average age was 60 in the Impella
and 51 in the LVAD group. More product transfusion occurred with LVAD
compared to Impella at time of OHT. Comparing all products transfused, only cryoprecipitate (p=0.01), cell saver (p=0.0005) and platelets
(p=0.003) were statistically significant. No difference with FFP or PRBC
transfusion was noted. Not surprisingly, median VIS score was lower in
the Impella group (6 vs 9.8, p=0.05). CPB time was also statistically lower
in the Impella group (p=0.003, 179 min vs 224 min). Our data suggests
intraoperative transfusion and post-operative vasopressor needs are
decreased in patients undergoing OHT with Impella support. We plan to
further evaluate this with 1-year survival data in our cohort.
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Does Preimplant LVEDD Impact Clinical Outcomes In Centrifugal Flow
LVAD Patients?
Mustafa M. Ahmed, MD1, Francis D. Pagani, MD, PhD2,
Lauren Meece, CRNP3, Eric I. Jeng, MD4, Claudius Mahr, DO5,
Nader Moazami, MD6, Nahush A. Mokadam, MD7,
Joseph G. Rogers, MD8; 1Cardiovascular Medicine, University of Florida,
Gainesville, FL, USA, 2Cardiothoracic Surgery, University of Michigan
Medical Center, Ann Arbor, MI, USA, 3Cardiovascular Medicine, University
of Florida, Gainseville, FL, USA, 4Cardiovascular Surgery, University of
Florida, Gainesville, FL, USA, 5Cardiology, University of Washington,
Seattle, WA, USA, 6Cardiothoracic Surgery, NYU Langone Health, New
York, NY, USA, 7Cardiac Surgery, Ohio State University Wexner Medical
Center, Columbus, OH, USA, 8Cardiology, Duke University Medical Center,
Durham, NC, USA

The Effects Of Baseline Right Ventricular Function On Mortality And
Morbidity In Patients Undergoing Hvad Implant With A Thoracotomy
Approach
Gurpreet S. Sodhi, MD1, Mary E. Keebler, MD2,
David E. Kaczorowski, MD3, Jason W. Smith, MD4,
Gavin W. Hickey, MD5, Claudius Mahr, DO6,
Nahush A. Mokadam, MD7, Anson Cheung, MD8,
Edwin McGee, MD9; 1Cardiovascular Medicine, Sutter Health,
Sacramento, CA, USA, 2Cardiology, Univerity of Pittsburgh Medical Center,
Pittsburgh, PA, USA, 3Cardiothoracic Surgery, Univerity of Pittsburgh
Medical Center, Pittsburgh, PA, USA, 4Cardiothoracic Surgery, University
of Wisconsin, Madison, WI, USA, 5Cardiovascular Medicine, Univerity of
Pittsburgh Medical Center, Pittsburgh, PA, USA, 6Cardiology, University
of Washington, Seattle, WA, USA, 7Cardiothoracic Surgery, Ohio State
University Wexner Medical Center, Columbus, OH, USA, 8Cardiothoracic
Surgery, St Paul’s Hospital, Vancouver, BC, Canada, 9Cardiothoracic
Surgery, Loyola University, Maywood, IL, USA

Study: Recent literature suggests that patients (pts) with small left ventricles (LV) supported with axial flow left ventricular assist devices (LVADs)
have worse survival than those with large LVs. The purpose of this analysis
was to define survival in destination therapy (DT) pts supported with the
HeartWare™ HVAD™ System in the ENDURANCE and ENDURANCE Supplemental Trials stratified by preimplant LV end-diastolic diameter (LVEDD).
Methods: HVAD pts with baseline LVEDD measurements were stratified
into 2 cohorts: small LV (<60 mm) and large LV (≥60 mm). Baseline differences and survival through 3 years were analyzed. Further stratification
by LVEDD <55 mm and female gender were also examined.
Results: Of the 604 HVAD DT pts, 487 (80.6%) had baseline LVEDD, 94
with small LV, 393 with large LV. Within the small LV cohort, 42 had an
LVEDD <55 mm. Compared to the large LV cohort, small LV pts were
more likely female (31.9% vs. 18.8%, p=0.008), had more ischemic heart
failure (68.1% vs. 56.0%, p=0.04), lower hemoglobin (11.2 ± 18.8 vs 11.9
± 23.1 gm/dL, p=0.004) and mean pulmonary artery pressure (30.1 ± 8.8
vs 33.0 ± 8.9 mmHg, p=0.02), higher LV ejection fraction (18.5 ± 4.4 vs.
16.9 ± 4.9%, p=0.004), and less moderate/severe mitral regurgitation
(48.9 vs. 68.8%, p=0.03). Three-year survival was not significantly different between the two cohorts (57.5% small and 57.1% large LV cohorts,
p=0.47, Fig. 1). Three-year survival in pts with LVEDD <55 mm was not
significantly different from either the small or large LV groups (p=0.77).
In an analysis limited to 2-years due to small numbers, survival in women
was not impacted by LVEDD (<55 mm: 77%, <60 mm: 77%, >60 mm: 78%,
p=0.34). Conclusion: This analysis demonstrates that preimplant LV size
does not significantly affect 3-year survival in DT HVAD patients. Additionally, women with very small LV (<55 mm) had comparable mortality
outcomes as those with larger LV size.

Study: To examine the effects of baseline right ventricular (RV) dysfunction, defined as the central venous pressure (CVP) to pulmonary capillary
wedge pressure (PCWP) ratio and pulmonary artery pressure index (PAPi)
score, on survival and adverse events in patients receiving the HeartWare™ HVAD™ System, via thoracotomy.
Methods: HVAD patients enrolled in the LATERAL trial with both CVP
(or RAP) and PCWP values and PAPi score at baseline were eligible in
this analysis (n=130). Patients were separated into three cohorts of
RV dysfunction: Mild: CVP/PCWP < 40% (n=58), Moderate: CVP/PCWP
40% - 60% (n=55), and Severe: CVP/PCWP > 60% (n=17). In the LATERAL
trial, patients with a mean CVP > 20 mmHg on multiple drips or RV ejection fraction < 15% with clinical signs of severe right heart failure were
excluded. Differences in baseline characteristics, adverse events, and
survival through six months were analyzed.

Results: Baseline characteristics were largely similar, except for more
females in the CVP/PCWP > 60% cohort. The PAPi score was significantly
different among the three CVP/PWCP groups (Mild: 5.4 ± 4.6 vs Moderate: 2.6 ± 1.3 vs Severe: 1.6 ± 0.6, p<0.0001) (Table 1). There were no
differences in rates of hemorrhage or ischemic stroke, gastrointestinal
(GI) bleed, renal failure or right heart failure requiring a right ventricle
assist device (RVAD) in the first six months (Table 1). Six-month survival
was also similar amongst the three cohorts of RV dysfunction: Mild: 95%,
Moderate: 90%, and Severe: 85%, p=0.57 (Figure 1). Conclusion: In the
prospective, single-arm, multi-center LATERAL trial, the severity of baseline RV dysfunction did not affect mortality and rates of adverse events at
six months in patients who received the HVAD system via a thoracotomy
approach.
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Air Exposure Role In The Inflammatory Response Related To
Cardiopulmonary Bypass
Mark Langley, BS, MS1, Matthew D. Johnson, MD1,
Joseph Hill, BS, MS1, Terry Major, BS, MS1,
Orsoyla Lautner-Csorba, PhD1, Adrianna Kayden, BS1,
Bailey Schneider, BS1, Daniel Drake, MD2, Jonathan Haft, MD1,
Alvaro Rojas-Peña, MD3, Robert Bartlett, MD1,
John Toomasian, CCP1; 1Surgery, University of Michigan Medical School,
Ann Arbor, MI, USA, 2Surgery, Cardiac Surgery, University of Michigan
Medical School, Ann Arbor, MI, USA, 3Surgery, Transplant, University of
Michigan Medical School, Ann Arbor, MI, USA
Study: Cardiopulmonary bypass (CPB) during cardiac surgery is associated with a systemic inflammatory response (SIR) from leukocyte and
platelet activation. Air exposure, foreign surface blood contact, ischemiareperfusion injury, and operative trauma are all causes. A porcine model
was developed to characterize the specific role of controlled air exposure
during CPB.
Methods: Swine (n=14) were cannulated via the right atrium and aorta
through a right mini-thoracotomy, supported on CPB for 2 hours and
recovered. Air exposure (A, n=9) had a 20–25% blood shunt in which air
was mixed at an approximate 4–5:1 ratio to mimic cardiotomy suction
and venting. Control animals (C, n=5) were placed on CPB in which no
air was administered. Blood samples were collected throughout the CPB
period and daily for up to 7d. At termination, tissue samples were sent
for histopathological analysis. Groups were compared using the MannWhitney U-test.
Results: In this model, air exposure did not result in any significant differences in morbidity or organ injury related to SIR. Granulocyte activation, measured by Cd11b expression (242 MFI vs. 224 MFI, p=0.218)
and platelet activation, measured by P-selectin expression (385 vs. 435
MFI, p=0.219) were not different between groups A and C, respectively.
Additionally, there were no differences in free plasma hemoglobin (3.0
vs. 2.01 mg/dL, p = 0.114) or serum lactate levels (2.1 vs. 1.2 mmol/L,
p=0.196). Histopathology did not show any differences in inflammationrelated organ injury. These findings suggest that air exposure of this duration may not be as significant a factor in CPB-related inflammation, and
that other potential causes may play a larger role.
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Calcium Homeostasis And Right Ventricular Function Following Left
Ventricular Assist Device Therapy
Kristin Stawiarski, MD, Olayinka Agboola, MD, Riya Bonde, None,
Pramod Bonde, MD; Bonde Artificial Heart Lab, Yale School of Medicine,
New Haven, CT, USA

Clinical Implication Of Optimal Heart Rate In Lvad Patients
Teruhiko Imamura, MD, PhD1, Koichiro Kinugawa, MD, PhD1,
Hidefumi Nishida, MD2, Besser Stephanie, BA2, Sean Pinney, MD2,
Valluvan Jeevanandam, MD2, Takeyoshi Ota, MD, PhD2; 1University of
Toyama, Toyama, Japan, 2University of Chicago, Chicago, IL, USA

Study: Heart failure progression has been linked to abnormal calcium
homeostasis in myocytes. Its implication on right ventricular function has
not been evaluated in end-stage heart failure patients undergoing left
ventricular assist device (LVAD) placement. We investigated the impact
of hypocalcemia on right ventricular function, post-operative recovery to
explant and all-cause mortality over a 24-month period post LVAD.
Methods: Study group comprised of 177 patients receiving LVAD therapy
from June 2011 and October 2018. Preoperative parameters were used
to stratify patients into hypocalcemia [(serum calcium < 8.7 mg/dL) n=40,
female = 7] or normocalcemia [(8.7- 10.2 mg/dL) n=108, female=30]
groups. Patients with missing data were excluded (n=29). Baseline and
adverse outcomes were compared using Fishers exact test. The association between the hypocalcemia and 24-month mortality was examined
via cox regression models. A Kaplan-Meir plot and log-rank statistics were
used to compare survival across patient groups.
Results: The LVAD cohort consisted of mainly males aged 60 with a
greater number of patients in the hypocalcemia group receiving LVADs as
a destination therapy (77 vs. 63%, p=0.09). The history of chronic kidney
disease was similar (21 vs. 28%, p=0.36). Baseline left ventricular ejection
fraction approximated 20% in both groups. However, the hypocalcemia group had a smaller left ventricular end systolic and end-diastolic
volume comparatively (55 vs 62mm, p=0.01 and 62 vs 69 mm, p=0.004).
24-month survival was equal across groups (Log-Rank p=0.13). There was
no difference in mortality seen on either the unadjusted [HR= 1.42 (0.89
- 2.27) (p=0.14)] or adjusted modelling [1.39 (0.86 - 2.24) (p=0.18)]. Hypocalcemia was associated with increased right ventricular assist device use
(23 vs 8%, p<0.02) but LV recovery was equivalent (12 vs 7%, p=0.33).
Persistent hypocalcemia maybe a prognostic marker for right ventricular
failure in patients receiving LVAD therapy.

Study: Heart rate (HR) reduction therapy using ivabradine has demonstrated its prognostic implication in patients with heart failure with
reduced ejection fraction. However, clinical implication of optimal HR in
patients with left ventricular assist device (LVAD) remains unknown.
Methods: The cohort included all consecutive patients undergoing LVAD
implantation between 2014 and 2018. The subjects who were not in
sinus rhythm and/or whose follow up period was less than one year were
excluded from the study. Ideal HR was calculated as follows: 96 - 0.13 ×
(deceleration time [msec]). The impact of “HR difference”, defined as the
difference of HR between the actual HR at discharge and the calculated
ideal HR, on one-year mortality and heart failure readmissions was
investigated.
Results: A total of 143 patients (55 years old, 101 males) were identified and stratified into three groups considering their HR differences: (1)
optimal HR group (N = 49; HR difference <27 bpm); (2) sub-optimal HR
group (N = 47; HR difference 27–42 bpm); (3) abnormal HR group; HR difference >43 bpm; Figure 1A). There were no significant differences in the
baseline characteristics and medications among the groups. Abnormal HR
group had significantly higher one-year cumulative event rate compared
with optimal HR group (38% vs. 16%, p = 0.029; Figure 1B) with a hazard
ratio of 1.66 (95% confidence interval 1.09–2.51) adjusted for age, body
surface area, ischemic etiology, and destination therapy. In conclusion,
non-optimized HR negatively affected clinical outcomes in LVAD patients.
Implication of aggressive HR optimization in LVAD patients is the next
concern.
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Psychosocial Characteristics And Two-year Outcomes In Patients With
Ventricular Assist Devices
Sanika Tolia, DO, Sabaa Ahmed, DO, Joseph Adams, DO,
Chad Morreale, DO, Robin Paliga, APRN-BC, Tracey Aicher, APRN-BC,
Laura Coyle, FNP-BC, Sunil Pauwaa, MD,
Gregory Macaluso, MD, Anjali Joshi, MD, Nikhil Narang, MD,
Jessica Pillarella, MD, Christopher Sciamanna, DO,
Antone Tatooles, MD, Patroklos Pappas, MD,
Edward Mahoney, MD, William Cotts, MD,
Ambar Andrade, MD; Advocate Christ Medical Center, Oak Lawn, IL, USA
Study: Patient selection for durable left ventricular assist device (LVAD)
implantation involves a comprehensive medical and psychosocial evaluation to determine candidacy. We aim to evaluate the patient psychosocial
risk profile and its impact on 2-year outcomes after VAD implantation.
Methods: This study was a single center, retrospective analysis of 237
patients who underwent durable LVAD implantation between 2015 and
2017. Patients were evaluated for psychiatric history, education, social
support, cognitive function, and screened for depression and anxiety.
Based off these criteria, the patients who were deemed low or lowmoderate risk were assigned to the “low-risk” group and those who were
moderate, moderate-high, or high risk were assigned to the “high-risk”
group. Statistical analysis was performed using Chi-Square and Student’s
t-tests, wherein p<0.05 was considered statistically significant.
Results: Of 237 patients, 138 patients were low psychosocial risk and
99 were high-risk. High risk patients were found to be younger (58 ±
13), more likely to have a history of illicit drug use (42 [42.9%] vs 25
[18.3%]), and more often lacked post-implant social support (85 [85.9%]
vs 133 [96.4%]). There was no difference in two-year survival, days to
first readmission, or mean number of readmissions within the first two
years. High-risk patients were more likely to experience pump hemolysis
and less likely to be waitlisted or transplanted (see Table). Psychosocial
characteristics play a significant role in determining a patient’s candidacy
for LVAD implantation. While patients with high-risk characteristics were
statistically more likely to experience pump hemolysis, no difference was
observed in readmission rates, driveline infection, bacteremia, CVA, pump
thrombosis, GI bleed, hemorrhage, or overall survival at 2 years. This
study highlights the importance of a multidisciplinary approach to patient
evaluation. Further research with longer term follow-up is needed.
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correlate with adverse events and survival in patients undergoing evaluation for advanced heart failure therapies. The limitations of our study
include the small sample size. Larger patient populations and extended
follow up is needed for further analysis.

Correlation Of Liver Biopsies And Outcomes In Patients Undergoing
Evaluation For Advanced Heart Failure Therapies
Sanika Tolia, DO, Nikhil Narang, MD, Jessica Pillarella, MD,
Anjali Joshi, MD, Christopher Sciamanna, DO, Sunil Pauwaa, MD,
Gregory Macaluso, MD, Antone Tatooles, MD,
Patroklos Pappas, MD, William Cotts, MD, Ambar Andrade, MD; Advocate
Christ Medical Center, Oak Lawn, IL, USA
Study: Patients with end-stage heart failure undergoing evaluation for left
ventricular assist devices (LVAD) or orthotopic heart transplant (OHT) may
often have evidence of hepatic dysfunction that necessitates liver biopsy
to rule out liver cirrhosis. We aimed to evaluate liver biopsy findings and
their respective impact on adverse events, candidacy for LVAD/OHT, and
two-year survival.
Methods: In this single center, retrospective analysis, we evaluated
4,536 patients who were referred to the advanced heart failure team for
evaluation between 2008–2020. We found 48 patients who underwent
liver biopsy and assigned those with absent or sinusoidal fibrosis (grade
1) to low-risk and those with central, bridging, and portal fibrosis or cirrhosis (grades 2–4) to high risk. P-values less than 0.05 were considered
significant.

Results: We found 14 patients who had low-risk pathology compared to
34 patients with high-risk pathology on biopsy. There was no significant
difference in age, etiology of heart failure or echocardiographic and
hemodynamic parameters among both groups. While high-risk patients
more often required paracenteses for ascites, there was no difference
in MELD-XI (Model for End-Stage Liver Disease excluding INR), baseline
labs, or etiology of liver dysfunction. Although the grade of fibrosis did
not correlate to outcome of VAD or OHT, patients with a higher grade of
fibrosis showed an increased trend of requiring palliative care. Survival at
1 and 2-years and cause of death were similar among both groups. These
results suggest that the grade of fibrosis on biopsies may not directly
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The Use Of Oncostatin M To Quantify Inflammatory Burden With MCS
Therapies
Hendra Setiadi, PhD1, Ahmed M. El Banayosy, MD1,
David W. Schmidtke, PhD2, David W. Vanhooser, MD1,
Douglas A. Horstmanshof, MD1, Aly El Banayosy, MD1,
James W. Long, MD, PhD1; 1Advanced Cardiac Care, INTEGRIS Baptist
Medical Center, Oklahoma City, OK, USA, 2University of Texas at Dallas,
Richardson, TX, USA

Gastrointestinal Bleeding In Patients With HeartMate 3 And HVAD Left
Ventricular Assist Devices: Incidence, Risk Factors And Outcomes
Thomas Schlöglhofer, MSc1, Philip Cichra, None1,
Julia Riebandt, MD2, Kamen Dimitrov, MD2,
Anne-Kristin Schaefer, MD2, Franziska Wittmann, MD2,
Philip Angleitner, MD2, Günther Laufer, MD2,
Dominik Wiedemann, MD2, Heinrich Schima, PhD1,
Daniel Zimpfer, MD1; 1Department of Cardiac Surgery, Center for Medical
Physics and Biomedical Engineering, Medical University of Vienna, Vienna,
Austria, 2Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria.

Study: Oncostatin M (OSM) (a member of Il-6 cytokine family) is a sensitive indicator of inflammation. We report, for the first time, its use to
assess baseline and peri-procedural states of inflammation for 3 Mechanical Circulatory Support (MCS) therapies in comparison to conventional
cardiac surgery with cardiopulmonary bypass (CPB).
Methods: Plasma OSM levels (pg/mL) were measured by ELISA in blood
samples collected from patients receiving Ventricular Assist Devices
(VADs), Total Artificial Hearts (TAHs), Veno-Arterial Extracorporeal Membrane Oxygenation (V-A ECMO) and, as controls, Coronary Artery Bypass
Grafting (CABG). Samples were collected within 12 hours before and 4–8
hours after the procedure.

Study: Continuous-flow LVADs (cf-LVADs) have demonstrated superiority
in patient survival and quality of life compared with pulsatile-flow LVADs,
but cf-LVADs have a higher risk of gastrointestinal bleeding (GIB). The aim
of this study was to characterize incidence, risk factors and outcomes of
GIB in HeartMate 3 (HM3) and HVAD recipients.
Methods: This single-center study, included 113 consecutive patients
(Age: 59.6±11.6 yrs, female: 13.3%, BMI: 27.9±5.2kg/m2, HM3/HVAD:
n=57/56) implanted between 2014 and 2017. Primary outcome was freedom from GIB one-year following implant, secondary outcomes included
etiology, outcomes and independent risk factors of GIB.
Results: 18.6% suffered GIB after a median time of 66 (5–333) days,
42.9% had at least one recurrent GIB event. The incidence of GIB was
non-significantly lower in HM3 vs. HVAD patients (15.8% vs. 22.4%,
p=0.32), without differences in recurrent GIB (33.3% vs. 50.0%, p=0.66).
90.5% GIB patients presented with melena and 9.5% with hematochezia. In 63.2% of the GIB group, the total number of PRBCs was 0–5,
6–10 in 21.1% and >10 in 15.8%. The most common treatment included
temporary cessation of anticoagulation (47.4%), reduction of antiplatelet
therapy (26.3%) and endoscopic intervention (15.8%). On the event day,
patients with GIB were less on ACE inhibitors or AT1 receptor blockers
(GIB: 41.2% vs. control: 90.4%, p<0.001). Multivariate cox-proportional
hazard model with GIB as time-dependent covariate showed no association with increased mortality [HR 0.99, 95% CI 0.93–1.01; p=0.72]. In
addition, temporary RVAD implant was an independent risk factor for GIB
(HR 2.55, 95% CI 1.05–6.46; p=0.035). GIB is common in cf-LVAD patients,
but no effect on survival or specific device superiority was found. Further
studies are needed to investigate possible mechanisms by which right
heart failure and temporary RVAD support increases the incidence of GIB.

Results: Pre-implant OSM levels of V-A ECMO patients were higher
than CABG patients (p=0.04) while levels in TAH and VAD patients fell
in-between. Post-implant OSM levels of VAD, TAH and V-A ECMO patients
were all higher than those of CABG patients (p<0.0001, p=0.012 and
p=0.032 respectively). The difference between pre-and post-implantation
(Delta) values in TAH patients and VAD were higher (both p<0.0001) than
those of CABG patients (Table 1).
Conclusion: Not surprisingly, decompensated patients in urgent need of
V-A ECMO exhibited the greatest level of baseline inflammation. However,
the added burden of inflammation due to the V-A ECMO procedure was
more like CABG with CPB than the implantation of TAH’s which markedly intensified the inflammatory state while VAD implantation fell
in-between. This methodology and the resultant characterization of the
inflammatory burden with MCS therapies should prove useful for patientand device-specific outcomes analyses and for providing guidance for
best use.
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Bleeding While On LVAD: Analysis Of The Competing Role Of Acquire
Von Willebrand Disease And Antithrombotic Strategy
Alessandra Marasi, MS1, Patrizia Della Valle, MS2,
Loris Pozzi, MS2, Elisabetta Pattarini, MS3,
Giuseppe Giardina, MS4, Marina Pieri, MD4,
Anna Mara Scandroglio, MD4, Alberto Redaelli, PhD1,
Alberto Zangrillo, MD4, Armando D’Angelo, MD2,
Federico Pappalardo, MD5, Filippo Consolo, PhD6; 1Department of
Electronics Information and Bioengineering, Politecnico di Milano,
Milan, Italy, 2Coagulation Service and Thrombosis Research Unit, IRCCS
San Raffaele Scientific Institute, Milan, Italy, 3Laboratory Medicine
Service, IRCCS San Raffaele Scientific Institute, Milan, Italy, 4Anesthesia
and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy,
5
Anesthesia and Intensive Care, IRCCS ISMETT, Palermo, Italy, 6Anesthesia
and Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy.

Synergistic Effect Of Shear And Adp On Thrombus Growth On Zta And
Ti6al4v Surfaces
Andrew Kang, BS1, Anjana Jayaraman, BS2,
Megan A. Jamiolkowski, PhD3, William R. Wagner, PhD4,
Brian J. Kirby, PhD1, James F. Antaki, PhD5; 1Mechanical and Aerospace
Engineering, Cornell University, Ithaca, NY, USA, 2Chemical Engineering,
Cornell University, Ithaca, NY, USA, 3Food and Drug Administration,
Silver Spring, MD, USA, 4University of Pittsburgh, Pittsburgh, PA, USA,
5
Biomedical Engineering, Cornell University, Ithaca, NY, USA
Study: In this work, we characterize real-time platelet deposition onto
clinically relevant surfaces and examine how the interplay of shear, platelet agonist, and artificial surface can facilitate thrombogenesis.

Study: Aim of the study was to analyze the competing role of acquired
von disease and antithrombotic (AT) strategy in the development of
bleeding events in patients implanted with continuous-flow LVADs.
Methods: The von Willebrand factor i) antigen level (vWf:Ag) and ii)
activity of high-molecular weight multimers (collagen binding test,
vWf:CB) were measured in 53 patients implanted with the HVAD (n=28,
53%) or the HeartMate3 (n=25, 47%). Values were measured preimplant
(PRE) and at short- (t1: <3mo) and long-term (t2: >12mo) follow up and
compared between patients who did (n=26, 49%) and did not suffer from
bleeding complications (n=27; 51%). Furthermore, incidence of bleeding
events was correlated with AT regimen, as aspirin was discontinued in the
bleeding group following a bleeding event.
Results: Preoperative characteristics and coagulation profile were comparable in the two groups. Median follow up was 324 days (IQR: 226–468).
The vWf:Ag and vWf:CB decreased significantly post-implant (vWf:Ag:
p=0.0003; vWf:CB: p<0.0001), and patients showing abnormal vWf activity to antigen ratio (vWf:CB/vWf:Ag ratio <0.7) increased progressively
with increasing time of support (PRE: 26%, t1: 58%, t2: 74%; p<0.0001).
However, no differences were noted for all vWf assays between bleeders and non-bleeders, indicating comparable acquired vWf deficiency
in the two groups, irrespective of the development of bleeding events.
Moreover, no differences were recorded in the vWf profile of patients
implanted with the HVAD or the HeartMate3. Following aspirin discontinuation, only 3 patients had recurrence of bleeding. This study highlights
that acquired vW disease is not pivotal in the pathophysiology of bleeding
in the setting of LVAD support with continuous-flow pumps, and suggests
that aspirin-free AT strategy is the only clinically reliable approach to
reduce bleeding. The interplay between these two mechanisms warrants
further studies.

Methods: Fresh whole blood was collected from healthy patients.
Platelets were extracted, fluorescently labeled with mepacrine and
resuspended in hemoglobin-depleted red blood cells to a final hematocrit
of 25% and a platelet concentration of 2.6 ± 0.43 x 108 per mL. A parallelplate flow chamber with an interchangeable, 10 mm square coupon was
designed to test deposition on titanium alloys (Ti6Al4V) and zirconium
toughened alumina (ZTA). A membrane-based agonist delivery system
was placed upstream of the deposition site to uniformly mix ADP to a final
concentration of 0, 5, or 10 nM. Blood was perfused to generate a wall
shear rate of 400 s-1 1000 s-1.Platelet deposition images were obtained in
real-time using an inverted epifluorescence microscope. Surface coverage
fractions and mean aggregate sizes were calculated at 10-second intervals
using a custom Matlab program. Statistically significant differences in
surface coverage fraction rates were extracted across the two shear rates
for each given combination of ADP and material surface.
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Eliquis: Alternative Anticoagulation For Heartmate 3 Ventricular Assist
Device
Katherine R. Whitehouse, MPH, Divya Avula, None,
Devan Costelle, ARNP, MSN, Christina L. Dunbar-Matos, DO,
Jaimin R. Trivedi, MD, MPH, Mark S. Slaughter, MD; Department of
Cardiovascular and Thoracic Surgery, University of Louisville, Louisville,
KY, USA
Study: Patients with left ventricular assist devices currently require longterm anticoagulation with Warfarin. Warfarin requires frequent blood
tests and is associated with adverse events when not in the therapeutic
range. Eliquis is a possible alternative which is potentially better for compliance and requires no additional testing. The purpose of this study is to
compare adverse events in patients with a HeartMate 3 LVAD receiving
Eliquis versus Warfarin.
Methods: 35 patients underwent HM3 implantation between 01/01/2016
to 01/31/2021. The groups compared were Eliquis (n=15, 43%) and Warfarin (n=20, 57%). All patients received 325 mg aspirin daily. Stroke, bleeding, and death were identified as primary outcomes after LVAD implant.
Univariate nonparametric statistical analysis was performed.

Results: There was a statistically significant difference (p < 0.05) in platelet surface coverage rate on Ti6Al4V at a shear rate of 1000 s-1 vs. 400 s-1
(Table 1 and Figure 1b). Across all other material and ADP combinations,
there were no statistically significant differences across the two shear
rates. Mean aggregate sizes were greater with larger fluctuations on
Ti6Al4V surfaces with 5 nM ADP for a shear rate of 1000 s-1 than for 400
s-1, indicating embolization. Large fluctuations were also visible across
both shear rates with 10 nM ADP on Ti6Al4V but were absent with 0 nM
ADP and on ZTA surfaces with 10 nM ADP.

Results: The median duration of treatment with Eliquis was 148 days
(37–606 days). The groups were comparable in terms of age (56 v. 54
years, p=0.19), gender (male, 85% v. 75%, p=0.45), and renal function
(Cr 1.5 v. 1.4, p=0.79). The Eliquis group had significantly higher mean
pulmonary artery pressure (41 vs 34, p=0.03) and there were more (p
< 0.05) ischemic cardiomyopathy and INTERMACS profile ≥ 3 in the Warfarin group (Table 1). At 1 year, thrombotic complications and death were
not different between the groups (Table 2). The two deaths in the Eliquis
group were from right heart failure. The Eliquis group had clinically lower
rates of bleeding complications (5% v. 30%, p=0.1).
The adverse events of bleeding, stroke and death were similar in HM3
patients receiving Warfarin or Eliquis. Eliquis may be a safe alternative
anticoagulant therapy in HM 3 LVAD patients. Additional studies are
needed to confirm our findings.
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Influence Of Textured Surface Topography Parameters On Biological
Response As Target Application In VAD Inflow Cannula
Przemyslaw Kurtyka, Master of Engineering1,
Roman Major, PhD, DSc2, Maciej Gawlikowski, PhD1,
Marcin Kaczmarek, PhD, DSc3,
Roman Kustosz, Master of Engineering1; 1Laboratory of Artificial Heart,
Foundation of Cardiac Surgery Development, Zabrze, Poland, 2Institute
Of Metallurgy and Materials Science, Polish Academy Of Sciences,
Krakow, Poland, 3Faculty Of Biomedical Engineering, Silesian University Of
Technology, Zabrze, Poland.

Platelet Microparticles Paradoxically Promote Thrombin Generation
While Inhibiting Platelet Aggregation
Samuel M. Miller-Gutierrez, BS1, Yana Roka-Moiia, PhD1,
Krisha Avalani, None1, Jawaad Sheriff, PhD2,
Danny Bluestein, PhD2, Marvin J. Slepian, MD1; 1Department of Medicine
and Biomedical Engineering, University of Arizona, Tucson, AZ, USA,
2
Department of Biomedical Engineering, Stony Brook University, Stony
Brook, NY, USA
Study: Increasingly, mechanical circulatory support (MCS) has been
recognized as being hampered by a coincident paradox of thrombosis
and bleeding (MCS). Platelet dysfunction resulting from MCS hypershear
stress plays a major role in this device-related coagulopathy. Previously
we demonstrated that MCS hypershear exposure promotes platelet
proapoptotic behavior and extensive generation of platelet-derived
microparticles (PDMPs). Here, we characterize PDMPs as to their effect on
platelet hemostatic function.
Methods: PDMPs were derived from human platelets after shear stress
and sonication. PDMP surface receptors GPIb, αIIbβ3, and P-selectin were
characterized by flow cytometry. Fluorescent nanobeads SPHEROTM were
used as size standard. Prothrombinase activity was evaluated by chromogenic thrombin generation assay. ADP mediated platelet aggregation in
plasma was assayed via light-transmission aggregometry.
Results: PDMPs demonstrated increased levels of adhesion receptors
αIIbβ3, P-selectin, and GPIb. Strikingly, the surface expression of αIIbβ3
and P-selectin on PDMPs exceeded that of platelets by 400% and 900%,
respectively. PDMPs promoted factor Xa activation of prothrombin
alone; or synergistically with resting or ADP-activated platelets (Fig. 1A).
Simultaneously, incubation of platelet-rich plasma with PDMPs resulted in
a 14% decrease of platelet aggregation amplitude induced by ADP compared with control (Fig. 1B). Our data reveal the concomitant dual role of
PDMPs in platelet hemostatic function - i.e promoting thrombin generation while inhibiting platelet aggregation. PDMP promotion of thrombin
generation stimulates clotting. Conversely, PDMPs enriched adhesion
receptors concurrently appear to block platelet-platelet interactions thus
impairing platelet aggregation. Our findings underscore the role of PDMPs
as central actors in device-related coagulopathy, paradoxically promoting
both a thrombotic and bleeding phenotype.

Study: In MSC clinical experience a positive effect of various surface
modifications was observed, and above all, the ability to control tissue
ingrowth in the context of the external surfaces of the inflow cannula. In
comparison smooth surface of the cannula results in tissue overgrowth
into the lumen flow and may be a source of emboli.
Methods: The paper presents the influence of different topographic properties to the biological response including in vitro and in vivo trials. The
aim is to obtain textured surfaces, which will stimulate cells for proliferation resulting in scar tissue formation to reduce inflammatory processes
and risk of pump emboli. In the first stage various surface configurations
of the Ti6Al7Nb obtained with the Vacuum Sintering technology were
characterized. During the process parameters such as size and shape of
powder grains were changed. Surfaces were characterized by wettability,
profilometry, digital microscope and scanning electron microscope. Then
cell culture was carried out using fibroblasts to exclude a cytotoxic effect
of the surface modifications and to determine cells proliferation. The
implantation using rabbits as a model within the in vivo trails included histological assessment and evaluation of tissue-implant adhesion strength.
Results: The results have shown that surfaces are characterized by
roughness in the range of Ra=14–35µm, porosity in range 44–74% and
wettability ≈100°. The cross section images revealed complex 3D morphology. Whereas SEM images highlighted the presence of empty micro
spaces that may stimulate cell growth. The material has not shown any
cytotoxic effects, and strength of the adhesion of the muscle tissue to the
sample was in range 2-5N. The surfaces presented potential to stimulate
cardiomyocytes to grow due to complex 3D morphology, high degree of
roughness and porosity.
Project supported by: National Science Centre, Poland: 2018/31/N/
ST8/01085 and NCBiR: RH-ROT/266798/STRATEGMED-II
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Demonstrating The Synergistic Effects Of Shear And Surface Roughness
Profile On Thrombosis In VADs
Anjana Jayaraman, BS1, Junhyuk Kang, BS2, James F. Antaki, PhD3,
Brian J. Kirby, PhD2; 1Chemical and Biomolecular Engineering, Cornell
University, Ithaca, NY, USA, 2Mechanical and Aerospace Engineering,
Cornell University, Ithaca, NY, USA, 3Biomedical Engineering, Cornell
University, Ithaca, NY, USA
Study: In VADs, pathological shear is known to enhance thrombosis. Their
Ti-alloy surfaces are often roughened on the micron scale accidentally
during manufacture or deliberately for biocompatibility; however, little
is known on how surface roughness affects thrombosis. Delineating the
combined effects of shear and surface roughness on thrombosis is critical
to future VAD design.
Methods: This study used microfluidic devices with roughened Ti6Al4V
surfaces to create shear-controlled, clinically relevant micro-scale environments to quantify thrombosis via platelet aggregation. Ti6Al4V surfaces
were roughened using diamond microparticles of various diameters. A
blood analog of hemoglobin-depleted red blood cells and platelet-rich
plasma with fluorescent mepacrine-labeled platelets, was perfused
through the microdevices. Two surface roughness levels were used:
mirror finish, and surfaces roughened by 6–12 µm particles. For both
roughness degrees, three shear rates were used: 400, 1000 and 2000 s-1.
Platelet aggregation was visualized with fluorescent microscopy and total
aggregate area was obtained from processed images.

Results: In Figure 1, blue, orange and purple markers represent shear
rates of 400, 1000 and 2000 s-1 respectively, and Figures 1 and 2 reflect
deposition on mirror finished and 6–12 µm particle-roughened surfaces
respectively. At 2000 s-1, percentage of total surface covered by platelet
aggregates was high at all roughness levels. At all three shear rates,
when surface coverage exceeded ~2%, large fluctuations were observed,
indicating the embolization of larger aggregates. In the latter half of the
perfusion time at 2000 s-1, the surface coverage percentages fluctuated
more on the roughened surface than on the mirror finished surface, with
maximum peak-to-peak amplitude 1.5 times higher on the rough surface.
This demonstrates that pathological shear and surface roughness combined lead to thrombus embolization.
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The Use Of Veno-Venous Extracorporeal Support To Rescue Patients
Who Experience Respiratory Failure Following General Thoracic Surgery
Ernest G. Chan, MD, MPH, Erin R. Feeney, MD, Eric J. Hyzny, BS,
Raj G. Ramanan, MD, Holt G. Murray, MD, James D. Luketich, MD,
Pablo G. Sanchez, MD; University of Pittsburgh Medical Center,
Pittsburgh, PA, USA

Association Of Caloric Intake And Mortality During Veno-Arterial
Extracorporeal Membrane Oxygenation In Adults
Ander Dorken Gallastegi, MD1, Anthony Gebran, MD1,
Leon Naar, MD1, Apostolos Gaitanidis, MD1,
Renee Reynolds, RD, CNSC2, Rachel A. Weiss, BS, RD, CNSC2,
Jessica R. Witchey, BS, RD, CNSC2, Amy L. Wourms, BS, RD, CNSC2,
Donna M. Belcher, MD2, Kerry Breen, BS1, Lydia Maurer, MD3,
Adam A. Dalia, MD4, Haytham M. Kaafarani, MD, MPH1,
George Velmahos, MD, PhD1, April E. Mendoza, MD, MPH1; 1Trauma
Emergency Surgery Surgical Critical Care, Massachusetts General
Hospital & Harvard Medical School, Boston, MA, USA, 2Clinical Nutrition,
Massachusetts General Hospital & Harvard Medical School, Boston, MA,
USA, 3Department of Surgery, Massachusetts General Hospital & Harvard
Medical School, Boston, MA, USA, 4Anesthesia, Critical Care and Pain
Medicine, Massachusetts General Hospital & Harvard Medical School,
Boston, MA, USA

Study: Postoperative acute respiratory distress syndrome (ARDS) following a general thoracic procedure is associated with high morbidity
and mortality. Extracorporeal membrane oxygenation (ECMO) offers an
alternate means of cardiopulmonary support in the setting of refractory
respiratory failure. We report indications and outcomes patients who
after complex general thoracic surgery who developed ARDS requiring
ECMO support.
Methods: We performed a retrospective analysis of all patients requiring
ECMO support in the post-operative period following a general thoracic
surgical procedure from January 2003-December 2019. Exclusion criteria
include those who underwent a cardiac procedure, cardiothoracic transplantation, or required ECMO only for intraoperative support.
Results: 44 instances of postoperative VV ECMO were utilized in 41
patients who underwent a surgery with the thoracic surgical service.
Esophageal procedures were the most common index operations performed (42.8%) followed by lung resection (33.3%). Median time to ECMO
initiation from the index operation was 10 days (range 1 day to 28.9
months). Median length of ECMO support was 8.29 days (range 18 hours
to 31 days). Majority of patients were cannulated in an urgent (71.43%)
or emergent (23.81%) fashion. ECMO related complications included
bleeding in 8 patients. 30-day survival was 69.1% for the entire cohort
and 54.7% of patients discharged from the hospital. Of the patients with
adequate follow-up of 90 days, 90.48% of patients who were discharged
were still alive.

Study: Evidence for the optimal amount of nutritional caloric delivery
during veno-arterial extracorporeal membrane oxygenation (VA-ECMO)
is inconclusive. The aim of this study was to describe the relationship
between caloric intake during VA-ECMO support and 30-day mortality.

Methods: Adult patients who received VA-ECMO for ≥5 days between
2015 - 2019 at a quaternary referral center were included. Caloric goal
was calculated as 25 kcal/kg/d. Three categories were defined based
on the cumulative caloric goal met throughout ECMO support: very-low
caloric intake (VCI, <20% goal); hypocaloric nutrition (HN, 20–50% goal)
and higher caloric intake (HCI, >50% goal). Multivariable cox regression
was used for 30-day survival adjusting for age, SOFA score and reason for
ECMO.

Conclusion: Extracorporeal membrane oxygenation is a safe and viable
means of cardiopulmonary support that can provide a survival advantage
for patients who experience severe refractory respiratory failure following
a complex general thoracic surgery.
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Impact Of Tracheostomy In Patients Receiving VV ECMO
Joel C. Boudreaux, BS1, Marian Urban, MD, PhD2,
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Study: Veno-venous extracorporeal membrane oxygenation (VV ECMO) is
utilized for critically ill patients with respiratory failure. Given that these
patients often require extended periods of ventilation, we examined the
role of tracheostomy on outcomes of patients supported with VV ECMO.
Methods: We conducted a retrospective review of all patients at our
institution who received VV ECMO between 2016 and 2020. Patients were
divided into two groups based on whether they received a tracheostomy
while on ECMO. Demographics, baseline characteristics, and outcomes
were collected, reviewed and summarized. The primary outcome measure was survival to hospital discharge. Secondary outcome measures
included length of ICU and hospital stay, as well as adverse events related
to the tracheostomy procedure. Multivariable analysis was performed to
identify predictors of in-hospital mortality. Patients receiving tracheostomy were divided into an “early” and “late” tracheostomy group based
on median days to tracheostomy following ECMO cannulation and separate outcomes analysis was performed.
Results: 150 patients met inclusion criteria, 32 received a tracheostomy.
Discharge survival was similar amongst the groups, no tracheostomy
57.5%, tracheostomy 53.1% (p=0.658). Predictors of mortality on multivariable analysis included RESP score (Odds Ratio [OR] 0.831, p=0.015),
and BUN (OR 1.026, p=0.011). Tracheostomy performance was not predictive of mortality (OR 0.837, p=0.658). Bleeding requiring intervention was
the most common complication after tracheostomy, occurring in 18.7%
of patients. Early tracheostomy (less than 7 days after ECMO initiation)
resulted in shorter ICU (25 vs. 36 days, p=0.043) and hospital (33 vs. 47,
p=0.017) length of stay. Conclusions: Tracheostomy can be performed
safely in patients receiving VV ECMO. Mortality in VV ECMO patients is
predicted by severity of underlying disease. Performance of tracheostomy
does not impact survival. Early tracheostomy may decrease length of stay.

Results: Analysis included 97 patients and 968 days of VA-ECMO support. VCI, HN and HCI groups included 47 (48%), 40 (41%) and 10 (11%)
patients respectively. Full daily caloric goal was met only on 53 days by
23 patients while none of the patients met the cumulative caloric goal
throughout the ECMO run. Enteral formula was the major energy (62%)
and protein (91%) source in all groups. There was a bimodal relationship
between percent cumulative caloric goal met and 30-day mortality where
the mortality nadir was seen in patients receiving 50% of their caloric
goal (Figure 1). Patients in the HN group had a significantly lower 30-day
mortality rate compared to the VCI group (HR: 0.454, p= .032) (Figure 2).
The difference in 30-day mortality between the HN and HCI groups did
not reach statistical significance although the analysis was limited by the
sample size of the HCI group. In-hospital complication rates were similar
in the 3-groups (Table 1). In conclusion, caloric intake and mortality had
a bimodal relationship where HN was associated with significantly lower
mortality compared to VCI. Conventional caloric goal definitions (25 kcal/
kg/d) may not be applicable nor practically achievable during VA-ECMO.
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It’s Not Only The Pump: Assessment Of Human Factors Of Wearable
Components And User Experience Of Patients With Left Ventricular
Assist Devices
Thomas Schlöglhofer, MSc1, Anna-Sophie Grausenburger, None1,
Lisa Haberl, None2, Harald Schwingenschlögl, None2,
Alexandra Schmied, MSc2, Sarah Muigg, None2,
Wolfgang Suda, None2, Johann Horvat, None2,
Francesco Moscato, PhD3, Daniel Zimpfer, MD2,
Heinrich Schima, PhD1; 1Department of Cardiac Surgery, Center for
Medical Physics and Biomedical Engineering, Medical University of
Vienna, Vienna, Austria, 2Department of Cardiac Surgery, Medical
University of Vienna, Vienna, Austria, 3Center for Medical Physics and
Biomedical Engineering, Medical University of Vienna, Vienna, Austria.

Impact Of Outpatient Cardiac Rehabilitation On Patient Health Status In
Left Ventricular Assist Device Patients
Laura Coyle, APRN-BC1, Colleen Gallagher, BSN1, Laura Rosner, BSN1,
Pam Dooley, MSN1, Mark Parson, BSN1, Gardner Yost, MD2,
Sunil Pauwaa, MD1, Antone Tatooles, MD1; 1Advocate Christ Medical
Center, Oak Lawn, IL, USA, 2University of Michigan, Ann Arbor, MI, USA
Study: Left ventricular assist device (LVAD) implantation effectively
improves hemodynamic performance, however these patients still have
many of the peripheral pathological changes present in end stage heart
failure. The available evidence for exercise training to improve exercise
capacity, functional and nutritional status, and quality of life in LVAD
patients is limited. We examined patient health status (PHS) before and
after cardiac rehab (CR), barriers to participation, and its clinical safety.
Methods: A retrospective analysis was performed on 57% (27/47) of
patients (median age 56 ± 15 years, 89% male) who attended outpatient
CR between 5/1/2018 and 2/1/2020 at our center. PHS was assessed
by comparing exercise time, 6-minute walk test (6MWT), gait speed,
New York Heart Association (NYHA) classification, hand grip strength,
body mass index (BMI), mini nutritional assessment (MNA), dietary
fat screener, patient health questionnaire-9 (PHQ-9), and Dartmouth
cooperative functional assessment (Dartmouth COOP) before and after
completing a 12-week CR program. Clinical demographics, adverse events,
and cause for premature termination of CR were documented.
Results: Median time from implant to CR was 209 ± 189 days, with 90 ±
18 days in CR, to average 28 ± 7 sessions. There were significant improvements in PHS (Table 1) and 0.4% (3/749 sessions) adverse events. 43%
(20/47) of patients did not complete CR: 6 medical complexities, 6 conflict
of interest, 3 childcare issues, 3 COVID-19 concerns, 1 return to work, and
1 lacked referral. Outpatient CR provides an opportunity for LVAD patients
to safely receive supervised, high-quality exercise interventions that
significantly improve overall patient health status. Despite improvements
in exercise capacity, muscular strength, functional status, and quality of
life, there was no difference in nutritional status or weight loss after a
12-week CR program.

Study: Despite design improvements in left ventricular assist devices
(LVADs) over the past decade, limitations of external, wearable components affect patient quality of life. The aim of this study was to describe
both user experience and human factor issues of two contemporary
LVADs.
Methods: This single-center, cross-sectional study of LVAD outpatients
who were at least 3 months post-LVAD implantation was conducted from
July to October 2020. Before developing a 16-item survey (multiplechoice and 4-point Likert scale), a literature review and 2-round Delphi
method involving 9 VAD clinicians were used to generate and select items
in 6 domains: power supply, emergency or challenging situations, wearability, mobility and freedom to travel, user modifications, lifestyle and
housing adaptations.
Results: 58 patients (Age: 61.6±1.5yrs, female: 13.8%, HM3/HVAD:
n=39/19) completed the one-time survey after a median of 853 days
on device. 10.3% reported problems changing power supply and 21.1%
unintentionally disconnected the driveline (HVAD: 26.3% vs HM3: 5.6%,
p=0.041), but only 13.5% felt unprepared for possible technical emergency situations, consequently 84.6% think equipment retraining was
not necessary. Against the recommendation 74.1% sleep with batteries
(HVAD: 44.4%, vs HM3: 88.9%, p=0.001). Weight and size of the transport
bag was criticized by 65.3% (HVAD: 50.0% vs HM3: 71.4%, p=0.035), thus
24.1% wear an own carrying system, 38.9% adapted their clothing to
wearable peripherals, 42.1% modified parts of their wearables and 65.3%
even had to adapt their housing to cope with life on LVAD support. 66.7%
still drive a car themselves (HVAD: 88.9% vs HM3: 56.4%, p=0.018), but
mobility is reduced due to limited wearability: only 18.9% went abroad
(3.7% by plane) and 40% use less public transport than before implantation. To conclude, HVAD and HM3 wearables still have many human
factors issues and potential for improved user experience.
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Prophylactic Antibiotic Therapy For Prevention Of Driveline Infections
Colleen LaBuhn, APNP, Vika Kagan, APNP, Karen Meehan, APNP,
Justin Okray, PA-C, Shana Creighton, APNP, Anna Chinco, RN,
Katie O’Halloran, APNP, Jon Grinstein, MD, Sean Pinney, MD,
Valluvan Jeevanandam, MD; University of Chicago Medical Center,
Chicago, IL, USA

There Is Only One Time To Get It Right: Establishing An Ex Vivo Lung
Perfusion Program Using The Organ Care System
Blaine Johnson, CCP1, Jamie Bucio, EMT2, Ana Fonceva, MS2,
Daniel Rodgers, BS2, Kelli Hu, None2, Hidefumi Nishida, MD2,
David Onsager, MD2, Takeyoshi Ota, MD, PhD2,
Valluvan Jeevanandam, MD2, Tae Song, MD2; 1Perfusion Services,
University of Chicago Medicine, Chicago, IL, USA, 2Department of Surgery,
University of Chicago, Chicago, IL, USA

Study: Driveline infections in patients with left ventricular assist devices
(LVAD) have long been an adverse event that has been difficult to eliminate. Driveline infections lead to an increased morbidity and mortality
and a decrease in quality of life for patients. This review served to determine if using antibiotics as prophylactic therapy can affect infection rates
and increase survival in patients who have had trauma or manipulation
of the driveline. Trauma or manipulation can consist of a controller drop,
driveline tug.
Methods: A retrospective chart review was done at a large academic
medical center. We reviewed all patients implanted with an LVAD within
the past 5 years. Patients were divided by infection vs non-infection;
patients were then evaluated by who was treated with prophylactic
antibiotic therapy and who developed an infection post antibiotic therapy
compared to patients that developed an infection with no prophylactic
therapy. We then reviewed survival rates within that cohort of patients.
Results: A total of 258 patients were evaluated for driveline infection. Of
those, 73 (28%) patients had developed a driveline infection. Of those
73, 62 (84%) were not treated with prophylactic antibiotic therapy and
11 (15%) received prophylactic antibiotics. Mortality within the group of
patients with no prophylaxis therapy was 25 (40%) vs 1 (9%) p=0.03 in the
patients that were treated with prophylaxis antibiotic therapy.

Study: Lung transplantation is a well-established life-saving treatment
for end-stage respiratory failure patients who do not respond to other
medical or surgical interventions. However, donor lung availability
remains a primary constraint to transplantation. The Organ Care System
(OCS) (TransMedics, Andover, MA) is one type of ex vivo organ perfusion technology that can expand the donor pool while reducing organ
recovery time limitations. Establishing a program of this magnitude can
be challenging and requires thoughtful interdisciplinary collaboration. We
present our single-center initial experience in establishing an OCS lung
program. To our knowledge, this is the first report of such a study.
Methods: The interdisciplinary team involved in each OCS Lung recovery
from May 2019 to January 2021 (n=23) participated in an email-based
debriefing. A multidisciplinary team of transplant coordinators, surgeons,
and perfusionists retrospectively reviewed each case and completed root
cause analyses and corrective action when necessary. We also annually
reviewed the process of establishing our OCS lung program to document
specific challenges and benefits. We constructed four main themes from
the qualitative analysis: clinical protocols, strategic restrictions, administrative needs, and operational aspects.
Results: A total of 70 debriefing responses were received and reviewed,
with three to five personnel contributing after each recovery. In total, the
debriefing responses contained 90 unique issues. Thematic categorization
revealed that most challenges occurred outside of the recovery process.
We provide documentation of the specific components in each area identified (Table 1,2). This study demonstrates that a framework for establishing a program of this magnitude requires a concerted interdisciplinary
effort to succeed. This qualitative review provides insight that can assist
other institutions seeking to establish an ex-vivo lung perfusion program.
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Topical Tranexamic Acid Application For Refractory Epistaxis In Patients
Supported On Left Ventricular Assist Device Therapy
McKenna Schimmel, BS1, Sarah Schettle, PA-C2,
Lindsay Moreland-Head, PharMD3, John Stulak, MD2,
Andrew N. Rosenbaum, MD4; 1University of Vermont Medical Center,
Burlington, VT, USA, 2Department of Cardiovascular Surgery, Mayo Clinic,
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Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic,
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VAD Patient Adjustment: Personal Perceptions Related To The VAD
Driveline & External Components
Brittany D. Rhoades, PhD1, Joan C. Engebretson, PhD2,
Rebecca L. Casareza, PhD2,
Jennifer E. Sanner Beauchamp, PhD2; 1Cardiothoracic Transplant
Program, Baylor St. Luke’s Medical Center, Houston, TX, USA, 2Cizik School
of Nursing, The University of Texas Health Science Center at Houston,
Houston, TX, USA
Study: Ventricular Assist Devices (VADs) create unique challenges and
complexities due to the external equipment. The purpose of the study
was to explore the VAD patient experience and describe how patients
construct the impact of the VAD, including driveline and external components, on daily life and self-care.
Methods: The study used a general qualitative methodology with a
purposeful sampling of 20 VAD recipients. Interviews were transcribed.
Data were analyzed via content analysis and managed with Atlas.ti V8.
Researchers achieved redundancy, identified themes, and provided
exemplars.
Results: VAD participant’s perceptions of the VAD driveline and external
components were very impactful to the patient adjustment process. Additionally, the participant’s perceptions of how others regarded the device
and external components were significant to one’s self-concept and
influenced daily life. Wearables and accessories (e.g., belts, vests, pants,
bags) that manage the external equipment had the potential to positively
or negatively impact the participant’s self-confidence, personal perception of safety, and daily activities. Some participants that chose to wear
the VAD equipment outside of clothing perceived others to regard the
equipment as a public safety and security risk. Participants also expressed
various situations where they were detained at a security checkpoint,
asked to remove the device from their body, or were observed suspiciously by police. Additional influences on adjustment included conflicting
perceptions of what activities they could participate in due to the device.
These perceived limitations often created psychological side effects and
hindered individuals from achieving normalcy. Learning how to manage
external equipment and trying various wearables can be time-consuming
and costly. This study demonstrates the need for best practice guidelines
and recommendations for managing VAD external components to optimize VAD adjustment.

Study: Mucosal bleeding is common in patients supported on continuous flow left ventricular assist devices (CF-LVADs). Although standard
local therapies are often utilized, there is scant data on use of topical
tranexamic acid (TXA) for refractory epistaxis in this population.
Methods: All patients implanted with continuous flow LVADs between
2007 and 2019 at a single institution were evaluated. Retrospective chart
review was utilized to identify patients treated with topical TXA for epistaxis, and descriptive statistics were applied.
Results: Ten patients treated for epistaxis with topical TXA were identified
(mean age 62 ± 13 years, 20% female, 70% HeartMate II, 30% HeartWare).
All patients had prior episodes of epistaxis and TXA was administered at
3.1 ± 1.7 years after implant. Mean hemoglobin on presentation was 9.1
± 4.1 g/dL, platelet count 167 ± 77 x109/L, and INR 2.7 ± 1.5 (mean goal
2.1–2.8). Three patients were on no aspirin, four were on 81 mg daily,
and three were on 325 mg daily. Three were being actively treated for
hemolysis with intravenous anticoagulation and antiplatelet therapy (tirofiban). Three patients required transfusion of two units of red blood cells.
Among the most common adjunctive therapies, 90% were treated with
oxymetazoline spray, 60% underwent nasal packing, and 30% were treated
with rose geranium spray. No patients developed new hemolysis or pump
thrombosis after topical TXA administration. 90% later experienced recurrent epistaxis. TXA may be a short-term adjunctive agent for refractory
epistaxis among patients supported on CF-LVAD therapy, and no pumprelated adverse effects were seen. Further work should elucidate the role
of TXA prospectively in the management of CF-LVAD associated epistaxis.
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Novel Approach To LVAD Education For Patients And Caregivers During
COVID-19
Chrystine L. Black, RN, BSN, Kirk L. Nelson, MS,
Lisa M. Fowler, MS, Patrick B. Prestemon, RN,
Christina A. Cheyne, MS; Advanced Heart Failure, VAD Team, UR
Medicine, University of Rochester Medical Center, Rochester, NY, USA

Mentorship Matters: An Assessment Of An Interdisciplinary Student
Mentorship Model In A Robust Clinical Research Program
Kelli Hu, BA, Yena Jang, BA, Umar Siddiqi, BA,
Corinne Stonebraker, BA, Daniel Rodgers, BS,
Pamela Combs, PhD; Cardiac Surgery, University of Chicago Medicine,
Chicago, IL, USA

Study: In March 2020, a novel method of Left Ventricular Assist Device
patient and caregiver education was implemented due to COVID-19 visitor restrictions.
Methods: LVAD training was restructured to utilize the UR Medicine VAD
resources website (www.vadresources.urmc.edu,) from the “evaluation
for LVAD” phase, through the “preparation for discharge” phase. LVAD
education aimed to foster independence with equipment, power and
alarm management, and driveline dressing changes. Short daily sessions
at the bedside were completed prior to discharge. Patients were taught to
change their own driveline dressings by bedside RN staff. They demonstrated proficiency with education by live demonstration and completing
a “patient review” test, tracked in the electronic medical record. Caregivers were required to complete remote LVAD education if able, using the
website. Some caregivers required additional educational materials be
sent by mail, including the Abbott “LVAD Patient Education Program”
DVD. Rarely, a caregiver not able to use the website, attended a single
training session in the Advanced Heart Failure clinic. Rare driveline dressing training was also conducted in the clinic, using a CPR mannequin with
a foley catheter mimicking driveline placement.
Results: 62 of the 81 LVAD implants from 2020 were done during visitor
restrictions. 55 of the 62 survived to discharge with an average length of
stay of 22 days. Utilizing short daily educational sessions for hospitalized
patients, and offering needs-based learning for caregivers yielded benefit
to patients, caregivers, RN staff, and VAD coordinators. Improvement in
patient retention was seen on review tests and greater patient independence resulted. Patients appreciated more review time with shorter,
less exhausting sessions that reduced interruption on nursing activities.
Remote learning benefitted caregivers by offering convenience and
reduced loss of work days and travel expenses.

Study: Despite the widespread study of mentoring and its proven benefits
in academic and organizational contexts, the impact of interdisciplinary
mentorship on clinical research remains unclear. We sought to analyze
a single center’s multidisciplinary ambassadorship program in order to
identify unique elements of a mentorship model that can lead to the
significant growth of a clinical research initiative and contribute to the
effective mentorship of the next generation of researchers and healthcare
professionals.
Methods: We utilized a multi-analysis approach to analyze the strength
of a mentorship program in a large academic medical institution. We collected quantifiable and qualitative data by comparing pre- and post-program research output and by surveying all alumni and research students
about their experiences.
Results: Within three years of the program’s conception (2017–2020),
the number of active studies significantly increased by 633% (3 to 22),
research team personnel increased by a factor of 4 (2 to 8), and the total
number of grants awarded to the program increased from 0 to 4, with
$28,000 received in 2020 alone. Furthermore, the number of manuscripts
published per calendar year skyrocketed from 10 in 2016 to 52 in 2020.
Program students represent geographical diversity from 7 different states,
with their matriculation spectrums ranging from undergraduates to surgical residents (n=11). Students are currently working on an average of 2.9
projects (ranging from 1–7), and 9 students (82%) are published authors
of an abstract or manuscript. All students were mentored by cardiac
surgeons, thoracic surgeons, heart failure specialists, nurses, and clinical
research coordinators, and all agreed that program mentors provide
opportunities to learn more about their discipline.
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Ensuring VAD Educational Opportunities For Staff During COVID-19: A
New Platform For Education
Janice Camuso, BSN1, Katherine Milley, BSN1, Tara Logan, BSN1,
Alexandra Anthony, BSN1, David D’Alessandro, MD2,
Van-Khue Ton, MD3, Erin Coglianese, MD3, Sunu Thomas, MD3,
Linda Irwin, MSN1; 1Transplant Center, Massachusetts General Hospital,
Boston, MA, USA, 2Cardiac Surgery, Massachusetts General Hospital,
Boston, MA, USA, 3Heart Failure, Massachusetts General Hospital, Boston,
MA, USA
Study: VAD programs are mandated by The Joint Commission to ensure
that staff have VAD education and competency training. In 2020 VAD
programs were challenged during the COVID-19 pandemic due to the
inability of staff to meet in-person. VAD programs needed to create
virtual platforms to ensure that staff were trained.
Methods: The Massachusetts General Hospital (MGH) VAD Program in
collaboration with MGH Norman Knight Nursing Center for Clinical and
Professional Development created 3 virtual platforms for training: VAD
Awareness (for employees), VAD Educated (for nurses), and VAD 101 (for
providers). Presentations were recorded on Zoom video conferencing and
posted on a learning system where staff were assigned to take a course.
Pre and post tests were given, and nurses could obtain nursing contact
hours (CEUs). Presentations were also housed on a VAD Share Point site;
accessible via computer and smart phone.VAD education was held via
video conference during the pandemic. Remote access enabled staff to
take classes which were previously held in-person allowing for continuing
education and CEUs. Staff attendance varied from 10–50 attendees per
session and evaluation forms revealed a high success rate. Staff who were
unable to attend and who would have missed sessions, now had the ability to enroll when convenient. A clinical library of courses was created and
assigned for staff to prove compliance with annual education.
Results: VAD programs can ensure training compliance despite the
COVID-19 pandemic by using virtual platforms and clinical libraries.
Coordinating efforts with the nursing education department offers an
opportunity for Joint Commission survey readiness - further expanding
access to educational opportunities.
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Bridging Failing Fontan Patients To Heart Transplantation—Successful
Development Of A Novel Cannula For Sub-pulmonary Mechanical
Circulatory Support
Ares K. Menon, MD1, Eugen Sandica, MD2,
Bart Meyns, MD, PhD3, Woehling Thomas, Master of Engineering1,
Heike Brockmann, Master of Engineering1,
Nils LeCerf, Master of Engineering1, Albena Tepavicharova, MD1,
Sven Hansen, MSc1, Joachim Photiadis, MD, PhD4,
Daniel Zimpfer, MD, MPH5, Michael Huebler, MD, PhD6,
Fabrizio DeRita, MD7, Hakan Akintuerk, MD, PhD8,
Kim Schlueter, MD1; 1Berlin Heart GmbH, Berlin, Germany, 2HDZ Bad
Oeynhausen, Bad Oeynhausen, Germany, 3Cardiac surgery, UZ Leuven,
Leuven, Belgium, 4DHZB, Berlin, Germany, 5AKH, Vienna, Austria, 6Pediatric
Cardiac Surgery, UKE, Hamburg, Germany, 7Pediatric Cardiac Surgery,
NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 8Pediatric
Cardiac Surgery, Pediatric Heart Center, Giessen, Germany.

Alteration In Cerebral Blood Flow During Pediatric Continuous Flow
Ventricular Assist Device Use
Kristen Nelson McMillan, MD1, Sarah Kane, CPNP-AC2,
Chelsea Kriesberg, CPNP-AC2, Cynthia Urbas, CCP2,
Narutoshi Hibino, MD, PhD2, Luca Vricella, MD2,
Rebecca Riggs, MD3; 1Pediatric Cardiac Critical Care, Advocate Children’s
Heart Institute, Oak Lawn, IL, USA, 2Advocate Children’s Heart Institute,
Oak Lawn, IL, USA, 3Pediatric Neuro Critical Care, Doernbecher Children’s
Hospital, Portland, OR, USA
Study: Alterations in blood flow of central retinal vessels (CRVs) detected
by Doppler ultrasonography are reflective of changes in cerebral blood
flow due to changes in intracranial pressure or poor cardiac output (Figure 1). There is continuity of the optic nerve sheath and the subarachnoid
space where cerebral spinal fluid freely flows and hemodynamic alterations of the distal most CRVs are directly reflective of changes in cerebral
perfusion. Patients on continuous flow ventricular assist devices (VAD)
have variable pulse pressure based on native heart function. However,
evaluation of cerebrovascular pressure has not been well studied in this
population and how native hemodynamics may impact long term cerebrovascular indices. Our preliminary data demonstrates potential clinical
value of studying Doppler waveforms of the distal CRVs within the optic
nerve sheath.

Study: Successful surgical palliation in children with a single ventricle
morphology (SV) led to an increasing number of patients suffering
from failing of the Fontan circulation. The absence of a sub-pulmonary
(SP) ventricle, leads to protein-losing enteropathy, hepatic and renal
dysfunction, and plastic bronchitis. The only therapeutic option is a heart
transplantation as a systemic ventricular assist device (VAD) is often not
enough to better end-organ function. The aim was to design a novel
venous cannula (VC) as an additional component of the EXCOR-VAD™ to
enable standardized sub-pulmonary (SP) mechanical circulatory support
(MCS).
Methods: Based on published successful surgical case series, a VC for
SP support as an additional component of a para-corporeal VAD (Berlin
Heart EXCOR™) has been designed. The VC is connecting the upper and
lower Vena cava and leads the blood flow to the EXCOR pump which is
connected to the pulmonary artery. The VC will facilitate a standardized
implantation of a SP VAD in SV patients for the first time. The device will
be able to provide supra-physiological and pulsatile pulmonary blood
flow and decongest the venous system. In several steps, the VC was flow
optimized in terms of Computerized Fluid Dynamics (CFD) in terms of
diameter and angulation and went through several animal studies and a
final virtual fitting based on magnet resonance imaging data of palliated
SV patients. The device can be used for SP support alone or in combination with a systemic VAD.
Results: The final design of the VC reflects the special requirements of
the complex anatomy of Fontan patients and enables a standardized
implantation for SP MCS. The VC recently gained CE approval and an
observational, prospective, international, multicenter, non-randomized
registry is planned to observe the clinical outcome of the patients in a
bridge-to-transplant setting.

Methods: Using a GE Logiq E ultrasound 10–22 MHz linear array probe,
we obtained non-invasive ophthalmic Doppler ultrasound images on 2
teenage patients with left VADs. One patient received a heart transplant
during the study period and we continued to obtain images posttransplant to document timeline of recovery of cerebrovascular pressure
waveforms.

Results: Both patients had significant vascular dilation, venous congestion, and collateralization of ophthalmic vessels (Figure 2). One patient’s
native cardiac function was enough to retain a degree of pulsatile flow in
ophthalmic circulation, showing less venous congestion and vascular dilation than her male counterpart with completely non-pulsatile flow (Figure
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3). The study team also obtained ophthalmic Doppler flow images of the
male 2 days and 10 days after he underwent a heart transplant (Figure3).
On day 2, the only differences in his ophthalmic ultrasound images were
return of pulsatile flow; however, at 10 days post-op, he no longer had
vascular dilation, venous congestion, and the collateralization was not
being utilized to the same degree (Figure 3).

Ventricular Assist Device After Pediatric Heart Transplant
Annemarie Krauss, MD1, Tara Pidborochynski, MSc1,
Holger Buchholz, MD2, Simon Urschel, MD1,
Mohammed Al-Akalabi, MD3, Paula Holinkski, MD4,
Jennifer Conway, MD1; 1Division of Pediatric Cardiology at the University
of Alberta, Stollery Children’s Hospital, Edmonton, AB, Canada, 2Division
of Cardiac Surgery at the University of Alberta in Edmonton, Alberta,
Canada, Stollery Children’s Hospital, Edmonton, AB, Canada, 3Division
of Cardiac Surgery, University of Alberta, Stollery Children’s Hospital,
Edmonton, AB, Canada, 4Pediatric Critical Care, University of Alberta,
Stollery Children’s Hospital, Edmonton, AB, Canada
Study: Implantation of a ventricular assist device (VAD) for early and late
graft failure after heart transplant (HTx) is a rare event in pediatrics. In the
last 5 years we have counselled families about the need for VAD in those
deemed high risk for graft failure (ex: high pulmonary vascular resistance
or single ventricle). In addition, we have taken an aggressive approach to
VAD early post-HTx to avoid the impact of right ventricular failure and low
cardiac output. Therefore, we sought to describe our single center experience with VAD support following HTx.
Methods: This is a retrospective analysis of all pediatric patients
implanted with a VAD following HTx between 01/05 - 12/20.
Results: There were 11 patients who underwent VAD insertion post-HTx
[45.5% male, median age 6.1 (IQR 3.9, 7.9) median weight 17.6 Kg (IQR
13.5, 24)]. The most common diagnosis was congenital heart disease
(n=8), followed by restrictive cardiomyopathy (n=2) and myocarditis (n=1).
Almost half (45.5%; n=5) were implanted after 2015 and 4/5 of these
patients had a plan for possible VAD insertion. Time of implant post-HTx
varied, with the median time being 0 days (IQR 0,11) and the longest
being 9.2 yrs. Early graft failure occurred in 9/11 patients (8 RVAD and 1
BiVAD), with 6 (5 RVAD and 1 BiVAD) implanted in the operating room.
There were 2 patients who required RVAD on day 2 and 11 post-HTx and
1 who was converted from ECMO to BiVAD on day 5. Two additional
patients underwent insertion for cardiac allograft vasculopathy (CAV) at a
median time of 5.7 yrs (IQR 2.2, 9.3) post-HTx. Total time on VAD support
was a median of 17 days (IQR 6, 115), with the longest being 478 days.
Over 60% of the patients were weaned from support or retransplanted
(n=7, 63.6%) with 4 (36.4%) dying or converted to ECMO.The outcome
of VAD support following pediatic HTx is encouraging. For those where a
need for VAD was predicted, outcomes were excellent (100% survival).
Unplanned insertion or those with CAV had worse outcomes. While these
results are promising, further work to verify these findings is needed.
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Novel Cannulation Strategies In Pediatric VAD Patients
Michael C. Monge, MD, Anna Joong, MD,
Allison Reichhold, APNP, Philip Thrush, MD; Ann & Robert H. Lurie
Children’s Hospital of Chicago, Chicago, IL, USA
Study: Variations in size, anatomy, and physiology of pediatric patients
presents challenges for ventricular assist device (VAD) placement. We
report cannulation of the left atrial appendage (LAA) in 2 patients, with
preserved left ventricular (LV) size and function and small left atrium (LA),
and use of a dilatable PTFE outflow graft in 3 patients.

t 3 is 5.5 kg with DCM with severely depressed LV function and mixed
mitral disease. Off-pump Left VAD was implanted, facilitated by a tapered
6mm dilatable PTFE graft secured to a 10-mm Berlin arterial cannula. Pt 4
is 12.5 kg with a history of partial atrioventricular septal defect, requiring
mitral valve replacement, admitted with mitral stenosis and decreased
LV function. Pt 4 underwent off-pump left VAD placement facilitated by
a 6-mm expandable ePTFE graft. Pt 5 is 12 kg with severe heart failure.
Off-pump VAD was implanted. 6-mm expandable ePTFE graft was used for
outflow cannulation, with partial aortic clamping only.
Results: 3 of 5 patients have been transplanted at 49, 68 and 202 days.
All transplanted patients are alive and doing well. 2 patients, supported
for 115 and 150 days, are awaiting transplant. No patient experienced a
thromboembolic event or surgical bleeding. There has been no reoperation for cannula obstruction, thrombus formation, or scarring.

Methods: Patient 1 (Pt 1) is 7.2 kg with histiocytoid cardiomyopathy with
preserved biventricular size and function but malignant arrhythmias. Pt
1 had bi-VAD placement with LV apical cannulation. 5 days later, inflow
cannula reconfiguration was required due to LV competition causing obstruction. LA was cannulated with a 10-mm ringed PTFE graft,
invaginated into the LAA, secured to a Berlin arterial cannula. Pt 2 is 30 kg
with history of heart transplantation for dilated cardiomyopathy (DCM)
complicated by graft vasculopathy, placed on ECMO for in-hospital arrest.
6 days later, bi-VAD was placed. Due to preserved LV size and function,
LAA was cannulated with a 14-mm ringed PTFE graft attached to a 9-mm
Berlin arterial cannula.
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New Quality Improvement Initiatives In Pediatric Heart Failure Through
The ACTION Collaborative Learning Network
Danielle S. Burstein, MD1, Joseph A. Spinner, MD2,
Chloe Connelly, MS3, Brian Feingold, MD, MS4,
Christopher Almond, MD, MS5, Kathleen Simpson, MD6,
Angela Lorts, MD7, David Rosenthal, MD5, Ryan Butts, MD8; 1Pediatric
Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA,
2
Pediatric Cardiology, Texas Children’s Hospital, Houston, TX, USA,
3
Pediatric Cardiology, Cincinnati Children’s, Cincinnati, OH, USA, 4Pediatric
Cardiology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA,
5
Pediatric Cardiology, Stanford Children’s Hospital, Palo Alto, CA, USA,
6
Pediatric Cardiology, Children’s Hospital of Colorado, Aurora, CO, USA,
7
Pediatric Cardiology, Cincinnati Children’s Medical Center, Cincinnati, OH,
USA, 8Pediatric Cardiology, Children’s Medical Center of Dallas, Dallas, TX,
USA

Contemporary Use Of Patient-Reported Outcomes (PROs) In Pediatric
VAD Recipients: Feasibility In Action
Lindsay J. May, MD1, Melissa K. Cousino, PhD2,
Lauren Smyth, Other3, Melissa McQueen, Other4,
Katherine Thompson, BSN1, Tiffany Hunter, BSN2,
Courtney Ventresco, BSN5, Katrina Fields, BSN3,
Jenna Murray, BSN6, Desiree S. Machado, MD7,
Farhan Zafar, PhD3, David N. Rosenthal, MD6,
Angela Lorts, MD3, Elizabeth D. Blume, MD5; 1Pediatrics, Primary
Children’s Hospital, Salt Lake City, UT, USA, 2Pediatrics, C.S. Mott Children’s
Hospital, Ann Arbour, MI, USA, 3Pediatrics, Cincinnati Children’s Hospital,
Cincinnati, OH, USA, 4Phoenix Children’s Hospital, Phoenix, AZ, USA,
5
Pediatrics, Boston Children’s Hospital, Boston, MA, USA, 6Pediatrics, Lucile
Packard Children’s Hospital at Stanford, Palo Alto, CA, USA, 7Pediatrics,
University of Florida Gainesville, Gainesville, FL, USA; Conclusions: Within
ACTION, use of electronic PROs is feasible among patients/parents at pilot
sites. Large scale data will help comprehensively assess symptom burden
and longitudinal QOL during VAD support.

Study: Due to the continued progress in improving outcomes in pediatric
ventricular assist device care, the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) learning collaborative has recently
expanded to form the ACTION Heart Failure (HF) Committee with an aim
to develop novel quality improvement initiatives to improve outcomes in
pediatric HF.
Methods: Given poor outcomes associated with acute heart failure
admissions in pediatric heart failure, ACTION developed three quality
improvement tools for the inpatient pediatric HF population.
Results: One initiative aims to improve the daily assessment of HF in children admitted for decompensated HF, including those who go on to VAD,
through the development of a daily rounding communication checklist
that incorporates both objective and subjective measures of pediatric
HF severity. The goal is to provide a standardized approach for daily
assessment of HF symptoms, thus potentially improving the assessment
of HF status and interventions. The second initiative is a comprehensive
pediatric HF discharge tool, modeled after the highly successful American
Heart Association TARGET:HF initiative, that aims to bridge the communication of complex HF management between the inpatient and outpatient
setting. The third initiative involves collaboration with the Pediatric Health
Information System (PHIS), an administrative database that contains
patient-level administrative information on inpatient hospital care, to
develop a novel data abstraction process aimed at reducing data entry
burden. The metrics used for assessing these quality improvement efforts
include 30-day HF hospital readmission, hospital length of stay, and
hospital mortality. ACTION HF aims to reduce the significant morbidity,
mortality, and resource utilization associated with pediatric HF through a
multistep approach and to bridge the gap between the acute and chronic
heart failure management.

Study: PROs are considered key in VAD clinical care and device trials in
adults. PRO use in children and young adults on VAD support has been
hampered by poor response rates, data collection burden, and lack of
VAD-specific content. We tested feasibility of electronic PRO data collection from VAD patients/parents in the Advanced Cardiac Therapies
Improving Outcomes Network (ACTION).
Methods: Patients/parents enrolled at 6 ACTION sites 7/20-11/30/20.
Patient Reported Outcomes Measurement Information Systems (PROMIS-25 parent proxy or PROMIS-29 adult self-report; 1, 3, 6 months postimplant) and network-derived measures (weekly x4) were used. Network
measures were developed with family and provider input and tested for
content, length. These included: Take ACTION symptom checklist, parent
survey, visual analog quality of life (VAS QOL) scale. Descriptive summary
statistics were performed.
Results: 22 patents (median age 5.4 yrs (IQR 0.5, 19.0)) enrolled. Median
time from implant was 67 days (IQR 34.5, 323). Enrollment was 91.7%
among those eligible. Attrition and measure missingness were zero.
Patient symptoms: fatigue (37%), stress with dressing changes (43%),
sadness (45%), activity limitations (55%). Parental concerns: financial
stress (43%), parent sadness (48%), parent worry (55%). Mean parentreported child VAS QOL was 5.4/10. Post-implant median PROMIS T
scores illustrated impaired physical function with normal median scores in
other domains. Clinically significant depression, anxiety, pain interference,
cognitive impairment were reported by 1/5 (20%) adult VAD patients.
Clinically significant depressive symptoms and anxiety were reported by
parent proxy for 1/3 (33%) of pediatric VAD patients, with fatigue and
pain interference in 2/3 (67%).
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Growth Adaptive Stent Design For Pediatric Heart Valves
Giselle Ventura, BS, MS1, Aisling McEleney, BS2,
David W. Sutherland, Jr., PhD1, Stephanie L. Golmon, PhD1,
Daniel F. King, MS1, Corin Williams, PhD1, Sitaram Emani, MD3,
Saeed Mossab, MD3; 1Draper, Cambridge, MA, USA, 2Boston University,
Boston, MA, USA, 3Boston Children’s Hospital, Boston, MA, USA

A Silicon Nanopore Membrane Oxygenator For An Artificial Placenta
David Blauvelt, MD, Bianca De, BS, Emily Abada, PhD,
Ben Chui, PhD, Jarrett Moyer, MD, Peter Oishi, MD,
Shuvo Roy, PhD; University of California, San Francisco, CA, USA
Study: Extremely preterm (EPT) infants have high morbidity and mortality
due to underdeveloped lungs, exacerbated by ventilator-induced lung
injury (VILI). Conventional hollow-fiber membrane oxygenators are limited
by need for high-dose anticoagulation, excessive pressure drop, and large
priming volumes. We are developing an artificial placenta oxygenator
comprised of rigid flat-plate gas exchange membranes constructed from
a silicon nanopore membrane (SNM) backbone covered with silicone.
These membranes allow unprecedented control of the blood flow path,
improving hemocompatibility and reducing both priming volume and
pressure drop.
Methods: SNM with 500 nm pores were adhered to a 5 µm silicone layer
via oxygen plasma bonding. The membranes were tested in both benchtop water studies and a pig model. Simultaneously, a mathematical model
for oxygen transfer into blood was developed, validated against empiric
data, and used to guide design of a clinical-scale device.
Results: Individual membranes showed a normalized oxygen flux of up
to 390 mL/min/m2. The mathematical model correlated strongly with
empirical data (r = 0.99, p <0.01). Using the model, we identified a design
consisting of 20 parallel channels. This device has a membrane surface
area of 0.16 m2, an oxygen flux of up to 6.4 mL/min, a priming volume of
5.5 mL, and a pressure drop of 18 mmHg at a blood flow of 100 mL/min.
This work demonstrates the potential feasibility of an SNM-based oxygenator to provide sufficient oxygen to support an EPT infant. Improvements
in priming volume, pressure drop, and hemocompatibility may overcome
shortcomings of hollow-fiber membranes.

Study: There are no heart valve prosthetics on the market designed to
accommodate growth in young children born with valve defects. Our
objective is to create a pediatric heart valve that will expand while maintaining function over a doubling in valve diameter (7 to 14 mm) as the
patient grows from infancy to age 5–6 years old.
Methods: Leveraging the results from previous work we optimized stent
designs and analyzed them using non-linear finite element analysis (FEA).
The analysis examined the geometries and output radial forces, stresses,
and strains. Configurations with no self-contact and radial forces of
interest were manufactured using ASTM F 2063 Nitinol via laser cutting.
To inform stent design, custom tissue testing apparatuses have been
constructed to collect mechanical property data from cardiac tissue at
the site of implantation. The first test setup is a uniaxial tester for ex vivo,
isolated tissue samples. A second method is under development to provide in vivo measurements in a non-destructive manner from preclinical
animal models.
Results: Different configurations involved increasing the number of
springs in a series for a less stiff stent and incorporating more rounded
geometry to disperse stress. Three stent geometries were prototyped to
achieve a 2-fold diameter expansion with various expansion forces. The
FEA predicted radial forces between 2–5 N per stent at the most compressed state. Stents will undergo radial force testing and dimensional
analysis to assess correlation with our FEA models. Data collected to date
from the custom tissue testing apparatus suggests that the designed
stent radial force is capable of falling within a safe threshold at the site
of implantation. Ongoing biomechanical testing will guide the design
of the next iteration of stents as well as provide a more comprehensive
understanding of the complex mechanical effects of growth-adaptive
stent implantation.
Work supported by the DoD USAMRAA under Award
No.W81XWH-20-1-0295. Results not necessarily endorsed by the DoD
USAMRAA.
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Hepatic Function After Artificial Placenta Support With Total Parenteral
Nutrition
Stephen L. Harvey, BS1, Brian P. Fallon, MD1,
Jennifer S. McLeod, MD1, Niki Matusko, BS2, Raja Rabah, MD3,
Meghan A. Arnold, MD4, Alvaro Rojas-Peña, MD5,
Robert H. Bartlett, MD1, George B. Mychaliska, MD4; 1Department of
Surgery, ECLS Laboratory, University of Michigan Medical School, Ann
Arbor, MI, USA, 2Department of Surgery, University of Michigan Medical
School, Ann Arbor, MI, USA, 3Department of Pathology, University of
Michigan Medical School, Ann Arbor, MI, USA, 4Department of Surgery,
Section of Pediatric Surgery, University of Michigan Medical School, Ann
Arbor, MI, USA, 5Department of Surgery, Section of Transplantation, ECLS
Laboratory, University of Michigan Medical School, Ann Arbor, MI, USA

Infliximab Post COVID-19 Multisystem Inflammatory Syndrome In A
Child On ECMO
Zasha F. Vazquez-Colon, MD1, Leandra Woolnough, MD, MS1,
K. Leslie Avery, MD1, Asad H. Bashir, MD1, Jennifer Co-Vu, MD1,
Giles J. Peek, MD2, Saleem Islam, MD, MPH2,
Desiree Machado, MD1; 1Pediatrics, University of Florida, Gainesville, FL,
USA, 2Surgery, University of Florida, Gainesville, FL, USA
Study: Introduction: Immunomodulators are gaining attention for multisystem inflammatory syndrome (MIS-C). A timely knowledge gap exists,
especially for refractory cases. We describe the use of Infliximab (INF),
a monoclonal antibody that binds TNF-alpha, for a child on ECMO with
MIS-C.
Methods: Case report
Results: Case: 13-year-old 86 Kg female presented with 4 days of fever,
rash, abdominal pain, diarrhea and vomiting. She tested positive for
COVID-19 34 days prior. She was treated with corticosteroids, Anakinra,
intravenous immunoglobulin (IVIG) and aspirin. On day 4 of admission,
she developed vasodilatory-cardiogenic shock and ventricular arrhythmia
despite escalation of vasopressin, epinephrine, intubation and lidocaine
infusion. She was percutaneously cannulated for VV-A ECMO (cannulation: 25 Fr femoral and 20 Fr internal jugular veins, 21 Fr femoral arterial,
6 Fr distal perfusion cannula) to support 4.5L/min flow. She received
INF 7.5mg/kg, IV, 5 hours post-cannulation. She was anticoagulated
with bivalirudin without complications. Anakinra was resumed 2 days
later. Laboratory and echocardiographic parameters are shown on Table.
Arrhythmia resolved 48 hours post-INF and she was weaned off inotropes. She was decannulated 131 hours post-INF (136 hours of ECMO), and
extubated the day after. She remains admitted at the time of this abstract
writing.
Conclusion: MIS-C post COVID-19 is a newly recognized disease process.
INF is a promising therapy to attenuate cytokine storm and a potential
rescue strategy for patients with disease refractory to corticosteroids,
IVIG, and IL-1 blockade.

Study: The artificial placenta (AP) promotes organ development and
reduces organ injury in a lamb model of extreme prematurity. Its effects
on the liver and the influence of total parenteral nutrition (TPN) during
AP support are unknown. This study evaluates hepatic outcomes after AP
support with TPN administration.
Methods: Premature lambs (116-121d estimated gestational age [EGA];
term =145) were cannulated for AP support with jugular vein drainage
and umbilical vein reinfusion. Lambs received TPN with SMOFlipid (SMOF;
n=7) or Intralipid (IL; n=5). After 7 days, animals were euthanized. Early
(ETC; 118±3d EGA; n=7) and late tissue controls (LTC; 128±3d EGA; n=7)
were delivered and euthanized. Histologic liver evaluation included 5
components: cholestasis, hepatocyte injury, congestion, fatty change, and
extramedullary hematopoiesis (EMH), each graded from 0 to 3 (0=none;
1=mild; 2=moderate; 3=severe). Groups were compared by ANOVA followed by Tukey’s multiple comparisons or linear mixed effects models.

Results: SMOF and IL groups had similar hemodynamics, blood gases,
ALT, Alk Phos, GGT, and total bilirubin. Both groups had increases from
baseline to day 7 in total bilirubin (IL 2.6±2.3 to 7.9±4.4; SMOF 0.3±0.1
to 5.5±2.3) as well as ALT and GGT (p<0.001 for all). The SMOF group
also had increases from baseline to day 7 in direct bilirubin (0.3±0.2 mg/
dL to 1.8±1.4 mg/dL; p=0.006) and AST (27±5 to 309±242; p<0.001),
and a decrease in INR (1.7±0.2 to 1.4±0.2; p=0.048). These were not
measured in the IL group. On liver histology, IL showed more cholestasis
than SMOF; both groups showed more than tissue controls. The IL group
alone showed hepatocyte injury and had more congestion than controls.
All livers had mild-moderate EMH. Lambs supported by the AP with TPN
administration maintain normal hepatic function and sustain minimal
hepatic injury. SMOFlipid is associated with decreased cholestasis and
hepatic injury versus Intralipid.
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most recent centerlines both at 67% compliance (Figure 1). Analysis of
individual bundle elements revealed that 19/48 (40%) safety items were
deficient at least once during the 36 ESRs (Table 1). Any individual bundle
element with greater than 2 noncompliance events prompted our team
to target interventions addressing these lapses, including new protocols
and education, conducting multidisciplinary reviews, and collaborating
with ancillary departments. We conclude that Pediatric ESR provides
real-time assessment of compliance, immediate corrective and education measures, and actionable data to drive performance improvement
around observed vulnerabilities in ECMO protocols.

Implementation Of Pediatric ECMO Safety Rounds For Real-time Quality
Improvement
Bridget Toy, RN, BSN1, Thomas Beaulieu, CCP2,
Krista LoRe, RN, MSN3, Erin Cicalese, MD4, Heda Dapul, MD5,
Mia Maldonado, MBA1, Jacyln McKinstry, MD6,
Sourabh Verma, MD4, Arun Chopra, MD, MPH5,
Jason C. Fisher, MD7; 1Transplant Institute, NYU Langone Health, New
York, NY, USA, 2Perioperative Services, NYU Langone Health, New York, NY,
USA, 3Nursing, NYU Langone Health, New York, NY, USA, 4Neonatology,
NYU Langone Health, New York, NY, USA, 5Pediatric Critical Care, NYU
Langone Health, New York, NY, USA, 6Pediatric Cardiology, NYU Langone
Health, New York, NY, USA, 7Pediatric Surgery, NYU Langone Health, New
York, NY, USA
Study: Our Pediatric ECMO Program implemented ECMO Safety Rounds
(ESR) as a quality improvement (QI) initiative. Objectives were to ensure
implementation of protocols, immediately correct quality/safety deficiencies, and provide real-time education to nurses and perfusionists. Our
specific aim was to track compliance with this process-improvement
bundle and identify areas to target with QI efforts, with a long-term global
aim of reducing quality/safety variances and patient harm over time.

Methods: Our team initiated Pediatric ESR in September 2019. Two process-based QI bundles were developed: (1) Circuit Safety - 35 bundle elements, including maintenance and emergency checks; (2) Patient Safety
- 13 bundle elements focused on nursing practices specific to minimizing
patient harm. Pediatric ESR consisted of these two bundle assessments
performed by designated ESR clinicians at the bedside with the patient’s
nurse and perfusionist. Credit for bundle compliance was awarded only if
all elements were properly met. Noncompliant elements were addressed
in real-time. All data was recorded in REDCap database.
Results: 36 Pediatric ESRs were completed (Sept. 2019 - Jan. 2021).
Monthly bundle compliance was reported using run charts. Median
compliance with both bundles appeared to improve over time, with their
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Utilization Of Novel Technology To Optimize Cardiac Rehabilitation
In Children Supported With Ventricular Assist Devices During The
COVID-19 Era
Jonathan B. Edelson, MD, Danielle Burstein, MD,
Dustin B. Nash, MD, Rachel M. White, RN,
Katherine Iacobellis, CPNP-AC, Shannon O’Malley, MS,
Stephen Paridon, MD, Matthew J. O’Connor, MD,
Joseph W. Rossano, MD, Lin Y. Kimberly, MD,
Carol Wittlieb-Weber, MD, Katsuhide Maeda, MD, PhD; Children’s
Hospital of Philadelphia, Philadelphia, PA, USA

Numerical And Experimental Approach To Characterizing Static And
Dynamic BLDC Motor Performance With Different Radial-Gap To
Facilitate Maglev System Design For A Pediatric LVAD
Simon Kiang, BS1, Neil Luo, BS1, Shweta Karnik, MS1,
P. Alex Smith, PhD1, Nobuyuki Kurita, PhD2, Charles D. Fraser, MD3,
Yaxin Wang, PhD1, O.H. Frazier, MD1; 1Texas Heart Institute, Houston, TX,
USA, 2Division of Electronics and Informatics, Gunma University, Gunma,
Japan, 3Texas Center for Pediatric and Congenital Heart Disease, Dell
Medical School - The University of Texas at Austin, Austin, TX, USA
Study: A miniature magnetic levitation (maglev) system was proposed to
eliminate mechanical wear in an implantable pediatric LVAD. The maglev
system comprises permanent magnet rings to levitate the rotor radially
and active maglev control to stabilize the rotor axially. To avoid high
shear stress on the blood, the motor gap can be enlarged, but this would
compromise motor performance. Thus, it is essential to characterize the
relationship between motor performance and motor gap to determine an
appropriate brushless DC (BLDC) motor size. We varied the rotor size and
investigated the radial force generated by rotor-stator eccentricity and
the torque generation capacity as a first step in the development of the
maglev system.
Methods: A BLDC motor model was established in COMSOL 5.4 and validated based on the unmodified motor specifications. The torque constant
was determined numerically for varied rotor diameters; additionally, the
numerical model also computed the magnetic force generated by rotorstator eccentricity. To validate the numerical results, the radial force was
measured by a torque transducer mounted on a micrometer-driven stage.
The magnetic force was then recorded with the relative radial displacement between the rotor and stator.
Results: The numerical model accurately matched the unmodified motor
specifications (torque constant: 3.60 vs. 3.62 mNm/A; speed constant:
2651 vs. 2640 rpm/V; terminal resistance: 8.37 vs. 8.38 Ohm). As the
rotor diameter decreased from 3.8 mm to 3.0 mm, the torque constant
reduced by 32%, showing a linear relationship between motor gap and
torque constant. The numerical and experimental static forces differed by
an average of 7.4%, validating the numerical model adequately to predict
the radial force for the future maglev system design. This model could
be expanded to include more geometric variables, thus accelerating the
design process for pediatric LVADs.

Study: Cardiac rehabilitation is critical for successful ventricular assist
device (VAD) support in children. Regular in-person rehabilitation can be a
challenge, particularly during the COVID-19 era.
Methods: We present 2 cases of adolescents supported with VADs in
whom wearable devices and a virtual exercise platform were used to augment cardiac rehabilitation.

Results: A 17-year-old male with tachycardia induced cardiomyopathy
underwent LVAD implantation as a bridge to decision. The distance
from the hospital and COVID restriction made frequent visits for cardiac
rehabilitation not feasible, yet aerobic activity was critical for myocardial
remodeling. A 15-year-old severely obese female with dilated cardiomyopathy underwent LVAD implantation as a bridge to candidacy. Engaging
her in physical activity was a challenge, but a necessary component of
her evaluation for bariatric surgery. For both patients, wearable devices
(Fitbit Versa 2) were placed to monitor and incentivize activity. Exercises
were designed based on available resources and include walking up stairs
and using resistance bands. Despite no palpable pulse both patients had
a pulse that registered on their wearable device, which helped to monitor
rehabilitation. Devices were paired with the MyHeart CHOP application,
a virtual platform for home exercise training that includes individualized
exercise prescriptions and the opportunity for virtual communication
with a pediatric cardiac exercise physiologist. In the >1 month since
incorporation of wearable technology, both patients have participated in
rehabilitation sessions on >50% of eligible days (25/31 d, 19/33 d) and
are being considered for VAD explant and bariatric surgery. Technologybased remote rehabilitation programs are a promising and feasible option
for children supported with VADs during the COVID era, and may be an
underutilized method by which to optimize outcomes.
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Sustaining Effective RVAD Anticoagulation In The Face Of Massive
Neurological Injury: A Case Illustration
Jenna Murray, CPNP-AC1, Katsuhide Maeda, MD1, John Dykes, MD2,
David Rosenthal, MD2, Kate Ryan, MD2, Sharon Chen, MD2,
Sarah Lee, MD2, Gerald Grant, MD2, Christopher Almond, MD2,
Shawna Collins, CPNP-AC2, Allen Shiu, RN2, Ozzie Jahadi, CCP2,
David Kwiatkowski, MD2; 1Lucile Packard Children’s Hospital, Palo Alto,
CA, USA, 2Lucile Packard Children’s Hospital, Palo Alto, CA, USA

Development Of A Guideline For Pediatric Bariatric Surgery After
Ventricular Assist Device Implantation—Challenges And Opportunities
Danielle S. Burstein, MD1, Elizabeth Prout, MD2,
Kristoffel Dumon, MD3, Rachel White, RN1,
Katherine Iacobellis, CRNP1, Kelsey Palm, RD, CNSC1,
Christine Giovinazzo, BS1, Shannon O’Malley, MS1,
Nicholas Seivert, PhD4, Haliey Collier, PharMD1,
Colleen Tewksbury, PhD5, Matthew O’Connor, MD1,
Joseph Rossano, MD, MS1, Jonathan Edelson, MD1,
Kimberly Lin, MD1, Carol Wittlieb-Weber, MD1,
Katsuhide Maeda, MD, PhD6; 1Pediatric Cardiology, Children’s Hospital
of Philadelphia, Philadelphia, PA, USA, 2Pediatric Gastroenterology,
Children’s Hospital of Philadelphia, Philadelphia, PA, USA, 3General
Surgery, Hospital of University of Pennsylvania, Philadelphia, PA,
USA, 4Pediatric Psychology and Behavioral Health, Children’s Hospital
of Philadelphia, Philadelphia, PA, USA, 5Gastroenterology, Hospital
of University of Pennsylvania, Philadelphia, PA, USA, 6Pediatric
Cardiothoracic Surgery, Children’s Hospital of Philadelphia, Philadelphia,
PA, USA

Study: Stroke is a rare but important complication in pediatric mechanical
circulatory support (MCS). Given concerns of obligate anticoagulation,
neurosurgical intervention after stroke may be underutilized. It is important to have a collaborative and established relationship between cardiology, ICU and neurosurgery to ensure timely assessment and intervention.
This case of a massive neurological event after right ventricular assist
device (RVAD) implant illustrates a successful immediate neurosurgical
intervention and long-term RVAD course, leading to ultimate transplant
and neurological recovery.
Methods: A 9 year-old male with severe Ebstein’s anomaly with severely
enlarged right ventricle was undergoing an EP procedure and suffered
a cardiac arrest, requiring ECMO support with transition to Centrimag
RVAD support. On POD 2 he became obtunded with a massively enlarged
right pupil and found to have a large right sided frontotemporal parietal
ischemic stroke with herniation. He underwent an emergent hemicraniectomy and intracranial drain. In the early post neurosurgery course, anticoagulation was held for about 4 days. Low dose bivalirudin was started at
that time with frequent imaging. Chronically with and without bone flap
replaced, bivalrudin was titrated for a PTT value of 50–70 seconds with
a single antiplatelet agent (low dose Clopidogrel) and low dose steroids
without intracranial hemorrhage. Anticoagulation was held on several
occasions for procedures. A single Centrimag circuit was used for the
entire duration until transplant (day 186 of support). Patient recovered
most mobility and was able to ambulate and had normal cognitive function at time of discharge.
Results: Patients on MCS can have successful neurological interventions
despite the need for significant anticoagulation to protect the devices.
Having a multidisciplinary institutional protocol prior to these events
occurring is crucial to post event survival and neurological recovery.

Study: Severe obesity in children with end-stage heart failure requiring
ventricular assist device (VAD) support is challenging due to the relative
contraindication for heart transplantation with a body mass index (BMI)
> 35 kg/m2. Despite increasing reports of bariatric surgery in adult VAD
recipients, no data exists in pediatrics.
Methods: A 15-year-old female with severe obesity (BMI 46 kg/m2) and
dilated cardiomyopathy underwent LVAD implantation as a bridge to candidacy. To optimize her opportunity for successful weight loss, pediatric
bariatric surgery was proposed, and a multidisciplinary working group
was organized to coordinate complex VAD-Bariatric Surgery management.
Results: Our center developed a guideline summarizing our novel, combined Pediatric Bariatric Surgery-VAD program. This program involves VAD
placement followed by 4-6 months of medical weight loss management
prior to laparoscopic sleeve gastrectomy. Challenging issues identified
include risks of post-bariatric nutritional and vitamin deficiencies affecting
hydration and anticoagulation. This is addressed through vitamin supplements and mandatory fluid intake goals. Psychologists trained in pediatric
bariatric surgical care and pediatric heart transplantation are critical to
this process. This novel guideline outlines recommended selection criteria
for pediatric VAD and bariatric surgery candidacy, VAD driveline site
placement, peri-operative VAD and bariatric surgery care, post-bariatric
nutrition and anticoagulation management, medical and psychosocial
evaluation and counseling for weight loss, guided exercise training while
on VAD support, pharmacologic management for weight loss (liraglutide), comorbidity evaluation and management. This Pediatric Bariatric
Surgery-VAD Program guideline provides a novel approach and potential
opportunity to help successfully bridge children with severe obesity to
heart transplantation.
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Clostridium Difficile Infection In Pediatric Pulsatile Flow LVAD: Successful
Management Of A Life-threatening Complication
Erika Mejia, MD, Matthew J. O’Connor, MD,
Joseph Rossano, MD, Kimberly Y. Lin, MD,
Carol Wittlieb-Weber, MD, Stephen Paridon, MD,
Danielle Burstein, MD, Jonathan B. Edelson, MD,
Katsuhida Maeda, MD, PhD; Children’s Hospital of Philadelphia,
Philadelphia, PA, USA
Study: Infection is one of the most common adverse events in pediatric
patients with ventricular assist devices (VAD), with antibiotics frequently
used for management. The resultant disruption of normal bacterial flora
in the colon can cause Clostridium difficile (C. diff) infection. C. diff is a
known contributor to morbidity in adults on mechanical circulatory support (MCS), however, its burden in pediatric LVAD cases is not reported.
Methods: We describe the presentation, management, and lessons
learned from a 27-month old child with left ventricular noncompaction,
restrictive cardiomyopathy, and severe malnutrition who received a Berlin
Heart ® (BH) EXCOR left ventricular assist device (LVAD) and developed C.
diff with numerous complications.
Results: The patient underwent implantation of a 15cc BH with left
atrial cannulation via a transseptal approach. He developed a fever on
post-operative day (POD) 6 and started on broad spectrum antibiotics;
although initial cultures did not reveal a clear source of infection, antibiotics were continued due to a high concern for sepsis. On POD 10 he developed abdominal distention, tenderness, and profuse diarrhea. Abdominal
ultrasound showed thickened loops of bowel and portal venous gas. C.
diff toxin assay was positive on POD 11. Due to profound dehydration,
he developed acute kidney injury and incomplete VAD filling. A pump
exchange was performed on POD 19 due to concern for thrombus. Enteral
vancomycin was given rectally for ileus. He required 12 days of bowel
rest and 21 days of parenteral nutrition. After 14 days of antibiotics the
patient recovered and is awaiting transplant. Conclusion: C. diff infection
in MCS is a life-threatening complication and poses significant challenges
to fluid balance, VAD hemodynamics, and nutritional support. Antibiotics,
which can predispose to C. diff infection, should be used judiciously.
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Experimental Measurements Of Blood Damage In Geometrical Variants
Of Membrane Based MicroﬂUidic Devices
Nayeem Imtiaz, BS, Mehran Mansouri, BS, MS,
Steven W. Day, PhD; Rochester Institute of Technology, Rochester, NY, USA

Effect Of Oxygenator Geometry On Performance Characteristics
Chris Dacey, CCP, Greg Johnson, PhD, Patrick Murawski, BS,
Anthony McCoppin, Other, Robert Svitek, PhD; CardiacAssist, Inc. dba
TandemLife, Pittsburgh, PA, USA

Study: The advancement of membrane based microfluidic devices, such
as dialyzers and oxygenators, plays a crucial role on the development of
portable dialyzers and oxygenators that may decrease patient complexity and mortality. The potential for such devices to damage blood has
not been studied and could benefit from in vitro analysis of prototype
devices. Geometrical mixing elements disrupt flow and have been proposed to increase transport, but these features engender the risk of additional stresses and damage. In this study physical models of microfluidic
devices of varying geometries were used to study how the flow-mediated
shear stress developed inside the microfluidic channels initiates the damage of red blood cells.
Methods: Four geometric variants (baseline, herringbone, reduced gap,
and reduced port) of the blood side of a micro-fluidic oxygenator were
fabricated to analyze the blood damage behavior with a reduced volume
recirculating loop driven by peristaltic pumps. Blood was circulated 620
times through each device at a flow rate of 100 ml/min and sampled
periodically to determine Hemolysis (fHb according to the Cripps method
converted to Index of Hemolysis, IH%). The slope of a linear regression
between IH% and number of passes through the device (IH%/pass) was
used as a comparative measure of damage and compared to results from
a prior numerical model.
Results: All devices caused low levels of damage (<0.001 IH%/pass). The
reduced gap and reduced port device were observed to be showing the
most amount of blood damage and the baseline device the least. Marginal increase of blood damage was observed on devices with herringbone mixture compared to the baseline.

Study: The EOS® and TandemLung® are membrane oxygenators designed
for long term extracorporeal membrane oxygenation (ECMO). Both
devices operate by the same principle, blood flowing across a bundle of
polymethylpentene hollow fiber membranes where O2 diffuses into the
blood and CO2 diffuses out of the blood. The EOS and the TandemLung
are both wound into a cylindrical, annular shape. However, the inner and
outer fiber bundle dimensions, the housing geometry, and the blood flow
path through the two devices is different. The dimensional and geometric
differences may lead to differences in performance that are important
to consider when choosing which oxygenator to use for a given clinical
scenario in terms of gas exchange, pressure drop, set-up, priming, and
hemolysis.
Methods: The differences in the two designs were evaluated in vitro with
a mock loop consisting of a reservoir, blood pump, and the test oxygenator. The loop was primed with 12 L of bovine blood and maintained at
37C and venous conditions: O2 saturation 65 ± 5%, Hemoglobin 12 g/dL,
pH 7.4. Gas exchange and pressure drop measurements were taken at
flowrates up to 5 L/min through the test device. In a separate experiment, two identical flow loops were constructed, and blood was pumped
through each oxygenator for 6 hours at 5 L/min. Plasma free hemoglobin
was measured over time to evaluate the hemolysis generated by blood
flowing through each oxygenator design.
Results: Gas exchange was comparable between the two devices at
approximately 300 mL O2/min despite the EOS oxygenator having a
smaller priming volume and surface area than the TandemLung. The
pressure drop was higher for the EOS oxygenator at 225 mmHg compared
to the TandemLung at 55 mmHg at 4.0 L/min. The lower pressure drop
and geometric flow path of the TandemLung led to easier set up and
priming compared to the EOS. Hemolysis was acceptable for both designs.
This study demonstrated that oxygenator fiber bundle design leads to
performance tradeoffs to be considered when choosing an oxygenator for
a given clinical scenario.
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Piv Validated CFD Analysis Of A Paired Membrane Umbrella Double
Lumen Cannula For Failing Fontan Support
Yulin Zhang, Master of Engineering; Materials Science and Engineering,
University of Kentucky, Lexington, KY, USA

Deep Vein Thrombosis: AI/ML Strategies To Determine The Impact Of
Coronavirus On Blood Rheology And Venous Valve Integrity
V M Krushnarao Kotteda, PhD, Herb Janssen, PhD,
Christopher Harris, PhD, Vinod Kumar, PhD; DeepVein Inc, Fremont, CA,
USA

Study: The current solution to the ventricle patients is the Fnatan circulation or total cavopulmonary connection (TCPC). However, TCPC will nullify
and lead to organ disfunction. Thus, extracorporeal mechanical support
is needed to solve failing TCPC induced issues. A novel double lumen cannula (DLC) is proposed to the Fontan patients after TCPC surgery in order
to provide cavopulmonary assistance (CPA). The distribution of blood flow
will be studied using both experimental and simulation results. Besides,
the performance of DLC will be evaluated.
Methods: An In vitro Fontan model including a double lumen cannula, a
CentriMag Acute Circulatory Support System and a reservoir is set up to
simulate a Fontan patient. A 36% glycerin-water solution with viscosity
of 3.47 cST is used as the flow. The range of flow rate is 3~5 L/min and a
flow split is set to 55: 45 for inferior vena cava (IVC) to superior vena cava
(SVC) and 50: 50 for right pulmonary artery (RPA) to left pulmonary artery
(LPA), respectively. A Particle Image Velocimetry (PIV) with a laser is used
to trace the fluorescent polymethyl methacrylate (PMMA) particles in
the flow. PIV data are processed at three planes from both the IVC and
SVC. The CFD simulation is based on the DLC geometry model with the
laminar flow patter, since the Reynold number is smaller than 2000. Rigid,
impermeable and no-slip wall condition and pressure-velocity coupling
method are used.
Results: Comparison between the experimental and computational
results indicate that both the flow distribution is very similar. the highest
velocities are always observed on the mid-plane. Besides, the maximum velocity increase with the increase of mass flow rate as expected.
Moreover, the umbrella sealed very well and no flow passed through
it.The flow distribution acquired at three planes in the DLC can be used
as validation data for computational modeling. The numerical analysis of
DLC achieves a good agreement with flow distribution obtained from the
experiment.

Study: Deep venous thrombosis (DVT) is said to be the most preventable
cause of death in hospitals today (Centers for Disease Control, February
2020). This silent killer most frequently starts in the lower extremities
as a small thrombus that initially forms in a valve pocket located behind
a venous valve leaflet. Failure to initiate preventative measures to
reduce the risk of DVT can result in the development of life-threatening
pulmonary emboli (PE) and chronic venous insufficiency (CVI). These risks
are currently exacerbated by the current SARS-CoV-2 pandemic that has
increased the frequency of DVT formation and PE in patients through
mechanisms that are not fully understood. The current study is using
artificial intelligence (AI) and machine learning (ML) to evaluate changes
in blood rheology, venous blood flow, and venous valve configuration that
can lead to increased risk of DVT, PE, and CVI.
Methods: In our model, AI/ML is used to evaluate previously recorded
images of normal and abnormal cadaver veins and venous valves. Using
these data, we can predict that previous DVT formation produced the
observed leaflet damage and will increase the risk of CVI and future DVT
formation. The contribution that changes in blood rheology could make
to venous blood flow abnormality will also be assessed. We leverage the
latest advances in image processing to quantify the valve leaflet geometry
with respect to the susceptibility to recurrent DVT.
Results: Based on this data, AI/ML will predict, on a patient-by-patient
basis, the probability of deep venous thrombosis formation. This will allow
healthcare professionals to determine when preventative measures are
most appropriate. It will also allow physicians to assess whether a patient
has an increased risk of developing a future DVT and/or CVI insufficiency.
With this information patient care can be improved and the debilitating
and life-threatening complications of DVT can be substantially reduced.
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Right Ventricular Failure In A Chronic Sheep Model Of Pulmonary
Hypertension
Rei Ukita, PhD1, John Stokes, MD1, W Kelly Wu, MD1,
Jennifer Talackine, MS1, Nancy Cardwell, BS1, Yatrik Patel, MD1,
Caitlin Demarest, MD, PhD1, Andrew Tumen, MD1,
Christopher Pinelli, DVM1, Kelsey Finnie, DVM1,
Emily J. Tsai, MD2, Erika Berman-Rosenzweig, MD3,
Keith Cook, PhD4, Matthew Bacchetta, MD1; 1Vanderbilt University
Medical Center, Nashville, TN, USA, 2Columbia University Vagelos College
of Physicians and Surgeons, New York, NY, USA, 3Columbia University
Medical Center, New York, NY, USA, 4Biomedical Engineering, Carnegie
Mellon University, Pittsburgh, PA, USA

Comparison Of Ex Vivo Versus In Vivo Extracorporeal Circulation Models
On Coagulation Outcomes
Teryn R. Roberts, PhD, George T. Harea, BS,
Andriy I. Batchinsky, MD; Autonomous Reanimation and Evacuation
Program, The Geneva Foundation, San Antonio, TX, USA
Study: Ex vivo hemocompatibility testing of extracorporeal life support
(ECLS) devices lacks standardization and clinical guidance. Variables
including blood source, anticoagulation, circuit design and outcomes
complicate meaningful, translational conclusions. We implemented a
sequential device testing approach involving both a 6-hour ex vivo and
multi-day in vivo model where blood source, anticoagulation, test device
and outcome measures are standardized between models. The objective of this study was to compare coagulation metrics for 6 hours blood
circulation ex vivo versus in vivo using the same ECLS system. Hypothesis:
Coagulation outcomes differ between models.
Methods: We performed a cross-study comparison of a 6-hour ex vivo
swine donor blood circulation model (n=4) and a 72-hour in vivo ECLS
model in uninjured swine (n=5). In both studies, the same pediatric ECLS
device with heparin coating (Maquet/Getinge; Germany) was used and
heparin administered to target activated clotting time (ACT) 125-160s.
Coagulation was assessed at circulation start (baseline/BL), 3-hours, and
6-hours via complete blood count, PT/aPTT, fibrinogen, D-dimer, ATIII,
TEG, platelet aggregometry and plasma free hemoglobin (PFHb). A one
way and two way repeated-measures mixed model were used to assess
within group (Dunnett adjustment) and between group differences (Tukey
adjustment), respectively (two-sided, p<0.05 significant).

Study: Decompensated right ventricular failure (RVF) due to pulmonary
hypertension (PH) is fatal, with limited medical treatment options. Developing and testing novel therapeutics for PH requires a clinically relevant large
animal model of increased pulmonary vascular resistance and RVF. Here,
we present the latest development of our previously published ovine PHRVF model utilizing pulmonary artery (PA) occlusion and left PA ligation. The
data suggest that this PH-RVF model is a versatile platform that can control
the severity of the disease as well as the RV’s phenotypic response.
Methods: Adult sheep underwent left PA ligation, and placements of a
main PA cuff and an RV pressure monitor, both connected to subcutaneous ports (Fig 1A). Subjects underwent chronic progressive PA banding
every 2-4 days for 9 weeks with sequential measurement of RV pressure,
PA cuff pressures, and mixed venous blood gas (SvO2). At the initiation
and endpoint of the PH-RVF model, ventricular function and dimensions
were assessed using echocardiography.
Results: Twelve sheep underwent PH-RVF development. RV mean and systolic pressure increased during the model, from 28 ± 8 and 58 ± 8 mmHg,
respectively, to 44 ± 8 and 93 ± 18 mmHg at Week 9 (mean ± standard
deviation). Echocardiography demonstrated characteristic findings of
PH-RVF, most notably as RV dilation, increased wall thickness, and septal
bowing (Fig 1B). Furthermore, the longitudinal trends of SvO2 and PA cuff
pressure (Fig 1C) demonstrate that our PA banding strategy can elicit varying RV phenotypes. A faster PA banding strategy led to precipitous decline
in SvO2, whereas a slower, more paced strategy allowed for better compensation and maintenance of physiologic SvO2. One animal that experienced
the faster PA banding strategy developed several liters of pleural effusion
and ascites by week 9 of the PH-RVF model. This ovine PH-RVF model is
therefore a valuable tool for studying RV adaptations during PH.

Results: Using the same heparin protocol, ACT and aPTT did not differ
between studies. No difference in D-dimer, ATIII or fibrinogen were
observed. Platelet loss was similar between groups, but platelet aggregation trends were significantly different (Fig 1). At 6 hours, PT increased
from BL in vivo (4±1% increase), but decreased ex vivo (-6±3%) (p=0.002).
Notable differences in hematocrit, PFHb and TEG R were observed (Table
1). Ex vivo coagulation outcomes did not mirror in vivo findings, stressing
importance of in vivo testing prior to clinical translation.
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Evaluation Of The Lifesparc® Pump And Tandemlung® Oxygenator For 14
Days In A Calf Model
Greg Johnson, PhD, Patrick Murawski, BS, Mike Linehan, BS,
Ruben Hartogs, BS, Robert Svitek, PhD; TandemLife dba CardiacAssist,
Inc., Pittsburgh, PA, USA

In Vitro Gas Exchange Performance Of A Pulmonary Assist Device
Designed To Support Chronic Lung Disease Patients
Kalliope G. Roberts, MS1, Erica M. Comber, BS1, Lisa Lee, BS1,
Matthew D. Bacchetta, MD2, David J. Skoog, PhD3,
Keith E. Cook, PhD1; 1Biomedical Engineering, Carnegie Mellon University,
Pittsburgh, PA, USA, 2Vanderbilt University Medical Center, Nashville, TN,
USA, 3Advanced Respiratory Technologies, LLC, Pittsburgh, PA, USA

Study: The LifeSPARC® Pump and TandemLung® Oxygenator comprise an
extracorporeal membrane oxygenation (ECMO) circuit that can provide
full cardiopulmonary support. The LifeSPARC® is a centrifugal pump with
a magnetic pivot bearing that can generate a flowrate of 8 L/min, and the
TandemLung is a radial flow oxygenator that uses plasma resistant fibers
and has pressure drop less than 75 mmHg at 5 L/min. The entire circuit
is compact, with a priming volume of 375 mL. In this study, the system
was used to provide Veno-Venous ECMO support in (n=9) calves (average
weight 85 kg) for 14 days via a Protek-Duo® dual lumen cannula placed in
the inferior vena cava.
Methods: Pump flow was maximized based on available intravascular
volume. Oxygenator performance was monitored daily by measuring
blood inlet and outlet oxygen content. Hematocrit, plasma free hemoglobin (PFH), LDH, platelet counts, and white blood cells were monitored
throughout the study. The safety of the system was evaluated by noting
clinically significant adverse events and by performing gross pathology
and histopathologic examination following euthanasia at the end of the
study.
Results: Eight of the nine animals survived the duration of the study. One
animal died on day 12 due to an acute coagulopathy. Bleeding at the
insertion sites necessitated transfusion in five of the animals. PFH and
LDH levels remained within normal limits throughout the experiment,
though there were transient spikes in PFH following transfusions not
attributed to the device. The LifeSPARC® Pump and TandemLung® Oxygenator demonstrated acceptable reliability and safety in vivo for 14 days.

Study: Over 15 million Americans suffer from chronic lung disease,
resulting in over 168,000 deaths and 726,000 hospitalizations each
year. Transplant is the only curative treatment, but there are only 2,700
transplant surgeries each year. Thus, there is a continuing need for longterm respiratory support. Current extracorporeal membrane oxygenation
(ECMO) cannot be used as permanent therapy due to rapid oxygenator
clot formation, which causes failure within 1-4 weeks, and large bulky
circuits that make patient ambulation impossible without support staff.
The purpose of this study was to test gas exchange performance of a new
Pulmonary Assist Device (PAD) with a smaller fiber bundle (0.9 m2) and
lower prime volume for use in a compact, low thrombogenicity ECMO
system designed to support chronic lung disease patients.
Methods: Bovine blood was citrated, heparinized, then conditioned to
AAMI venous standards in a circuit containing a centrifugal pump, commercial gas/heat exchanger, and a blood reservoir. For O2 transfer measurement, blood was pumped at 1, 2, and 3 L/min with 100% O2 provided
as sweep gas at twice the blood flow rate. At each flow rate, duplicate
blood gas samples were drawn from the inlet and outlet of the PAD and
analyzed to determine PO2, PCO2, pH, and hemoglobin concentration. For
CO2 transfer measurement, blood was pumped at 2 L/min through the
PAD with 100% O2 delivered as the sweep gas at 2.5, 5, and 7.5 L/min. At
each flow condition, duplicate blood inlet and sweep gas outlet samples
were drawn and analyzed for PCO2.
Results: The CO2 transfer rates were measured as 110 ± 2.4, 140 ± 8.7,
and 155 ± 6.1 ml/min at O2 sweep gas rates of 2.5, 5, and 7 L/min, respectively. O2 transfer rates and outlet oxygen saturations were measured as
66.3 ± 0.71 ml/min and 99.8%, 105 ± 1.7 ml/min and 95.9%, and 121 ±
1.6 ml/min and 91.3%, at blood flow rates of 1, 2, and 3 L/min, respectively. The PAD provides sufficient gas exchange to serve as a booster lung
for patients with chronic lung disease.
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The Outcomes Of Mobile Intensive Care Unit With Double Lumen
Catheter Cannulation At Referring Facility For Veno-venous
Extracorporeal Membrane Oxygenation Interfacility Transfer
Toshinobu Kazui, MD, PhD1, Chiu-Hsieh Hsu, PhD2,
Richard Smith, Master of Engineering3,
Cameron Hypes, MD, MPH4, Bhupinder Natt, MD4,
Joshua Malo, MD4, Jarrod Mosier, MD4, David Bull, MD1; 1Cardiothoracic
surgery, Banner University Medical Center Tucson/ University of Arizona,
Tucson, AZ, USA, 2Epidemiology and Biostatistics, Mel and Enid Zuckerman
College of Public Health, The University of Arizona, Tucson, AZ, USA,
3
Artificial heart department, Banner University Medical Center Tucson/
University of Arizona, Tucson, AZ, USA, 4Medicine, Banner University
Medical Center Tucson/ University of Arizona, Tucson, AZ, USA

Outcomes In Patients Requiring Recannulation For Venovenous
Extracorporeal Membrane Oxygenation
Susan Ansley Smith, MD1, Jaimin R. Trivedi, MD, MPH2,
Michael Ritchie, MD2, Matthew C. Black, MD2,
Victor H. van Berkel, MD, PhD2, Matthew P. Fox, MD2; 1Surgery, University
of Louisville, Louisville, KY, USA, 2Cardiovascular and Thoracic Surgery,
University of Louisville, Louisville, KY, USA
Study: Little data exists regarding second-run venovenous extracorporeal
membrane oxygenation in adults. The purpose of this study is to determine outcomes in patients who undergo multiple runs of VV-ECMO within
the same hospitalization for respiratory failure.
Methods: The ELSO database was used to identify all patients over age
18 with respiratory failure who required recannulation for multiple
episodes of VV-ECMO support during the same hospital stay from 1998
to 2018. Patients who underwent lung transplantation were excluded
from analysis. The primary outcome was survival to discharge. Patients
were categorized as survivors or non-survivors and univariate analysis was
performed to compare the two groups.
Results: A total of 500 patients requiring multiple runs of ECMO for respiratory failure were identified. Of these, 12.2% (61) underwent more than
two runs. Patient demographics, laboratory data, and circuit variables are
shown in Table 1. Survival to discharge occurred in 272 patients (54.4%).
Survivors were slightly younger than non-survivors with a mean age of
43 years (range 30-55; p<0.01) versus 49 years (34-60). Survivors and
non-survivors had similar arterial blood gases prior to initiation of ECMO
and a total of 21 patients (11 survivors, 10 non-survivors) underwent
pre-ECMO arrest. No statistical difference was found between duration of
initial or last ECMO run between groups. More non-survivors experienced
neurological (14% v 3%; p<0.01) complications as well as gastrointestinal
bleeding while on ECMO (12% v 6%; p=0.02). Surgical, mechanical, renal,
infectious, and other complications were similar between the two groups.
This is one of the first studies that evaluates adult patients undergoing
multiple runs of VV-ECMO for respiratory failure. Survival to discharge
was slightly lower at 54.4% than overall survival according to the ELSO.
Neurologic and gastrointestinal complications were significantly higher in
non-survivors.

Study: To assess the feasibility of interfacility transfer with mobile intensive care unit (MOBI) after single double lumen catheter cannulation at
referring facility for veno-venous extracorporeal membrane oxygenation
(VV-ECMO).
Methods: This is a single center retrospective data analysis. We utilized
our institutional data from 2015-2019. We divided 2 groups, patients who
had interfacility transfer with MOBI after single double lumen cannulation for VV-ECMO (group A) and patients who had single double lumen
cannulation for VV-ECMO at our institution (group B). Cannulation was
performed at referring facility by either transport team or a surgeon at
the referring facility under fluoroscopic guidance. MOBI consisted of
ECMO physician (either a surgeon or an intensivist), respiratory therapist,
ECMO nurse, and transport nurse. Two groups were compared pre support, complications during the ECMO support, and survival.
Results: There were 20 patients in group A and 33 patients in group
B. Average age were 48.4 ± 13.5 and 45.1 ± 18.0 in group A and B
respectively. Pre ECMO pH, PCO2, PO2, and SaO2 were 7.3 ± 0.2, 7.2
± 0.2 (p=0.08), 59.3 ± 24.2mmHg, 65.0 ± 21.6mmHg (p=0.27), 66.6 ±
45.0mmHg, 69.8 ± 26.3mmHg (p=0.18) in group A and B respectively.
There were 13 and 18 complications in group A and B during the ECMO
support (p=0.57). Circuit component clots 4 and 5 (p=0.72), circuit
exchange 2 and 3 (p=1.00), creatinine 1.5 - 3.0, 1 and 5 (p=0.39), creatinine >3.0 3 and 2 (p=0.35), renal replacement therapy 4 and 6 (p=1.00).
50.0% and 69.7% of patients came off from ECMO support, 50.0% and
45.4% of patients survived to discharge (p=0.18). Double lumen catheter
cannulation at referring facility with MOBI demonstrated good results.
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Utilization And Outcomes Of Extracorporeal CO2 Removal: Systematic
Review Meta-Analysis Of Pumpless And Pump-Based Approaches
Tiffany Z. Yu, BA1, Abhiraj Saxena, BS1, Colin C. Yost, BA1,
Robert T. Tatum, BA1, Elizabeth J. Maynes, MD1,
Thomas J. O’Malley, MD1, Howard T. Massey, MD1,
Justyna Swol, MD2, Bryan A. Whitson, MD, PhD3,
Vakhtang Tchantchaleishvili, MD1; 1Surgery, Thomas Jefferson University,
Philadelphia, PA, USA, 2Department of Respiratory Medicine, Allergology
and Sleep Medicine, Paracelsus Medical University Nuremberg,
Nuremberg, Germany, 3Cardiac Surgery, Ohio State University, Columbus,
OH, USA
Study: Extracorporeal carbon dioxide removal (ECCO2R) is a valuable technique of providing respiratory support to patients suffering from hypercapnic respiratory failure. We sought to evaluate the existing literature
evidence in aggregate and compare the subgroups of patients supported
on pump-based and pumpless ECCO2R devices.
Methods: An electronic search was performed to identify all relevant
studies published between 2000-2019. Demographic information,
medical indications, perioperative variables, and clinical outcomes were
extracted for systematic review.
Results: This analysis included 25 studies comprising 826 patients. 60% of
patients (497/826) were supported on pump-based ECCO2R therapy. The
most frequently observed indications for therapy were acute respiratory
distress syndrome (ARDS) [69%, (95%CI: 53-82%)] and chronic obstructive pulmonary disease (COPD) [49%, (95%CI: 37-60%)]. Mean duration
of support was 6 (95%CI: 4-7) days. Mean time in the ICU was 18 (95%CI:
10-25) days and mean hospital stay was 34 (95%CI: 10-58) days. PaCO2
decreased from 63.1 (95%CI: 55.6-70.7) mmHg pre-intervention to 48.2
(95%CI: 41.5-54.9) post-intervention (p<0.01). In-hospital mortality was
30% (95%CI: 22-38%). When compared to the pumpless ECCO2R subgroup, the pumped ECCO2R subgroup had lower rate of presentation with
ARDS [52% (95%CI: 33-69%) vs 94% (95%CI: 76-99%), p<0.01] and COPD
[42% (95%CI: 32-53%) vs 76% (95%CI: 42-93%), p=0.06]. ICU length of
stay was significantly shorter in the pumped group compared to pumpless
ECCO2R [15 (95%CI: 7-23) vs 42 (95%CI: 17-67) days, p=0.05]. Mean blood
flows were comparable [0.08 (95%CI: 0.5-1.2) vs 1.2 (95%CI: 0-2.6) liters,
p=0.57]. In-hospital mortality was not significantly different [27% (95%CI:
18-38%) vs 36% (95%CI: 24-51%), p=0.26]. Conclusion: Despite effective
CO2 removal, mortality associated with ECCO2R remains high. No ECCO2R
approach appears to have a distinct advantage over the other.

64

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

ASAIO RENAL ORAL ABSTRACTS
REN 2-2
A New Strategy For Treatment Of Patients With Type 1 Cardiorenal
Syndrome With The Impella Microaxial Ventricular Assist Device
Yuriy Dudiy, MD1, Raghad Said, MD2, Mark Anderson, MD1; 1Cardiac
Surgery, Hackensack University Medical Center, Hackensack, NJ, USA,
2
Internal Medicine, Hackensack University Medical Center, Hackensack,
NJ, USA
Study: We evaluated the use of the Impella 5.0 and 5.5 heart pumps as a
strategy to treat CRS and to improve candidacy for heart transplantation
or permanent LVAD implant in a Type 1 CRS patient population who had
developed diuretic resistance and/or inotropic therapy intolerance at a
single U.S. center.
Methods: A chart review of patients diagnosed with CRS Type 1 from
October 2018 to March 2020 treated with the Impella 5.0 or Impella 5.5
heart pumps prior to RRT was conducted. The trigger for primary Impella
heart pump therapy in CRS Type 1 patients was diuretic resistance and/
or inotropic therapy intolerance. Patient demographic, procedural, hemodynamic, blood laboratory results, and outcomes data were obtained and
analyzed.
Results: All patients exhibited improvement in both cardiovascular hemodynamic and renal function. The eGFR demonstrated significant improvement from baseline after 24 hours on Impella support (Pre-Impella eGFR
25 ± 8 mL/min, Post 24 hour Impella 34 ± 13 mL/min, p-value = 0.002),
and after 7 days on support (Post 7 days Impella 51± 18 mL/min, p-value
< 0.001). Patients exhibited reduction in both the pulmonary capillary
wedge pressure (pre-Impella 36.6 ± 8.71 mmHg to post-Impella 18.4
±7.3 mmHg, p-value = 0.02) and central venous pressure (pre-Impella
20 ± 6.95 mmHg to post-Impella 8.88 ± 6.4 mmHg p-value <0.001) with
sustained mean arterial pressures throughout support duration. Impella
was explanted for recovery in three patients, bridge to durable VAD in
nine patients, and bridge to transplant for one patient. This case series
demonstrates the feasibility in using Impella pump support to improve
cardiovascular and renal function in patients with CRS Type 1. Primary
Impella in place of high dosage diuretics, inotropes, and RRT may be used
as strategy for improved candidacy in CRS Type 1 patients for the longterm treatment of heart failure.
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Optimization Of Filtration Flow Rate During Cell-free And Concentrated
Ascites Reinfusion Therapy
Toshiya Okahisa, MD, PhD1, Masahiro Sogabe, MD, PhD1,
Shohei Sato, MEng2, Ryosuke Ogata, MEng2,
Takatoshi Komatsu, MEng2, Yoshiaki Ohnishi, MEng2,
Akira Fukuya, MD3, Kumiko Tanaka, MD, PhD3,
Tetsu Tomonari, MD, PhD3, Hiroshi Miyamoto, MD, PhD3,
Tetsuji Takayama, MD, PhD3; 1General Medicine and Community Health
Science, The University of Tokushima Graduate School, Tokushima, Japan,
2
Clinical Engineering, Tokushima University Hospital, Tokushima, Japan,
3
Gastroenterology and Oncology, The University of Tokushima Graduate
School, Tokushima, Japan.

Some Rheological Effects On Dialyzer Transport Characteristics
Daniel Schneditz, PhD; Physiology, Medical University Graz, Graz,
Austria.
Study: The significant reduction of in-vivo compared to in-vitro dialyzer
clearance has been explained by the viscosity of plasma and by the
reduced diffusivity (D, [m2/s]) of solutes in plasma compared to that in
crystalloid solutions regularly used for in-vitro dialyzer characterization.
The validity of this hypothesis was examined in a series of lab-bench
experiments using homogenous viscous test solutions.
Methods: Low- and high-flux (LF, HF) dialyzers with identical membrane
material, identical membrane area and capillary geometry, but with
different hydraulic membrane permeability were studied (Polyflux 21L,
Polyflux 210H, Gambro Dialysatoren GmbH). Dilute solutions of neutral
dextran (70 kDa, Dextran 70, Carl Roth) and anionic alginate (≈300 kDa,
Algizoon, bizoon GmbH) simulating the range of relative viscosities and
colloid osmotic pressures expected under in-vivo conditions were used
to perfuse the dialyzer blood compartment. Blood- and dialysate side
urea clearances were measured with standard dialysis equipment and
corrected by the magnitude of internal filtration (IF) quantified by a
mathematical model. The resulting clearance (K’) was used to determine
the diffusive dialyzer mass transfer coefficient (K0’, [m/s]) using Michaels’
equation. Results were compared to predictions form the in-series
boundary layer resistance model for solute transport across hollow fiber
membranes and analyzed using the Wilson-plot (Fig. 1, theory shown by
full lines).
Results: For a 4 to 6-fold increase in viscosity K’ only decreased with alginate solutions. This decrease corresponded to the expected increase in
overall transport resistance (1/K0’) as predicted by theory after correcting
for effects of variable IF in both HF and LF dialyzers (Fig. 1a). The correction for IF was not effective for alginate solutions where 1/K0’ decreased
with decreasing D in-spite of comparable relative viscosity and in-spite of
identical magnitudes in IF (Fig. 1b). The mechanisms for this discrepancy
remain to be examined.

Study: Cell-free and concentrated ascites reinfusion therapy (CART) is a
safe and effective treatment for refractory ascites caused by advanced
cancer or cirrhosis. Fever is the most problematic adverse event in CART.
Since filtration flow rate is considered to be associated with fever, low
flow rate (< 50 mL/min) was used. However, to prevent a decrease in
blood pressure and renal damage after ascites drainage, it is desirable
to start reinfusion earlier by processing ascites in a shorter time. In this
study, to optimize the filtration flow rate, we examined the condition of
fever during CART when ascites processing was performed with different
filtration flow rates in the same patient.
Methods: Six patients with advanced cancer underwent 30 sessions of
CART with ascites treatment at two different filtration flow rates (50 mL/
min or 100 mL/min). Ascites processing was performed using the CART
equipment (M-CART), filtration filter (AHF-MOW), and concentration filter
(AHF-UP). Prophylactic infusion of steroids (prednisolone 20 mg or 30 mg)
was administered in all the cases.
Results: Twelve sessions of CART were performed at a flow rate of 50 mL/
min (low-flow group), and 18 sessions were performed at a flow rate of
100 mL/min (high-flow group). The body temperatures of the low-flow
group and the high-flow group before CART were 37.1 ± 0.5 °C and 37.0 ±
0.6 °C, respectively, with no significant increase in body temperature after
CART. The degree of increase in body temperature of the low flow rate
group and the high flow rate group was 0.18 ± 0.60 °C and 0.06 ± 0.52
°C, respectively, with no significant difference. These results indicate that
CART could be performed without fever by prophylactic administration of
steroids, even at a filtration flow rate of 100 mL/min.
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Wearable Device For Measurement Of Intraperitoneal Volume In
Peritoneal Dialysis
Caleb M. Clark, None, Jeremy D. Wasowicz, None,
Christopher Nasseh, BS, Qing tong Xie, None,
Chase H. Rutan, None; Weldon School of Biomedical Engineering, Purdue
University, West Lafayette, IN, USA
Study: The goal of this design is to provide an easy-to-use, wearable
bioimpedance (BI) sensor with a custom circuit design that can measure
impedance across the abdomen during peritoneal dialysis (PD) treatment.
This information can later be used to work as a feedback system for a
cycler PD pump through the circuit design and a signal processing unit.
The pump can be activated at the optimal time for refilling and will stop
pumping once a target IPV is reached. PD is an alternative to hemodialysis as a treatment where fluid waste is filtered through the peritoneum
rather than directly from the blood. Presently, PD machines cannot accurately and continuously measure the intraperitoneal fluid volume (IPV)
during treatment. This limits the efficacy of the treatment and can cause
pain to the patient due to overfilling of the peritoneum with dialysate.
Figure 1. Wearable Measurement Device (Top) Connected to Model
Abdomen and DF50 (Bottom)
It has been previously theorized that an inverse linear relationship exists
between IPV and BI in patients, but this has not been tested with an electrode placement simplified for patient comfort, an issue in the past.
Methods: The methodology continuously records changes in BI as IPV is
adjusted in 500mL increments in a simulated abdomen, through the addition of ionized water in the interior cavity, from an empty state (0mL) to
a filled state (2000mL). These results were gathered from a DF50 device
that was integrated with the model abdomen and fabric.
Results: Through in-vitro testing in a model of a human abdomen, an
inversely proportional relationship between IPV and BI of -0.0273 Ω/
mL across the abdomen was confirmed, providing a linear model for the
calculation of IPV by the signal processing unit that can then be stored
digitally. These early results prove that using BI as a continuous and linear
measurement of IPV during PD is feasible, and that this device shows
promise in being able to optimize the use of PD with patients undergoing
this treatment at home.
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A New PD Catheter To Provide Faster And More Complete Drainage Of
The Peritoneum; In Vitro Studies
Stephen R. Ash, MD1, David J. Carr, MEng2; 1Nephrology, Indiana
University Health Arnett and HemoCleanse Technologies, LLC, Lafayette,
IN, USA, 2R&D, HemoCleanse Technologies, LLC, Lafayette, IN, USA
Study: Tenckhoff catheters drain the peritoneum slowly, with decelerating flow at the end of drainage and varying residual volumes. We have
designed a catheter (Channel Catheter) with long flow channels along
the surface to diminish fluid velocity on outflow and inflow. Small holes
connect each channel to a central lumen. We compared outflow rates of
Tenckhoff and Channel catheters in a realistic physical model of intraperitoneal hydraulics.
Methods: The model was a 5-liter tank half-filled with bowels simulated
by sections of 1” diameter cellulosic dialysis tubing partially filled with
saline. The PD catheter was placed in the middle of the bowels, 1.5 L free
fluid was added to the tank, pressure was applied to the bowel loops, and
catheter outflow rate was measured at -100 cm H2O hydrostatic pressure.
For the Channel catheter outflow rate was over 1200 ml/min regardless of
applied bowel pressure, and flow did not decelerate as free fluid diminished (Figure 1). For curled Tenckhoff catheters (3.5 mm ID), outflow was
about 300 ml/min when 14 cm H2O pressure was applied to the bowels,
and flow decelerated near the end of outflow (Figure 1).
Results:: The Channel Catheter should provide faster and more complete drainage of the peritoneum than the Tenckhoff catheter. It also
should avoid the deceleration which makes “end of outflow” unclear to
patients on peritoneal dialysis. The catheter may also aid in Hyperthermic
Intraperitoneal Chemotherapy (HIPEC), a flow-through procedure which
requires very high outflow rates.
Figure 1. (Left) Channel Catheter, with a straight intraperitoneal portion of
8 mm diameter containing four grooves of 1 mm diameter with numerous
holes in the bottom of each groove. (Right) Rate of fluid outflow from a
Channel Catheter in the physical model of the peritoneum, showing that
outflow rate remains stable at all levels of simulated intraperitoneal pressure (blue line) and rate of outflow from a Tenckhoff curled tip catheter in
the same model (red line).
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Collapsing Glomerulopathy In COVID Patient—A Case Report
Sreedhar Reddy Adapa, MD1, Mytri Pokal, MD2,
Vikram Sangani, MD2, Sasmit Roy, MD3; 1Internal Medicine, Kaweah
Delta Medical Center, Visalia, CA, USA, 2Internal Medicine, Navicent
Health, Macon, GA, USA, 3Internal Medicine, Lynchburg General Hospital,
Lynchburg, VA, USA
Study: In the era of the COVID pandemic, although COVID-related pneumonia is the dominant presenting illness in a majority of these patients,
with significant number of patients developing renal failure. Collapsing
Glomerulopathy has been described in few cases with renal failure who
has African lineage with an APOL1 risk variant allele.
Methods: This case report is focused on acute kidney injury (AKI) associated with Collapsing Glomerulopathy in the setting of COVID associated
pneumonia. A middle aged African American female presented with
pneumonia developed an acute worsening of renal function with proteinuria. Renal biopsy revealed Focal Segmental Glomerulosclerosis with
a collapsing lesion and very extensive effacement of foot process along
with significant tubular injury.
Results: Collapsing Glomerulopathy (CG) was first characterized in the
setting of HIV infection. It was also described in other viral infections,
some drug therapies and auto immune diseases. CG has been recently
described in few patients of African ancestry during COVID pandemic.
It is characterized by a disruption of autophagy and mitochondrial
homeostasis which ultimately induces glomerular epithelial cell death.
A common denominator for many etiologies of CG is the activation of
interferon. Polymorphisms in Apolipoprotein L1 (APOL1) gene in African
ancestry predisposes them to chronic kidney disease. Although precise
mechanism by which APOL1 gene interacts with interferon signaling
pathways is unclear, experimental work has shown that interferon markedly up-regulates levels of APOL1. Acute Kidney Injury is present in one
third of patients infected with COVID-19. CG in setting of COVID has been
only described in patients with African lineage. This suggests that the
presence of genetic predisposition of both African descent and high risk
APOL1 variants in the presence of cytokine mediated acute injury secondary to the virus may be the culprit.
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Outcomes Of COVID-19 Patients With Right Ventricular Dysfunction
Supported On Extra-corporeal Life Support
Jordan Graham, MD, Bindu H. Akkanti, MD, Kha Dinh, MD,
Rahat Hussain, MD, Sachin Kumar, MD,
Ismael A. Salas de Armas, MD, Angelo Nascimbene, MD,
Sriram Nathan, MD, Biswajit M. Kar, MD, Igor D. Gregoric, MD; Advanced
Cardiopulmonary Therapies and Transplantation, The Univ. of Texas
Health Science Center-Houston, Houston, TX, USA.

How Should ECMO Be Utilized During Conditions Of Severe Scarcity? A
Population Study
Max Shin, BA, Jason J. Han, MD, William L. Patrick, MD,
Akhil Rao, BS, Mark Helmers, MD, Amit Iyengar, MD, Salim Olia, PhD,
John J. Kelly, MD, Jacob T. Gutsche, MD,
Christian A. Bermudez, MD, Marisa Cevasco, MD; University of
Pennsylvania, Philadelphia, PA, USA.
Study: Extracorporeal membrane oxygenation (ECMO) is a valuable
rescue option for select COVID-19 patients; however, societal preferences
regarding its allocation remain unknown.
Methods: A 26-question survey regarding ECMO utilization and allocation was distributed to a nationally representative sample via Amazon
Mechanical Turk with minimal incentive ($0.20). Participants were stratified by age (&lt or %gt 40 years) to assess whether belonging to an age
group where ECMO is more clinically relevant would influence people’s
responses. Standard descriptive statistics were utilized.

Study: The aim of this study is to investigate whether right ventricular
(RV) dysfunction is predictive of higher mortality in patients placed on
veno-venous (VV) or veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) due to coronavirus disease-2019 (COVID-19).
Methods: All patients who were diagnosed with COVID-19 acute respiratory distress syndrome (ARDS) and received ECMO support between
2020-2021 were retrospectively identified. Patients were excluded if there
is no documented echocardiogram during the hospital stay or if pointof-care ultrasound examinations were undocumented. Transthoracic
Echocardiogram (TTE) measured RV function.

Results: In total, 1,041 responses were included. They were 37.9±12.6
years old, generally Caucasian (65%), and college-educated (66.1%). Many
reported working in a healthcare setting (22.5%) and having a friend or
family member who was admitted to the hospital (43.8%) or died from
COVID-19 (29.9%). Given a hypothetical scenario regarding themselves
or their immediate loved ones, participants were overall hesitant to
initiate ECMO (NPS -24.4, -19.6, respectively). Over half (54%) reported
they would be unwilling to stay on ECMO for &gt1 week without signs of
recovery. However, at a policy level, participants were highly supportive
of ECMO utilization. When presented with a scenario where resources
became extremely scarce, a near consensus (96.7%) desired the continued use of ECMO to treat COVID patients. Most advocated for prioritizing
those with highest likelihood of recovery (50%) followed by those who
were sickest regardless of survival chances (31.7%) (Figure 1). When
stratified by age, patients &gt 40 years old were more likely to prefer distributing ECMO on a first-come first-serve basis (21.5% vs. 13.3%, p<0.05).

Results: There were 52 COVID-19 patients who were placed on V-V ECMO
or V-A ECMO since the beginning of the COVID-19 pandemic. Of these,
61% had RV dysfunction/failure. Of note, 5 patients did not have a TTE
done while on V-V ECMO/V-A ECMO. When grouped by the presence
or absence of RV failure, there was no statistical difference in baseline
characteristics (hypertension, dyslipidemia, diabetes, history of coronary
artery disease/peripheral artery disease, and tobacco use). In the RV
dysfunction group, the mortality rate was 59% vs. 33% in those without
RV dysfunction (Table 1 and Figure 1). In conclusion, COVID-19 ARDS
patients with RV dysfunction appear to have a higher mortality rate than
those without RV dysfunction. Due to the small cohort size, this trend did
not reach statistical significance. Future studies should be done to further
understand the impact of COVID-19 on the cardiovascular system.
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VV ECMO And Oxy-RVAD As Therapeutic Modalities For Respiratory
Failure In COVID-19 Patients: Preliminary Experience
Kelli Hu, None, Viktoriya Kagan, ARNP, MSN, Rebecca Rose, Other,
Karen Meehan, Other, Justin Okray, PA-C,
Shana Creighton, Msn, ACNP-BC, Colleen LaBuhn, ARNP, MSN,
Valluvan Jeevanandam, MD, Tae Song, MD,
Sandeep Nathan, MD, MS; Cardiac Surgery, University of Chicago,
Chicago, IL, USA.

Low-flow Respiratory Dialysis System To Improve Refractory Hypercarbic
Respiratory Acidosis In COVID-19
Bindu Akkanti, MD1, Kha Dinh, MD1, Sugeet Jagpal, MD2,
Ribal Darwish, MD3, Ramiro Saavedra-Romero, MD4,
Keith Scott, MD5, Sabiha Hussain, MD2, Kyle Enfield, MD6,
Mohamed Saad, MD7, Vernick Bill, MD8, Abhijit Duggal, MD9,
Sean Lee, MD10, Bhupinder Sangha, MD11,
Steven Conrad, MD12; 1Medicine, Divisions of Pulmonary and Critical
Care, UT McGovern Medical School, Houston, TX, USA, 2Medicine,
Divisions of Pulmonary and Critical Care, Rutgers Robert Wood Johnson
Medical School, New Brunswick, NJ, USA, 3Critical Care Medicine,
Palm Beach Gardens Medical Center, Palm Beach Gardens, FL, USA,
4
Critical Care Medicine, Abbott Northwestern Hospital, Minneapolis,
MN, USA, 5Medicine, Louisiana State University Health Sciences Center,
Shreveport, TX, USA, 6Medicine, Divisions of Pulmonary and Critical
Care, University of Virginia Health, Charlottesville, VA, USA, 7Medicine,
University of Louisville, Louisville, KY, USA, 8Cardiothoracic Surgery,
University of Pennsylvania, Philadelphia, PA, USA, 9Medicine, Cleveland
Clinic Foundation, Cleveland, OH, USA, 10Emergency Medicine, Wellstar
Medicine, Marietta, GA, USA, 11Medicine, Guadalupe Regional Medical
Center, Seguin, TX, USA, 12Medicine, Louisiana State University Health
Sciences Center, Shreveport, LA, USA.

Study: COVID-19 carries a high mortality rate in severe cases and in
those that develop severe acute respiratory distress syndrome (ARDS).
Veno-venous extracorporeal membrane oxygenation (VV ECMO) can
offer mortality benefits in cases of COVID-19 associated ARDS. Here we
describe our center’s initial experience with COVID-19 patients requiring
VV ECMO support.
Methods: We retrospectively reviewed all COVID-19 patients who were
placed on VV ECMO or oxy-RVAD support from May 2020 to January 2021
at a high volume academic medical institution. Collected data included
patient demographics, length of support, type of cannulation, LOS after
decannulation, and survival to discharge.
Results: A total of 16 patients required VV ECMO support for COVID19 associated ARDS. Of these, 5 were subsequently converted to an
Oxy-RVAD (31.25%). The median length of VV ECMO support and LOS
after decannulation was 25.37 days and 8.62 days, respectively. In total,
9 patients survived to discharge (56%) and 3 are currently admitted
(18.75%). Our data adds to the support of using VV ECMO to treat ARDS
in COVID-19 patients. Further, we demonstrated how oxy-RVAD can offer
additional ambulatory and right ventricular support for patients who
develop RV dysfunction.

Study: COVID-19 has led to significant morbidity and mortality worldwide.
While lung protective ventilation leads to improved mortality, it may also
lead to the detrimental consequence of severe hypercapnic respiratory
failure. In these cases, low flow dialysis system such as ECCO2R may have
a potential role. Hemo-Lung, a ECCO2R device by Alung technologies was
granted EUA by FDA in setting of COVID-19 and objective of the study
was to evaluate the clinical outcomes of patients supported on low-flow
extracorporeal carbon dioxide removal in the setting of COVID-19.
Methods: This is a retrospective cohort analysis of patients that have
been supported with ECCO2R in the setting of hypercapnic respiratory
failure secondary to COVID-19. Those with discharge data available were
evaluated for outcomes from centers across the United States that have
utilized this device.
Results: In total, data is currently available from fifty-three patients that
have been supported on the Hemo-Lung in setting of COVID-19 ARDS with
discharge status known. The primary outcome studied was survival at
48hrs post cannulation and secondary outcomes studied included mortality and adverse events. Hemo-Lung was also utilized in two sites that did
not have established ECMO programs. The average age of the cohort
was 55 years of age with a BMI of 33.41 with no significant difference
between survivors and non-survivors. The median duration of Hemo-Lung
in survivors was 8.9 days in survivors and 6 days in non-survivors with no
statistical significance. Seventeen percent of the patients (25% survivors,
13% non-survivors) were bridged from Veno-Venous ECMO to Hemo-Lung
or were cannulated with Hemo-Lung for persistent respiratory acidosis
after decannulation from Veno-Venous ECMO. Two patients had adverse
events due to vascular access complications. The overall survival at 48 hrs
post cannulation was 85 percent in the cohort with survival at discharge
of 30 percent.
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Results: We cannulated 15 patients for VV ECMO via RIJ dual lumen catheter cannulation between 3/1/2020 and 12/31/2020. Mean duration of
VV ECMO was 859 hours, and survival to discharge is 53% with 2 patients
still in the hospital after decannulation. There were no major cannulationassociated complications.

A Safe Bedside Protocol For Dual Lumen RIJ Cannulation For
Venovenous ECMO In COVID-19 Patients With Severe ARDS
Stephanie Cha, MD1, Bo S. Kim, MD2, Errol Bush, MD3; 1Department of
Anesthesiology and Critical Care Medicine, Johns Hopkins University,
Baltimore, MD, USA, 2Department of Pulmonology and Critical Care
Medicine, Johns Hopkins University, Baltimore, MD, USA, 3Department of
Surgery, Johns Hopkins University, Baltimore, MD, USA.
Study: In appropriately selected patients with COVID-19 ARDS, venovenous extracorporeal membrane oxygenation (VV ECMO) may offer a
promising bridge to lung recovery. Cannulation for VV ECMO via a RIJ
dual-lumen catheter technique vs. conventional technique may provide
improved delivery of oxygenated blood by utilizing bicaval venous drainage and improve overall survival. Placement of RIJ dual-lumen catheters,
however, requires guidance by either fluoroscopy or transesophageal
echocardiography (TEE) to minimize risk of cardiac perforation, vascular
injury, or malposition. Transport to the operating room is not always
feasible in unstable patients. Here we describe our center’s experience
developing a bedside protocol for RIJ dual lumen cannulation under TEE
guidance, with special attention to infection control, as well as patient
and personnel safety.

Methods: COVID-19 patients were selected for VV ECMO by a designated
panel. Bedside cannulation was performed by a small, multi-disciplinary
team, equipped with an “ECMO Go-Bag” of surgical equipment. Cannulation was achieved by RIJ venous access and TEE monitoring during placement of distance-marked wires, dilators, and ultimately the dual-lumen
catheter. Room choreography is shown in Figure 1. Surgical prep is shown
in Figure 2. Example TEE imaging is shown in Figure 3.
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Platelet Function At The Intersection Of COVID-19 Cytokines And
Mechanical Circulatory Support: A Closed Loop In Vitro Study
Kaitlyn R. Ammann, PhD, Sami B. Muslmani, None,
Samuel M. Miller-Gutierrez, BS, Yana Roka-Moiia, PhD,
Marvin J. Slepian, MD; University of Arizona, Tucson, AZ, USA.

A Virtual Collaborative Heart Failure Shared-care Clinic For Underserved
Patient Populations In The Covid-19 Pandemic.
Angela M. Washenko, RN, BSN1, Rachell L. Mayberry, Other1,
Johanna Loftis, Other2, Shamika Homer, Other2,
Erin S. Davis, RN, BSN1, Marci D. Berry, RN, BSN1,
Marisca A. Nelson, RN, BSN1, Stephanie N. Ung, RN, BSN1,
Jayne K. Magish, RN, BSN3, William H. Perry, RN3,
Craig H. Selzman, MD1, Omar Wever-Pinzon, MD1,
Josef Stehlik, MD, MPH1, Kevin S. Shah, MD1,
Stavros G. Drakos, MD, PhD1, Michelle S. Khoo, MD2; 1University of Utah
Health, Salt Lake City, UT, USA, 2Khoo Cardiology, Albuquerque, NM, USA,
3
Abbott Laboratories, Pleasanton, CA, USA.

Study: A pathophysiologic component of severe COVID-19 is release and
circulation of pro-inflammatory cytokines or “cytokine storm,” with associated thrombus formation and embolization often occurring. Compromised patients often require extracorporeal oxygenation and mechanical
circulatory support (MCS), further imparting blood flow disturbances
which amplify thrombosis. Central to these processes is the platelet.
The dynamic interaction of MCS flow/shear + inflammatory cytokines
and their propensity for altering platelet function remains unknown.
We hypothesized that platelet aggregability is modified in an MCS + proinflammatory cytokine environment. We examined platelet aggregation
as a function of time, exposing platelets to COVID-19-associated cytokines
under MCS flow in vitro.
Methods: An Impella 5.5 was affixed in a Tygon closed loop and
positioned with outflow cannula in a 1-inch tube region, maintained at
60mmHg pressure. Porcine PRP, obtained via centrifugation of fresh,
anticoagulated (10% ACD) whole blood was used as circulating fluid.
Cytokines alone or “COVID-19 cocktail” of porcine IL-6 (4.5 ng/mL), IL-1β
(0.5 ng/mL), IL-8 (2.7 ng/mL), and TNFα (1 ng/mL) were added to PRP and
circulated at 5 L/min. At 0, 1, and 4 hrs, platelet aggregation with ADP
(20uM), collagen (5ug/mL), or calcium ionophore (CaI; 5uM) was determined using light transmission aggregometry.

Study: In the Mountain West, there is less access to centers that provide
advanced heart failure therapy (AHFT) such as mechanical circulatory support (MCS) and heart transplantation. Many patients in the broader areas
of New Mexico may be unaware of AHFT treatment options. They have to
travel great distances and across state lines for AHFT with additional fears
related to the COVID-19 pandemic. In order to overcome these obstacles,
we initiated a virtual collaborative shared-care (VCSC) model for underserved patient populations.
Methods: The University of Utah AHF program began virtually collaborating with a private cardiology practice in Albuquerque, New Mexico. This
collaboration involved meeting monthly virtually in clinic for early identification and safe implementation of treatment strategies for patients with
AHF in the setting of a pandemic. This clinic allowed a MCS nurse and
AHF cardiologist to remotely connect and consult with the New Mexico
cardiologist and prospective patients.
Results: In these VCSC clinics, we achieved joint patient care planning
safely and efficiently during the pandemic. Potential AHFT patients
were identified earlier in their disease process and enhanced trust and
understanding was fostered between providers and patients. A total of 20
AHF patients were evaluated. Two patients received successful elective
durable MCS implantation. Two patients were identified and began evaluation for heart transplantation. The remaining patients are being closely
followed through VCSC. Since the COVID-19 pandemic outbreak in the
United States, we have used this VCSC approach to reach underserved
patients. This approach demonstrates shared effort to deliver efficient
and effective care to underserved patient population that may benefit
from AHFT. Future efforts to utilize VCSC clinics should be considered, and
additional research is needed to assess patient and provider satisfaction
of this approach.

Results: Shear/flow exposure in the cytokine environment led to a
decrease in agonist-mediated aggregation (53% w/ADP, 57% w/collagen)
compared to resting. Fig. 1 depicts (A) ADP-mediated platelet aggregation
(area-under-curve; AUC) and (B) collagen-mediated platelet aggregation
at each timepoint, standardized to resting PRP. A non-significant decrease
in aggregation was observed with 5uM CaI. These findings suggest that
in the setting of shear, cytokines are pro-aggregatory; however they are
inducing effects via specific pathways or receptors.
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“Digital Dance”: Signatures Of A Demi Plié Via Stretchable Electronic
Wearable Sensors
Karli G. Ramsey, None, Hailey L. Swanson, BS,
Kaitlyn R. Ammann, PhD, Marvin J. Slepian, MD; University of Arizona,
Tucson, AZ, USA

Thrombogenic Activity Of Von Willebrand Factor Under Shear On
Biological Substrates In A Microfluidic Device
Connor T. Watson, BS, Shane C. Ward, None,
Keefe B. Manning, PhD; Biomedical Engineering, The Pennsylvania State
University, University Park, PA, USA

Study: Dance is a form of artistry that has increasing medical value. To be
effective dance must be performed correctly with exacting body and limb
movements. In classical ballet, classes/training are specifically designed to
promote proper muscular engagement and alignment, fostering accuracy
and safety. We developed a range of wearable sensors using stretchable
electronics that may be utilized to define and quantitate human motion.
Here we evaluated the movements of the demi plié, the most foundational ballet move, using these sensors ‒examining the path of knee
motion and orientation of the pelvis. We hypothesized that deviations in
motion signatures are identifiable between subjects correctly vs. incorrectly performing demi pliés.
Methods: Stretchable motion sensors (BioStamps) were placed on the
left tibialis anterior and sacrum of three classically trained, injury-free,
collegiate-level dancers as they participated in all three of the following
conditions: (1) correct demi pliés, (2) incorrect demi pliés with an anterior
pelvic tilt, and (3) incorrect demi pliés with a posterior pelvic tilt. For all
conditions, acceleration and gyroscope data was collected in the X, Y, and
Z axes.
Results: In all cases knee and pelvic motion signatures were detectable,
clearly defined and analyzable. Inter-participant variations of knee movement during correct demi pliés were found. One-way ANOVA indicated
knee range of motion across conditions was insignificant with an average
amplitude of -0.775g (p>0.05). In contrast, sacrum acceleration was
significantly different between all three conditions, with conditions 2 and
3 having the same amplitude but opposite directionality (p<0.01). Hence
wearable sensors offer the potential for tracking limb and other body
element movement during classical ballet and related dance forms. This
approach offers great potential for enhanced accurate and safe dance
‒for both artistry and medical dance therapy.

Study: A crucial component of the coagulation cascade is the von Willebrand Factor (vWF). This bloodborne glycoprotein functions by connecting platelets in the freestream to the subendothelial matrix in high shear
flows. Left ventricular assist devices (LVADs) apply pathological shear
significantly higher than that of physiological conditions. The primary
goal of this study is to observe the adhesive behavior and thrombogenic
contribution of vWF on biomaterials, leading to novel strategies to reduce
thrombosis mediated by implanted devices.
Methods: A microfluidic channel was fabricated to serve as a base for
collagen and cultured endothelial cells (ECs). Human type I collagen
was diluted to 100ug/mL and used to coat the channel area. Human
pulmonary artery ECs were passaged and adhered to an initial fibronectin
coating. Titanium alloy Ti-6Al-4V was polished to a mirror finish to mimic
surface conditions within an LVAD. Conjugated antibodies specific to vWF
were acquired to allow for immunofluorescent microscopy. Platelets
were stained through incubation with lipophilic dye DiOC6. Micro-particle
image velocimetry was used to quantify the flow.
Results: Deposition of isolated vWF onto a collagen substrate was
characterized, demonstrating that shear rate has a direct effect on
deposition of vWF multimers or mechanically cleaved monomers, while
having little effect on the chemically fragmented subdomains generated
by ADAMTS13. Investigating vWF deposition in low shear conditions is
crucial in understanding how high shear alters adhesive function. This
study has taken a step towards understanding the behavior of vWF under
physiological conditions in relation to the presence of biomaterials.
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Digitizing the Range of Motion in Bicep Curl Exercise: Signatures of
Exercise Movements of Motion via Stretchable Electronic Wearable
Sensors
Marvin J. Slepian1, Sage I. Nye, MD2, Brayden R. Kaiser, MD2,
Hailey L. Swanson, MD2, Rebecca C. Slepian, MD2; 1Medicine and
BioMedical Engineering, University of Arizona, Tucson, AZ, USA, 2Sarver
Heart Center, University of Arizona, Tucson, AZ, USA

Remote Joint Motion Flexibility Assessment Utilizing a Cell-Phone Based
Capture and Analysis System
Hailey L. Swanson1,2, Karli G. Ramsey1,2, Joseph M. Hoffman1,
Jung Hung Chien PhD4, Haley E. Furman, Ashley C. Vincent,
Rebecca C. Slepian1,2, Ka-Chun Siu PhD4,
Marvin J. Slepian MD1,3; 1Department of Medicine, Sarver Heart Center,
University of Arizona, Tucson, AZ, 2Department of Physiology, College of
Medicine, University of Arizona, Tucson, AZ, 3Department of Biomedical
Engineering, College of Engineering, University of Arizona, Tucson, AZ,
4
University of Nebraska Medical Center, Omaha, NE

Study: Analysis of motion signatures during exercise training is beneficial in prediction, diagnosis and treatment of improper musculoskeletal
activation. In the “COVID/post-COVID” world, at-home exercising has
become a new standard, placing unprecedented reliance on the individual
to maintain proper form, independent of outside coaching. Recognition of
abnormalities in muscular activity in 3-dimensions will allow for accurate
monitoring of human exercise techniques. We developed wearable
sensors utilizing stretchable electronics capable of monitoring triaxial
acceleration and angular velocity; as well as EMG. We hypothesized that
these sensors, would capture exercise muscular activity, generating a
“signature” for analysis of improper and proper form.
Methods: Wireless, stretchable sensors (BioStampRC, MC10) were placed
on the dominant right arm of regular gym attenders (1M, 2F). All subjects
were healthy controls and free from neuromuscular diseases. Subjects
were asked to perform a series of bicep curl exercises with various dumbbell weights that activated a variety of limb muscles over a fifteen-minute
session. EMG, angular velocity, and acceleration were measured for all
participants, both pre-and post-workout.
Results: A clearly defined and analyzable bicep curl motion signature was
detectable for all cases.
The average time of repetition for five series of one bicep curl variation
across subjects was 3.79 ± 0.17 s. EMG activation of the biceps brachii,
triceps brachii, brachioradialis, and medial deltoid were compared for the
whole range of motion. The biceps brachii showed statistically significant
differences (p < 0.05) with an average EMG reading of 9.66 ± 0.169 mV
activation, while the triceps brachii, brachioradialis and medial deltoid
show statistically insignificant differences (p > 0.01). These signatures of
motion demonstrate clear potential for tracking musculoskeletal activation during strength-and-conditioning exercises. The use of wearable
sensors and motion capture offers opportunity for improved form and
safety of strength training exercises for both athletic training and strength
rehabilitation.

Study: Human motion while a primary component of daily living is
often one of the first life functions effected by aging and disease. Joint
flexibility is vital element of normal human motion often compromised
by injury and arthritis. Ready characterization of joint compromise and
flexibility is a desired goal to aid diagnosis and management. Previously
we developed a smart phone-based motion analysis tool, Mo2Ca, able
to characterize overall human movement. Here we advance this method
to be able to capture and characterize body component movements
indicative of joint flexibility. We hypothesized that this tool will effectively
capture and quantitate the movement of large and small joints defining
their flexibility. We specifically determined the angle (degrees) produced
in a select series of range of motion routines.
Methods: Normal volunteers (n=4, 2M/2F, average age= 22±2) placed
visual markers (1cm2) on lateral aspects of ankle-knee-hip joints, or
forearm-wrist-fingers. Subjects performed a defined knee and wrist
flexion and extension protocol which was captured by local smartphone.
Images were sent to investigators and then analyzed remotely using the
Mo2Ca system to assess extent of flexibility (flexion and extension) for
both large-joint and small-joint movement. The protocol was purposely
performed with a remote analysis component to demonstrate utility for
telehealth applications.
Results: The smart-phone MoCa2 system was able to capture motion
of both large and small joints. Utilizing the markers placed, the system
had the resolution to calculate the extent of joint motion to determine
overall flexibility. After setting the maximum peak flexion as “zero,” the
average maximum peak extension angle was calculated as 73 ± 2° for the
knee joint and 59 ± 3° for the wrist joint (see figure). These measurement
now serve as a baseline for future analysis of normal volunteers over a
range of ages; and subsequently patients with a range of arthritides. The
digital recording of joint range of motion has the potential to expand the
realm of telehealth within medicine and surgery, offering the capability to
assess and track joint flexibility with illness, injury, treatment and following joint replacement procedures as well.
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Successful Resuscitation Of Ex-vivo Hearts After Twelve Hours Of Cold
Ischemia Using Normothermic Perfusion
Matthew D. Johnson, MD1, Brian P. Fallon, MD1,
Hannah Shenton, BS1, Mark Langley, BS, MS1,
Adrianna Kayden, BS1, Jonathan Haft, MD2,
Daniel H. Drake, MD1, Gabe Owens, MD, PhD3,
Alvaro Rojas-Peña, MD1, Robert H. Bartlett, MD1; 1Department of Surgery,
University of Michigan, Ann Arbor, MI, USA, 2Department of Cardiac
Surgery, University of Michigan, Ann Arbor, MI, USA, 3Department of
Pediatrics, University of Michigan, Ann Arbor, MI, USA

Use Of Three Dimensional Echocardiography To Determine Impella
Device Positioning And Potential Impact On Hemolysis
Alexander Qin, BS, Minnu Mudigonda, MD,
Richard Cheng, MD, Claudius Mahr, DO,
Jennifer Beckman, MSN, ARNP, James N. Kirkpatrick, MD; University of
Washington, Seattle, WA, USA
Study: Cardiogenic shock (CS) is a state of hypoperfusion due to low
cardiac output and insufficient oxygen delivery to end-organs.Temporary
percutaneous ventricular support devices (pVADs) have been increasingly employed to treat refractory cardiogenic shock. Impella (Abiomed,
Danvers, MA) devices are continuous flow, catheter-based pVADs that
provide circulatory support using a microaxial rotor. The company’s user
manual suggests placing the inflow port (IP) 3.5cm below the aortic valve
(AV). However, there is limited evidence to support what positions reduce
adverse outcomes. We developed a novel three-dimensional echocardiography (3DE) analysis protocol to measure the distance between the
device and intracardiac structures. We then assessed the association of
various echocardiographic-based measurements with hemolysis.
Methods: Using the QLAB software (Philips, Amsterdam, Netherlands)
we analyzed 198 3DE full volume PLAX acquisitions TTE studies from
112 patients. The AV, MV, and apical axis are used to orient the coordinate system. The XY plane is orthogonal to the apical axis. The YZ plane
intersects both the AV and MV coaptation points. Three positions were
marked along the Z axis to measure the device in the XY plane.

Study: The current standard for organ preservation is cold storage up to
6hr, with resuscitation upon transplantation. Being able to extend organ
preservation length could impact the limitations of heart transplantation.
This study aims to assess heart resuscitation and organ viability using a
novel normothermic ex-vivo heart perfusion (NEVHP) system with continuous hemofiltration (HF) after 12hr of cold ischemia.
Methods: Hearts from 6-10kg piglets were procured after antegrade cardioplegia. Cannulae placed in the aorta, pulmonary artery, and left ventricle (LV) maintained the NEVHP circuit. An LV pressure balloon allowed
for hemodynamic monitoring. After procurement and cannulation,
hearts (n=3) were stored in University of Wisconsin solution at 5 degrees
centigrade for 12hr. The circuit was primed with heparinized platelet- and
leukocyte-reduced blood. Hearts then underwent NEVHP for 8hr with
in-parallel HF (Prismaflex HF1000) at 1cc/hr/g cardiac tissue and Filter
Replacement Fluid infusion at an equal rate to maintain circuit euvolemia.
Hemodynamic and laboratory data were compared using paired student’s
t-tests (p<0.05 considered significant).
Results: All hearts were viable at 8hr, at which point they were electively
terminated. Mean LV systolic pressure was 43.6±9.8 mmHg (Figure 1A).
Mean coronary resistance was 0.64±0.10 mmHg/mL/min/100g tissue
(Figure 1B). Mean oxygen consumption was 5.45±0.68 mL/min (Figure
1C). Mean serum lactate was 2.58±0.21 mmol/L (Figure1D). These values
did not significantly change from the time of NEVHP initiation to hour 8.
Average weight gain was 6±2 grams. All hearts had an increased inotropic
and chronotropic response to epinephrine at hour 8. NEVHP successfully
resuscitates donor hearts after 12hr of cold ischemia without significant
deterioration in tissue viability at 8hr. This has potential to increase organ
availability for transplantation by circumventing the time restrictions
imposed by geographic location.

Results: We performed a longitudinal analysis using Generalized Estimating Equations. All analyses were adjusted for age and gender. The odds
ratio for correlation of LVEDD to the occurrence of a hemolysis event was
significant at 0.5, indicating a 50% decreased risk of a hemolysis event
for every 1 cm increase in LVEDD (p = 0.029). For continuous LDH, a 1 cm
increase in LVEDD was correlated with a decrease in LDH by 426 u/l/cm.
There was a nonsignificant trend toward a correlation between MV-IP
distance and LDH greater than 600 g/dL (p=0.061). For time between
implantation and time between study, one additional day was correlated
with a decrease in LDH by 86 u/l/days.
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Vasoactive Inotrope Score And Outcomes In Patients Bridged To Heart
Transplantation With Axillary Impella 5.5 Vs Durable Left Ventricular
Assist Device
Rohan M. Goswami, MD1, Alexander Heckman, MD2,
Krithika Krishnarao, D.O.1, Parag Patel, MD1,
Basar Sareyyupoglu, MD3, Daniel Yip, MD1, Juan C. Leoni, MD1,
Si Pham, MD3, Kevin Landolfo, MD1; 1Department of Transplant, Mayo
Clinic Florida, Jacksonville, FL, USA, 2Department of Cardiology, Mayo
Clinic Florida, Jacksonville, FL, USA, 3Department of Cardiothoracic
Surgery, Mayo Clinic Florida, Jacksonville, FL, USA

Creating SARS-CoV-2 (COVID-19) Sample Collection Test Kits
George Pantalos, PhD1, Sienna Shacklette, BS2, Clara Jones, BS2,
Justin Gillham, BS3, Forest W. Arnold, MD4,
Phillip Bressoud, MD5, Donghoon Chung, PhD6,
Gerald Grant, Other7; 1Cardiovascular and Thoracic Surgery, University
of Louisville, Louisville, KY, USA, 2Bioengineering, University of Louisville,
Louisville, KY, USA, 3Mechanical Engineering, University of Louisville,
Louisville, KY, USA, 4Division of Infectious Diseases, University of Louisville,
Louisville, KY, USA, 5Campus Health Services, University of Louisville,
Louisville, KY, USA, 6Center for Predictive Medicine, University of Louisville,
Louisville, KY, USA, 7Department of Rehabilitative and Restorative
Dentistry, University of Louisville, Louisville, KY, USA

Study: Optimization prior to heart transplantation (OHT) is key to
improved outcomes and reduced post-operative complications. Higher
vasoactive inotrope scores (VIS) have been associated with worse outcomes in the critically ill. As a result of advances in device technology and
recent UNOS listing changes, durable left ventricular assist devices (LVAD)
have been thought to confer limited benefit in patients awaiting OHT as
bridge therapy (BTT).
Methods: We performed a retrospective single center review of patients
who underwent orthotopic heart transplantation between January 1,
2019 and December 31, 2020. All patients with axillary impella or LVAD
were evaluated. Descriptive statistical analysis was performed to assess
VIS, cardiopulmonary bypass time (CPB) and length of stay.
Results: 82 patients underwent OHT during our study period of which
28 (34%) utilized a device as BTT. 15 (54%) underwent axillary impella
placement and 13 (46%) had durable LVAD. Average age was 60 in the
impella group (13M and 2F) and 51 in the LVAD group (8M and 5F).
Median VIS score was lower, p=0.05, in the impella group (6, IQR 4-12)
compared to the LVAD group (9.8, IQR 7- 14). CPB time was statistically
shorter when comparing impella vs. LVAD groups, p=0.009 (179 min vs.
221 min). Multivariate analysis did not demonstrate a statistically significant difference between VIS score and time from transplant to discharge
(p=0.277). Median days from transplant to discharge was 12 (IQR 11-15)
in the impella group and 14 (IQR 12-32) in the LVAD group. This data
demonstrates the potential benefits of axillary support prior to transplantation with a significantly lower VIS, likely due to improved pre-transplant
optimization leading to statistically shorter CPB times and less post-cardiotomy shock. Larger studies and pooled center data may provide further
insight into the benefits of impella support as BTT for OHT.

Study: The rapid transmission of COVID-19 exceeded the availability of
commercially produced detection methods. An interdisciplinary collaboration was organized to identify, validate, and implement a component
fabrication and assembly process for sample collection test kits used to
detect COVID-19 by RT-PCR analysis to meet clinical and research needs at
the University of Louisville.
Methods: A review of commercial kits determined six components were
needed: (1 & 2) a 6”x9” biohazard bag with a document pouch was use
for the kit container and sample transport bag, (3) instructions for use
(reviewed by public health nurses) were printed on stickers and adhered
to the biohazard bag, (4) a sterile 15 mL centrifuge vial with a sealed cap
was used for the sample vial, (5) sterile viral transport media prepared
from a CDC recipe was dispensed into the vials, and (6) a sterile nasopharyngeal swab (FDA Class 1 device) with a domed, open lattice tip designed
in Autodesk Fusion 360 and printed from Envisiontec E1 guide soft material resin by direct light projection on a NewPro1 3D printer. Every swab
was inspected for defects. Accepted swabs were packaged and sterilized
using steam autoclave. Swab efficacy was validated in a cohort prospective clinical study of 30 non-consecutive patients and healthcare workers
with paired samples taken with commercial and 3D printed swabs. With
confirmation of agreement between the swab types, production of test
kits with 3D printed swabs began.
Results: It was determined that 350 swabs could be made per print
run with two print runs possible daily. The swab inspection acceptance
rate was 80-85%. Test kit assembly rates of 600 to 1000 kits/day were
achieved with costs ($3.50) ≤ commercial kits. Clinical comparison of
swab types found 90% agreement, 89% sensitivity, and 92% specificity.
Feedback from kit users was acceptable with over 11,500 kits distributed
for use to date. This rapid, collaborative development process provided
effective sampling test kits to support COVID-19 research and clinical
screening.

77

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

ASAIO DISPLAY POSTER ABSTRACTS
P9

P10

Modulation Of COVID-19-associated Cytokines In Mechanical Circulatory
Support: A Closed Loop In Vitro Study
Kaitlyn R. Ammann, PhD, Sami B. Muslmani, None,
Samuel M. Miller-Gutierrez, BS, Yana Roka-Moiia, PhD,
Marvin J. Slepian, MD; University of Arizona, Tucson, AZ, USA

Paralysis Secondary To Intracranial Venous Hypertension Following VV
ECMO Dual-Lumen Jugular Cannulation: A Sentinel Report
Fatima G. Wilder, MD, MS1, Zachary O. Enumah, MD1,
Jinny Ha, MD2, Bo Soo Kim, MD3, Sung-Min Cho, D.O.4,
Stephanie Cha, MD5, Ferdinand Hui, MD6, Michael Grant, MD5,
Stephen Broderick, MD2, Errol L. Bush, MD2; 1Cardiothoracic Surgery,
Johns Hopkins Hospital, Baltimore, MD, USA, 2Thoracic Surgery, Johns
Hopkins Hospital, Baltimore, MD, USA, 3Pulmonary Critical Care, Johns
Hopkins Hospital, Baltimore, MD, USA, 4Neurology, Neurosurgery,
Anesthesia/Critical Care, Johns Hopkins Hospital, Baltimore, MD, USA,
5
Anesthesiology and Critical Care Medicine, Johns Hopkins Hospital,
Baltimore, MD, USA, 6Radiology and Neuroradiology, Johns Hopkins
Hospital, Baltimore, MD, USA

Study: Severe COVID-19 infection results in pulmonary and cardiac
compromise, often requiring extracorporeal oxygenation and mechanical circulatory support (MCS). Accompanying severe COVID-19 is a burst
of hyperinflammatory cytokines referred to as “cytokine storm.” Prior
studies have shown MCS shear forces alter circulating protein structure
and function, e.g. von Willebrand factor, yet it is unknown what effect
MCS device flow and shear has on COVID-19-associated cytokines. We
hypothesize that MCS-generated flow alters cytokine binding, structure,
or function. Utilizing a closed loop in vitro we investigated alterations of
COVID-19-associated cytokines following circulation with MCS (Impella
5.5 or CentriMag).
Methods: CentriMag or Impella 5.5 were affixed in a Tygon closed loop.
Impella was positioned with outflow cannula in a 1-inch tube region and
maintained at 60 mmHg pressure. Porcine platelet poor plasma (PPP)
obtained via centrifugation of fresh, anticoagulated (10% ACD) whole
blood was the circulating fluid. Cytokines alone or “COVID-19 cocktail’’
containing porcine IL-6 (4.5 ng/mL), IL-1β (0.5 ng/mL), IL-8 (2.7 ng/mL),
and TNFα (1 ng/mL) were added to PPP prior to filling loops. Loops were
run at 5 L/min and sampled at 0, 1, and 4 hrs for analysis of cytokine binding via ELISA, compared to resting.
Results: Cytokine-antibody binding was altered following circulation,
indicative of flow-mediated modulation of cytokine epitope availability. After 4 hrs, an increase in IL-6 antibody binding was observed with
Impella, and a similar increase in IL-8 detected with CentriMag. No
significant change was noted for IL-1β or TNFα after 4 hrs circulation with
either system. Interestingly, when cytokines were combined, changes
in antibody binding were no longer evident. Future investigation, e.g.
with whole blood, is required to define additional mechanistic aspects of
these cytokine alterations to offer potential clinical utility for informing
improved therapy.

Study: Veno-venous extracorporeal membrane oxygenation (VV-ECMO)
has become established as adjunctive therapy for patients with severe
ARDS secondary to COVID-19. We report the first case of self-limited
neurologic sequelae secondary to intracranial venous hypertension after
initiating VV-ECMO in a patient with COVID-19 respiratory failure.
Methods: A 60-year-old healthy male was found to be COVID-19 positive with associated Klebsiella pneumonia. Despite maximal medical
and mechanical ventilatory therapy, his disease progressed and was
complicated by disseminated HSV and barotrauma induced right lung
bronchopleural fistula. Due to inadequate ventilation, he was initiated on
VV-ECMO via a dual lumen right internal jugular venous (RIJV) cannula. He
experienced recurrent episodes of transient neurological deficits such as
facial droop, encephalopathy, quadriplegia, and sensory loss that would
self-resolve within hours. Head/spine computed tomography, spinal angiography, and lumbar puncture were unremarkable. Cerebral angiography/
venography demonstrated an elevated venous pressure (15 mmHg) at
the torcula along with a lack of blood flow in the RIJV. A loss of intracranial venous pulsatility was observed in cerebral venous system that was
restored at the SVC. He ultimately underwent successful bilateral lung
transplantation after 62 ECMO days and was successfully decannulated
on post-transplant day 1. Interval cerebral venography demonstrated
occluded RIJV but with restored venous pulsatility after the decannulation. RIJV blood flow was restored by venous angioplasty with stenting.
Patient had no further neurologic events.
Results: VV-ECMO associated neurologic events have been previously
reported in the literature. However, intracranial venous hypertension is a
unique but potentially underrecognized case of neurologic consequences
of cerebral venous stasis secondary to a RIJV cannula that should be
further investigated.
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Bedside Dual-lumen Internal Jugular VV-ECMO Cannulation In A
Jehovah’s Witness Patient For COVID-19
Zachary O. Enumah, MD, Nicholas Clarke, MD, Stephanie Cha, MD,
Bo Kim, MD, Jinny Ha, MD, Errol O. Bush, MD; Johns Hopkins Hospital,
Baltimore, MD, USA

ASAIO, YOU Can Do THIS
Arnold J. Lande, MD; Northport Navigable Waters Institution, Northport,
MI, USA
Study: There is a way forward from this dilemma!
ASAIO can help resolve-circumvent the current COVID dilemma, of
having to choose between providing best protection and care for the
most endangered, verses allowing societies to reopen and build their
economies.
Circumvent, by exercising ASAIO’s unique ability to recognize the need for
and develop better medical devices-----a redesigned ECMO System
Methods:
Suggested Design Principles: 1. Design for EARLY application. Stocked and
inexpensively trained-ready In most locations around the World. 2. Design
for EASY, perfect, automatic CO2-vacuum priming during opening box,,
as operator turns his-her attention to cannulation. 3 Select-develop most
EFFICIENT membrane oxygenator, which cannot accumulate or embolize
air, because all blood passages are upwardly inclined and therefore needs
not be so intensively monitored. 4. Fail-safe pneumatic or emergency
manual-pedal powered pump
Suggested Implementation: Encourage ongoing series of Early Conventional ECMO (by others) to demonstrate comfort and hoped-for survival.
Research CO2-vacuum packaging in can and bag. Consider alternative
oxygenators. Easier to go with what already exists. Landé-Edwards LEMO
Membrane Oxygenator (Kolobow?). Best use silicone membrane for days
to weeks-long ECMO. Excellent flat- plate, press-housing. Proven folded
membrane manifolding. Stand housing on side or “on pointe” with plates
and fluid paths vertical (or nearly vertical) to facilitate air elimination.
Multiple non-critical tradeoffs available to idealize upward blood and
downward gas flow patterns. Efficient silicone-surfaced hollow oxygenating fibers membrane spacing screens, likely. Microfluidic “capillaries”
possible.
Results: ASAIO, We can do this!

Study: Jehovah’s Witness patients may not consent to receiving allogeneic blood products. It is well established that blood transfusions are
often needed during veno-venous extracorporeal membrane oxygenation
(VV-ECMO) given the inherent, acquired coagulopathy. There is a theoretical and ethical concern of offering ECMO without being able to transfuse
blood products. To our knowledge, no one has reported the use of VVECMO for Jehovah’s Witness patients in the COVID-19 era.
Methods: Here we present the first reported case of successful use of
veno-venous ECMO for refractory ARDS due to COVID-19 infection in a
Jehovah’s Witness patient.
Results: The patient is a 36-year-old Jehovah’s Witness with hypertension,
obesity, depression and diabetes who presented with acute hypoxic and
hypercarbic respiratory failure with COVID-19 ARDS requiring mechanical
intubation, renal replacement therapy and eventual VV-ECMO therapy via
right internal jugular size 32Fr dual-lumen catheter. He was cannulated at
the bedside utilizing TEE guidance and with only a heparin IV bolus at the
time of initiation. His hospital course was notable for deep venous thrombosis secondary to heparin induced thrombocytopenia and thrombosis
requiring systemic anticoagulation. He did not require blood transfusions.
Adjuncts included vitamin B12, folate, epoetin alfa-epbx, iron, and pediatric tubing for phlebotomy. The patient was weaned and decannulated
after 21 days on VV-ECMO and survived. He was discharged home where
he resumed riding his bicycle. Initial hemoglobin was 10.9 g/dL, nadir was
4.8 g/dL, and discharge was 8.1 g/dL. Post-recovery cognitive scores demonstrated results in the low average range on tests of learning, processing
speed, and executive functioning.
VV-ECMO was successfully used as a treatment modality in a patient who
did not consent to blood transfusions. Patient choice in blood consent
should not be an absolute contraindication to pursuing VV-ECMO.
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Heartmate 3 Implantation In A Severely Calcified Left Ventricular Apex
Krystina Chickerillo, APRN-BC, Ambar A. Andrade, MD,
Pat S. Pappas, MD, Antone J. Tatooles, MD; Advocate Christ Medical
Center, Oak Lawn, IL, USA
Study: Ischemic cardiomyopathy (ICM) is the second most common indication for durable left ventricular assist device (LVAD) implantation. These
patients may present with calcification of the left ventricular apex, which
may make LVAD implantation challenging. We present successful use of
the PhotoFix, decellularized bovine pericardium patch, during implantation of Heartmate 3 (HM3) in a heavily calcified left ventricular (LV) apex.
Methods: 72 year old male with end stage ICM secondary to coronary
artery disease, aortic insufficiency, atrial fibrillation, TIA, diabetes,
and chronic kidney disease presented in acute decompensated heart
failure and underwent evaluation for LVAD implantation. Pre-operative
echocardiogram revealed scarring of the anteroseptal myocardium and
aneurysmal deformity of the apical myocardium. CT chest demonstrated
severe calcification of the LV apex. He was deemed a suitable candidate
for LVAD implantation with concomitant aortic valve replacement and
preoperative planning included determination of ideal LVAD inflow cannula and outflow graft placement. As suspected, following sternotomy,
extensive calcification of the LV apex was visualized preventing ideal
placement of the inflow sewing cuff. Patch ventriculoplasty of the LV
apex was performed utilizing the PhotoFix membrane. A portion of the
calcific wall was debrided and the sewing cuff of the HM3 was secured to
the PhotoFix membrane. An intraoperative transesophageal echocardiogram confirmed adequate positioning of the inflow cannula. Patient was
discharged home after 39 days. Patient continues to do well at home with
stable VAD function 18 months post-surgery.
Results: LVAD candidates can have complex comorbidities which present
unique surgical challenges for LVAD implantation. Our case shows successful LV reconstruction with HM3 implantation utilizing the PhotoFix
patch with implantation directly into the membrane.
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Quantification Of Thrombosis Threat Levels In Clinically-Relevant
Circulatory Assist Devices
Greg W. Burgreen, PhD1, M Zhussupbekov, BS, MS2,
R Mendez-Rojano, PhD2, J F. Antaki, PhD2; 1Mississippi State University,
Starkville, MS, USA, 2Cornell University, Ithaca, NY, USA

Identifying The Operating Envelope Of A Motion Capture System For The
Future Of Telemedicine
Jung Hung Chien, PhD1, Haley Furman, MS2,
Ashley C. Vincent, None2, Carson Di Maria, None2,
Hailey L. Swanson, None2, Rebecca C. Slepian, None2,
Marvin J. Slepian, MD2, Ka-Chun Siu, PhD1; 1University of Nebraska
Medical Center, Omaha, NE, USA, 2University of Arizona, Tucson, AZ, USA

Study: Published in its initial form in 1999, the Cornell thrombosis model
has evolved in its complexity and sophistication to simulate thrombogenesis within medical devices. Like other CFD-based models, presence
of thrombus is predicted to exist within a device when a single threshold
metric is exceeded. However, even the best models are not exact predictors of thrombosis, and predicted locations and extents of thrombosis
based on a binary threshold can be misleading and unrealistic. The purpose of this study is to introduce the concept of thrombosis threat levels
and to apply it to several clinically-relevant VADs.
Methods: High fidelity CFD is performed on six well-known circulatory
assist devices. To consistently capture blood shearing effects, mesh
generation is performed to intentionally match near-wall mesh resolution in each device. Thrombosis simulations are performed using the
Cornell model and identical model parameters. Thrombosis threat levels
are defined by a sequence of interval thresholds on thrombus volume
fractions. Direct comparisons are made between each device based on
predicted thrombosis threat levels.
Results: As expected, degrees and locations of thrombosis threat significantly vary between the six devices, but reflect engineering intuition well.
Results from this study represent an initial standard, numerical protocol,
and preliminary database of thrombosis threat levels that can be used
to compare thrombotic behaviors in other existing and future devices.
Standardized thrombosis threat levels can serve as an efficient diagnostic
tool for designers, clinicians, and regulators.

Study: Active movement is vital for human function and health. There
is a need to better assess movement and motion in clinical medicine in
an objective way. A smartphone-based motion capture (MO2CA) system
presents a solution to not only better assess human motion in clinical setting, but also virtually via telemedicine. The MO2CA system has recently
demonstrated its capability to accurately capture human walking on a
treadmill without defining the full range of efficacy and parameters of
use. Therefore, in this study, we aimed to define and delineate the operating envelope of the MO2CA system in order to determine the parameters
of the system that can be used in the healthcare setting.
Methods: By using single marker and multiple targets spaced at varying
distances apart, implementing and tracking a moving target, and varying
lighting conditions we were able to identify the operating envelope of the
MO2CA system.
Results: Our results show that MO2CA system is able to track a single
target within the boundary from 1 ft to 18 ft, multiple targets from 1 ft to
11 ft, a moving target with minimal errors from 2 ft to 8 ft and can accurately identify a target from 1 ft to 18 ft under specific lighting conditions
(100, 200, and 300 lumens). Thereby, we defined the practical operating
envelope of the system. These results suggest that the MO2CA system has
the efficacy at a range of distances, light intensities, speeds, and target
sizes. With the current COVID-19 pandemic, the MO2CA may be utilized in
facilitating the expansion of telemedicine for a variety of remote clinical
assessments including functional and range of motion examinations,
hospital discharge evaluations and response to therapy and rehabilitation
at home.
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Characterization Of Atrial And Ventricular Cannulation For Biventricular
Circulatory Support
Christine Flick, MS, Chihiro Miyagi, MD, Barry D. Kuban, BS,
Takuma Miyamoto, MD, PhD, Kiyotaka Fukamachi, MD, PhD,
Karimov Jamshid, MD, PhD; Cleveland Clinic, Cleveland, OH, USA

3D Image Modelling -registration Of Image Modalities For In Depth
Analyses Of Tissue Samples
Juliane Hermann, MSc1, Kai Brehmer, MSc2,
Vera Jankowski, Other1, Herbert Thiele, Other3,
Joachim Jankowski, Other1; 1Institute for molecular cardiovascular
research, Aachen, Germany, 2Institute for Electrical Engineering in
Medicine, Lübeck, Germany, 3Fraunhofer Institute for Digital Medicine
MEVIS, Lübeck, Germany.

Study: In patients with biventricular heart failure, biventricular assist
device (BVAD) may be needed for hemodynamic support. BVAD inflows
can be established through cannulation of either atrial (AC) and/or ventricular (VC) chambers, and there is no consensus on optimal cannulation
technique. This study aimed to characterize BVAD performance related to
cannulation types (AC and VC).
Methods: Both methods of cannulation (AC and VC) were tested on a
mock loop using dual pulsatile ventricles with valves (AB5000; ABIOMED)
paired as the native ventricles and a continuous-flow total artificial heart
(CFTAH) as BVAD. The CFTAH is double-ended centrifugal pump with one
rotor and two volutes. Pressures were collected at the inlet and outlets
of the AB5000s (LAP, RAP, AoP, PAP) and the CFTAH (Lin, Rin, Lout, Rout).
Two flows exiting the CFTAH (LPF, RPF) and total flow (TO), exiting systemic resistance, were monitored. Several heart failure conditions were
simulated with adjustment of the pneumatic pressures of the AB5000.
Results: Trends between the AC and VC were similar where RAP, Lin, and
Lout decreased, and AoP, PAP, TO, LPF, and RPF increased with increased
support. The trends differed in LAP with an increase during AC as oppose
to a decrease during VC. As a result, with this set up, balance was more
suitable during VC. TO was higher with AC, even though LPF and RPF were
lower. This meant the flow going through the aortic valve (TO - LPF) and
pulmonary valve (TO - RPF) was higher with AC. The increased TO and
valvular flow favor AC for introducing BVAD to the native heart in these
conditions.

Study: MALDI mass spectrometric imaging (MALDI MSI) is a powerful
tool for the analysis of the distribution of biomolecules in tissue samples.
However, for a detailed analysis of MALDI MSI data, a correlation of
molecular and histologic data, is crucial. By combining MALDI MSI data
and histological data, more detailed information are obtained compared
to separate analysis of the data. Therefore, we setup a method for fusion
of MALDI MSI data sets and histological staining date in a 3D model
presenting a biomolecule distribution of the whole organ. We developed,
established and validate an algorithm for the automatic registration
including cross-evaluation of the multimodal data sets. This multimodal
image approach will improves molecular analyses of tissue samples clinical research and diagnosis.
Methods: We fused mass spectrometric data as well as histological and
immunohistochemical staining methods in this study. Histological tissue
sections of a completemice kidney was used for proving and evaluating the approach. MALDI MSI data were accumulated using the Rapiflex
mass-spectrometer (Bruker-Daltonic). Hematoxylin-eosin and Gomori
staining were chosen for histological staining. For immunohistochemical
double staining and immunofluorescence, we stained collagen type I,
smooth muscle actin and cell nuclei.
Results: By developing, establishing and validating a mathematical registration approach, a perfect superposition of the individual histological
sections mass spectrometric data was achieved. The fusion of the data
also offers the option of virtual incision of the organ from any angle and
level. The algorithms were adapted to for automatic data fusion offering a
high-throughput approach for clinical diagnostics as well as the possibility to involved artificial intelligence in its interpretation in research in the
future.
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Suspension Force Evaluation Of Active Magnetic Bearing For Blood
Shear Stress Device
Nobuyuki Kurita, PhD1, Eiji Ogiwara, BS1, Yaxin Wang, PhD2,
Peter Alexander Smith, PhD2, Shweta Karnik, BS, MS2,
Oscar Howard Frazier, MD2; 1Division of Electronics and Informatics,
Gunma University, Kiryu, Japan, 2Texas Heart Institute, Houston, TX, USA

Endothelialization Spreading Mechanics: An In-silico Model For The
Rational Design Of Surface Functionalized TEVGs
Juan S. Bermudez Paz, BS1, María A. Rodriguez, MSc1,
Alejandra A. Riveros, BS1, Natalia A. Suarez, MSc1,
Carolina A. Muñoz Camargo, PhD1, Juan C. Cruz, PhD1,
Nestor Sandoval, MD2, Juan C. Briceño, PhD1; 1Department of Biomedical
Engineering, Universidad de los Andes, Bogotá, Colombia, 2Cardiovascular
Surgery, Fundación Cardioinfantil Instituto de Cardiología, Bogotá,
Colombia.

Study: We recently proposed a blood shear stress device (BSSD) to
evaluate the blood damage caused by individual LVAD components. The
BSSD mitigates blood damage by employing a brushless DC motor, an
active magnetic bearing (AMB) to stabilizes axial translation, and passive
magnetic bearings to stabilize radial translation and tilt. In this study, we
evaluate the magnetic forces induced within the AMB by a control current
and AMB rotor-stator gap.
Methods: The AMB comprises a rotor with a permanent magnet (PM)
ring (magnetized axially) and a stator with a winding (Fig. 1A). The PM’s
outer diameter is 9 mm and the inner diameter is 7 mm. Two PM thicknesses (1 mm and 2 mm) were tested. We varied the control current from
−2 A to 2A and the rotor-stator gap from 0.1 mm to 0.5 mm. We measured the magnetic forces experimentally (Fig. 1B). A force gauge holds a
non-magnetic shaft connected to the rotor, and a micrometer-driven XYZstage supports the stator to set the rotor-stator gap. The DC power supply
input the current command value to the linear amplifier. According to the
current command value, the control current passes through the coil. A
multimeter measures the actual current, which generates control flux in
the winding. The PM attached to the rotor creates bias flux. We measured
the magnetic force generated by the interaction between the control flux
and the bias flux.

Study: Endothelialization of Tissue Engineered Vascular Grafts (TEVGs) is
a key step to assure its functionality due to the critical regulatory activity
of endothelial cells. Endothelial progenitor cells (EPCs) in the bloodstream
attach and spread to the TEVG’s surface through cell membrane integrins.
To favor such interactions, the TEVG’s lumen can be functionalized with
peptides with strong affinity for EPCs. Herein, we studied optimal ligand
distribution to improve integrin-TEVG interaction and spreading mechanics through a finite element model implemented in COMSOL Multiphysics
5.5®.
Methods: Cell adhesion process was evaluated based on high affinity
integrin’s traction forces present during the cell cytoskeleton remodeling
through stress fibers. Forces were included in the computational model
considering the change of state between an undeformed cell and the
deformed cell after integrin binding to a fraction of available peptides on
the TEVG surface. The effect of blood flow shear stresses was included by
means of a fluid-structure interaction model between the cell geometry
and the laminar blood flow throughout the TEVG. Pulsatile conditions
were established to mimic the physiological blood flow baseline.
Results: Velocity fields showed a parabolic behavior across the TEVG section with flow perturbations surrounding the cell domain. The pressure
distribution exhibited a gradient related to the vessel resistance. Contour
plots reflected the pulsatile flow evidenced by time-spatial dependent
values. Higher stress values found in the lower region of the cell domain
correlate with the presence of focal adhesions. To achieve higher deformations and allow cell spreading, the peptide availability on the TEVG
surface should reach about 70% of the total number of the high affinity
integrins on the EPC surface. This model contributes to provide relevant
insights for optimizing TEVGs surface functionalization for a successful
endothelialization process.

Results: Magnetic force generated by the 1 mm and 2 mm PM is shown
in Fig. 2A and 2B, respectively. We examined current stiffness (magnetic
force/control current) and found that the stiffness is lower with a thinner
PM; for example, at a 0.2 mm gap with a current of ±0.5A, the stiffness
was 1.22N/A with a 1 mm PM versus 1.35N/A with a 2 mm PM. We could
obtain sufficient current stiffness to control the proposed BSSD rotor.
When the bias flux and control flux strengthen each other at small gaps
and high current, the stiffness is reduced. We intend to use higher saturation magnetic flux density materials to avoid magnetic saturation and
improve AMB efficiency in the future.
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Chemical Polishing Method To Improve The Surface Roughness Of FDM
Printed Component Of Blood Wetted Devices
Ravinder Reddy Pinninti, PhD,
Rugveda Thanneeru, Masters, Engineering; Mechanical Engineering,
Chaitanya Bharathi Institute of Technology, Hyderabad, India.
Study: 3D Printing is one of the best ways to convert the ideas into
prototypes, especially in the development of medical devices. It requires
a greater number of iterations to develop the device. The components
printed with FDM printer will have a surface roughness value of more
than 20 μm. Most of the blood-wetted prototypes like blood pumps need
a surface roughness less than 1 μm. Therefore, the aim of this research
was to develop a methodology to improve the surface roughness quality
of 3D printed components of blood-wetted devices like blood pumps.
Methods: A multiple test samples of the same dimensions printed using
FDM 3D printer with Nylon, ABS, and PLA material. By studying their
material chemistry, Nylon was most reactive with formic acid and ABS
with acetone and PLA with dichloromethane. The surface roughness
(Ra value) of each test sample was taken before and after the chemical
process. 45 test samples were prepared for each material and exposed/
dipped in the chemical in different durations of time, accordingly the
surface roughness was measured. Then top sample with the improved
surface roughness was sent to an autoclave sterilization process. Each
sample was placed inside a container with 15 ml of human blood and was
kept in a horizontal motion, to check any form of hemolysis.

Figure 1. Surface roughness of different nylon test samples concerning the
time of dip.
Figure 2. Nylon 3D printed parts (left - before treating with formic acid
and right - After treating with formic Acid)

Results: Out of all the materials, their combinations and the dipping time
of 135 seconds for Nylon material in formic acid improved the surface
roughness from 17.5 μm to 1.73 μm shown in Fig: 1 and Fig: 2 shows a
Nylon 3D printed parts (left - before treating with formic acid and right after treating with formic acid) and there is no significant change in the
hemolysis in the Nylon material.
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Design Of A Mock Circulatory Test Loop With Lv Simulator For A
Centrifugal Flow Blood Pump
Rugveda Thanneeru, Masters, Engineering, Sadia Alvi, MEng,
Ravinder Reddy Pinninti, PhD; Mechanical Engineering, Chaitanya
Bharathi Institute of Technology, Hyderabad, India
Study: Heart disease is attributed as the highest cause of death in the
world. Due to a chronic shortage of donor’s hearts, mechanical solutions
are being considered. Many Ventricular Assist Devices (VADs) are being
developed in an effort to increase life expectancy for end-stage heart
failure patients. The objective of this research was to develop and validate
a model of a Mock Circulatory Loop (MCL) with a Left ventricle simulator which is a simulation of the heart proximal systemic circulation. This
resembles the environment in which the LVAD will be operating. Thereby,
a hydraulic system has been constructed that will be used to mimic congestive and end-stage heart failure patient’s conditions to optimize the
characteristics of the LVAD, specific to each patient. By using this in-vitro
test loop, the effect of the LVAD pressure on the left ventricle is studied
and pressures are found.

Results: A MCL was successfully setup and run with the LVAD connected
to it as shown in the fig: 1 and 2. The LV pressure corresponding to each
patient was setup and the effect of the LVAD was studied accordingly. The
MCL mimicked the LV and aortic pressures within the range of human
heart. The pressure plots obtained are shown in fig 3. This testing method
was found to be efficient for pre-clinical trials to optimize the characteristics of the LVAD specific to each patient.

Methods: This model uses an LV simulator which is operated with a stepper motor mechanism. The precise movement of the stepper motor was
controlled using Arduino software, thereby enabling an efficient way to
replicate the systolic and diastolic movements of the chamber belongs
to each heart failure patient. An aortic compliance chamber, an atrial
compliance chamber, and a reservoir were included in the loop. Different
parts of the system were modeled and 3D printed. Pressure, flow sensors,
and DataQ system were integrated to get the required plots for pressures
of LV chamber and LVAD pump.
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CFD Study Of Heart Valve With Implicit Fluid-structure Interaction And
Autonomous Cartesian Cut-Cell Mesh
Yanheng Li, PhD, David H. Rowinski, PhD, Jasim Sadique, PhD; Convergent
Science Inc., Madison, WI, USA
Study: Artificial heart valves are crucial replacement devices for related
disease. Computational Fluid Dynamics (CFD) is a low-cost/risk approach
to evaluate device performance and blood clotting risk. Due to close
leaflet-to-blood density ratio, especially for biological heart valves, the
added mass effect (AME) is significant and presents great numerical challenge for fluid-structure interaction (FSI) solver. CONVERGE CFDTM, which
needs no user meshing and has implicit FSI solver, is used to model an
idealized 3D mechanical heart valve (Banks, 2018) with large AME, and
compare with published simulation data.

Methods: With mesh created automatically on-the-fly, the domain
volume is strictly conserved. Adaptive Mesh Refinement (AMR) is used to
refine the mesh based on local velocity gradient. Newtonian blood is used
for the high shear rate. Local velocity field is visualized and valve motion
is compared with literature for different density ratios. Grid uncertainty is
evaluated.

Results: The velocity field is visualized, overlaid with grid to demonstrate
the mesh’s good orthogonality/aspect ratio, and only refined where it is
needed(Fig. 1). The leaflets motion matches well with the literature, not
sensitive to the given small density ratios, which has dominant AME over
inertial effect (Fig. 2). The valve open/close timing is accurately captured.
Grid sensitivity study on the rotational velocity also suggests small grid
uncertainty for the studied mesh sizes (150% to 15% of the baseline
resolution, Fig. 3). Time steps as large as 2ms can be achieved within a
few hours wall time on a desktop, without stability issue. The results suggests the method is an accurate/efficient way to model heart valves with
AME challenge, with potential to apply in other blood-tissue interaction
problems.
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A General Protocol For Lumped-parameter Model Input Identification To
Simulate Resting Cardiovascular Physiology
Akash Gupta, MSc1, Aseem M. Pradhan, MSc1, Tyler Schmidt, MSc1,
Surya P. Sharma, PhD2, Ethan O. Kung, PhD3; 1Mechanical Engineering,
Clemson University, Clemson, SC, USA, 2Electrical and Computer
Engineering, Clemson University, Clemson, SC, USA, 3Mechanical
Engineering and Bioengineering, Clemson University, Clemson, SC, USA
Study: Lumped Parameter Network (LPN) models can simulate cardiovascular physiology with closed-loop cardiac feedback, and have been
applied to surgical planning, medical device design, etc. However, the
determination of appropriate LPN input parameters, remains a challenge.
In this work, we address this gap by describing our protocol (Fig 1A) which
given the subject attributes, i.e., age, height, and weight, provides suitable parameter values for an LPN model (Fig 1B) that reflects the typical
hemodynamics of a healthy subject at rest.

Methods: We obtain target hemodynamic parameters (THP) as a function of the subject attributes from existing literature. In the protocol, we
use a neural network which predicts critical LPN inputs such as those
governing the ventricles, and a scaling procedure for the LPN inputs of
the systemic components. The scaling procedure operates on a reference set of LPN inputs which reflect nominal hemodynamics. We use a
previously proposed neural network architecture designed specifically for
non-linear regression to predict the critical LPN inputs, using the THP as
the predictors. The training data for the neural network was obtained by
running the LPN with 151,456 combinations of the critical LPN inputs and
recording the corresponding hemodynamic outputs. To test the protocol
performance, we have used 100 realistic combinations of the attributes,
and have compared the protocol output to the THP.
Results: All simulated hemodynamic parameters (SHP) in the protocol
test set fall within clinically normal ranges, exhibit good agreement with
the THP, and the maximum deviation of the SHP from the THP fall within
the 95% confidence intervals for the THP predictions. In all test cases, the
mean PA pressure and both the left and right mean atrial pressures also
lie within clinically normal ranges (≤ 20,7, and 10mmHg respectively).
Therefore, our proposed protocol can simulate typical, healthy, resting
hemodynamics for a given set of subject attributes.
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Using CFD And FSI To Improve The Numerical Modelling Of Positive
Displacement Artificial Hearts
Joseph Bornoff, MEng1, Nimesh Singh, MEng1,
Maria Carnarius, MEng1, Richie Gill, PhD1, Azad Najar, Other2,
Ina Laura Perkins, Other2, Andrew Cookson, PhD1,
Katharine Fraser, PhD1; 1University of Bath, Bath, United Kingdom,
2
Scandinavian Real Heart AB, Västerås, Sweden.

Treatment By Heated, Oscillating Flow Decreases Viable Biofilm On
Luminal Surface Of Indwelling Central Venous Catheters In Rats Infected
With Staphylococcal Epidermidis
Joanne K. Beckwith, MS1, Shannon M. VanAken, MS2,
J. Scott VanEpps, MD, PhD2, Michael J. Solomon, PhD1; 1Chemical
Engineering, University of Michigan, Ann Arbor, MI, USA, 2Emergency
Medicine, University of Michigan, Ann Arbor, MI, USA

Study: The Realheart®, a total artificial heart developed by Scandinavian
Real Heart, mimics the mechanics of the native heart by translation of an
atrioventricular (AV) plane. Past numerical models of the Realheart® were
not flow-driven but relied on prescribed motion of AV and semilunar (SL)
valves. The objective was to develop a new modelling strategy, combining
computational fluid dynamics and fluid-structure interactions that generalized the pumping mechanics of the Realheart®, using only the essential
and most challenging modelling aspects.
Methods: A fluid cylinder containing two bileaflet mechanical heart
valves, representing the AV (upstream) and SL (downstream) valves (fig
1a) was modelling in Fluent (Ansys Inc). A restriction (fig 1b) represented the resistance of the downstream vasculature. The Navier-Stokes
equations were solved assuming Newtonian rheology. Overset meshing
allowed for a refined leaflet boundary (fig 1c). The 6DOF solver computed
the leaflets’ rotation, whilst the AV overset mesh zone underwent vertical
sinusoidal translation, achieving rotation and translation of the AV valve.

Study: Medical device infections caused by biofilms are a leading causes
of bloodstream infections and cost hospitals millions annually. Biofilm
infections are resilient, providing protection from host defense and
antimicrobial treatment. Treatment can require removal and replacement of the device, which is costly and increases morbidity and mortality.
We have previously shown that modest levels of heat decreases biofilm
viability and increases detachment in biofilm flow cell systems. This work
applies the knowledge from these in-vitro studies, to an in vivo animal
model. The overall aim is to apply elevated temperature and fluid shear
stress via heated, oscillatory flow to infected central venous catheters
(e.g., hemodialysis catheters).
Methods: Jugular-vein catheters were surgically implanted in SpragueDawley rats and inoculated with S. epidermidis by direct injection,
followed by biofilm growth for 72 hours. Heparinized saline at room
temperature or 48°C was cycled in and out of the catheter for 2 hours.
Catheter segments were visualized using scanning electron microscopy
(SEM) and surrounding tissue was sent for histopathologic examination. Quantitative culture was performed on blood, organ, and catheter
samples.
Results: SEM showed biofouling is visually reduced but not eradicated
with heat treatment. Quantitative culture confirmed a 3-log reduction in
bacterial load on the tip of treated vs untreated catheters. Histopathology
of the surrounding vein and skin track show evidence of thermal injury
associated with heat treatment. However, the treatment had minimal
effect on core body temperature.This work confirms that heated, oscillating flow is a plausible remediation method to debride biofilm from
catheter surfaces. Future work will focus on identifying a therapeutic window where the benefits of biofilm clearance are balanced with preventing
thermal injury to the surrounding tissue.

Results: A modelling strategy has been successfully developed that
defines AV plane translation and AV/SL valve rotation. The SL valve
opened at 0.15 s as fluid was pushed through the domain by the AV valve,
and closed at 0.43 s, due to backflow (fig 2). Fluttering occurred upon SL
valve opening, due to high pressures caused by downward AV motion.
When the SL valve fully opened, fluid followed the leaflet motion, moving
from the cylinder wall towards the center, forming a faster flowing central
region (fig 1d). Further work will replace the constriction with a Windkessel model to capture physiological conditions and improve modelling flexibility. Additional studies will be used to understand the interplay between
stroke parameters, and efficiency and valve leakage.
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Observation Of White Thrombus Formation Around Tavi Models
Including Leakage Flows By Optical Systems In Vitro And The Evaluation
By CFD Analysis For Pulsatile Flow
Masaaki Tamagawa, PhD; Kyushu Institute of Technology, Kitakyushu,
Japan

Rational Design Of TEVGs: Insights From Kinetic Modeling Of Protein
Adsorption
Alejandra Riveros, BS1, Maria A. Rodriguez-Soto, MSc1,
Natalia A. Suarez V., MSc1, Andres J. Garcia-Brand, BS1,
Carolina Muñoz-Camargo, PhD1, Juan C. Cruz, PhD1,
Nestor Sandoval, MD2, Juan C. Briceño, PhD1; 1Department of Biomedical
Engineering, Universidad de los Andes, Bogotá D.C., Colombia, 2Instituto
de Cardiología, Fundación CardioInfantil, Bogotá D.C., Colombia

Study: There is a possibility of leakage flow for TAVI (Transcatheter Aortic
Valve Implantation) valve and a high risk of thrombus formation near the
valve. Then it is necessary to find out the mechanism of thrombus formation by the leakage flow of TAVI. In our previous studies, effects of the
shear rate on the thrombus formation rate at wall on orifice flow were
examined by observation of thrombus formation by optical system, and
found that the thrombus formation rates near the reattachment point
increases with shear rates. This study describes observation of thrombus
formation around TAVI models including leakage flows by optical systems
in vitro, and the evaluation method by CFD analysis with thrombus formation model.
Methods: Experimental objects are orifice pipe flow and the orifice flows
with small leakages (Fig.1) for observation of thrombus formation. Each
leakage size h is 0mm, 0.5mm, 1mm respectively in case of 20 mm diameter pipe with stenosis to simulate valve part. The target flow filed with
blood plasma of pigs is illuminated by laser sheet, and the images are
taken by high speed CCD camera. Once the thrombus formation starts,
the scattering wave can be detected by this system. The movies for three
kinds of geometries and two flow rates (3 and 5l/min). As for CFD analysis
with finite difference method, the momentum equations and transport
equation of species with chemical reaction are used.

Study: The currently available small diameter vascular grafts (<6mm)
present several long-term limitations, mostly related to their low regenerative capacity, which has prevented their full clinical implementation.
Alternatively, Tissue Engineered Vascular Grafts (TEVGs) provide a route
for superior regeneration but show significant thrombogenicity. This process exhibits considerable complexity as it involves the interplay of several variables. Computational modeling and simulation emerge as tools
to study and optimize the rational design of small diameter TEVGs. This
study aims to model the correlation between mechanical-hemodynamicbiochemical variables on TEVGs’ protein adsorption as it appears central
to thrombogenicity and ultimately to their regenerative potential.
Methods: Here, we addressed this challenge by implementing a two-way
Fluid-Structure Interaction (two-way FSI) model in ANSYS Fluent 2019R3®
and ANSYS Transient Structural® software. Experimental pulsatile
pressure was included as a user-defined function (UDF). Subsequently,
a kinetic model, linked to two-way FSI velocity profiles, of the proteinsurface interaction between albumin and fibrinogen, and the intima layer
of the TEVGs, was implemented in COMSOL Multiphysics5.3®.
Results: The two-way FSI model provided physiological baseline of wall
shear stress distributions and velocity profiles compared to previous rigid
wall models. TEVG wall properties appear therefore critical to understand
responses under different hemodynamic stimuli. In addition, the kinetic
model showed saturation times of 1.39s for albumin adsorption and of
0.8s for fibrinogen adsorption on the TEVG’s intima layer. These results
suggest higher affinity for fibrinogen adsorption. Our computational
models provide a robust platform to study multiparametrically the performance of TEVGs in terms of protein adsorption, which is key to approach
to their rational design.

Results: As for visualization results, Fig. 1 shows typical distribution of
thrombus formation area at h= 0, 0.5, 1mm. Due to the increasing of
leakage size, the thrombus formation area on the outer wall is decreasing.
In case of leakage size h=0.5 and 1 mm, these areas correspond to wake
size at the back side of the stenosis by CFD result (Fig.2). It is considered
that there is a possibility to use the length ratio of wake and recirculation
area as an index of thrombus formation rate by comparing CFD result and
visualization result.
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Experimental And Numerical Studies Of A Centrifugal Heart Pump Used
For Total Artificial Heart (TAH)
Ganesh K. Gampa, III, PhD, Sridhar Kanduri K, III, PhD,
Venu Madhav Kottur K, III, PhD, Eswaraiah Kesha K, III, PhD,
Ashoka Reddy Kommalla, III, PhD; Mechanical Engineering, Kakatiya
Institute Of Technology And Science, Warangal, Warangal, India

Comparative Studies On Six And Four Bladed Centrifugal Heart Pump
Used For Left Ventricular Assisted Device (LVAD)
Ganesh K. Gampa, III, PhD, Sridhar Kanduri K, III, PhD,
Venu Madhav Kottur K, III, PhD, Eswaraiah Kesha K, III, PhD,
Ashoka Reddy Kommalla, III, PhD; Mechanical Engineering, Kakatiya
Institute Of Technology And Science, Warangal, Warangal, India

Study: Literature reports exhaustive studies are being performed on TAH.
In view of this, it is proposed to simulate an extracorporeal centrifugal
heart pump used in TAH. This work involves design, development and
analysis of a continuous flow centrifugal heart pump with bearing less
magnetic levitation (TAH). A simulation model was designed in Creo 2.0.
Analysis was performed in ANSYS work bench to generate Head-Discharge
curves for studying the performance of the centrifugal pump. An experimental model was also fabricated using Mark Forged Mark Two 3-D Printing to analyze the pump performance.
Methods: Parametric study was performed in detail on fluid flow
parameters -- shear strain, strain rate, velocity gradient, pressure,
viscosity-- assuming blood as a working media. A mock circulatory loop
was designed and fabricated for the experimental studies to validate
the CFD predictions Prototype that was fabricated is ~ 0.4kg. The blood
flow rate was varied from 4L/min to 9L/min with speed ranging from
3000-5500 rpm. The density of the blood was taken as 1060kg/m3and the
viscosity as 0.0035 kg/ms. The designed impeller has six blades with a
blade angle of 22.5O. Blood compatibility was evaluated in vitro. Flow rate
and fluid pressures were measured using laboratory sensors. The figures
below detail velocity and turbulence contours generated from the study.
Results: The variation of velocity inside casing of centrifugal pump is
shown in Fig.1. A study was performed for input of 4500 rpm and the flow
rate at 6L/min. It can be observed that disturbance is larger at the outer
most part of the casing and smaller at the center entry, as expected from
the magnitude of the centrifugal force as a function of radial position. Fig.
2 shows turbulence intensity inside the pump. A fixed input of 4500 rpm,
6L/min is taken for the study. It can be seen that the turbulence intensity
is of about 0.4064 at outer most part of the casing while it is maximum at
center of about 0.669.

Study: Comparative Studies on Six and Four Bladed Centrifugal Heart
Pump Used for Left Ventricular Assisted Device (LVAD) This study investigates the number of blades on LVAD performance. A numerical model
of impeller with casing was generated in CFD Work Bench; the number
of blades was varied between 2 to 10. Six and four bladed centrifugal
heart pump simulated models are shown below as an illustration for the
purpose.
Methods: The design specifications considered followed the standard literature, e.g., speed - 300-5500 rpm, flow rate 3-9 L/min, density--1060kg/
m3, viscosity -- 0035 kg/ms, blade angle-- 22.5O. A k-ε model was used for
the analysis using boundary conditions defined as per the specifications in
ANSYS Fluent Workbench. To validate the CFD results a mock-up loop was
used to generate H-Q (Head-Discharge) curves experimentally.
Results: As an illustration, the components of six, bladed centrifugal
pump fabricated in Mark Forge Mark Two 3D printing using Onyx material
is shown in Figure 1. Formic Acid was used to improve the surface finish
of the models. The experiment was performed both with glycerin as well
as water in the mock-up loop. Figure 2 shows the wall shear for six bladed
is more than four bladed pump. It is observed that max wall shear is
65.33 Pa for six bladed centrifugal pump while 98.3 for four bladed pump.
Hence, six bladed pump is more suitable than four bladed pump
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Patients With Ductal-dependent Circulation: Computational Simulations
On Real Geometries
Camila Castro, MSc1, Juan Bermudez, BS1, Diana Herrera, MSc1,
Juan Cruz, PhD1, Alberto García, MD2, Juan Briceño, PhD1; 1Universidad de
los Andes, Bogota DC, Colombia, 2Fundación Cardioinfantil - Instituto de
cardiología, Bogota DC, Colombia

Ostomy Skin Barrier Biomaterials—A Unique Percutaneous Adhesive
Challenge
Adrian P. Defante, PhD, Abram D. Janis, MS; R&D, Hollister Incorporated,
Libertyville, IL, USA
Study: Effective ostomy dejecta containment appliances are reliant
upon the adhesive interface around the percutaneous stoma, a fixation
interface with additional challenges. Modern ostomy pouches are affixed
to the peristomal skin by “barriers” composed of biomaterials including
silicone and hydrocolloids, which offer adhesion and absorption. Absorption is an important design feature, as urostomies continually release
urine, ileostomies release enzymatically active intestinal contents and
colostomies release fecal matter. Individuals with ostomies typically wear
barriers for varied durations, depending on ostomy type, output volume,
activity and skin condition considerations. Given stoma surgery can be a
permanent procedure, many users are reliant on their disposable adhesive barriers over years or decades. Ostomy barriers must reliably adhere
to and protect the skin, while not limiting range of motion or choice of
activities. Recent advances in ostomy materials have incorporated skin
friendly components and added functionality, such as pH buffering. An
overview of modern ostomy adhesive solutions will offer instructive
examples and novel insights for other artificial organ technologies reliant
upon long-term percutaneous access.

Study: Congenital heart disease originates as an abnormal formation of
the heart or major blood vessels. Abnormalities with ductal-dependent
pulmonary blood flow are risky because the newborn’s life depends on
keeping a connection between the aorta and the pulmonary arteries to
assure proper oxygenation. The clinical options are stenting the Ductus
Arteriosus (DAS) or placing an artificial shunt (MTBS). Even though MTBS
has been used for decades, recent studies have demonstrated that DAS is
a reasonable alternative. Procedure selection depends on the availability
of trained physicians and infrastructure, patient condition, and technical
aspects, such as anatomical features and ductal tortuosity. Therefore,
we study the ductal circulation from a fluid mechanics perspective, to
develop a helping decision-making tool.
Methods: We built a 3D ductal reconstruction in silico from magnetic
resonance and computed tomography images, for 7 patients. These
3D models were imported into a multiphysics simulation software to
conduct CFD simulations, using a module of Single-Phase Laminar Flow
interface (with Navier-Stokes equations for incompressible fluid flow).
Blood was modeled as a Casson fluid. Boundary conditions were complete developed flow at the aortic section inlet and outlets (pulmonary
arteries, coronary arteries and downstream aorta). A non-slip condition
was defined for the vessel wall. Pressure drop was used to estimate differences between the studied ductal morphologies after conducting a sensitivity analysis over the parameters of interest. To validate the simulation
results, we compared the calculated mean velocity with that measured by
echocardiograms.
Results: The results of our models indicate a significant pressure drop for
patients with both tortuous ductus and narrower ductal diameter. These
findings suggest that geometrical features might impose a higher flow
resistance, which in turn, may explain the limited performance observed
for the DAS procedure.

91

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

ASAIO ELECTRONIC POSTER ABSTRACTS
EPBio19

EPBio20

Ostomy Products, The Original Artificial Internal Organ?
Abram D. Janis, MS; R&D, Hollister Incorporated, Libertyville, IL, USA

In Vitro Study Of Novel Pulsatility Modes In LVAD Therapy:
Intraventricular Hemodynamics And LVAD Dynamics Under A Wide
Range Of Preloads And Afterloads
Nazanin Maani, PhD1, Fanette Chassagne, PhD2,
Marissa Miramontes, BS1, Venkat Keshav Chivukula, PhD3,
Song Li, MD4, Jennifer Beckman, MSN, ARNP4,
Claudius Mahr, DO4, ALberto Aliseda, PhD1; 1Mechanical Engineering,
University of Washington, Seattle, WA, USA, 2École des Mines de SaintÉtienne, Saint-Étienne, France, 3Mechanical Engineering, Florida Institute
of Technology, Melbourne, FL, USA, 4Cardiology, University of Washington,
Seattle, WA, USA

Study: An ostomy is the surgical creation of a percutaneous communication between the lumen of a hollow organ and the skin in order to pass
waste material (dejecta). In order of number of surgeries per year, the
major categories of ostomy are colostomy, ileostomy, and urostomy,
which are performed in over 140,000 patients a year in the United States
for conditions including autoimmune or inflammatory bowel disease,
trauma, and cancer., These patients add to the existing population of
750,000-1 million Americans living with ostomies, reliant on external
collection products to replace the dejecta retention functionality of the
excised or bypassed colon, small bowel, or bladder. The first description of
these ostomy product “artificial organs” was provided in 1743 by Heister,
who described the use of a tin and cloths to capture dejecta. The first
patent for an ostomy appliance was granted in 1913, to be followed by a
reusable rubber pouching system affixed with belts and adhesives in 1920.
Following major advancements in materials and improved understanding
of human factors, these Class I, non-sterile medical devices now utilize
plastic films, filters and skin-friendly adhesives designed for comfort,
discretion, and dignity. A review of the history and evolution of ostomy
products will offer instructive examples and novel insights for other artificial organ technologies reliant upon long-term percutaneous access.

Study: This study aims to investigate the effect of novel VAD pulsatility
modes on the flow-pressure relationship, for a wide range of operating
and physiological conditions. these conditions are determined by different timing and magnitude of the Left Ventricle (LV) preload, as well as the
systemic resistance and capacitance. The hemodynamics of the LV and
ascending aorta are then characterized.
Methods: Time-resolved Particle Image Velocimetry (PIV) experiments
are performed, in order to collect the velocity fields in coronal and sagittal planes across a patient-specific LV. High temporal resolution flow rate
and pressure measurements are obtained in LV model in a flow loop
mimicking the systemic circulation, including preload and afterload as
the resistance and capacitance are controlled independently. Using a
novel pulsatility mode, the influence of LVAD pulsatility on the ventricular
hemodynamics is fully characterized. The effect of peak intraventricular
pressure and the timing between the preload cycle and the initiation of
the LVAD speed modulation is included.
Results: The stagnation and recirculation inside LV, as well as the aortic
root/LVAD outflow graft anastomosis, is highlighted and quantified. The
thrombogenic potential is calculated from measurements of 1- Residence
Time and 2- Shear Stress History along platelet trajectories (obtained
from PIV/PTV measurements). Two other metrics of LV thrombogenicity, the Stagnation Index (SI) and the Ventricle Stagnation Index (VSI),
are also reported, in an effort to quantify the impact of LVAD pulsatility
in reducing intraventricular stasis. The effect of afterload, preload and
synchronicity of the LVAD cycle with native heart systole and diastole is
characterized, in order to emphasize the impact of the instantaneous
pressure difference across the pump on LVAD performance in the presence of a strong unsteadiness in its angular velocity.
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Development Of A Computational Framework For Predicting
Thrombosis And Thromboembolism: Reynolds Number Effects In A
Backward-facing Step
Nicolas Tobin, PhD, Keefe B. Manning, PhD; Biomedical Engineering, The
Pennsylvania State University, University Park, PA, USA
Study: Work is presented on the development of a thrombosis &
thromboembolism (T&TE) computational model which incorporates a
reduced-order model of the coagulation cascade and can be run at high
Reynolds number. This work is of interest for evaluating thrombosis risk
in high-Reynolds number blood-contacting biomedical devices such as
artificial hearts and blood pumps.
Methods: The biochemical reactions included in the model are based on
a reduced-order model of the coagulation cascade and are converted to
their Lagrangian forms. The coagulation modeling results in the production of thrombin, which numerically activates platelets and polymerizes
fibrinogen to fibrin. Activated platelets and thrombin combine to create
source terms in a subsequent T&TE model, whereby cohesive links and
cohesive stresses are formed, allowed to interact with the flow, and
break. Simulations have been run of clots forming in a backward-facing
step geometry to match benchmark MRI data. Several flow rates were
simulated to investigate the impact of Reynolds number (ranging from
100 to 5000) on clot formation in this particular geometry.
Results: There is a strong trend toward clot volume decreasing with
increasing Reynolds number. Simulations at Reynolds number 5000 did
not clot, suggesting that the chaotic flow structures and higher levels
of shear stress prevent clot growth. Thrombosis is found to be strongly
dependent on Reynolds number, with high shear stress restricting clot
growth.
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A Systematic Review Of Continuous Flow Bi-ventricular Assist Devices
Lauren E. Meece, APRN-BC, Julia Yu, BS,
Mustafa M. Ahmed, MD; Division of Cardiovascular Medicine, University
of Florida, Gainesville, FL, USA

2-year Outcomes Of LVAD Patients With Chronic Kidney Disease
Krystina Chickerillo, APRN-BC, Ambar A. Andrade, MD,
Lisa Kukla, APRN-BC, Nora Krause, APRN-BC,
Tracy Aicher, APRN-BC, Robin Paliga, APRN-BC,
Nicole Graney, APRN-BC, Nicole Glowacki, MPH,
Sunil Pauwaa, MD, Gregory Macaluso, MD, Anjali Joshi, MD,
Christopher Sciamanna, MD, Nikhil Narang, MD,
Jessica Pillarella, MD, Vinh Chau, MD, Muhyaldeen Dia, MD,
William G. Cotts, MD, Antone J. Tatooles, MD,
Pat S. Pappas, MD; Advocate Christ Medical Center, Oak Lawn, IL, USA

Study: As the incidence of heart failure increases, so too has that of
biventricular failure. While transplantation remains the gold standard
therapy, the need for durable mechanical circulatory support has grown.
We therefore sought to conduct a systematic review of continuous flow
ventricular assist devices in a biventricular configuration (CF-BiVAD).
Methods: An electronic search of PubMed and Cumulative Index to
Nursing and Allied Health Literature (CINAHL) databases was performed
using the keyword “BIVAD”. Pediatric studies, those related to temporary
circulatory support, extracorporeal VADs, and total artificial heart were
excluded as well as any single case reports (Fig). Studies were reviewed
to identify discrete variables, including indication at implant, INTERMACs level at time of implant, timing of implant, the mean age and BMI
of implanted patients, and the anticoagulation/antiplatelet regimens
employed post implant. Outcomes of interest included mortality rate and
the incidence of thrombus, bleeding, infection, stroke and renal failure.
Results: 22 studies met inclusion criteria with a total of 1277 patients. No
single variable was consistently reported throughout studies, with only 4
reporting all 5 adverse effects. INTERMACs level at implant and anticoagulation/antiplatelet regimen were reported in less than 50% of studies. Of
those reporting mortality, there was a wide range of follow-up, from less
than 6 months to >10 years, and the survival rate mortality was similarly
widely variable. Additionally, more than 50% of studies failed to isolate
CF-BiVAD from alternative means of biventricular support, such as temporary support platforms, TAH, and pulsatile VADs. Therefore high-quality
quantitative analysis is not possible. In conclusion, the CF-BiVAD literature
has a very heterogenous reporting of data. Standard reporting criteria
may allow for future analyses to determine which patient characteristics
portend a favorable outcome with CF-BiVAD implantation.

Study: Left ventricular assist devices (LVAD) are an effective long-term
option for end-stage heart failure patients. Patients with concomitant
renal dysfunction are presumably at increased risk for adverse events
post implant. Our study sought to determine the outcomes of patients
with chronic kidney disease (CKD) stages 3-5 who receive LVAD therapies.
Methods: CKD stages 3-5 patients implanted with LVADs between January
2015 and December 2018 were evaluated. Patients lost to follow up or
undergoing second LVAD implant were excluded. CKD stages were stratified by eGFR <15-59, utilizing the eGFR within 24 hours of LVAD implant.
Results: Our study found 154 patients who underwent LVAD implant with
CKD stage 3-5. Prior to implant, 59.1% of patients had diabetes and 76%
had hypertension. Ninety percent of patients had CKD stage 3 and 10%
had stage 4. The median eGFR prior to LVAD implant was 44, at 1 week:
49, 1 month: 56, 3 months: 53, and 6 months: 50. The median eGFR at 1
and 2 years was 51. Adverse events included: 64.3% bleeding (including
gastrointestinal bleeding, epistaxis, and mediastinal hemorrhage), 33.1%
driveline infection, 34.4% bacteremia, 22.7% hemolysis, 24.7% stroke/TIA,
and 12% were sent home on inotropes for right ventricular dysfunction.
Post-operatively, 19.5% required renal replacement therapy (RRT) and
3.2% of those persisted to have renal dysfunction requiring hemodialysis
(HD) at the time of discharge. Furthermore, 12.3% required HD at some
point after their initial discharge. Of these patients, 76.6% were implanted
as destination therapy, while 15.6% progressed on to heart or heartkidney transplantation. The 1-year survival rate was 77.3%, the 2-year
survival was 61.7%. Our findings suggest that patients may successfully
undergo LVAD implant, despite concomitant renal dysfunction. While
these patients still experience adverse events, the survival rates suggest
that these patients should still be considered for LVAD implant, especially
if they are to be listed for transplantation.
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A New Cardiac Overload Index To Assess Risk Of Right Heart Failure
During Speed Optimization For LVAD Patients
Venkat Keshav Chivukula, PhD1, Andrea Montalto, MD2,
Cristiano Amarelli, MD3, Vito Piazza, MD2, Kali Hopkins, MD4,
Marina Comisso, MD2, Romina Pantanella, MD2,
Francesco Musumeci, MD2.; 1Biomedical and Chemical Engineering and
Sciences, Florida Institute of Technology, Melbourne, FL, USA, 2Cardiac
Surgery and Heart Transplantation, San Camilo Hospital, Rome, Italy,
3
Cardiac Surgery and Heart Transplant, Monaldi Hospital, Azienda
dei Colli, Napoli, Italy, 4Department of Pediatrics, division of pediatric
cardiology, Northwestern University Feinberg School of Medicine, Chicago,
IL, USA

Sternasafe®or Pillow: A Randomized Trial For Pain Management
Following Median Sternotomy
Allison Nowak, RN1, Charocka Hartzol Coleman, ARNP, MSN1,
Jennifer Cruz, None1, Ryan Hoang, None1, William Cohen, BA2,
Pamela Simone, PharMD1, Yena Jang, None1,
Sydney Lupo, None1, Takeyoshi Ota, MD1,
Valluvan Jeevanandam, MD1, Pamela Combs, PhD1.; 1Cardiac and
Thoracic Surgery, University of Chicago, Chicago, IL, USA, 2Perelman
School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Study: Patients who undergo median sternotomy are often advised to
use pillows for extra support to their sternum when engaging in high
pressure movements such as coughing or deep breathing. However, there
is concern regarding the effectiveness of this solution and the ability for
patients to consistently utilize the pillow. The Sternasafe® support device,
an elastic band continuously worn circumferentially around the thorax,
has been offered as a potential replacement. We compare pain levels in
post-operative cardiac surgery patients who utilized either a standard pillow or the novel SternaSafe® support device.
Methods: A parallel, randomized, open-label trial with 1:1 allocation compared pain management among cardiac surgery patients using a standard
pillow or SternaSafe® support device. Resting pain levels (0-10 with zero
being no pain) were recorded pre-operatively, one day post-operatively,
and in each of the subsequent four weeks. A P-value <0.05 was considered statistically significant.
Results: Twenty-eight patients met inclusion criteria. There were no
significant differences in demographics or comorbidities between groups.
While reported pain was less in the Sternasafe® group at all post-operative
timepoints, only post-operative day +30 reached statistical significance
(p=0.041) (Table 1). Reduced patient reported pain on post-operative
day +1 only approached statistical significance (p=0.061), likely due to
small sample size. Expanded trials should be conducted to further assess
SternaSafe efficacy and patient satisfaction.

Study: Right ventricular failure (RVF) is a severe event that increases perioperative mortality after Left Ventricle Assist Device (LVAD) implantation.
LVAD speed profoundly influences preload and afterload for both left and
right circulations. This study focuses on the relationship between LVAD
hemodynamic optimization, LV, RV preload and afterload in the context of
development of RVF.
Methods: Between 2015 and 2019, 50 consecutive patients received
LVAD implantation (Heartmate 3) at San Camillo Hospital in Rome. 38
who underwent pump speed optimization were included, and appropriate consent was obtained. Pre and post optimization hemodynamic data
were collected. We defined a new index - Cardiac Overload Index (COI) as
follows: COI = (CVP/MPAP)*(PCWP/MAP)*CO (i.e. an overload corrected
cardiac output) that incorporates the preload to afterload ratio for both
left and right circulations. COI was analyzed pre and post speed optimization for the patients that developed late RVF (RVF group) in comparison
to the subset that did not (no RVF group), using statistical significance
analysis.
Results: 10 patients had late RVF after LVAD implantation. Median COI
Pre-optimization was not statistically significant for both subsets of
patients (9.65 vs 10.05), indicating that it is not straightforward to know
the risk of late RVF apriori. However after speed optimization, those that
developed late stage RVF had a statistically significantly greater increase
in median COI compared to the subset that did not develop late stage RVF
(26.88 vs 18.89, p<0.05). This indicates that the RV was working harder
for the subset that eventually developed RVF, i.e. was overloaded in the
RVF group. This demonstrates that the COI metric could potentially be
used as a predictor for those that may develop RVF. This index, which can
be easily calculated during routine standard of care, could be used during
the follow-up to stratify the different hemodynamic profiles and modify
therapeutic strategies.
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Early Diagnosis Of LVAD Thrombosis Via Time-Frequency Analysis Of
Circadian Patterns Of Pump Parameters: Are We Ready For Clinical
Translation?
Filippo Consolo, PhD1, Federico Pappalardo, MD2; 1Anesthesia and
Intensive Care, Università Vita-Salute San Raffaele, Milan, Italy,
2
Anesthesia and Intensive Care, IRCCS ISMETT, Palermo, Italy

Development Of A Novel Integrated Organ Perfusion Chamber And
Reservoir For Ex-vivo Perfusion System
Brandon D’Aloiso, CCP1, Selma Sosic, MS1,
Caroline Schoenwald, MS1, Sreyas Ravi, BS1,
Kelsey Cox, RN, BSN1, Richard Schaub, PhD1,
Garrett Coyan, MD, MS2, Sarah Burki, MD2,
Harvey Borovetz, PhD1, Christopher Sciortino, MD, PhD3.; 1Department of
Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA, 2McGowan
Institute for Regenerative Medicine, Pittsburgh, PA, USA, 3Sentara MidAtlantic Cardiothoracic Surgeons, Sentara Health System, Norfolk, VA, USA

Study: In the setting of LVAD implantation, no clinically reliable tools exist
for the early diagnosis (prediction) of pump thrombosis (PT). We showed
that time-frequency analysis (TFA) of the HVAD log files allows diagnosis
of the early stage of development of PT according to the detection of
instability/disruption of circadian patterns of pump parameters several
days before clinical manifestation of the thrombotic event. Aim of this
study was to test the potential for effective clinical translation of this tool,
that is, to assess its real-time early diagnostic capability.
Methods: We analyzed 173 log files of 48 HVAD patients simulating
longitudinal real-time data acquisition and analysis. In detail, the 30-days
log files records were discretized into consecutive windows of 24-hours
duration and iteratively acquired and processed via TFA. This way, we
simulated the real-world scenario, i.e., longitudinal analysis of pump
parameters over the time of support. Data analyzed include 24 files (14%)
associated with a clinical diagnosis of PT and 149 (86%) controls. The tool
was instructed to automatically identify a log file of the PT group according to the detection of instability of the circadian rhythm in pump power
consumption for at least 2 consecutive days.
Results: Sensitivity and specificity of the tool were 95% and 84%, respectively. Early signs of a forthcoming PT were identified 10±8 days prior to
its clinical manifestation. Importantly, false positives analysis highlighted
patient-specific profiles/characteristics affecting the physiologic circadian
pattern, irrespective of PT development. This study confirms the potential
for effective clinical translation of TFA of the log files for the early diagnosis of a forthcoming PT. Incorporating this tool on board of the HVAD
controller might dramatically improve the timing of diagnosis of PT, with
important implications in terms of efficacy of non-invasive intervention.

Study: Heart transplant is the standard treatment for end-stage heart
disease. The waitlist greatly exceeds the number of donor organs. Hearts
are conventionally donated following brain death. The technique of donation following cardiac death (DCD) has become an alternative pathway
for donation. At present it is difficult to obtain an assessment of organ
viability for transplant. A system that can characterize organ viability
could greatly expand the donor pool. We are developing an ex-vivo perfusion system for recovery and viability assessment of hearts donated via
DCD. An integrated organ perfusion chamber and reservoir have been
developed for the ex-vivo perfusion system.
Methods: Initial chamber/reservoir design criteria included: 1)Volume
placement of a human heart, 2)mesh/pseudo-pericardium to support the
heart, 3)reservoir holding 500 mL to 1L of perfusate, 4)incorporation of
sensors for monitoring of temperature, flow, perfusion pressures. Three
design iterations were investigated; each successive prototype improvement based on ease of manufacturing and clinical use. Figure 1 displays
our prototype development photos (V0.03 is the current design).
Results: Our V0.03 prototype met all design requirements. A brief survey
was taken by cardiovascular perfusionists as regards our final Figure 1
prototype (V0.03). The survey was based on a Likert Scale with 1 being
the worst and 5 being the best. The results were: Ease of Heart Fit 5/5,
Ease of Heart Monitoring 3/5, Ease of Interfacing to Circuit 5/5. Based on
feedback, future prototypes will be modified accordingly to incorporate
additional sensors for measurement of organ biomechanic viability over
time in a smaller overall footprint. The successful design and testing of an
integrated organ perfusion chamber and reservoir were completed. Users
appreciated the design and made important suggestions which we will
incorporate in our next design iterations.
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Characterization Of A Multi-Scale Computational Model And A Mock
Circulatory Loop To Simulate Cardiogenic Shock
Christian Contarino, PhD1, Francesco Chifari, MS1,
Gavin A. D’Souza, PhD2, Luke H. Herbertson, PhD2.; 1Computational Life
Inc., Wilmington, DE, USA, 2CDRH/OSEL, Food and Drug Administration,
Silver Spring, MD, USA

Bloodless Stage II Norwood Palliation In A 6kg Jehovah’s Witness Patient
Daniel Duncan, CCP, Paul Kerins, CCP, Christian Pizarro, MD; Nemours
Cardiac Center, Nemours A.I. DuPont Hospital for Children, Wilmington,
DE, USA
Study: While maneuvers such as acute normovolemic hemodilution
(ANH), retrograde autologous priming (RAP), and modified ultrafiltration
(MUF) have proven efficacious in the reduction and occasional elimination
of heterologous blood administration, their use adds complexity to the
procedure, may result in low intraoperative nadir hematocrits, and must
sometimes be abandoned due to hemodynamic instability or mechanical
difficulty. We report a case of successful Stage II Norwood palliation in a
6kg Jehovah’s Witness patient without the use of heterologous blood.
Methods: Our standard 3/16 x 1/4 CPB circuit was further miniaturized
by adding a 3/16 pump boot, and mounting the circuit so that the top of
the venous reservoir was at the level of the patient’s right atrium. The
pump was positioned as close to the table as possible, and the arterial
and venous lines were pulled taught before trimming to minimize their
lengths. These modifications resulted in a total static prime volume of
100 mL. The patient’s pre-operative hematocrit of 45% was reduced to
32% upon initiation of CPB, and fell to a nadir of 26% following cardioplegia administration. After hemofiltration, the hematocrit was raised to
30%, where it remained through rewarming and termination of CPB. Following decannulation, 100 mL of autologous blood was sequestered from
the circuit. This volume was reinfused by the anesthesiologist, resulting in
a post-pump hematocrit of 35%. Hemostasis was secured, and the patient
was transported to the ICU with an uneventful post-operative course.
Results: This case illustrates the ability of aggressive circuit miniaturization and positioning to enable bloodless cardiac surgery in a small,
complex patient, without the use of adjunctive maneuvers such as ANH,
RAP, or MUF. This simple, safe, and repeatable approach requires no
manipulation of pre-operative hemodynamics, results in less profound
intraoperative hemodilution, and allows rapid reversal of anticoagulation
following cessation of CPB.

Study: Before conducting costly animal studies and high-risk clinical
trials, pre-clinical tools including computational models and benchtop
mock circulatory loops (MCLs) are being used more frequently to evaluate device performance. However, the accuracy and credibility of these
tools are highly dependent on their ability to reproducibly assess device
performance while closely mimicking pathophysiologic hemodynamics.
In this study, a multi-scale cardiovascular computational model and an
MCL are comprehensively characterized to replicate the hemodynamics
associated with cardiogenic shock (CS), which is an end-stage heart failure
condition often requiring ventricular assist device therapy. Credibility and
reliability of the model are demonstrated using input parameter uncertainty quantification.
Methods: The target pathophysiologic hemodynamics of the CS condition
include a cardiac output (CO) of 3 L/min, 110 bpm heart rate (HR), blood
pressure of 80/50 mmHg, and a mean left atrial pressure > 15 mmHg.
These target conditions were first generated using the MCL, representing
the left heart. Ten replicate tests were performed to quantify the uncertainty in CO, HR, and systemic vascular resistance (SVR). Subsequently, a
sensitivity analysis was performed using the multi-scale computational
model to quantify the uncertainty in model outputs (i.e., peak systolic
and diastolic pressures, mean left atrial pressure, and stroke volume)
due to the uncertainty in model inputs (i.e., CO, HR, and SVR) measured
experimentally.
Results: The MCL and computational model closely mimic the target
hemodynamics of the CS condition, and the pressure waveforms (Figure
1) show good agreement between the experimental measurements and
the numerical predictions. The uncertainty estimates of key outputs
demonstrate the credibility and reliability of the MCL and model in simulating relevant pathophysiologic hemodynamics for pre-clinical device
performance evaluation.
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Case Study: Baseline Hemodynamics Including Aortic And Pulmonary
Flows In A Survival Bovine Model
Angel Moctezuma-Ramirez, MD,
Abdelmotagaly Elgalad, MD, PhD, Kelly Handy, BS,
Payam Safavi-Naeini, MD, Gil Costas, DVM, O.H. Frazier, MD; Texas Heart
Institute, Houston, TX, USA
Study: Large animal models have played an increasingly valuable and
expanding role in the preclinical setting by providing invaluable data for
the safety and efficacy evaluation of new therapies, devices, or disease
models. This case aimed to provide baseline hemodynamic values, including aortic and pulmonary flows for a bovine model at rest and during
exercise. This study will help device engineers, researchers, and manufacturers to understand the normal bovine cardiovascular physiology for
technical consideration during device development for preclinical trials.

Results: The hemodynamic data obtained with the animal at rest in the
ICU of our laboratory is depicted in Table 1; parameters such as heart
rate, pressure, flows, and vascular resistances were included. Pressures
and flow rates at baseline and during treadmill trials were compared in
Table 2. The average treadmill trial duration was 22.5 min with an average
distance walked of 674.5 m. Figure 1 depicts the flow rate through the
aorta, and pulmonary artery, a steady increase in flow rates is observed.

Methods: A calf weighing 80.9 kg undergone left lateral thoracotomy.
Fluid-filled pressure lines (aortic pressure [AoP], right atrial pressure [RAP], left atrial pressure [LAP], and pulmonary artery pressure
[PAP]) and left and right flow probe lines were implanted. Flow probes
(Transonic Systems Inc., 24 mm) were then placed on the aorta and
pulmonary artery. The calf was continuously monitored throughout the
postoperative period. Physiologic pressures, animal vital signs, aortic
and pulmonary flows, and pulmonary and systemic vascular resistance
were recorded hourly. Treadmill exercise evaluations were conducted,
Pressures (AoP, RAP, LAP, and PAP) and flows (aortic and pulmonary) were
monitored to determine the animal’s hemodynamic response to exercise.
All hemodynamic data were described as means, standard deviations, and
a 95% confidence interval.
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Validation Of Numerically Predicted Shear Stress-Dependent Dissipative
Losses Within A Rotary Blood Pump
Carsten Strauch, MSc1, Andreas Escher, MSc2,
Sebastian Wulff, PhD1, Ulrich Kertzscher, PhD3,
Daniel Zimpfer, MD, PhD2, Paul Uwe Thamsen, PhD1,
Marcus Granegger, PhD2.; 1Department of Fluid System Dynamics,
Technische Universität Berlin, Berlin, Germany, 2Department of Cardiac
Surgery, Medical University of Vienna, Vienna, Austria, 3Biofluid
Mechanics Laboratory, Charité-Universitätsmedizin Berlin, Berlin,
Germany

Effect Of Ischemic Time During Cardiac Transplantation On Survival
Outcome Within Certain Patient Groups
Ahad Firoz, BS, Mohammed Abul Kashem, MD, PhD,
Hiromu Kehara, BS, Kelsey Muir, BS, Labiba Islam, Other,
Manish Suryapalam, Other, Shaira Jafar, Other,
Gengo Sunagawa, MD, Yoshiya Toyoda, MD, PhD; Lewis Katz School of
Medicine, Philadelphia, PA, USA
Study: Numerous studies have shown that an increase in donor age or a
mismatch in donor-to-recipient gender can have a negative effect on overall survival following heart transplantation (HTx). However, due to a shortage of donor hearts, the ability to fully individualize HTx is greatly limited.
Fortunately, superior surgical techniques can be used to offset the relative
risks associated with an appropriate, yet imperfect, match. One such area
of interest is by decreasing ischemic time as supported by many studies;
however, there are limited investigations on the extent of this relationship
within specific patient groups. Our study aims to determine the relative
effects of prolonged ischemic time during HTx on survival outcome within
different donor/recipient age and gender groups.
Methods: We retrospectively analyzed 65,396 patients within the UNOS
registry between the ages of 20-79yrs who underwent HTx from 19872020. Patients were ultimately stratified into 16 groups based on donor
age (≤30yrs and >30yrs) and gender, and recipient age (20-50yrs and
>50yrs) and gender. Survival outcomes were then analyzed based on ischemic time (≤4hrs and >4hrs) using log-rank tests and Cox-regression.

Study: Computational fluid dynamics find widespread application in the
development of rotary blood pumps. Yet, corresponding simulations rely
on shear stress computations that are afflicted with limited resolution
while lacking validation. This study aimed at the experimental validation
of integral hydraulic properties to illuminate global shear stress resolution
across the operational range of a novel rotary blood pump.
Methods: Pressure head and impeller torque were numerically predicted
based on unsteady Reynolds-averaged Navier-Stokes simulations, and validated on a testbench with integrated sensor modalities (flow, pressure,
torque). Validation was performed by linear regression and Bland-Altman
analysis across 9 operating conditions. In power loss analysis, in-silico
hydraulic power losses were derived based on the validated hydraulic
quantities and compared with in-silico shear-dependent dissipative power
losses. Equal in theory, discrepancies among both terms provided a measure of in-silico shear stress resolution.
Results: In-silico and in-vitro data correlated with low discordance in pressure (r=0.992, RMSE=1.02mmHg), torque (r=0.999, RMSE=0.034mNm)
and hydraulic power losses (r=0.990, RMSE=0.015W). Power loss analysis
revealed numerically predicted dissipative losses to be up to 34.4%
smaller than validated computations of hydraulic losses. This study
confirmed suitability of uRANS settings to predict integral hydraulic properties. However, numerical credibility was hampered by lacking resolution
of shear-dependent dissipative losses.

Results: The log-rank test results for each patient group comparing the
survival outcome between both ischemic time periods are listed in Table
1. Findings revealed the following three significant groups: young male
donors to young male recipients, young female donors to old female
recipients, and old male donors to old male recipients. These three
groups were then further analyzed to obtain their survival rates at 1, 5,
and 10 years after HTx, as well as median hazard ratios, which are listed
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in Table 2. From our study, while there are other groups that appear
to trend towards significant, such as old female donors to old female
recipients, surgeons should be especially conscious about ischemic times
for the three significant groups mentioned previously to maximize patient
survival outcome.

Temporary Left Ventricular Assist Device As A Bridge To VA ECMO
Decannulation
Annika M. Gallandt, BA1, Jacob C. Richards, BA1,
Stanley B. Wolfe, MD1, Jerome C. Crowley, MD, MPH2,
Van-Khue Ton, MD, PhD3, David A. D’Alessandro, MD1.; 1Cardiac Surgery,
Massachusetts General Hospital, Boston, MA, USA, 2Anesthesia, Critical
Care and Pain Medicine, Massachusetts General Hospital, Boston, MA,
USA, 3Cardiology, Massachusetts General Hospital, Boston, MA, USA
Study: The Impella 5.5 temporary left ventricular assist device was
approved for use in the United Stated in September 2019. Early studies
show promising rates of survival and recovery of native heart function.
We aimed to review our institution’s experience using the Impella 5.5
to facilitate venoarterial extracorporeal membrane oxygenation (ECMO)
decannulation.
Methods: Patients who underwent ECMO and Impella 5.5 therapy in the
same admission were identified through an institutional database. Retrospective chart review was performed.
Results: Eleven patients received ECMO and Impella 5.5 support (82%
male, mean age 58). Cardiogenic shock following myocardial infarction
was the most common indication for ECMO. Seven patients received concomitant ECMO and Impella while four patients were placed on Impella at
ECMO decannulation. The mean SAVE score was -2 and mean pre-ECMO
LVEF was 16%. Inotrope scores decreased after ECMO cannulation and
continued to trend down following Impella insertion (Figure). Patients
spent 106 ± 60 hours on ECMO and 239 ± 149 hours on Impella support.
Two patients experienced embolic stroke and three required new dialysis
during support. One patient had the Impella purge line clot requiring
the device be explanted. Seven (64%) survived to ECMO decannulation,
Impella removal, and ICU discharge. The Impella 5.5 is a useful adjunct
to ECMO when used to expedite decannulation. Additional research is
needed to determine if this practice provides a survival advantage over
historical experience.
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A Universal Device To Convert A Continuous Flow Assist Device To A
Pulsatile Flow Device
Rabin Gerrah, MD; Cardiothoracic Surgery, Stanford University, Corvallis,
OR, USA

Bicarbonate As An Alternative To Heparin In Impella Purge Fluid:
Understanding The Biochemical Basis
Vladimir Gilman, PhD1, Soumen Das, PhD1, Mark Popovsky, MD1,
Shannon McMinn, BS2, Frederic Wolf, PhD2,
Svenja Berth, BS, MS3, Eveline Bennek Schoepping, BS, MS3,
Gary Stacey, BS1, Claudia Mourran, PhD3,
Jeremy Moretz, PharMD1, Christoph Nix, MD3,
Scott Corbett, PhD1.; 1Engineering, Abiomed Inc, Danvers, MA, USA,
2
Engineering, Abiomed Inc, Aachen, Germany, 3Research, Abiomed Inc,
Aachen, Germany.

Study: Continuous follow assist devices (CFAD) are used more often than
pulsatile flow assist devices (PFAD). Despite the benefit of providing more
physiologic type flow that mimics native circulation, PFADs contain more
components which account for more complications and more complex
management. Some complications with withdrawal of CFAD for recovery
or heart transplant are attributed to lack of pulsatility. Presented here is
a concept of a universal converter device that can be added inline to any
other CFAD to convert the flow from continuous to pulsatile. After initial
implantation and stabilization with a CFAD, adding this converter will
potentially provide the benefits of pulsatile physiologic flow.
Methods:. The device is made of 2 components connected in parallel, each made of an outer and a rotating inner chamber, and a flexible
diaphragm. The 2 components are working in tandem, one serving as a
reservoir and the other as a pumping chamber in cycles determined by
the user. Both chambers have an inlet and an outlet opening, placed in a
specific alignment to direct the flow in one direction only. The compression of the diaphragm, timed to rotation of the chamber, creates the
pulsatile flow. A microprocessor controls the timing of the rotation of
the inner chamber, that dictates the duration of flow, and the force that
is applied on the diaphragm, analogous to heart rate and contractility
respectively.
Results: The idea behind this concept is to generate pulsatility for other
assist devices. This device has no conventional valves or major moving
components and it is failure free; if deactivated, it will not block or affect
the flow. Conversion of continuous flow to physiologic pulsatile flow can
potentially prevent some CFAD complications especially those seen with
withdrawal of CFAD.

Study: The Impella® pumps are microaxial flow pumps that use a purge
fluid containing heparin. The absence of heparin in the purge fluid
increases the risk of biobuildup in the purge gaps (Figure 1A). Sodium
bicarbonate may interfere with biobuildup by suppressing fibrin assembly,
improving major blood protein stability, and influencing biobuildup lysis
via buffering effect. This study evaluated bicarbonate-based purge solution (BBPS; 25mEq/L-D5) to support the purge patency of Impella devices
using benchtop and animal model.
Methods: The impact of BBPS on bovine serum albumin’s stability (BSA;
as a model protein) was evaluated using HPLC in a ratio of blood mixed
with the purge (blood to purge fluid =6:4). Human blood coagulability was
investigated with BBPS using thromboelastography (TEG). Next, BBPS was
also evaluated in a 14-day ovine model (n=3) using Impella 5.5 pumps.
We selected Impella 5.5 as a challenge pump due to low purge flow and
a longer indication of use. The controller data of purge flow, purge pressure, and motor current trends were analyzed.
Results: HPLC analysis showed a 50% reduction of BSA oligomer in BBPS
than heparin-purge fluid due to neutralization of the acidic pH of D5
(Figure 1B). TEG data showed similar clot strength (MA) with BBSP and
heparin-purge solution; however, the rate of lysis (LY 30) was significantly
increased with BBPS Vs. heparin-based purge solution (1.5% vs. 0%,
respectively). In the animal study, purge pressure, purge flow, and motor
current were stable with BBPS. The preliminary data indicate that the
use of BBPS maintains the Impella pump’s purge reliability. BBPS could
simplify overall systemic anticoagulation management and support of
heparin intolerant patients.
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Log Files Analysis Demonstrates Circadian Variation Over The First-year
Post Implantation Of Continuous Flow-left Ventricular Assist Device
Joel Graham, MEng1, Tanvir Kahlon, MD2,
Jaimin Trivedi, MBBS, MPH2, Christina Dunbar-Matos, DO2,
Mark Slaughter, MD2.; 1Bioengineering, University of Louisville, Louisville,
KY, USA, 2University of Louisville, Louisville, KY, USA

LVAD Implantation Off-pump Through Median Sternotomy Vs Sternal
Sparing Approach
Igor D. Gregoric, MD, Manish K. Patel, MD, Mehmet H. Akay, MD,
Ismael A. Salas de Armas, MD, Jayeshkumar A. Patel, MD,
Mateja Jezovnik, MD, PhD, Rajko Radovancevic, MD,
Biswajit Kar, MD; Advanced Cardiopulmonary Therapies and
Transplantation, The University of Texas Health Science Center-Houston,
Houston, TX, USA

Study: Cardiovascular circadian variation is attenuated in cardiovascular
disease including chronic heart failure. Relatively little is known about
resumption of cardiovascular circadian rhythm post durable left ventricular assist device (LVAD) implantation. This study characterizes the diurnal
and nocturnal variation in flow parameters observed in 121 patients with
the HeartWare HVAD (Medtronic, Inc., Minneapolis, MN) device over a
one-year period following surgical implant.
Methods: Retrospectively compiled device parameter data were downloaded from all available controller log files for patients implanted from
9/2010 through 9/2020 at a single center. Controller log data including
flow (LPM), speed (RPM), and power (W) were collected every 15 minutes
and analyzed using LabVIEW software. Device parameter data was averaged by the hour for each patient and normalized using the daily average
for 1-year post LVAD implant. BSA at time of implant was used to index
flow. Logfiles were excluded if the day included a speed change, if power
was outside of expected operation range, or less than 30 days of data was
available.
Results: Circadian data was analyzed for 19,378 controller log-days in
119 patients (165 +/- 93 days per patient) for 1-year following surgical
implant. Average and standard deviation parameters for flow, index flow,
speed, and power were 4.96 ± 0.87 LPM, 2.40 ± 0.37 LPM/m2, 2736 ±
141 RPM, and 4.40 ± 0.80 W respectively. Nocturnal decrease (2.8% from
12 to 7 AM) and diurnal increase (2.1% from 12 to 7 PM) were observed
for normalized flow (Figure 1). Indexed flow decreased over one year
following implant though circadian changes for normalized flow were
consistent.
Conclusion: While blood pressure and heart rate variability are typically
considered the markers of circadian variation, our study demonstrates
that LVAD flow can be used as a surrogate marker of cardiovascular circadian autonomic function in LVAD recipients.

Study: There remains debate on best surgical approach for left ventricular
assist device (LVAD) implantation. A sternal sparing procedure is done
through right and left minithoracotomies with a small subxiphoid incision.
We compared this sternal sparing approach to the conventional median
sternotomy in patients who received a LVAD without the use of cardiopulmonary bypass support (also known as “off pump”).
Methods: At our center, 80 patients received an LVAD (Heartware ventricular assist device, Medtronic) that was implanted off-pump from January
2013 till September 2020. Patients who had biventricular support or any
other additional procedures were excluded from the analysis. Thirteen
patients underwent the Sternal Sparing procedure. The other 67 patients
underwent a classical median Sternotomy. We compared their short-term
postoperative outcomes (30-days).
Results: Preoperatively, both groups had similar demographic, functional
and hemodynamic characteristics as well as INTERMACS scores. Compared to the Sternotomy group, the Sternal Sparing group patients had
significantly longer anesthesia (421±50 vs 302±58 min; p= 0.0003) and
surgery time (291±68 vs 204±51 min; p= 0.0026). The sternal sparing procedure had more operative bleeding (median 900 mL [range, 500-1000
mL] vs 500 mL [350-700 mL]; p= 0.03). There was a trend toward more
blood transfusions and platelet doses in Sternal Sparing group patients
(1.5 [1-2] vs 1.0 [1-3] RBC units; p=0.81, and 2.0 [2-2] vs 1.0 [1 -2] platelet
doses; p=0.44); however, this did not reach statistical difference. Duration
of mechanical ventilation (20 [18-47] vs 21 [16-68] hours, p= 0.72) as well
as hospital stay (20 [18-27] vs 21 [15-34] days, p= 0.15; Sternal sparing vs
Sternotomy group, respectively) were similar between groups.
Conclusion. These data indicate that the sternal sparing approach did not
result in a significant benefit regarding duration of surgery and bleeding
when compared with the conventional sternotomy.
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First Isolated Single-ventricle Working Porcine Heart Model
Massimo Griselli, MD1, Tinen Iles, PhD2, Subin Jang, MBA1,
Paul Iaizzo, PhD3.; 1Pediatric Cardiac Surgery, University of Minnesota,
Minneapolis, MN, USA, 2Department of Surgery, Bioinformatics and
Computational Biology, University of Minnesota, Minneapolis, MN, USA,
3
Department of Surgery, University of Minnesota, Minneapolis, MN, USA

Comparison Of Strategies To Assess Bridge To Recovery With Rotary
Blood Pumps: An In Vitro Evaluation
Andrew B. Haymet, M.B.B.Ch.1, Jo P. Pauls, PhD1,
Maryam Memar, BS1, Michael P. Vallely, MD, PhD2,
Jacky Y. Suen, PhD1, John F. Fraser, MD, PhD1, Eric L. Wu, PhD1.; 1Critical
Care Research Group, Brisbane, Australia, 2Division of Cardiac Surgery,
The Ohio State University Wexner Medical Center, Columbus, OH, USA
Study: Prior to explantation of rotary blood pumps (RBPs) in bridge to recovery (BTR) candidates, ventricular function needs to be adequately assessed,
which is typically done at rest and exercise. Different clinical strategies have
been used to assess haemodynamic performance and their efficacy has
been compared in preclinical studies during simulated patient rest; however,
the efficacy of these strategies during exercise is less clear. This study aimed
to compare the in vitro haemodynamic performance of four clinical strategies used to assess BTR during simulated patient rest and exercise.
Methods: A previously validated mock circulatory loop was used to compare
four clinical strategies used to assess BTR, using a HeartWare HVAD RBP during
simulated patient rest and exercise. These strategies included 1) turning the
RBP off, 2) turning the RBP off combined with outflow graft occlusion, and
operating the RBP at both 3) its lowest manufactured speed (1800 RPM) and
4) speed lower than designed (1500 RPM). Maintainance of zero flow through
the device was desired to appropriately assess haemodynamic performance.
Results: During rest and exercise, RBP flow with RBP off was -2.4 and
-2.0 L/min, RBP off combined with outflow graft occlusion maintained RBP
flow at 0.0 L/min, RBP on at 1800 RPM was 0.6 and 1.3 L/min, and RBP on
at 1500 RPM was 0.0 and 0.6 L/min, respectively.
This in vitro study found that switching the RBP off combined with outflow graft
occlusion, and RBP on at 1800 RPM demonstrated similar unloading during rest
and exercise. However, this study was limited by a lack of biological responsiveness. Therefore, future work may include validation in animal models.

Study: Isolated heart models have been used for years with the great
advantage to focus on cardiac performances and they constitute an
important substrate for reproducing physiological parameters, testing
pathological modifications and therapies. Single-ventricle (SV) congenital
heart diseases result usually with palliative ‘Fontan’ circulation associated
with morbidity and mortality despite recent advances in the management
of SV. Establishing a SV porcine isolated heart model allows to investigate
the physiology of SV cardiac function and reproducing the pathological
variations seen in humans. Possible therapies including different mechanical circulatory supports (MCS) could be tested on this model.
Methods: We chose pig hearts due the similar characteristics with human
heart anatomy and physiology. After the standard cardiac harvesting, 3
pig hearts were converted in SV functioning organs by creating an atrial
septal defect via right atriotomy and a ventricle septal defect via right
ventriculotomy. The main pulmonary artery was divided above the pulmonary valve and closed off. SV hearts were connected to the apparatus
and re-perfused with heparinised pig blood and maintained at temperature of 38ºC. The apparatus was set in resting or working conditions, by
tuning preload and afterload, and hemodynamic data were collected
by echocardiography, electrocardiography, and pressures in all cardiac
chambers.
Results: Isolated SV isolated pig heart is easily reproducible which shows
a decrease in the cardiac function during time, which could be the substrate for testing therapies, particularly MCS devices. SV ex-vivo pig heart
model provide a tool to study cardiac responses in resting and working
conditions and to assess variations observed in SV patients and responses
to different pharmacological, electrical and mechanical modifications.
Absence of neuro-humoral response is a disadvantage but reproducibility
and accuracy of data make this platform an elegant tool for cardiovascular
research.
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Performance Evaluation Of Artificial Pulses Produced By A
Programmable Centrifugal VAD In A Mock Circulatory Loop
Britton E. Richardson, None, Gavin A. D’Souza, PhD,
Masoud Farahmand, PhD, Jean E. Rinaldi, MEng,
Luke H. Herbertson, PhD; Center for Devices and Radiological Health,
U.S. Food and Drug Administration, Silver Spring, MD, USA

Laparoscopic Sleeve Gastrectomy Supported With A Temporary Microaxial Flow Pump In A Patient With Alstrom Syndrome
Luis A. Hernandez Mejia, MD1, Nader H. Hanna, MD1,
Kevin Leung, MD1, Monica Segura, MD2, Diana Miranda Ruiz, MD1,
Jose Sleiman, MD1, Eduardo Perez, MD1, Abdullah Sarkar, MD1,
Manojna Nimmagadda, MD1, Steven Minear, MD3,
Edward Noguera, MD3, Lilibeth Fermin, MD3,
Gaston Cudemus, MD3, Nicolas Brozzi, MD4, Cedric Sheffield, MD4,
Emad Hakemi, MD1, Raul Rosenthal, MD5, Mauricio Velez, MD1,
Elsy V. Navas, MD1, Jaime Hernandez-Montfort, MD1.; 1Cardiology,
Cleveland Clinic Florida, Weston, FL, USA, 2Internal Medicine, Cleveland
Clinic Florida, Weston, FL, USA, 3Anesthesia, Cleveland Clinic Florida,
Weston, FL, USA, 4Cardiothoracic Surgery, Cleveland Clinic Florida,
Weston, FL, USA, 5General Surgery/Bariatric Surgery, Cleveland Clinic
Florida, Weston, FL, USA

Study: Artificial pulses can be generated by controlling the rotor speed
of continuous flow ventricular assist devices (VADs) to improve patient
hemodynamics by augmenting pressure and flow pulsatility. Pulsatility
can potentially prevent thrombus deposition, improve endothelial cell
growth, and augment cardiovascular response. However, there are no
established pass-fail criteria or quantifiable metrics for characterizing VAD
pulsatility. The purpose of this study was to characterize the influence of
artificial pulses generated by a programmable in-house VAD on the pathophysiologic hemodynamics of a heart failure patient simulated in a mock
circulatory loop (MCL).
Methods: A centrifugal pump was programmed to represent a VAD and
generate artificial pulses of varying shape, pulse width, amplitude, and
frequency. The programmable VAD was integrated within an MCL, which
simulated the left heart hemodynamics of a heart failure patient. Six
asynchronous speed modulation algorithms, including multiple step functions and sine and triangle waves, were compared to non-pulsed steady
flow devices. Key parameters such as total cardiac output, VAD flow rate,
aortic pressure, and left ventricular pressure were measured for each
inputted artificial pulse algorithm.
Results: Asynchronous pulses were characterized in the MCL over the
entire VAD operating range, in terms of the atrial, ventricular and aortic
pressures and flows, phase shift, and ejection fraction. The figure below
shows baseline pressure and flow waveforms for a steady flow VAD
providing 80% support for a simulated heart failure patient. The VAD
maintained native pulsatility while supporting a total mean blood flow
rate of 4.6 L/min at 90 bpm. This study is a first step for developing
standard pre-clinical test methods to effectively evaluate the impact of
asynchronous and synchronous artificial pulses on the flow performance
of VADs earlier in the total product life cycle.

Study: Alstrom syndrome (AL) is a rare cause of dilated cardiomyopathy
(DCM), hearing impairment, Morbid Obesity (MO), and type 2 diabetes.
Patients with MO are often excluded from heart transplant (HT) or left
assisted ventricular devices (LVAD). Bariatric surgery has been successfully
used for weight loss as a bridge to HT. Transitions to durable replacement
among patients with heart-failure cardiogenic shock (HF-CS) requiring
temporary support remains elusive.
Methods: 26-year-old with history of Alstrom Syndrome (DCM, MO) and
chronic kidney disease transferred from an outside facility due to HF-CS
secondary to ventricular tachycardia. In our facility patient, BMI 58,
clinically volume overloaded and echo showed EF 21%, with moderately
decreased RV function and RVSP 46 mmHg. He underwent right heart
catheterization that showed RA 29mmHg PAP 55/25/39 mmHg and PCWP
25 with CO 4.5L/min and CI 1.6 L/min/m2. He was started on diuresis and
inotropes. Based on his prohibitive risk for replacement therapies (LVAD/
HT) laparoscopic sleeve gastrectomy (LSG) supported with Impella CP for
weight loss was offered as a bridge to decision. He underwent LSC without complications and was discharged home on inotropic support with a
weight loss of 49 pounds after 2 weeks.
Results: Several centers use body mass index (BMI) >35 kg/m2 as a
contraindication to proceeding with replacement therapies due to high
risk of complications. Several studies showed bariatric surgery reduces
the risk of heart failure development and reverses abnormalities in
cardiac mass. LSG has been previously performed safely with successful
progression to cardiac transplant listing and transplantation for patients
with HF-CS and MO. To our knowledge, this is the first reported case of
LSG in a patient with AL in CS supported with Impella CP combined with
inotropes as a safe and feasible bridge to replacement therapies candidacy. More research is needed in order to best understand this vulnerable
population.
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The Effect of N-linked Deglycosylation on vWF and ADAMTS13 Structure
and Function Under VAD-like Shear Stress
Victoria Higginbotham, MSc1, Christian R. Sargent, PhD2,
Sabrina Ali, PhD2, Stuart McConchie, BS2,
Venkateswarlu Kanamarlapudi, PhD, DSc3.; 1Calon Cardio-Technology Ltd,
Swansea University, Swansea, United Kingdom, 2Calon Cardio-Technology
Ltd, Swansea, United Kingdom, 3Medical School, Swansea University,
Swansea, United Kingdom.

Galectin-3 In Patients With Left Ventricular Assist Devices: A Prognostic
Biomarker Of Post-implantation Outcomes
Ryan Hoang, None1, Jennifer Cruz, None1, Mary Acosta, MD2,
Sydney Lupo, None1, Corinne Stonebraker, BA1,
Nabeel Rasheed, BA1, Colleen Labuhn, APNP1, Sean Pinney, MD1,
Valluvan Jeevanandam, MD1, Jonathan Grinstein, MD2.; 1Section of
Cardiac Surgery, The University of Chicago Medicine, Chicago, IL, USA,
2
Section of Cardiology, The University of Chicago Medicine, Chicago, IL,
USA

Study: While ventricular assist devices (VADs) provide effective circulatory
support in heart failure patients, the adverse effects include gastrointestinal (GI) bleeding and thrombosis. High molecular weight (HMW) von Willebrand Factor (vWF) is a multimeric blood circulating glycoprotein. HMW
vWF has two critical roles in promoting platelet adhesion to damaged
blood vessels and enhancing clot formation. vWF has twelve N-linked
glycosylation sites and two of them are located at the A2 domain, a site
for ADAMTS13 cleavage. Therefore, we hypothesised that N-linked deglycosylation of HMW vWF affects its interaction with ADAMTS13 under
VAD-like shear stress.
Methods: His6-vWF or mCherry-ADAMTS13 expressing HEK293 cells
were treated with tunicamycin for N-linked deglycosylation whereas the
corresponding purified His6-tagged proteins were subjected to N-linked
deglycosylation by PNGase F. These proteins were then added to human
whole blood and exposed to VAD-like shear stress. The structure of
deglycosylated vWF monomers and ADAMTS13 were then analysed by
non-native immunoblotting. In addition, the effect of N-linked deglycosylation and shear stress on HMW vWF multimer integrity was analysed by
native immunoblotting. Furthermore, the binding of deglycosylated vWF
to ADAMTS13 was studied by an ELISA.
Results: Our preliminary results propose that N-linked deglycosylation
could promote vWF interaction with ADAMTS13 under static and VADlike shear stress. Therefore, this study of deglycosylation may provide
useful information to define the structural properties of vWF. Also, the
development of synthetic deglycosylated HMW vWF could be beneficial
in treating patients with VAD-induced GI bleeding. However, to prevent potential thrombus-promoting events this vWF would require an
enhanced susceptibility for ADAMTS13 breakdown. Further research is
required to establish this effect and determine the N-linked glycosylation
sites responsible for these changes.

Study: Galectin-3 is a novel biomarker that has been used to categorize
HF patients by risk. Elevated levels are linked with poor outcomes and
higher cardiovascular risk with values greater than 25.9 ng/mL associated
with high risk. The relationship between Galectin-3 and outcomes in Left
Ventricular Assist Device (LVAD) patients has not been well-explored.
Methods: From 2012 to 2016, 159 patients with heart failure at our institution had lab values collected for Galectin-3. Among them, 108 patients
were implanted with an LVAD. Galectin-3 was collected for all patients
prior to LVAD implant. Their clinical outcomes, including right ventricular
failure (RVF), time on inotropes, need for right ventricular assist device
(RVAD), length of intensive care unit (ICU) stay, and mortality were collected retrospectively.
Results: Patients who experienced RVF (n=42) had a higher mean Galectin-3 value compared to those who did not (n=66), with 33.75 ng/mL ±
18.4 compared to 25.76 ng/mL ± 10.46 (p=0.002). Those who received an
RVAD (n=22) had higher Galectin-3 levels with mean 32.58 ng/mL ± 17.24
compared to those that did not (n=86) with mean 26.66 ng/mL ± 12.71
(p=0.138). Galectin-3 lab values were positively correlated with inotrope
duration (r=0.223, p=0.026), and length of ICU stay (r=0.257, p=0.006).
Galectin-3 levels in patients who died (n=49) were higher than in those
who did not (n=59), with a mean of 29.18 ng/mL ± 15.45 compared to
26.26 ng/mL ± 12.29 (p=0.208).
These results show the Galectin-3 biomarker can be used as a predictor of
post-LVAD implantation outcomes, elevated levels being associated with
RVF, longer time on inotropes, increased length of ICU stay, and higher
mortality.

105

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

ASAIO ELECTRONIC POSTER ABSTRACTS
EPCardiac23

EPCardiac24

Galectin-3: A Prognostic Biomarker Of Clinical Outcomes In Patients
With Heart Failure
Ryan Hoang, None1, Jennifer Cruz, None1, Nabeel Rasheed, BA1,
Corinne Stonebraker, BA1, Sydney Lupo, None1, Mary Acosta, MD2,
Colleen Labuhn, APNP1, Sean Pinney, MD1,
Valluvan Jeevanandam, MD1, Jonathan Grinstein, MD2.; 1Section of
Cardiac Surgery, The University of Chicago Medicine, Chicago, IL, USA,
2
Section of Cardiology, The University of Chicago Medicine, Chicago, IL,
USA

In Vitro And Ex Vivo Assays Of Vascular Calcification
Jana Holmar, PhD, Heidi Noels, PhD, DSc,
Joachim Jankowski, PhD, DSc, Setareh Orth-Alampour, PhD, DSc; Institute
for Molecular Cardiovascular Research, RWTH Aachen University Hospital,
Aachen, Germany.
Study: Vascular calcification (VC) is one major complication in patients
with chronic kidney disease whereas a failed calcium and phosphate
metabolism plays a crucial role. Since the mechanisms underlying VC
have not been entirely revealed to date, the highly relevant studies aiming at the identification and characterization of the mediators/uremic
toxins involved in VC are ongoing. The fact that many different protocols
being used in the studies of vascular calcification processes complicates
the comparison of study outcomes, composing systematic reviews, and
meta-analyses. Moreover, the reproducibility of data is hampered, and
the efficiency in calcification research through the lack of a standardized
protocol is reduced. In this study, we developed a standardized operating
protocol for in vitro and ex vivo approaches to aiming at the comparability of these studies.
Methods: Vascular smooth muscle cells (HAoSMCs) were used for in vitro
experiments and aortas from Wistar rats were used for ex vivo experiments. The influence of the following conditions was studied in detail:
phosphate and calcium concentrations in calcifying media; incubation
time; fetal calf serum (FCS) concentration. The degree of calcification was
estimated by quantification of calcium concentrations that were normalized to protein content (in vitro) or to the dry weight of the aortic ring
(ex vivo). Additionally, the aortic rings were stained using the von Kossa
method.
Results: We were able to demonstrate that the degree and the location of VC in vascular smooth muscle cells and aortic rings were highly
dependent on the phosphate and CaCl2 concentration in the medium
as well as the incubation time. Furthermore, the VC was reduced upon
increasing fetal calf serum concentration in the medium. The developed
and validated final step-by-step protocol presented in the figure will help
to standardize in vitro (A), and ex vivo (B) approaches to investigate the
processes of medial vascular calcification.

Study: Heart failure (HF) is associated with poor prognosis, with common
end-stage treatments including LVAD implantation and heart transplantation. Galectin-3 is a novel biomarker, with elevated levels being linked to
greater cardiovascular risk and poor outcomes in HF patients. We sought
to further investigate the relationship between Galectin-3, pre-implant
outcomes and mortality.
Methods: Between 2012 and 2016, 159 heart failure patients at our
institution had Galectin-3 biomarker lab values collected. A retrospective
study was performed investigating the clinical outcomes of these patients,
looking at outcomes of LVAD implantation and heart transplantation,
mortality, and the Intermacs score at the time of implant.
Results: In patients receiving an LVAD implant or heart transplant (n=107),
the mean Galectin-3 lab value was 27.49 ng/mL ± 14.86, compared to
31.72 ng/mL ± 13.72 (p=0.077) in those with neither (n=52). Galectin-3
values were negatively correlated to the Intermacs score at time of LVAD
implant or heart transplant (r=-0.307, p=0.001). Galectin-3 values were
higher in patients who died (n=82) than in those who did not (n=77),
with a mean of 31.09 ng/mL ± 15.87 compared to 26.55 ng/mL ± 12.78
(p=0.047).

106

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

ASAIO ELECTRONIC POSTER ABSTRACTS
EPCardiac25
Advanced Graphical User Interface For Continuous Flow MCS Devices
Dennis Horvath, BS, Christine R. Flick, BS,
Takuma Miyamoto, MD, PhD, Chihiro Miyagi, MD,
Jamshid Karimov, MD, PhD, Barry D. Kuban, BS,
Anthony R. Polakowski, BS, MS, Kiyotaka Fukamachi, MD, PhD; Cleveland
Clinic Lerner Research Institute, Cleveland, OH, USA
Study: The Cleveland Clinic continuous-flow total artificial heart (CFTAH)
uses an automatic speed control system to regulate the pump’s output in
response to hemodynamic changes. The system responds to changes in
systemic vascular resistance (SVR) and can predict, detect and respond to
pump suction. A user interface for the CFTAH, called the advanced pump
controller interface (APCI), is being developed to manage and monitor the
controller during in vitro and in vivo testing.
Methods: The APCI accurately estimates hemodynamic parameters, such
as SVR and the pump’s pressure gradients, by analyzing power consumption and the axial position of the pump rotor using regression equations
and artificial neural networks. The data, calculations, and state of the
controller are visualized by the APCI (Fig. 1). The interface makes it possible to fine tune the neural networks and calculation parameters during
operation.
Results: The APCI and CFTAH controller system can model and estimate
basic hemodynamic parameters and is capable of automatic speed control in initial testing. The APCI is also a prototype for a continuous patient
monitor; a software tool that will be used by patients and physicians to
monitor relative hemodynamic changes over time. Validating and improving accuracy and usefulness of the CFTAH control system will be a lengthy
process, involving large sets of chronic in vivo data that cover a variety of
dynamic situations, such as suction events and blockages proximal to the
pump. The in vivo studies and in vitro validation with the APCI is ongoing.
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Predictors Of Feasibility Of Ventricular Assist Device Explantation With
Stable Myocardial Recovery In Chronic Non-ischemic Cardiomyopathy
Mariano Francisco del Maria Javier, III, MD1,
Eva Maria Javier Delmo, MD, PhD2, Dietmar Böthig, MD, PhD3,
Michael Dande, MD, PhD4,
Roland Hetzer, MD, PhD1.; 1Universitätsmedizin Berlin-Charité, Berlin,
Germany, 2Charité Research Organization, Universitätsmedizin BerlinCharité, Berlin, Germany, 3Hannover Medical School, Hannover, Germany,
4
Cardio Centrum Berlin, Berlin, Germany.

Twenty-four-hour Normothermic Ex-Vivo Heart Perfusion Using
Hemofiltration
Matthew D. Johnson, MD, MS1, Bailey A. Schneider, BS1,
Mark Langley, BS, MS1, Adrianna Kayden, BS1,
Brian P. Fallon, MD1, Jonathan Haft, MD1, Daniel Drake, MD1,
Gabe Owens, MD, PhD2, Alvaro Rojas-Peña, MD1,
Robert H. Bartlett, MD1.; 1Surgery, University of Michigan Medical School,
Ann Arbor, MI, USA, 2Pediatrics, University of Michigan Medical School,
Ann Arbor, MI, USA; We show EVHP maintenance for 24h with HF toxin
removal allows for preservation of myocardial function, improved tissue
viability, decreased tissue edema, and less myocardial injury. These data
suggest the possibility of prolonged heart survival using HF EVHP for
future clinical translation.

Study: This meta-analysis aims to evaluate clinical parameters reflecting successful reverse remodeling and the viability of echocardiographic
parameters as predictors of sustained recovery to determine VAD explantation feasibility.
Methods: PubMed was searched for VAD-implantation outcome studies
in heart failure (HF) patients with non-ischemic cardiomyopathy. Inclusion
criteria were echocardiographic data (pre-during, post-VAD implantation/
explantation) with ≥one-year follow-up and myocardial recovery,HF recurrence or death as endpoints.
Results: Our meta-analysis encompasses 11 studies with 98 patients. Data
on age at implantation, gender, pre-explantation LVEDD/LVEF, off-pump
trial and pre-explantation stress tests were available in 83 patients.
Additional data on HF duration, pre-explantation LV geometry (sphericity index, relative wall thickness) and reduced off-pump arterial diastolic
pressure was known for 51 patients. Stepwise cox-regression in 51
patients demonstrated age at implantation (HR 1.094, p=0.002), HF duration (HR 1.438,p= 0.001) and sphericity index change (HR 1.541,p= 0.000)
as significant risk factors for HF recurrence during VAD-weaning, while in
83 patients, pre-explantation LVEDD (HR 1.126, p=0.031) and LVEF (HR
0.080,p=0.007) were significant predictors (Fig.1) of myocardial recovery
sustainment. Freedom from HF recurrence: 82%, 78%, 58% and 42% at
1,5,10 and 15 years, respectively. Post-weaning survival:100% and 80%
at 30 days and 5 years respectively and 78% at 10-15 years. Risk factors:
age at implantation (HR 1.098,p=0.004) and off-pump arterial diastolic
pressure of 50 mmHg (HR 0.095,p=0.040). Neither gender (p=0.862) nor
VAD-type (p=0.662) revealed statistical significance. Follow-up deaths
were non-cardiac (infection, stroke).LV-geometry and functional off-pump
stability may differentiate potential post-weaning clinical stability and HF
recurrence.

Study: Normothermic ex-vivo heart perfusion (EVHP) for >24h is possible
with both continuous paracorporeal plasma cross-circulation and continuous plasma exchange without paracorporeal support. We present a model
of EVHP using continuous hemofiltration (HF) with myocardial viability up
to 24h.
Methods: Hearts from 6-10kg piglets were procured after antegrade
cardioplegia. Cannulae placed in the aorta, pulmonary artery, and left
ventricle (LV) maintained the EVHP circuit. An LV pressure balloon allowed
for hemodynamic monitoring. The circuit was primed with platelet- and
leukocyte-reduced blood. The HF group (n=10) underwent EVHP with
in-parallel HF (Prismaflex HF1000) at 1cc/h/g cardiac tissue and Filter
Replacement Fluid (FRF), an isotonic electrolyte crystalloid, at equal rate
to maintain circuit euvolemia. The control (C) group (n=10) used EVHP
alone. Groups were compared using student’s t-test and Fisher’s exact
test.
Results: All HF vs 3 C hearts were viable at 24h (p=0.001). HF hearts had
higher LV systolic pressures (63.5±7.5 mmHg vs 47.7±8.0 mmHg, p<0.001)
and lower serum lactate (2.9±0.4 mmol/L vs 4.1±0.6 mmol/L, p<0.001)
than C hearts. Heart weight gain at experiment end was lower in HF
than C hearts (0.42±15.7% vs 11.42±7.4%, p=0.047). All HF vs 5 C hearts
responded to epinephrine at experiment end (p=0.03). Histopathologic
examination showed less extensive myocardial damage in HF vs C hearts.
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Log Files Analysis Demonstrates Reduction In Flow In First Year Post
Implantation Of Continuous Flow -left Ventricular Assist Device
Tani Kahlon, MD, Joel Graham, Master of Engineering,
Jaimin Trivedi, MBBS, MPH, Christina Dunbar-Matos, DO,
Mark Slaughter, MD; University of Louisville, Louisville, KY, USA

Mechanical Circulatory Support For Biventricular Heart Failure Using
Single And Dual Device Configuration
Jamshid H. Karimov, MD, PhD, Christine Flick, BS,
Chihiro Miyagi, MD, Takuma Miyamoto, MD, PhD,
Barry Kuban, BS, Kiyotaka Fukamachi, MD, PhD,
David Horvath, MEng; The Cleveland Clinic, Cleveland, OH, USA

Study: Log files from HeartWare HVAD (Medtronic, Inc., Minneapolis,
MN) device were analyzed for temporal trends in pump flow, a derived
parameter that is inversely related to difference in inflow and outflow
pressures, to investigate sustained shifts in hemodynamics due to longterm use of CF-LVAD devices.
Methods: Retrospectively compiled device parameter data was downloaded from all available controller log files for patients from 3/2013
through 09/2020 at a single center. Controller log data including flow
(LPM), waveform peak and trough (LPM), speed (RPM), and power (W)
were collected every 15 minutes and analyzed using LabVIEW software
for the first year following implantation. Log files data was averaged for
each day of available data. Flow parameters were indexed to BSA at time
of implant. Log files were excluded if the day included a speed change, if
power was outside of expected operation range, or less than 30 days of
data was available.
Results: 12,405 controller log-days in 90 patients (138 +/- 80 days per
patient) were included for analysis. Average and standard deviation
parameters for indexed flow, peak, trough, speed, and power were 2.42
± 0.37, 5.18 ± 0.65, 1.53 ± 0.40 L/min/m2, 2726 ± 137 RPM, and 4.37 ±
0.78 W, respectively. Indexed flow decreased over one year following
implant despite corresponding increase in pump speed in accordance
with clinical standard of care. Significant decrease in flow index was
observed at day 60 with continued reduction over the year, compared to
baseline at 7 days (2.5 vs 2.7 L/min/m2, p=0.008) while corresponding
speed was significantly higher at these timepoints (2735 vs 2660 RPM,
p=0.010). Conclusion: Decreasing requirements in flow with continued
presence of CF-LVAD to reach perfusive hemodynamics has not previously
been described. Further studies are needed to elucidate whether worsening RV adaptation, increasing aortic wall stiffness or myocardial remodeling are responsible for this phenomenon.

Study: In patients with severe biventricular heart failure (HF) and cardiogenic shock, use of biventricular assist device (BVAD) can be a treatment
of choice. We are developing advanced ventricular assist device (AVAD)
and continuous-flow total artificial heart (CFTAH), with capability to support biventricular HF (BHF). The purpose of this initial in vitro study was
to explore performance and regulation features that both systems could
provide as BVAD.
Methods: The mock loop testing was conducted using two pulsatile ventricles for simulation (AB5000; Abiomed, Danvers, MA) of hemodynamic
parameters within the BVAD-supported systolic HF cardiovascular system.
The AVAD (Fig.1A) and CFTAH (Fig.1B) were used as BVAD (CFTAH: 3500
RPM: left AVAD: 3200 RPM; right AVAD: 2000 RPM) to get comparable
systemic flow and pressure outputs. For BVAD using CFTAH and AVAD, the
support was adjusted to maintain 4-5 L/min total systemic flow. Type of
cannulation (atrial - AC; ventricular - VC; atrio-ventricular - AVC), degrees
of valve closure has been evaluated.
Results: The BVAD performance was maintained for both CFTAH and
(AVAD left and right support) within specified speed range of 2000 - 3500
RPM. Both device use configurations provided sufficient support for
HF conditions, although demonstrated variability in tolerance to aortic
and pulmonary valve regurgitation. Both devices demonstrated selfregulation, performance was demonstrated with the left (LAP) and right
(RAP) atrial pressure difference (LAP-RAP) falling predominantly within
the range of - 5 to 10 mm Hg in left and right heart failure conditions.
BVAD speed, left and right, and total flow remained stable throughout the
experiment. These initial bench evaluation demonstrated that use of the
universal AVAD and CFTAH as BVAD supports cardiac output and arterial
pressure in BHF. Each system demonstrated variability of features related
to device control, physiologic response and system regulation.
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Design Method Using Statistical Model To Predict Static Force Due To
Rotor Eccentricity In A Hemolysis Assessment Platform
Shweta Karnik, MS1, P. Alex Smith, PhD1, Nobuyuki Kurita, PhD2,
Yaxin Wang, PhD1, Charles D. Fraser, Jr., MD3, O H Frazier, MD1.; 1Texas
Heart Institute, Houston, TX, USA, 2Division of Electronics and
Informatics, Gunma University, Kiryu, Japan, 3Dell Medical School,
Austin, TX, USA
Study: A hemolysis assessment platform (HAP) could reliably quantify
blood trauma contribution from each component through iterative
testing of LVAD designs. So the HAP does not confound hemolysis
data, we proposed an enlarged gap motor coupled to a magnetic levitation (maglev) system. Characterization of the radial force generated
by rotor-stator eccentricity is essential for maglev development. Since
most experimental test systems have physical limitations, a method
that can overcome those limitations to provide accurate results is
valuable. In this study, we established a design method wherein
empirical static forces are used to derive a statistical model to predict
static force generated by motor eccentricity. The statistical model was
then validated numerically.
Methods: The radial forces generated by a motor with variable rotor
diameter were measured by a torque transducer mounted on a
micrometer-driven stage in a static force test rig (FTR). Parabolic curves
were generated to fit the force vs. rotor diameter data and used to
extrapolate forces produced by 3 rotor diameters which exceeded the
FTR limitations. The rotors were also modeled using finite element
method in COMSOL 5.4 to compute the magnetic force generated by
rotor-stator eccentricity.

Results: The static forces increase linearly with radial displacement
(RD) numerically, whereas they increase linearly at small RD but
gradually progress into parabolic curves at larger RD experimentally;
this can be explained by rotor-shaft deflection in the (FTR). Since the
numerical and experimental results matched at small RDs, we derived
the statistical model from experimental data, which was then used
for 3 rotor diameters (10.0, 9.5, 9.0 mm). The numerical and statistical static forces differed by ~5%, thereby validating the statistical
model as a radial force prediction tool. Further development upon
this method could include more geometric variables to accelerate the
maglev system design process.
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Influence Of Motor Speed On Shear Stress For A Hemolysis Assessment
Platform: A Computational Fluid Dynamics Approach
Shweta Karnik, MS1, P. Alex Smith, PhD1,
Charles D. Fraser, Jr., MD2, O. H. Frazier, MD1, Katharine Fraser, PhD3,
Yaxin Wang, PhD1.; 1Texas Heart Institute, Houston, TX, USA, 2Dell Medical
School, Austin, TX, USA, 3University of Bath, Bath, United Kingdom.

Transcatheter Treatment Of Twisted Outflow Graft Of HeartMate 3 Left
Ventricular Assist Device
Nail Khissamutdinov, MD, Abdurashid Mussayev, MD, PhD,
Serik Alimbayev, MD, Roman Salov, MBA,
Saltanat Andossova, MD, Serik Bekbossynov, MD,
Assel Medressova, MD, PhD, Makhabbat Bekbossynova, MD,
Yuriy Pya, MD; JSC National Research Center for Cardiac Surgery, NurSultan (Astana), Kazakhstan.

Study: We recently proposed a hemolysis assessment platform (HAP) that
can be used to identify sources of blood damage in a left ventricular assist
device (LVAD). Unlike conventional tests that evaluate the overall blood
damage, this HAP was designed to quantify blood trauma contribution
from individual components before building the complete LVAD. To eliminate the hemolysis induced by the HAP itself, we incorporated magnetic
levitation bearings which maintain a large gap between the rotor and stator. In this study, we established a numerical model of the HAP motor gap
to evaluate shear stress on the blood at different operating speeds.
Methods: We evaluated the HAP motor gap analytically and numerically
at 4 motor speeds from 5,000-20,000 rpm with a 200 mL/min flow rate.
Shear stress was estimated analytically before solving the unsteady Reynolds Averaged Navier-Stokes equations in Fluent 2020R1. A 1M element
structured mesh was selected with time step 1.67E-5 s. Blood was defined
as Newtonian. Boundary conditions were: uniform velocity inlet; constant
pressure outlet; and no-slip walls. The k-ω SST model was selected for
turbulence. Scalar shear stress (SSS) was calculated and the simulation
ran until the averaged SSS was constant (~8,100 timesteps). The index of
hemolysis (IH) was estimated from SSS and average time in the motor gap
using a power law model.

Study: Left ventricular assist device (LVAD) is a widespread option for
patients with advanced heart failure (HF). One of the rare and potentially
dangerous complication in the postoperative period is outflow graft (OG)
twisting. We identified 3 cases of twisted OG (2,4%) occurring in 123
HeartMate 3 LVAD (Abbott, Chicago, IL, USA) implants before Outflow
Graft Clip use. We report two unique cases of successful transcatheter
treatment of twisted OG of HeartMate 3 LVAD.
Methods: OG twisting was diagnosed with comprehensive assessments
including a clinical presentations, device parameters, laboratory data,
transthoracic echocardiography (TTE) with ramp study and computed
tomography angiography (CTA).
Results: Patient 1 was admitted to our center with low flow alarms (up to
0.6 lpm) with dizziness, dyspnea, weakness. Patient 2 was admitted as a
follow-up. Laboratory studies revealed no signs of hemolysis. TTE-monitored ramp study was showed that LVAD pump speed increasing from
5000 RPM to 6000 RPM presented no any changes of the left ventricular
end-diastolic internal diameter and pump flow. Patients underwent CTA
that revealed OG twisting at the proximal part. Due to the high risk for
redo surgery, multidisciplinary team decided to consider percutaneous
intervention for treatment of twisted OG. Procedure was carried out
under local anesthesia through the femoral artery. In first case balloonexpandable AndraStent 43 mm and CP Stent 45 mm on MaxiLD 14/40
dilatation balloon were implanted. After procedure the peak-to-peak
gradient at twisted part was decreased from 136 to 5 mmHg. In second
case we used three balloon-expandable stents on Atlas Gold 16/60 balloon. The peak-to-peak gradient was decreased from 42 to 22 mmHg. The
patients were discharged 3 days later after procedure and remain stable
to current date.Transcatheter treatment could be an alternative option to
redo surgical procedure in high-risk patients and have been shown to be
feasible and effective.

Results: As the motor speed increased, the SSS increased from 5.43 Pa to
21.72 Pa analytically but increased from 7.11 Pa to 27.97 Pa numerically.
Though the trends were similar, the numerical model estimated ~30%
higher SSS than the analytical model, which can be explained by the presence of Taylor vortices. At 20,000 rpm, the IH was found to be 0.0055%
whereas it was negligible at 5,000 rpm. This numerical model enables us
to predict the hemolysis rate in the HAP motor gap at a given rotational
speed. Furthermore, blood trauma will be analyzed at varied motor
geometries and flow rates before HAP manufacture.

111

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.

ASAIO ELECTRONIC POSTER ABSTRACTS
EPCardiac33

EPCardiac34

Higher Patient Compliance With CardioMEMS™ Is Associated With A
Lower Rate Of Heart Failure-Related Admissions
Srisha R. Kotlo, BS1, Nathan J. Smith, MD2, Bi Qing Teng, MS3,
Aniko Szabo, PhD3, Asim Mohammed, MD4,
Lyle D. Joyce, MD, PhD2, David L. Joyce, Other2.; 1Medical College of
Wisconsin, Milwaukee, WI, USA, 2Department of Surgery, Division of
Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI,
USA, 3Department of Biostatistics, Institute for Health and Equity, Medical
College of Wisconsin, Milwaukee, WI, USA, 4Department of Medicine,
Lutheran Health Network, Fort Wayne, IN, USA

New Noninvasive Method To Monitor Cardiac Recovery During VA
ECMO*
Nikolai Krivitski, PhD, DSc; Transonic Systems Inc., Ithaca, NY, USA
Study: Early identification of heart recovery may shorten a patient’s time
on VA ECMO, thus reducing complications and costs. Currently, there is
no simple, noninvasive technology to continuously assess heart recovery.
The aim of this study is to develop an operator independent monitoring
system for the quantitative assessment of cardiac recovery in VA ECMO
patients.
Methods: The blood flow of a centrifugal pump depends on the characteristics of the ECMO circuit and is influenced by the patient’s hemodynamics. In the order to evaluate this influence, an equivalent hydraulic
electric model of VA ECMO connected to the patient was investigated. To
solve the model’s equations the superposition theorem, and frequency
analysis were used to address the issues related to multiple pressure
sources and frequency dependent characteristics of the model. One of
the model parameters that is sensitive to heart recovery was coefficient
R%, which is the ratio of pulsatile component of arterial ECMO flow
QECMO-p to average ECMO flow QECMO: R%= QECMO-p/ QECMO *100% ≈ COp/
(PPUMP/ZSYS - CO). Where CO and COp - average and pulsatile components of
blood flow in the aorta that perfuses the organs, PPUMP - pump pressure,
ZSYS systemic vascular resistance. The flow data recorded by ELSA monitor
(Transonic Systems Inc. USA) in 28 pediatric (n=95) and in 112 (n=512)
adult patients was examined retrospectively.
Results: Most of the patients start VA ECMO with a small pulsatile
component of less than 100 ml/min and with R% in the order of up to
5% (Table1). With heart recovery the pulsatile component significantly
increased, while the average flow drops if the pump setting is not
changed.
Conclusion. Continuous monitoring of the blood flow during VA ECMO
allows quantitative assessment of the heart recovery. The next step is to
validate the current methodology and to establish clinical thresholds of
heart recovery.

Study: Hospital admission rates for acute on chronic heart failure (HF)
remain high despite modern advances. Wireless pulmonary artery pressure (PAP) monitoring systems allow for remote monitoring to facilitate
early intervention and reduce admissions. While beneficial in reducing
hospital admissions, no study has quantified the relationship between
patient compliance and HF admission rate.
Methods: This was an IRB-approved retrospective cohort study of
patients implanted with a CardioMEMS™ HF device (Abbott, Abbott Park,
IL) between April 2016 and June 2020 at our institution. Daily PAP readings were extracted for all patients from date of implant to either death
or June 19, 2020. Recording days were then grouped into 30-day intervals
and compliance calculated as a percent of days with readings per days
implanted. A logistic regression model using generalized estimating equations was fitted. PA pressures were recorded and correlated with hospital
admissions.
Results: During the study period, 73 patients underwent CardioMEMS™
implant; 36 (49.3%) had HF with reduced ejection fraction (HFrEF) and
37 (50.7%) had HF with preserved ejection fraction (HFpEF). Mean follow
up was 1.46±0.97 years. There was no significant difference in compliance rate between HFrEF and HFpEF (56.7 vs 65.2%, p=0.258). Increased
compliance was associated with a statistically significant reduction in
the odds of HF admission. For every 10% increase in compliance rate,
there was an associated 11% decrease in the odds of admission (OR 0.89
[0.82,0.96], p=0.003). There was no significant trend in systolic, diastolic,
or mean PAP in the days prior to heart failure admission in either HFrEF or
HFpEF. Increased compliance with daily CardioMEMS™ PAP readings may
help decrease HF-related hospitalizations for those with chronic HF. It is
possible that regularity in transmitting readings may be an indicator of
adverse outcomes so identifying these patterns in the future may lead to
earlier interventions.

*- patent pending
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Low Molecular Weight Heparin As An Effective Outpatient Treatment Of
Early Ventricular Assist Device Thrombosis
Sylvie Baudart, RN, MSN, Leticia Curiel, BSN, RN, CCRN,
Waiyee Kwong, Msn, ACNP-BC, Liviu Klein, MD, MS; Mechanical
Circulatory Support, University of California San Francisco, San Francisco,
CA, USA

Incidence Of Driveline Infections In Heartmate 3 Compared To
Heartmate 2
Antonio R. Malkoun, BS1, Russell O. Hoffman, III, CNP2,
David Feldman, MD, PhD2, Juliane Vierecke, MD, MPH2.; 1University
of Cincinnati College of Medicine, Cincinnati, OH, USA, 2Department of
Cardiology, University of Cincinnati Medical Center, Cincinnati, OH, USA

Study: Pump thrombosis is a devastating complication of ventricular
assist devices (VAD). Treatment modalities include pump exchange and
thrombolytic therapy. We aimed to evaluate the effectiveness and safety
of treating early VAD thrombosis with low molecular weight heparin
(LMWH) in an outpatient setting.
Methods: We reviewed 49 patients (pts) with a VAD followed in our
program over 5 years and evaluated the treatment trigger (hemolysis
markers and VAD parameters), efficacy [reduction in hemolysis markers,
heart failure biomarkers (BNP) and VAD parameters] and complications of
outpatient LMWH treatment for early VAD thrombosis.
Results: Pts were 55 years of age, 8% were women, 37% were INTERMACS 1&2 at implant with average support on VAD of 2.3 years. Early
VAD thrombosis was identified in 6 patients (5 HeartWare HVAD and 1
HeartMate II) after median of 26 months of support. Eighty three percent
of pts were diagnosed with early VAD thrombosis from elevated hemolysis markers [LDH 329 ± 82 U/L, plasma free hemoglobin (pfHb) 35.9
± 19.4 mg/dL] and 17% from having elevated VAD powers (0.6 W over
baseline) as identified through our remote monitoring program. All pts
had therapeutic INR at time of thrombosis (INR 2.3 ± 0.2) and were continued on warfarin (INR goal 2.0-3.0). Pts were treated with consecutive
courses of LMWH 40-60 mg BID for 3-5 days. Hemolysis markers improved
(decreased over baseline: LDH 17.1 ± 17.7%, pfHb 72.6 ± 9.5%) for all pts,
and BNP improved (decreased 20.8 ± 21.8% over baseline) for 67% of pts.
VAD power (decreased 5.1 ± 3.6% over baseline) and flow improved or
remained stable for all patients. The only complication was an episode of
minor epistaxis that resolved within 48 hours. Conclusion: Use of LMWH
in the outpatient setting can be an effective and safe treatment of early
VAD thrombosis with improvement in hemolysis markers, heart failure
biomarkers and VAD parameters.

Study: Driveline infections (DLI) are a common complication and remain
a major source of morbidity and mortality in patients with left ventricular
assist devices (LVADs). This study compares DLI rates between the HeartMate II (HM2) and HeartMate 3 (HM3). The HM3 has a new modular
driveline that facilitates simple replacement of the externalized portion.
Methods: This is a retrospective cohort study of patients from UC’s
Advanced Heart Failure Clinic who have received an LVAD from 3/2011
- 8/2020. We obtained data by device, demographic data, risk factors
for DLI, time until first DLI, pathogens, and treatment. We calculated the
relative risk of DLI in the HM3 group compared to the HM2 group and
compared mean days to DLI using a Mann-Whitney U Test.

Results: 75 patients received an LVAD between 2011-2020 at UCMC.
Two were excluded from the study due to loss to follow-up. 56 patients
received the HM2 while 17 received the HM3. 5.4% of HM II patients
developed a DLI by 3 months post implantation compared to 18% in the
HM3 group. (Figure 1). The relative risk for HM3 patients developing
DLIs was 1.372 (CI .681 - 2.2381, p=.694) compared to HM2 patients.
The mean time to DLI post implantation was 379.9 days in the HM2
group compared to 174.8 days in the HM3 group (Table 1). In our patient
population DLI occurred earlier and more often in the HM3 group. A possible reason could be that the modular DL is heavier and more difficult to
stabilize with an anchor. The use of a second anchor is often difficult for
patients to handle. Further studies with a larger patient population are
needed to confirm our results.
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Ex Vivo Safety Testing Of Lvad Control Algorithms For Clinical Application
Martin Maw, MSc1, Philipp Aigner, MSc2,
Anne-Margarethe Kramer, DVM3, Francesco Moscato, PhD1,
Daniel Zimpfer, MD, PhD4, Rob Stadler, PhD5,
Christoph Gross, PhD1, Thomas Schlöglhofer, MSc4,
Heinrich Schima, PhD1.; 1Center for Medical Physics and Biomedical
Engineering, Medical University of Vienna, Vienna, Austria, 2LudwigBoltzmann-Institute for Cardiovascular Research, Vienna, Austria, 3Center
for Biomedical Research, Medical University of Vienna, Wien, Austria,
4
University Clinic for Cardiac Surgery, Medical University of Vienna,
Vienna, Austria, 5Medtronic plc., Minneapolis, MN, USA

Using A VAD Outcomes Predictor Tool (VAD-OPT) Score To Predict
Negative Outcomes: A Retrospective, Proof-of-Concept Study
Katherine Milley, RN, BSN, Monica Prario, BS, Annika Gallandt, BA,
Van-Khue Ton, MD, PhD, Sunu Thomas, MD,
David D’Alessandro, MD, Janice Camuso, RN, Tara Logan, RN,
Alexandra Anthony, RN, Erin Coglianese, MD; Massachusetts General
Hospital, Boston, MA, USA
Study: The impacts of psychosocial risk factors on morbidity and mortality
of patients with left ventricular assist devices (LVADs) are not welldefined. We developed a VAD Outcomes Predictor Tool (VAD-OPT) that
included: distance to VAD center, language barriers, history of substance
abuse, depression/anxiety, smoking, social supports, living situation, and
quality of life.
Methods: We performed a retrospective chart review of consecutive
patients with LVADs at our center in 2017-19. The above factors were
scored from 1-3 (low risk to high risk) and were tabulated into a single
VAD-OPT score. Descriptive statistics and regression modeling were performed with STATA 15.1.
Results: 118 patients were included with a mean age of 57 years. The
median VAD-OPT score was 10 (IQR 9-12). There was no correlation of
VAD-OPT score with mortality or major complications. Patients with higher
VAD-OPT score tended to have a greater number of readmissions in the
first year post-implant (α = 0.164, p=0.05), but the number of days spent
readmitted was not different. Individual risk factors that comprise the
VAD-OPT score were compared to number of readmissions and patient
outcomes, however none was found to be statistically significant. In
conclusion, although there was a slight association between the VAD-OPT
score and number of readmissions in the first year, the VAD-OPT score and
the individual psychosocial factors studies were not significantly associated
with readmission or survival in a recent era of LVAD implants. Further work
in a larger database is needed to validate the VAD-OPT score.

Study: An algorithm for real-time physiological control of LVAD speed was
developed. Before starting clinical use with real-time control, an environment for evaluation has to be created and tested. The presented work
outlines ex vivo testing to prove feasibility and safety for clinical application of novel control algorithms for LVADs.
Methods: The Medtronic HVAD allows communication via a serial port. A
microcontroller based environment (MicroLabBox, dSpace, Germany) was
designed to interface with this port. A mechanical switch could be used to
rapidly toggle between three sources of speed change commands sent to
the controller: 1) Standard commands from the clinical monitor, 2) Speed
commands from the dSpace box, and 3) A safety command for 2400 RPM
pump speed, sent in case of unexpected, unsafe behavior. Outgoing waveform data from the controller was duplicated to both the clinical monitor
and dSpace box. The final version of the setup was tested in three acute
isolated-heart experiments. Manipulation of heart rate, preload, afterload
and contractility tested stability and efficacy of the controller. Technical
safety endpoints such as rate limits and absolute limits were defined,
as well as physiological safety endpoints such as accurate detection of
suction.
Results: Unexpected or unsafe speed changes were not observed. Out
of 126 preload reduction maneuvers, 27 produced ventricular suction
and 49 atrial suction. The algorithm was able to detect and react to 26
(96.3%) of the ventricular episodes and 31(63.3%) of the atrial episodes
without any false positives. Technical safety endpoints such as minimum
time between transmissions (1sec), amplitude (2000-3400 rpm) and rate
of speed changes (200 rpm /10sec) were not violated and continuous
datastream was ensured. The developed novel control algorithm demonstrated to be safe and it is currently used in an ongoing clinical study.
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The Effect Of Permissive Hypertension On Cerebral Perfusion During
Treatment Of Embolic Stroke In LVAD Patients
Marissa Miramontes, BS1, Keshav Venkat, PhD2,
Jennifer Beckman, ARNP, MSN3, Song Li, MD3,
Claudius Mahr, MD3, Alberto Aliseda, PhD1.; 1Mechanical Engineering,
University of Washington, Seattle, WA, USA, 2Biomedical and Chemical
Engineering and Sciences, Florida Tech, Melbourne, FL, USA, 3Dept.
Cardiology, University of Washington, Seattle, WA, USA

Bicarbonate-based Purge Solution As A Bleeding Reduction Strategy In
Patients On Impella Support
Jeremy Moretz, PharMD1, Soumen Das, PhD1,
Craig Beavers, PharMD2, Doug Jennings, PharMD3,
Jenna F. Cox, PharMD4, Robert DiDomenico, PharMD5,
Steve Dunn, PharMD6, Long To, PharMD7, Toby Trujillo, PharMD8,
Phillip Weeks, PharMD9, Scott Corbett, PhD1.; 1Abiomed, Danvers, MA,
USA, 2University of Kentucky College of Pharmacy, Lexington, KY, USA,
3
Long Island University College of Pharmacy, Brooklyn, NY, USA, 4Prisma
Health Richland Hospital, Columbia, SC, USA, 5UIC College of Pharmacy,
Chicago, IL, USA, 6University of Virginia Health System, Charlottesville, VA,
USA, 7Henry Ford Health System, Detroit, MI, USA, 8University of Colorado
Skaggs School of Pharmacy, Aurora, CO, USA, 9Memorial Hermann Texas
Medical Center, Houston, TX, USA

Study: This study aims to investigate the effect of permissive hypertension, a deliberate raising of the Mean Arterial Pressure (MAP), on cerebral
perfusion in LVAD patients, as treatment of embolic stoke.
Methods: A Lumped Parameter Model (LPM) of the entire human circulation that includes pulmonary and systemic circulation, as well as the
four heart chambers, is modified to split the systemic circulation into the
lower body and upper body. The upper circulation is subsequently split
into the extracranial and intracranial vasculatures to study the perfusion
to the brain as a function of MAP, peripheral and intracranial resistances.
HVAD H-Q relationships are incorporated to model the instantaneous
LVAD response. The impact of MAP values within a wide range, caused by
changes in the systemic resistance, on intracranial flow rate is established.
Increased resistance in the intracranial vasculature is then set to mimic a
major embolic stroke, and its influence on cerebral perfusion is studied
for a wide range of LVAD speeds, baseline MAPs, and systemic resistances.
Results: Flow to the intracranial vasculature significantly decreases when
MAP is allowed to rise, at all LVAD speeds, consistent with the reduction
in LVAD output for higher afterload. While at higher speeds, total cardiac
output is higher and the fraction of total flow that goes to the brain is
also higher than for lower speeds, the net intracranial flow rate always
decreases with an increase in MAP. This remains true and is exaggerated
when intracranial resistance is increased to model an embolic stroke.
These results show how the increased sensitivity to afterload of thirdgeneration LVADs, compared to the native heart, invalidates the paradigm
that permissive hypertension can lead to an increase in cerebral perfusion. This study highlights the phenomenon that letting MAP increase in
LVAD patients as a treatment of embolic stroke could negatively affect
cerebral perfusion.

Study: The Impella Catheters require a heparin-containing purge solution
to maintain proper pump function by reducing the risk of biomaterial
deposition in the purge gaps. A bicarbonate-based purge solution (BBPS)
has been proposed as an alternative to a heparin-based purge solution. We review performance in patients supported to date with a BBPS
(heparin-induced thrombocytopenia patients were excluded from this
analysis).
Methods: This review includes patients (n=26) supported using sodium
bicarbonate (25 mEq/1L of D5W) in the purge from September 2020 to
February 2021. These patients were supported with BBPS post-operatively where heparin in the purge was not desired or were transitioned to
BBPS because of bleeding issues. Case data were collected from an internal database to develop the clinical narrative and cross-referenced against
Impella Controller data logs to assess purge trends and pump function.
Results: All pumps were switched to BBPS in the purge if not started
with BBPS (Figure 1A). The average time to initiating BBPS was 1.6 days
(excluding n=3 outliers where time to switching was >15 days). The
average duration of support with BBPS was 5 days and a maximum duration of 22 days (Figure 1B). Figure 1C shows clinical indications for use.
Purge pressure and purge flow remained stable while on BBPS (Figure
1D). In conclusion, this preliminary experience suggests the feasibility
of using BBPS to maintain purge patency, ensure pump motor reliability,
reduce bleeding risk, and simplify anticoagulation management. Use of
a BBPS may be a safe and effective alternative to heparin in the purge
for patients in which heparin is contraindicated or not feasible. More
patient experience and analysis are needed to evaluate how bicarbonate
compares to heparin in the purge for all patients.
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Bicarbonate Purge Solution To Support Impella Devices For
Patients With Clinically Suspected Or Confirmed Heparin-induced
Thrombocytopenia
Jeremy Moretz, PharMD1, Soumen Das, PhD1,
Craig Beavers, PharMD2, Doug Jennings, PharMD3,
Jenna F. Cox, PharMD4, Robert DiDomenico, PharMD5,
Steve Dunn, PharMD6, Long To, PharMD7, Toby Trujillo, PharMD8,
Phillip Weeks, PharMD9, Scott Corbett, PhD1; 1Abiomed, Danvers, MA,
USA, 2University of Kentucky College of Pharmacy, Lexington, KY, USA,
3
Long Island University College of Pharmacy, Brooklyn, NY, USA, 4Prisma
Health Richland Hospital, Columbia, SC, USA, 5UIC College of Pharmacy,
Chicago, IL, USA, 6University of Virginia Health System, Charlottesville, VA,
USA, 7Henry Ford Health System, Detroit, MI, USA, 8University of Colorado
Skaggs School of Pharmacy, Aurora, CO, USA, 9Memorial Hermann Texas
Medical Center, Houston, TX, USA

Percutaneous Access Device For Preventing LVAD Driveline Infection
Tadashi Motomura, MD, PhD1, Shinsaku Koarashi, None2,
Nozomi Koike, None3, Kenji Yamazaki, MD, PhD4,
Yasuyuki Shiraishi, PhD5, Tomonori Yambe, MD, PhD5; 1Evaheart,
Inc., Houston, TX, USA, 2Hi-Lex Corp, Takarazuka, Japan, 3Sun Medical
Technology Corp., Suwa-shi, Japan, 4Hokkaido CV Hospital, Sapporo,
Japan, 5Institute of Development, Aging and Cancer, Tohoku University,
Sendai, Japan.
Study: A durable left ventricular assist device (LVAD) requires long-term
circulatory support capability, yet driveline infection (DLI) due to the percutaneous driveline access is an inevitable adverse event, which is one of the
major causes of hospital readmission impeding the patient quality of life.
Totally implantable system with a percutaneous energy transmission system
may be an ultimate solution for this adverse event, but another potential
approach historically attempted is a percutaneous access device (PAD).
Methods: PAD prototypes were fabricated for the in-vitro fitting tests,
handling feasibility, and, in-vivo implantation tests. Control smooth
surface (non-textured titanium surface), blasted rough surface, multiple
sintered beads surface, and 3D-titanium sponge material was evaluated
in tissue healing and integrity between skin-titanium interface. To identify
the optimal animal model and chronic study protocol, working prototypes
with sealed mechanism were designed based upon an anatomical fitting
study (on the bovine study) and evaluated with goat and swine models
(Mexican hairless and Göttingen mini pig) for chronic implantation. After
termination, histopathology analysis was performed.
Results: Non-textured titanium surface developed poor tissue adhesion
and developed epidermal down-growth. Titanium beads (spherical/asymmetrical) sintered surface establish better tissue ingrowth but inflammatory cell infiltration was sustained around the skin interface. Titanium
sponge structure appeared to develop stable skin and subcutaneous healing without the evidence of active inflammation and infection on the Göttingen minipig model up to 60 days chronics implantation. Histopathology
study demonstrated tight tissue adhesion and micro vascularization. Skin
button PAD may be a potential technology for preventing DLI by offering
mechanical barriers for the driveline exit site avoiding bacterial invasion
from the interface between the driveline and adjacent tissue.

Study: The Impella catheter is a transvalvular, micro-axial left ventricular
assist device that provides temporary mechanical circulatory support
and requires a heparin-containing purge solution to reduce the risk of
biomaterial deposition in the purge gaps and also maintain proper pump
function. For patients with suspected or confirmed heparin-induced
thrombocytopenia (HIT), direct thrombin inhibitors (DTI) have been proposed as an alternative to heparin in the purge, but have been associated
with pump failure requiring temporary tPA in the purge solution to normalize pump function. In this report, we review HIT patients supported
with a sodium bicarbonate-based purge solution (BBPS).
Methods: Patients with suspected or confirmed HIT on Impella support
using sodium bicarbonate (25 mEq in 1L D5W solution) in the purge
from September 2020 to January 2021 were reviewed. Case data were
obtained from Impella Quality (IQ) database for those supported with
a BBPS and clinically suspected or confirmed HIT. Purge pressures and
purge flows were evaluated from the Automated Impella Controller (AIC).
Results: Ten patients were supported with a BBPS during this period.
Impella support was begun either with no anticoagulant (n=5), DTI (n=2),
or heparin (n=3) and then switched to BBPS. Impella run time using a
BBPS ranged from 1-14 days; five pumps had a run time with a BBPS > 10
days (Figure 1). Systemic DTI use was used in five cases along with a BBPS.
No purge pathway thrombosis or bleeding events were observed, along
with no changes in purge flow or purge pressures observed. In conclusion,
preliminary experience suggests the use of BBPS in the setting suspected
or confirmed HIT patients supported with an Impella is safe and effective and may provide a useful therapeutic option for heparin intolerant
patients. Future work should investigate mechanisms and purge reliability
of BBPS in this setting.
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Contraceptive Use On Ventricular Assist Device Therapy
Kristen Nelson McMillan, MD1, Sarah Kane, CPNP-AC2,
Chelsea Kriesberg, CPNP-AC2, Viktoriya Kagan, APRN-BC3,
Amber Truehart, MD, MS3, Sadia Haider, MD, MPH3,
Laura Coyle, ARNP4, Sunil Pauwaa, MD4, Tae Song, MD3,
William Ravekes, MD5, Narutoshi Hibino, MD, PhD2,
Luca Vricella, MD2; 1Pediatric cardiac critical care, Advocate Children’s
Heart Institute, Oak Lawn, IL, USA, 2Advocate Children’s Heart Institute,
Oak Lawn, IL, USA, 3University of Chicago, Chicago, IL, USA, 4Advocate
Christ Hospital, Oak Lawn, IL, USA, 5Johns Hopkins University School of
Medicine, Baltimore, MD, USA

Contraceptive Use On Ventricular Assist Device Therapy
Kristen Nelson McMillan, MD1, Sarah Kane, CPNP-AC2,
Chelsea Kriesberg, CPNP-AC2, Viktoriya Kagan, APRN-BC3,
Amber Truehart, MD3, Sadia Haider, MD, MPH3,
Laura Coyle, APRN-BC4, Sunil Pawaa, MD4, Tae Song, MD3,
William Ravekes, MD5, Narutoshi Hibino, MD, PhD1,
Luca A. Vricella, MD1; 1Advocate Pediatric Heart Institute and University
of Chicago, Oak Lawn, IL, USA, 2Advocate Pediatric Heart Institute, Oak
Lawn, IL, USA, 3University of Chicago, Chicago, IL, USA, 4Advocate Heart
Institute, Oak Lawn, IL, USA, 5Johns Hopkins University School of Medicine,
Baltimore, MD, USA

Study: Recommendations regarding contraception in pediatric and adult
patients on Ventricular Assist Device (VAD) support are sparse and may be
center-specific.
Methods: We present a case involving a complication of necessary anticoagulation for VADs in females experiencing ovulation and results of a pilot
survey evaluating local practice regarding contraception on VAD.
Results: A 15-year old female with dilated cardiomyopathy requiring left
VAD implantation 16 months earlier presented with abdominal pain. She
was on warfarin, aspirin and clopidogrel for her VAD. Imaging revealed
ovarian torsion due to a ruptured hemorrhagic cyst. Gynecology performed a salpingo-oophorectomy following reversal of anticoagulation.
Post-op, she was started on depo-provera to avoid estrogens and increase
compliance. A pilot survey evaluating use of contraception on VAD
therapy was subsequently developed by the study team via a modified
Delphi method and disseminated to four local VAD program coordinators
or directors. Results revealed pediatric and adult VAD programs have a
significant portion of patients who are sexually active, but discussion of
medical contraception is inconsistent. Most or all patients are on teratogenic medications, but consultation with gynecology is infrequent or
non-existent. Some patients present with amenorrhea, such that discussion of contraception may be overlooked. All respondents reported that a
tool to aid in gynecologic referral and/or medical contraception would be
beneficial. While adult VAD recommendations include counseling regarding birth control and pregnancy prevention, there is no recommendation
for method of contraception. No pediatric guidelines currently exist.
Results from our pilot survey suggest that collaboration with gynecology
to develop guidelines regarding contraceptive use in VAD patients is warranted. We now aim to disseminate the survey to additional pediatric and
adult VAD programs to further define gaps and better inform guideline
development.

Study: Recommendations regarding contraception in pediatric and adult
patients on Ventricular Assist Device (VAD) support are sparse and may be
center-specific.
Methods: We present a case involving a complication of necessary anticoagulation for VADs in females experiencing ovulation and results of a pilot
survey evaluating local practice regarding contraception on VAD.
Results: A 15-year old female with dilated cardiomyopathy requiring left
VAD implantation 16 months earlier presented with abdominal pain. She
was on warfarin, aspirin and clopidogrel for her VAD. Imaging revealed
ovarian torsion due to a ruptured hemorrhagic cyst. Gynecology performed a salpingo-oophorectomy following reversal of anticoagulation.
Post-op, she was started on depo-provera to avoid estrogens and increase
compliance.
A pilot survey evaluating use of contraception on VAD therapy was subsequently developed by the study team via a modified Delphi method and
disseminated to four local VAD program coordinators or directors. Results
revealed pediatric and adult VAD programs have a significant portion of
patients who are sexually active, but discussion of medical contraception
is inconsistent. Most or all patients are on teratogenic medications, but
consultation with gynecology is infrequent or non-existent. Some patients
present with amenorrhea, such that discussion of contraception may be
overlooked. All respondents reported that a tool to aid in gynecologic
referral and/or medical contraception would be beneficial. While adult
VAD recommendations include counseling regarding birth control and
pregnancy prevention, there is no recommendation for method of contraception. No pediatric guidelines currently exist. Results from our pilot
survey suggest that collaboration with gynecology to develop guidelines
regarding contraceptive use in VAD patients is warranted. We plan to disseminate the survey to adult and pediatric programs across the country in
an effort to provide data for guideline development.
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Missed Opportunities To Study The Association Of Female Sex With
Aortic Insufficiency In LVAD Patients: A Systematic Assessment Of
Observational And Preclinical Studies
Brice E. Nouthé, MD, MS1, Arnold Onana, MD, MPH2,
Julienne Nouthé-Djubgang, MD, MS3, Emmanuel Egom, MD, PhD4,
Yin Sia, MD5, Marco Spaziano, MD6; 1Department of Medicine, University
of British Columbia/ Fraser Health Authority, Vancouver, BC, Canada, 2Task
Force for Global Health, Decatur, GA, USA, 3CESSTAD-KOHEN, Delta, BC,
Canada, 4Dalhousie University, Halifax, NS, Canada, 5University Institute of
Cardiology and Respirology of Quebec, Quebec, QC, Canada, 6Department
of Medicine, McGill University, Montreal, QC, Canada

Feasibility Of Online Estimation Of Systemic Vascular Resistance Using
On-board LVAD Signals
Suraj Pawar, Masters, Engineering1,
Ethan Rapp, Masters, Engineering1, Jeff Gohean, PhD2,
Erik Larson, PhD2, Richard Smalling, MD3, Raul Longoria, PhD1; 1The
University of Texas at Austin, Austin, TX, USA, 2Windmill Cardiovascular
Systems, Inc., Austin, TX, USA, 3Cardiology Division, UT Health-Houston,
Houston, TX, USA
Study: A method for estimating systemic vascular resistance (SVR) of heart
failure patients with an implanted left-ventricular device (LVAD) is presented. LVAD systems able to estimate flow rate and differential pressure
can adopt this ad hoc approach to track changes in SVR without additional
sensors. Model simulations and hybrid mock circulatory loop experiments
(hMCL) are used to demonstrate the approach. These experiments use
a cardiovascular system model with known physiological parameters,
thereby allowing a basis for evaluating the accuracy of the algorithms.
Methods: To enable online implementation, a simplified two element
Windkessel model is used to define an ad hoc SVR estimate in the form,
SVRest = [Σ (-ΔP + PLVp) Δt] / [Cs(ΔPf - ΔPo) + Σ Qvad Δt], using available
differential pressure, ΔP, and VAD flow, Qvad, measurements. Values for
systemic compliance, Cs, and passive left ventricle pressure, PLVp, are
initially tuned to match a known SVR in simulations or adjusted to a physiologically expected value in testing, without significant error if the ad hoc
measurement is performed during diastole. LVADs able to synchronize
with the cardiac cycle using ECG signals can ensure pumping occurs during diastole (counter-pulse mode) while SVR estimates are made. Fig 1
shows how the ad hoc measurement tracks the preset SVR value during a
mock loop experiment.

Study: Left ventricular assist device (LVAD) is associated to a 1-year
survival of 80% but also to higher rates of deaths and re-hospitalizations,
specifically in patients with aortic insufficiency (AI). Although it has been
reported since 2004, the reason why female sex is a risk factor for AI in
LVAD is still not well understood. Here we reviewed preclinical studies of
LVAD and systematically assessed female representation in observational
plus registry-based data of patients with LVAD.
Methods: EMBASE, MEDLINE, PubMed and CINAHL were searched for
preclinical studies of LVAD (Jarvik 2000, EvaHeart, DuraHeart and HeartMate I-III) carried since 2004. In addition, we retrieved clinical studies
reporting on AI post LVAD.
Results: From 936 patient-related citations, 29 observational studies
(2773 patients) showed comparable female representation (28.47% vs
22.2) to the INTERMACS interim report (10,603 patients between 20062016). Before resolution, inter rater agreement for study inclusion was
99.6% (κ=0.95). Incidence of de novo AI at 6 months varied from 5.5%
to 68.8% using classical echocardiographic criteria. Out of 83 preclinical
studies giving the number of animals used (including 52 with at least 5
animals), 71.1 % did not mention the sex of the animal(s). Although more
frequent in female patients post LVAD, current data from clinical and preclinical studies of LVAD are not specific enough to help further elucidate
the relation between female sex and AI in LVAD.

Results: The proposed ad hoc measure can predict SVR with an accuracy
of 4.7% (R^2 = 0.99) and 6% (R^2 = 0.83) during simulations and hMCL
experiments, respectively. Fig 2 summarizes results for the latter case.
The ad hoc measurement relies only on data provided by the LVAD system, and can be used for online and remote diagnostics of LVAD patients.
Ongoing work is evaluating this method using data collected from acute
animal experiments, allowing ad hoc measurements to be compared to
SVR estimates based on the classical relation, SVR = (MAP-CVP)/CO, which
relies on invasive measurements.
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A Case Of Recurrent Serratia Marcescens Endocarditis In Native And
Bioprosthetic Mitral Valves
Tasha Ramparas, MD1, Raghvendra Tirupathi, MD2,
Bishnu H. Subedi, MD3, Ali Rabaan, PhD4; 1Xavier University School of
Medicine (XUSOM), Oranjestad, Aruba, 2Penn State University School of
Medicine, Hershey, PA, USA, 3Penn State University School of Medicine,
Hershey, PA, USA, Hershey, PA, USA, 4Molecular Diagnostic Laboratory,
Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia, Dhahran,
Saudi Arabia.

Potential Of Medical Management To Mitigate Suction In LVAD Patients
Maria Rocchi, Master of Engineering, Steven Jacobs, MD, PhD,
Bart Meyns, MD, PhD, Libera Fresiello, PhD; Cardiovascular Sciences, KU
Leuven, Leuven, Belgium.
Study: Ventricular suction can be due to multiple underlying pathophysiological conditions. Aim of this study is to analyze the potential of different
therapeutic interventions to mitigate suction in different pathophysiological conditions.
Methods: A suction module (SM) consisting of a compliant latex tube
was embedded in a cardiovascular hybrid (hydraulic-computational)
simulator. The SM mimics the ventricular apex, it is connected on one
side to a hydraulic chamber reproducing left ventricular flows, and on
the other side to a HeartWare HVAD system (Medtronic). Starting from a
patient profile with severe dilated cardiomyopathy, 4 different pathophysiological conditions leading to suction were simulated: hypovolemia
(-900 mL), right ventricular failure (contractility -70%), vasodilation (8.3
Wood Units), and tachycardia (185 bpm). Once suction was obtained,
different interventions (blood volume infusion (Vol+), right ventricular
contractility increase, systemic vasoconstriction, heart rate increase, and
pump speed reduction) were simulated and compared in terms of general
hemodynamic.
Results: Each intervention elicited a different effect on the hemodynamic
for every pathophysiological condition. Pump speed reduction mitigated
suction but did not ameliorate the hemodynamic. Vol+ was the most
efficient in mitigating suction and increasing the cardiac power. The measured cardiac powers in the conditions of hypovolemia, right ventricular
failure, vasodilation and tachycardia when simulating Vol+ increased
respectively by 38%, 25%, 42%, and 43%. In conclusion, VAD patient
management should be carefully evaluated since suction is strictly related
to the underlying physiological patient condition. Identifying the right
therapeutic intervention can result in a better hemodynamic outcome
than that obtained by simply decreasing the pump speed.
Acknowledgements: The study was supported by an FWO project
1SD0321N and by an internal KU Leuven C3 project C3/20/033

Study: Serratia marcescens is a known cause of native valve endocarditis
(NVE). It is an uncommon cause of infectious endocarditis (IE), and can be
challenging to treat. We describe a case of a recrudescence of S. marcescens IE in a bioprosthetic mitral valve 3 months after valve replacement
surgery for NVE. We explore the challenges of treating S. marcescens in
an intravenous drug use (IVDU) patient.
Methods: Clinical management of a 41 year old Caucasian female with
an IVDU history who was diagnosed with S. marcescens NVE in December
2019, treated with antibiotics and mitral valve replacement but developed S. marcescens prosthetic valve endocarditis (PVE), was documented
over the course of her multiple hospitalizations and compiled into a case
report. We conducted a systematic search of PubMed, Sciencedirect and
Google scholar for articles on S. marcescens IE. We extracted and synthesized data on circumstances, treatment and patient outcomes and tabulated our findings to explore antibiotic resistance in the context of our
patient. Our search included the following terms within the title, abstract
and author keywords: “Serratia marcescens”, “infective endocarditis”,
“recurrence”, “IVDU” and “prosthetic mitral valves”. We had no start date
or country requirements and limited our search to papers in English. Our
search included case reports, case series, original studies and letters of
correspondence reporting small clinical studies.
Results: Following multiple courses of treatment including 6 weeks of
Cefepime, mitral valve replacement and tricuspid annuloplasty with 4
weeks of Ciprofloxacin and Gentamicin post-MVR, 6 weeks inpatient
treatment with Ciprofloxacin and Ertapenem and finally 6 weeks of oral
Ciprofloxacin, the patient passed away. Our literature review explored
Serratia’s ability to affect left-sided heart valves, its virulence, antibiotic
sensitivity and difficulty to treat in PVE in IVDU patients given the current
opioid crisis.
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Real-time Visualization Of Thrombus Formation In An Extracorporeal
Membrane Oxygenator Using Indocyanine Green Fluorescence
Hironobu Sakurai, MD1, Tatsuki Fujiwara, MD, PhD1,
Katsuhiro Ohuchi, PhD2, Wataru Hijikata, PhD3,
Yusuke Inoue, PhD4, Tomohiro Mizuno, MD, PhD1,
Hirokuni Arai, MD, PhD1; 1Department of Cardiovascular Surgery, Tokyo
Medical and Dental University, Tokyo, Japan, 2Department of Advanced
Surgical Technology Research and Development, Tokyo Medical and
Dental University, Tokyo, Japan, 3School of Engineering, Tokyo Institute
of Technology, Tokyo, Japan, 4Advanced Medical Engineering Research
Center, Asahikawa Medical University, Hokkaido, Japan.

The Effects Of LVAD Pump Speed On Coronary Perfusion: Reanimated
Heart Studies
Emma Schinstock, MS1, D’Anne Kudlik, MS2,
Michael Eggen, PhD2, Paul A. Iaizzo, PhD1; 1University of Minnesota,
Minneapolis, MN, USA, 2Medtronic, Mounds View, MN, USA
Study: Left ventricular assist devices (LVADs) are implanted in patients
who require support to maintain adequate systemic perfusion. While
pump flows and systemic perfusion have been studied clinically and
preclinically, few studies have assessed the relative impact of LVAD
settings on coronary blood flow, despite potential for future LVAD
designs to use dynamic speed changes. This preliminary study was
performed to assess the impacts of LVAD speed change on coronary
perfusion with varied heart rates using a healthy reanimated swine
heart model.

Study: During extracorporeal membrane oxygenation, thrombi in a
membrane oxygenator can cause embolisms and oxygenator performance
deterioration. Hence, anticoagulation therapy is required, although it
causes bleeding. Real-time thrombus visualization may be effective in
preventing these complications. This study demonstrated a novel method
to visualize thrombi in a membrane oxygenator using indocyanine green
(ICG) fluorescence imaging.
Methods: ICG is a cyanine dye used in various medical fields. It binds to
proteins in blood and is excited by 750-800-nm light and emits infrared
light with a central wavelength of 840 nm. The ranges of absorption and
excitation wavelengths are slightly affected by hemoglobin and water
absorption. The high spectral sensitivity of the absorbed and exciting light
enables to obtain blood information. Moreover, ICG can be repeatedly
administered because of its half-life of 3-4 min. To verify the efficacy of
ICG fluorescence, animal experiments were conducted in pigs equipped
with an extracorporeal circuit comprising a centrifugal pump (CAPIOX SL)
and oxygenator (QUADROX-i). ICG was administered hourly and observed
using a dedicated optical detector (PDE-neo). The fluorescence images of
the oxygenator were compared with eye observations before and after
rinsing with regular saline.
Results: The figure shows ICG fluorescence images (A, B) and eye observations (C, D) of the oxygenator. The fluorescence image (B) revealed the
thrombi as black areas in the oxygenator 8 h after initiation. The areas
were similar to those detected by eye observation after rinsing with saline
(D).ICG fluorescence imaging is feasible to visualize thrombus formation
in a membrane oxygenator in real time. Thrombus visualization may lead
to the prevention of complications and optimization of anticoagulant
therapy in clinical situations and may be efficient in evaluating device
antithrombogenicity at the research and development stage.

Methods: The Visible Heart laboratories has developed in vitro methodologies that preserve cardiovascular system behavior while simultaneously testing complex cardiac devices. One swine heart was reanimated
via perfusion with a modified Krebs-Henseleit buffer; viscosity was 2.7
cP. Medtronic’s HeartWare HVAD was implanted, and temporary pacing
leads were placed to control heart rate. Flow data was collected from
the outflow graft and descending aorta for three heart rates (sinus
rhythm, 100 BPM, and 120 BPM) for three pump speeds (2800, 3200,
and 3600 RPM).

Results: Average coronary flow increased 14.2-16.1% (0.20-0.23 L/min)
when pump speed increased from 2800 RPM to 3600 RPM, though pulsatility of coronary flow lessened as speed increased. Compared to pacing
at 100 BPM, pacing at 120 BPM increased average coronary flow by
9.0-9.6% (0.05-0.14 L/min) for pump speeds 2800 and 3200 RPM, but had
no impact for 3600 RPM. In the case presented, there was likely no clinically relevant impact to coronary flow with speed changes, but additional
testing with a heart failure model and a wider range of pump speeds is
needed for additional clarity.
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Evaluation Of Four-Factor Prothrombin Complex Concentrate Use For
Intracranial Hemorrhage In Patients With Durable Left Ventricular Assist
Devices
Alissa Shega, PharMD, Pamela Simone, PharMD; Pharmacy, University of
Chicago Medicine, Chicago, IL, USA
Study: The literature surrounding management of intracranial hemorrhage
(ICH) in patients with left ventricular assist devices (LVAD) is limited, and
safety and efficacy of using 4-factor prothrombin complex concentrate (4FPCC) to reverse international normalized ratio (INR) in this cohort is not
well known. The purpose of this evaluation is to describe an experience of
using 4F-PCC for reversal of INR for ICH in patients with durable LVADs.
Methods: We performed a retrospective chart review of adult LVAD
patients who received 4F-PCC for INR reversal for ICH. The 4F-PCC dosing
at our institution is INR-based in concordance with the package insert
recommendation. Demographic data, medication data, and clinical information within 90 days after reversal were recorded. The primary outcome
was successful reversal of INR to less than 1.5.

Results: A total of 15 cases of ICH in LVAD patients in which 4F-PCC was
administered were identified and reviewed. Of these patients, 14 (93.3%)
received vitamin K at the time of reversal. The mean INR prior to reversal
was 5.9 and 8 (53.3%) patients were successfully reversed after 4F-PCC.
The mean 4F-PCC dose was 33.3 units/kg and the median time from
head CT scan to initiation of 4F-PCC was 122 minutes (IQR 50-204). On
repeat head CT after reversal, 6 (40%) patients had no change in the size
of bleed while 9 (60%) patients had expansion of their bleed. In-hospital
mortality was recorded in 8 (53.3%) patients, and of those who survived
to discharge, 5 (71.4%) patients had neurologic deficits, 5 (71.4%) patients
were alive at 3 months, and there were no incidences of thrombotic
events. In conclusion, although INR was significantly lower in patients
after receiving 4F-PCC, only 53.3% of patients were considered successfully reversed. Administration of 4F-PCC appears to be safe in regards to
sparing LVAD patients from thrombotic events after reversal.
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Panel-reactive Antibody Results Prognosticate Mortality And Graft
Survival After Heart Transplantation: A National Study Using The UNOS
Database
Umar A. Siddiqi, None1, Pamela S. Combs, PhD2,
Sean Pinney, MD2, Valluvan Jeevanandam, MD2; 1Section of Cardiac
Surgery, University of Chicago Medicine, Elmhurst, IL, USA, 2Section of
Cardiac Surgery, University of Chicago Medicine, Chicago, IL, USA

Predictors Of Epistaxis In Patients With Left Ventricular Assist Devices
Umar A. Siddiqi, None, Pamela S. Combs, PhD, Sean Pinney, MD,
Valluvan Jeevanandam, MD; Section of Cardiac Surgery, University of
Chicago Medicine, Chicago, IL, USA
Study: Patients with left ventricular assist devices (LVADs) are at a high
risk for epistaxis due to the use of anticoagulation and the development
of acquired von Willebrand syndrome (avWS). This adverse event is frequently recurrent and a common source of emergency department visits.
We evaluated various risk factors for their potential to predict epistaxis
occurrence after LVAD implantation.
Methods: We retrospectively reviewed 103 LVAD patients implanted at
our center from 2015-2020. Various baseline characteristics were collected, including whether a patient’s INR at discharge and event were in
therapeutic range (2-3). Univariate and subsequent multivariate analyses
were conducted to determine independent predictors of epistaxis
occurrence.
Results: In total, 33 (32%) patients developed epistaxis. Out of range
INR at discharge (OR 4.13; 95% CI 1.75-10.14), fall implant (OR 3.5; 95%
CI 1.05-12.7), and HeartWare HVAD usage (OR 2.56; 95% CI 1.07-6.27)
were significant risk factors in univariate analyses (p <0.05 for all). In
the multivariate analysis, out of range INR at discharge emerged as an
independent predictor of epistaxis occurrence (OR 3.49; 95% CI 1.39-9.06;
p = 0.009). In patients with epistaxis, INR at event did not significantly
differ from INR at discharge (p = 0.3). 25 (76%) patients with epistaxis had
recurrent events. Those who had an event ≤ 20 days post-implantation
were at an increased risk for recurrence when adjusting for age (OR
12.56; 95% CI 1.59-295.5; p = 0.04). The lack of a significant change in INR
from discharge to time of event suggests that INR at discharge may be
useful for risk stratification regarding propensity for epistaxis. Particular
attention should be given to patient who present with epistaxis ≤ 20 days
post-implantation due to their increased likelihood of recurrence. Further
multi-center studies should be conducted to corroborate these findings.

Study: Panel-reactive antibody (PRA) screening is routinely performed
prior to heart transplantation (HTx) and is important for the measurement of sensitization. We assessed the use of PRA for risk stratification
after HTx using the United Network for Organ Sharing (UNOS) Standard
Transplant Analysis and Research Database.
Methods: We retrospectively reviewed heart transplants performed
from January 2004 to September 2020. Multi-organ transplants and
re-transplants were excluded from analysis. Most recent PRA Class I and
Most Recent PRA Class II were used as other measures of PRA were missing in at least two-thirds of the sample. Patients were stratified into three
groups: (1) No PRA (PRA% = 0), (2) Some PRA (PRA% >0 and <50), and (3)
High PRA (PRA% >50). Survival curves were calculated using Kaplan-Meier
analysis and compared by log-rank test and Cox proportional hazard
model.
Results: A total of 41,537 patients were included in this study. When
stratifying based on Most Recent PRA Class I, the Some PRA and High PRA
groups had significantly worse survival (HR 1.14, 95% CI 1.1 - 1.2 and HR
1.24, 95% CI 1.1 - 1.4, respectively) and graft survival (HR 1.13, 95% CI
1.1 - 1.2 and HR 1.24, 95% CI 1.1 - 1.4, respectively) compared to the No
PRA group (p <0.0001 for all). When using Most Recent PRA Class II, the
Some PRA and High PRA groups similarly had worse survival (HR 1.1, 95%
CI 1.03 - 1.2 and HR 1.24, 95% CI 1.1 - 1.4, respectively) and graft survival
(HR 1.08, 95% CI 1.02 - 1.2 and HR 1.26, 95% CI 1.1 - 1.4, respectively)
compared to the No PRA group (p <0.05 for all). Our results suggest that
PRA status is predictive of long-term outcomes post-transplant. Further,
prospective studies should be conducted to investigate the utility of PRA
for risk stratification, accounting for possible confounders.
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A Review Of Intra-aortic Balloon Pump Mortality And Morbidity In
Randomized Controlled Trials
Taylor R. Sing, BS1, Geoff D. Tansley, PhD1, Jo P. Pauls, PhD1,
John F. Fraser, MD, PhD2, Isuru F. Ranasinghe, MD, PhD3,
Niranjan Gaikwad, MD4; 1School of Engineering and Built Environment,
Griffith University, Southport, Australia, 2Critical Care Research Group,
Chermside, Australia, 3Faculty of Medicine, University of Queensland,
Herston, Australia, 4Coronary Care Unit, The Prince Charles Hospital,
Chermside, Australia.

Myocardial Recovery Following Left Ventricular Assist Device
Implantation: A Single-institution Experience
Nathan J. Smith, MD1, Nicholas Collar, BS2, Padmaraj Duvvuri, MD3,
Bryan Miles, BS2, Ruizhe Wu, MS4, Aniko Szabo, PhD4,
Nunzio Gaglianello, MD3, Lyle D. Joyce, MD, PhD1,
David L. Joyce, MD1; 1Cardiothoracic Surgery, Medical College of
Wisconsin, Milwaukee, WI, USA, 2Medical College of Wisconsin,
Milwaukee, WI, USA, 3Cardiovascular Medicine, Medical College of
Wisconsin, Milwaukee, WI, USA, 4Biostatistics, Medical College of
Wisconsin, Milwaukee, WI, USA

Study: Intra-aortic balloon pump (IABP) applications have steadily
decreased worldwide since the publication of the IABP SHOCK II Trial,
which indicated that there was no significant benefit in post-operative
mortality and morbidity indices for patients with acute myocardial
infarction (AMI) complicated by cardiogenic shock (CS) when supported
by IABPs. A systematic search of literature was performed to investigate
whether these results were an outlier or consistent with other randomized controlled trials reported in literature.
Methods: Publications were drawn from the Scopus, PubMED and Web
of Science databases and, in accordance with the PRISMA guidelines,
weighed against inclusion and exclusion criteria. Sixteen publications
were included in this analysis that reported both mortality and morbidity
indices. Once data on the statistical significance of mortality and morbidity had been reported on, additional studies on device cost-effectiveness
were viewed to determine the economic benefit of IABPs.
Results: A total of four studies included in this systematic review reported
a significant decrease in short- and/or long-term mortality in patients randomized to receive IABP insertion, with one of these four trials reporting
a significant decrease in short-term mortality (28 control mortalities vs
15 IABP, P < 0.05) for patients with complicating CS. Some improvements
in patient morbidity indices were noted in a total of six studies (P < 0.05),
with IABP found to stabilize patients intra- and post-operatively, with one
study reporting improvements in both mortality and morbidity. One of
the studies reporting morbidity benefits also noted a significant increase
in minor bleeding associated with IABP insertion. Seven studies reported
no results of statistical significance associated with IABP utilization. It can
be determined that IABP insertion has ambiguous benefit on mortality
and morbidity indices in critical AMI patients.

Study: Myocardial recovery following left ventricular assist device (LVAD)
implantation occurs, but the true incidence of myocardial recovery to
facilitate device liberation is unknown, nor are there standardized protocols to screen and identify patients suitable for device liberation.
Methods: All destination therapy (DT) LVADs at our institution between
January 1, 2017 and November 23, 2020 were reviewed. The primary
outcome was cumulative incidence of myocardial recovery defined
by institutional criteria based on clinical echocardiographic and right
heart catheterization (RHC) parameters followed by device liberation.
Baseline characteristics and operative outcomes were compared between
recovered and non-recovered DT patients to identify factors predictive of
recovery.
Results: Forty-nine patients underwent DT LVAD implantation. The majority of patients (40.8%) were implanted as INTERMACS 3 and were urgent
(73.8%) implantations. Eight (16.3%) patients had a concomitant coronary
bypass. 40.8% of patients developed right ventricular failure requiring
RVAD. In-hospital mortality was 12.2%. According to an institutional
protocol, 11 (22.4%) patients met screening criteria for evaluation of
myocardial recovery after at least six months of support. Among them, 9
(18.4%) patients underwent formal turndown study with RHC. Additionally, 4 (8.2%) patients who did not meet screening criteria underwent a
turndown study with RHC for other various. Of these 13 patients who
underwent turndown study with RHC, 6 (12.2%) underwent successful
explantation, 3 (6.2%) were defunctionalized, and 1 (2.0%) met criteria
for recovery but declined explant. Three (6.1%) of eight coronary bypass
patients recovered. The cumulative incidence of recovery was 25.1% at
29 months post-implant. All recovered patients were alive at most recent
follow-up. Myocardial recovery occurs in a notably higher percentage of
patients than previously thought if proactively screened for.
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Seasonal Trends In Donor Heart Availability - An Analysis Of The UNOS
Database
Nathan J. Smith, MD1, Mohammed Kamalia, BS2, Lisa Rein, MS3,
Adhitya Ramamurthi, MD1, Bryan Miles, BS2,
Lyle D. Joyce, MD, PhD1, Asim Mohammed, MD4,
David L. Joyce, MD1; 1Surgery, Medical College of Wisconsin,
Milwaukee, WI, USA, 2Medical College of Wisconsin, Milwaukee, WI,
USA, 3Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA,
4
Cardiovascular Medicine, Medical College of Wisconsin, Milwaukee, WI,
USA

Platelet: Lymphocyte Ratio And Cardiac Recovery Post Left Ventricular
Assist Device Placement
Kristin Stawiarski, MD, Olayinka Agboola, MD, Riya Bonde, None,
Pramod Bonde, MD; Bonde Artificial Heart Lab, Yale School of Medicine,
New Haven, CT, USA
Study: The platelet: lymphocyte ratio (PLR) is a novel prognostic marker is
associated with poor outcome in heart failure. However, it’s significance &
impact in patients with left ventricular assist devices (LVAD) has not been
explored. We systematically investigated the impact of PLR on adverse
events, recovery to explant, and all-cause mortality in this population
over a 24-month period post LVAD implantation.
Methods: Study population of 177 patients received LVAD therapy
between June 2011 and October 2018. No patients were excluded. PLR
were divided into tertiles (<150; n=42, 150-300; n=84, and > 300; n=42)
based on preoperative levels. Adverse outcomes were compared using
Fishers exact test. The association between the PLR and 24-month mortality was examined via unadjusted and adjusted cox regression models.
A Kaplan-Meir plot and log-rank statistics were used to compare survival
across patient groups.
Results: The mean age across groups was 60 with up to 35% females.
Patients with PLR > 300 had a greater use of intra-aortic balloon pump (30
and 21 vs. 34%, p<0.04) and ≥ two inotropes at admission (20 and 15.5 vs.
43%, p<0.05). This group also had a significantly lower baseline hematocrit (39.5 and 37.1 vs. 33.8, p<0.001).
24-month survival (Log-Rank p<0.29) and adverse events were equally
distributed. There was no difference in mortality seen on either the
unadjusted or adjusted modeling among tertiles [PLR 1 vs 2, HR 1.05
(0.50-2.22); p<0.73 and adjusted HR 1.05 (0.49-2.23); p<0.81] and [PLR
2 vs 3, HR 1.42 (0.66-3.04); p<0.39 and adjusted HR 1.34 (0.60-2.98);
p<0.50]. However, recovery to explant of LVAD was seen in 14 patients
with PLR 150-300 compared to only 1 and 2 patients in the 1st and 3rd
tertiles respectively, p<0.02.
PLR represents global burden of inflammatory and thrombosis cascades.
A preoperative PLR ration between 150-300 may help identify and target
patients with maximal medical therapy to facilitate ventricular recovery.

Study: Despite the widespread belief that donor organ availability varies
around holidays and with seasons, there is little empiric data supporting
this long-held belief. Variations in donor heart availability may be of interest to patients and clinicians in determining transplant listing strategies,
such as left ventricular assist device patients with 30 days of enhanced
status time (EST). We sought to identify any meaningful differences in
organ availability based on calendar trends.
Methods: The UNOS/OPTN registry was queried and data for all heart
donations from October 1987 through March 2017 was abstracted and
analyzed. Monthly heart donation rates were modeled using Poisson
regression including month (categorical) and a spline term for year. Daily
heart donation rates were modeled using cosinor Poisson regression,
assuming a 12-month seasonal period. The holiday effect was assessed
using conditional logistic regression.
Results: Seasonal plots suggest a significant, although modest, increase
in organ availability during the summer months, except for region 1. The
regions with the highest amplitude were region 7 (peak: July 20th, amplitude: 13.7%) and region 6 (peak: July 4th, amplitude: 11.1%). There was
no significant difference in the odds of heart donation when comparing
holidays vs. non-holidays using national data (odds ratio [95% CI]: 1.00
[0.97, 1.03], p = 0.99) or any regional subsets. There was no observable
correlation between donor heart availability and holidays. However, a
significant seasonality effect was observed with higher donation rates
occurring during warmer months. These findings shed objective light on
previously held anecdotal trends and may add another consideration to
end-stage heart failure patients being evaluated for heart transplantation
listing.
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In Vitro Evaluation Of A Newly Designed Bicuspid Pediatric Pulmonary
Heart Valve
Kenji Suzuki, MD, PhD1, Hirohito Sumikura, PhD2; 1Department of
Cardiovascular Surgery, Nippon Medical School Musashikosugi Hospital,
Kawasaki, Japan, 2Department of Science and Engineering, Tokyo Denki
University, Hiki-gun, Japan.

Evaluating Long Term Outcomes Of Palliative Inotropes In End-stage
Heart Failure Patients
Muhammad A. Khan, MD, Sanika Tolia, DO, Sameer Khan, None,
David Alexander, None, Marianne Soltys, None,
Kathleen Kamba, None, Sharon Brennan, None,
Sujeen Adhikari, D.O., Sheraz Hussain, MD, Anjali Joshi, MD,
Christopher Sciamanna, DO, Nikhil Narang, MD,
Jessica Pillarella, MD, Sunil Pauwaa, MD, Gregory Macaluso, MD,
William Cotts, MD, Ambar Andrade, MD; Advocate Christ Medical Center,
Oak Lawn, IL, USA

Study: To evaluate the hemodynamics of a newly designed conduit with
a bicuspid valve (figure) under the hydrodynamic conditions found in
pediatric pulmonary circulation, in a simulation study.
Methods: The bicuspid polytetrafluoroethylene valves we developed are
constructed from a cusp made of a 0.1-mm expanded polytetrafluoroethylene (ePTFE) sheet with a posterior central fixation of the free edge
(Nunn et. al. 2008) to provide a wide coaptation zone consisting of the
cusp and a graft (figure). The new bicuspid valve also has a bulging sinus
to reduce the regurgitant flow and a micro-pore on the cusp ensure the
regurgitant flow for the prevention of thrombogenesis. We used a pediatric pulmonary mock circulation system consisting of a right ventricular
chamber, a reservoir tank, and a resistor. We determined the hemodynamic characteristics of the ePTFE conduit along with those of the
ePTFE tricuspid-valved conduit we use at our institute (14-mm dia.; the T
conduit, n=3), the newly designed conduit (14-mm dia.) with a bicuspid
valve (B conduit, n=3) and an ePTFE graft (22-mm dia.) with Magna EASE
(19-mm dia.; M conduit, n=3). We used two pressure transducers and a
ultrasonic flowmeter to measure the transvalvular pressure gradient and
regurgitant flow ratio at heart rates (HR) of 100, 120 and 140/min.
Results: The transvalvular pressure gradients of the T, B, and M conduits
were 13.0, 8.6, and 4.6 at HR100, 15.9, 9.6, and 8.1 at HR120, and 17.3,
11.2, and 9.2 at HR140, respectively. The transvalvular pressure gradient
of the B conduit tended to be lower than that of the T conduit (p=0.218).
The regurgitant flow ratios of the T, B, and M conduits were 18.1, 15.7,
and 14.7 at HR100, 15.9, 14.5, and 14.7 at HR120, and 14.4, 13.7, and
14.8 at HR140, respectively. The regurgitant flow ratio of the B conduit
tended to be lower than that of the T conduit (p=0.286) and equal to that
of the M conduit.

Study: Inotrope therapy is frequently used as a palliative option for
patients with end stage heart failure who are not deemed candidates for
durable advanced heart failure therapies. With the advent of improved
medical therapy, early intervention, and the use of devices, the impact of
inotropes on survival may be more significant than earlier reported. We
aimed to evaluate the impact of palliative inotrope therapy on patient
survival and outcomes over an extended period.
Methods: We retrospectively assessed 224 patients within our center
with ACC/AHA stage D heart failure who were discharged with palliative inotrope therapy after January 1, 2010. Patients who underwent
mechanical circulatory support (MCS) or those who underwent heart
transplant were excluded. Statistical analysis was completed using univariable analysis in SAS software.

Results: Demographics, comorbidities, medications, and devices are listed
in the Table. 86.6% of patients were discharged with milrinone and 21.4%
on dobutamine. The average duration on therapy was 168 (53-387) days.
Average number of hospitalizations within 2-years was 1 (0-3), and average number of clinic visits at 3, 6, and 12 months were 2 (0-3), 3 (0-6),
and 4 (1-11), respectively. 4.5% of patients were found to have PICC line
infections and 9.8% had new arrhythmias. 6-, 12-, and 24-month survival
were 63.1%, 53.1%, and 41.9% respectively (see figure for product limit
survival estimate). Palliative inotrope therapy shows modest survival benefit in conjunction with other advanced heart failure interventions.
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Berlin Explantation In An Infant With Refractory Chaotic Tachycardia
Diana M. Torpoco Rivera, MD, David Lawrence, MD,
Jennifer Blake, MD, John Dentel, MD, Swati Sehgal, MD; Pediatric
Cardiology, Children’s Hospital of Michigan, Detroit, MI, USA
Study: Berlin Heart ventricular assist device (VAD) explanation in children
is uncommon. There is limited data on selection of suitable candidates
and systematic approach to pediatric VAD explanation. We report a case
of VAD explant in an infant with tachycardia-induced cardiomyopathy
(TIC).
Methods: A 3 month-old presented to the emergency department in
cardiogenic shock. Heart rate on arrival was 250 beats/min and electrocardiogram revealed narrow complex tachycardia that was resistant
to multiple antiarrhythmics. Echocardiogram (ECHO) showed severely
dilated left ventricle (LV) with severely decreased function. Cardiac
decompensation led to placement on veno-arterial extracorporeal
membrane oxygenation and subsequent Berlin VAD implantation. He was
listed for heart transplant as he continued to have refractory arrhythmias.
While awaiting heart transplant, serial ECHOs showed recovery of LV function and VAD explanation was discussed. We followed our newly developed protocol that consisted of two phases. First trial-off was conducted
with manual pumping of the VAD at 3/min with ECHO imaging. One week
later, second trial-off in the catheterization suite with manual pumping at
3/min showed no differences in hemodynamics. Data obtained met our
established criteria to undergo explant. Explant was performed the next
day, after 142 days of VAD support. Patient was discharged two weeks
later on triple antiarrhythmic regimen and was well when seen for follow
up in our clinic.
Results: We established guidelines for trialing off VAD support to optimize
screening and explant success in potential candidates. VAD explant is
feasible in young infants.
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Successful Use Of VA-ECMO Without Systemic Anticoagulation In The
Management Of Cardiac Arrest Secondary To Amniotic Fluid Embolism
Jonathan Urbach, MD1, Michael Mooney, MD1,
Roman Melamed, MD2, Susan Seatter, MD2, Elizabeth Elfstrand, MD3,
Kelly Tointon, CCP4, Katarzyna Hryniewicz, MD1; 1Minneapolis Heart
Institute at Abbott Northwestern Hospital, Minneapolis, MN, USA,
2
Department of Critical Care Medicine, Abbott Northwestern Hospital,
Minneapolis, MN, USA, 3Department of Obstetrics and Gynecology, Abbott
Northwestern Hospital, Minneapolis, MN, USA, 4Abbott Northwestern
Hospital, Minneapolis, MN, USA

Thoracoabdominal Normothermic Perfusion In Donation After
Circulatory Determined Death
Marian Urban, MD, PhD1, Kim Duncan, MD1,
Nicholas Markin, MD2, Megan Chacon, MD2, Lance Fristoe, CCP3,
John Um, MD1; 1Cardiothoracic Surgery, University of Nebraska Medical
Center, Omaha, NE, USA, 2Cardiothoracic Anesthesia and Intensive care,
University of Nebraska Medical Center, Omaha, NE, USA, 3Perfusion
Services, University of Nebraska Medical Center, Omaha, NE, USA
Study: Donation after circulatory death (DCD) is emerging as an alternative pathway to traditional donation after brain death (DBD) in expanding
the pool of cardiac allografts available for transplantation. Evidence suggest improved outcomes and decreased complication rate for abdominal
organs transplanted after a short period of donor in-situ reperfusion
compared to ultra-rapid recovery. Compared to ex-situ perfusion platform, it also enables a functional assessment of cardiac allografts before
transplantation.
Methods: We describe our experience with both cardiopulmonary bypass
(CPB) and veno-arterial extracorporeal membrane oxygenation (VA
ECMO) in experimental as well as clinical setting of cardiac allograft recovery after a variable period of warm ischemia in donors after circulatory
determined death. Technical aspects (cannulation technique, need for left
ventricular vent), management considerations (anticoagulation, composition of a priming solution, physiologic targets on support and after weaning), logistical challenges (in-house versus distant procurements) of both
techniques are described in detail.
Results: Based on our experience the use of CPB is superior to VA ECMO
in DCD NRP organ recovery. The advantages of CPB are: better cardiac
decompression during mechanical support, ability to return blood from
the surgical field and lower cost. The strategies to overcome the shortcomings of VA ECMO are: left ventricular venting, donor transfusions with
banked blood, using non-proprietary components of VA ECMO circuit.
Conclusions: Employing various strategies to address limitations of VA
ECMO in DCD NRP, this technique could be safely use in instances when
CPB is not available.

Study: Amniotic fluid embolism (AFE) is a catastrophic complication of
pregnancy, associated with cardiovascular collapse, respiratory failure,
coagulopathy, and a high mortality rate. The use of venoarterial extracorporeal cardiopulmonary resuscitation (VA-ECMO) in the management of
AFE remains controversial.
Methods: 29-year-old healthy G1P1 presented at 39 + 0 for elective
induction of labor. She was given misopostol and went into active labor,
though started feeling presyncopal and fetal bradycardia was noted.
She was taken for emergent Caesarean section and suffered profound
peri-procedural hemorrhage and ultimately VT arrest. Bedside ultrasound
was suggestive of acute cor pulmonale, and a presumptive diagnosis
of AFE was made. Per hospital eCPR protocol, she was cannulated with
VA-ECMO by an interventional cardiologist (via 17Fr femoral arterial and
23Fr femoral venous cannulas). Given her coagulopathy, no systemic
anticoagulation was used at the time of cannulation or during ECMO
support and a modified therapeutic hypothermia protocol was utilized.
Her hemodynamics improved rapidly and she was decannulated within 48
hours, though she remained comatose. Brain imaging revealed scattered
ischemic and hemorrhagic strokes, but no evidence of a significant anoxic
injury. Supportive care was continued and she ultimately began to show
neurologic and physical improvement and was discharged to rehab on
hospital day 25 and home on day 29 with minimal deficits.
Results: Our case suggests the use of ECMO without systemic anticoagulation can be a successful strategy for hemodynamic support in patients
with AFE.
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Hemodynamic Effects Of Integrating Compliance In The Design Of An
Artificial Lung: Assessment With A Hybrid Simulator
Tom Verbelen, MD, PhD1, Michael Halwes, MSc2,
Ulrich Engelmann, MSc2, Krzysztof Zielinski, MSc3,
Bart Meyns, MD, PhD1, Ralf Borchardt, MSc2,
Libera Fresiello, MSc1; 1Cardiac Surgery, University Hospitals Leuven,
Leuven, Belgium, 2Enmodes GmbH, Aachen, Germany, 3Cardiac Surgery,
Nałęcz Institute of Biocybernetics and Biomedical Engineering, Polish
Academy of Sciences, Warsaw, Poland.

Assessing The Effect Of Blockage On Blood Flow In A Heart-lung Machine
(ECMO) Using A Computational Hemodynamic Model
Ruth White, BS1, Srivats Sarathy, PhD2, Aditya Badheka, Other3,
Joseph Turek, MD, PhD4, Suresh Raghavan, PhD5,
Venkat Keshav Chivukula, PhD1; 1Biomedical and Chemical Engineering
and Sciences, Florida Institute of Technology, Melbourne, FL, USA, 2The
University of Iowa, Iowa City, IA, USA, 3Pediatric Intensive Care Unit,
University of Iowa Stead Family Children’s Hospital, Iowa City, IA, USA,
4
Section of Pediatric Cardiac Surgery Division of Cardiovascular and
Thoracic Surgery, Duke University School of Medicine, Durham, NC, USA,
5
Biomedical Engineering, The University of Iowa, Iowa City, IA, USA

Study: To assess the hemodynamic effects of an artificial lung (AL) with
fiber-bundle-integrated compliance (RAS-Q® technology) implanted
between pulmonary artery (PA) and left atrium (LA).
Methods: A hybrid cardiovascular simulator was used, including a model
of atrial, ventricular, pulmonary and systemic circulation. The simulator
was adapted to reproduce 4 pulmonary hypertension (PH) profiles: mild,
moderate, severe and cardiogenic shock. A RAS-Q prototype was connected
between the simulated PA and LA. For each profile, the hemodynamic
effects of this prototype with and without integrated compliance were
assessed in terms of pressures, flows and right ventricular (RV) volumes.

Study: Clot formation within the ECMO (heart-lung machine) circuit is a
common complication and the current methods for monitoring for such
blockages have limitations. It is hypothesized that the flow in a small
shunt tube in the ECMO circuit (through which a small amount of blood
flow is redirected to the pump and used for blood access) will be affected
by oxygenator clotting or other obstructions in the veno arterial ECMO
(VA-ECMO) circuit. The goal of this study is to test the hypothesis that
blood flow rates in the shunt could be used to monitor for circuit obstructions using a computational model of the VA-ECMO system.
Methods: A computational hemodynamic lumped parameter model
(CHLPM) representing the blood flow within both the VA-ECMO circuit
and native cardiovascular system (including both right and left heart, systemic and pulmonary circulations) was used for a comprehensive hemodynamic parametric analysis. The pressures and flow rates at several
critical locations (ECMO pump, oxygenator inlet and outlet etc.) along the
ECMO-patient circuit were investigated for various levels of ECMO support (2 - 5 L/min). Several degrees of obstructions within the oxygenator
and inlet and outlet cannulas were simulated, and the flow in the shunt
was monitored in each case to assess its sensitivity to circuit obstructions.
Results: We simulated a range of oxygenator blockages (from 10% - 50%),
and demonstrated that shunt flow increased linearly with increasing
oxygenator obstruction for each ECMO flow rate tested. Similar correlations were established between shunt flow and inflow / outflow cannula
blockage. The findings are consistent with our hypothesis, indicating the
sensitivity of the blood flow rate in the shunt as a hemodynamic predictor
of VA-ECMO circuit obstructions. Further, the CHLPM simulated realistic
flows in the ECMO circuit and hence can be used for further interrogation
of other aspects of the ECMO circuit such as oxygenator, cannula, and
pump characteristics.

Results: Results are reported in the table and figure for the severe PH
profile, as an example. The introduction of RAS-Q with disabled compliance led to an increase of arterial blood pressure and cardiac output in
all PH profiles as well as a decrease in central venous pressure, peak RV
pressure, end-diastolic volume, and pressure-volume area. Additionally,
an increase in stroke work and RV power was observed in the severe PH
and cardiogenic shock profiles. Enabling the integrated compliance in this
RAS-Q prototype amplified these hemodynamic and ventricular energetic
improvements even further, which came into their own in a severe PH
status. In conclusion, RAS-Q technology exhibits a compliance integrated
completely within the fiber bundle of an AL. This innovative RAS-Q
prototype, when tested in a PA-LA configuration results in improved organ
perfusion, RV unloading, and RV recovery for different stages of PH. The
integrated compliance elicits more pronounced improvements compared
to an equivalent AL without compliance. Our results support applying this
strategy in the severe PH status before cardiogenic shock emerges.
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Continuum Model Simulation Of VWF Unfolding In A Cross-slot
Extensional Flow Microchannel
Mansur Zhussupbekov, MS, James F. Antaki, PhD; Biomedical
Engineering, Cornell University, Ithaca, NY, USA

Mechanical Circulatory Support As A Bridge To Transplant Candidacy:
When Does It Work?
Michael Zaliznyak, BA, Lily Stern, MD, Robert Cole, MD,
Adriana Shen, BS, Keith Nishihara, BS, Carmelita Runyan, RN,
Alisa Fishman, Other, Linda Olanisa, Other, Megan Olman, Other,
Tahli Singer-Englar, MPH, Eric Luong, MPH, Susan Cheng, MD, MPH,
Jamie Moriguchi, MD, Jon Kobashigawa, MD,
Fardad Esmailian, MD, Michelle M. Kittleson, MD, PhD; Departments of
Cardiology and Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles,
CA, USA

Study: von Willebrand Factor (vWF) has been established as the primary
mediator of high-shear thrombosis. Bleeding events in LVAD patients have
been linked to the loss of large-molecular-weight vWF. Both vWF binding
to collagen/platelets and its mechanoenzymatic cleavage are preceded by
the unfolding of collapsed vWF chains. Therefore, it is essential to account
for the state of these multimers in modeling thrombosis or vWF degradation. This study isolates the vWF component of our multi-constituent
model of thrombosis and examines vWF subjected to planar extensional
flow. The model predicts vWF unfolding in response to extensional flow
kinematics with literature-derived unfolding thresholds.
Methods: The flow was simulated in a cross-slot microfluidic channel
by Alves (2008) where the geometry was optimized to obtain a homogeneous elongation rate around the stagnation point spanning the
orthogonal flow axes. vWF was modeled as two interconvertible scalar
species representing its two conformational states: collapsed, vWFc, and
stretched, vWFs. The inlet BCs and domain initial concentrations were
prescribed as [vWFc]=1000 nmol/m3 and [vWFs]=0. vWF collapsed-tostretched transition takes place if the local flow type parameter and Weissenberg number (Wi) exceed the critical values for unfolding.
Results: The cross-slot geometry and the simulated flow field are shown
in Figure 1(A). The device creates near-perfect extensional kinematics
along the flow axes and in the region surrounding the central stagnation
point, demonstrated by the flow type parameter in Figure 1(B). Flow
type = 1 corresponds to purely extensional kinematics, 0 is simple shear,
and -1 is pure rotation. Wi is scaled by the square root of flow type and
induces vWF unfolding in the extension-dominated regions. The resulting
concentration of the stretched vWFs, shown in Figure 1(C), peaks along
the outflow axis and resembles a typical polymer birefringent strand
produced in cross-slot extensional rheometers.

Study: Durable mechanical circulatory support (dMCS) devices can be
offered as a bridge-to-transplant (BTT) strategy for candidates awaiting
a donor heart, or as a bridge-to-candidacy (BTC) strategy for candidates
with contraindications to transplant listing, including pulmonary hypertension (BTC-PH), morbid obesity (BTC-Obes), social issues (BTC-Soc), or
chronic illness (BTC-Illness). In a BTC strategy, the dMCS device would provide time to allow resolution of the medical or social contraindications to
transplant listing so that patients may ultimately undergo transplantation.
The purpose of this study was to compare the outcomes of patients who
underwent dMCS as a BTC strategy by indication to those who underwent
dMCS as BTT. An understanding of the trajectory of BTC patients could
guide future triage of advanced heart-failure patients who are not candidates for transplantation.
Methods: We performed a retrospective review of hospital medical
records and identified all patients who underwent dMCS implantation
as either BTT (206 patients) or BTC (114 patients) from January 1st, 2010
through March 31, 2020. Clinical characteristics and post-transplant
outcomes were compared.

Results: There was no significant difference in mortality between BTC
patients and BTT patients. Compared with the BTT group, significantly
more patients in the BTC-PH group were transplanted (81% vs 63%,
p<0.05) and significantly fewer patients in the BTC-Obes group (44%,
p<0.05) and BTC-Soc group (39%, p<0.05) were transplanted. Additionally, the readmission rate was higher for those in the BTC-Obes (3.42
vs 1.88, p<0.05), BTC-Soc (6.04, p<0.05), and BTC-Illness (3.93, p<0.05)
groups. Overall, BTC patients generally had poorer post-dMCS trajectories than BTT patients. Centers should not be dissuaded from pursuing
a BTC strategy for qualified patients; however, careful consideration of
potential adverse outcomes as part of a shared decision-making strategy
is necessary.
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Platelet Receptor Glycoprotein Shedding In Patients Supported By Left
Ventricular Assist Device: A Comparison Between HeartMate 3 And
HeartWare HVAD Recipients
Nandan K. Mondal, PhD1, Harveen K. Lamba, MD1,
Samuel I. Hudson, MS1, Camila Hochman-Mendez, PhD2,
Alexis E. Shafii, MD1, Gabriel Loor, MD1,
Aladdein Mattar, MD1, Ravi K. Ghanta, MD1,
O Howard Frazier, MD1, Kenneth K. Liao, MD, PhD1; 1Michael E. DeBakey
Department of Surgery, Baylor College of Medicine, Houston, TX, USA,
2
Regenerative Medicine Research, Texas Heart Institute, Houston, TX, USA
Study: This study quantified and compared temporal changes in
platelet-receptor-glycoprotein (PRG) shedding in two current generation
continuous-flow left ventricular assist device (CF-LVAD) recipients. We
also identified and compared short-term postoperative bleeding complications in those patients.
Methods: We enrolled 24 subjects into three groups; (i) non-heart
failure control group (n=8), heart failure patients undergoing (ii)
HeartMate3(HM3) (n=8) and (iii) HeartWare HVAD (n=8) implantation.
PRG shedding was measured for GPIbα (vWF receptor), GPVI (collagen
receptor) and GPIIbIIIa (fibrinogen receptor). PRG shedding was quantified pre-implant (baseline) and weekly for 4 weeks post-implant in platelet free plasma samples. Patients were evaluated for any bleeding events
within 4 weeks post-implant.
Results: At baseline, no significant differences in PRG shedding were
observed between the non-heart failure controls, HM3 and HVAD patients
(Fig.1A-C). Interestingly, the two patients with higher baseline PRG
shedding were the only ones to experience post-operative bleeding. The
patient implanted with the HVAD bled on POD 13 and the HM3 patient
bled on POD 25 (Fig.1A-C). PRG shedding of GPIbα and GPVI increased at
1 week post-implant, but subsequently returned to baseline by 4 weeks in
both types of CF-LVAD recipients. HVAD showed significantly higher shedding at 2 weeks post-implant compared to HM3 (Fig.1D-E). The GPIIbIIIa
receptor shedding was similar for both HM3 and HVAD recipients (Fig.1F).
Patients with higher baseline PRG shedding may be more susceptible to
postoperative bleeding, and based on these results, device selection may
be particularly important considering the extent of GPIbα and GPVI shedding in the HVAD compared to the HM3.
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Midterm Outcomes Of Orthotopic Heart Transplantation Versus Left
Ventricular Assist Device In Patients 70 Years And Older
Abdulaziz Alhossan, MD, Mohamed Hassanein, MD,
Amy Roach, MD, Fardad Esmailian, MD, Carmelita Runyan, MSN,
Tahli Singer-Englar, MS, Robert Cole, MD, Joanna Chikwe, MD,
Danny Ramzy, MD, PhD; Cardiac Surgery, Cedars-Sinai Medical Center,
Los Angeles, CA, USA

Outcome Of Percutaneous Hearmate3 Deactivation A Single Center
Experience
Hassane Abdallah, MD; Prince Sultan Cardiac Center, Hofuf, Saudi Arabia.
Study: To spotlight the role of percutaneous LVAD deactivation as a safe
procedure after myocardial recovery in advanced heart failure patients,
aiming to minimize the surgical risks of explantation. The HeartMate3
left ventricular assist device (Abbott, Chicago, IL) is designed to provide circulatory support with enhanced hemocompatibility for patients
with advanced heart failure. Most VADs are used as a bridge to heart
transplantation, however, in certain cases, myocardial function recovers
and VADs can be explanted after the patient is weaned. While surgical
explantation remained the gold standard, minimally invasive percutaneous deactivation has been described as a successful alternative. Within
this study, we present our experience, one year outcomes, and adverse
events of the percutaneous LVAD deactivation
Methods: We conducted a retrospective review of the data of six consecutive patients underwent percutaneous LVAD deactivation.
Results: Six patients were enrolled into the study, with all of them completing at least six months after HM3 deactivation. No technical complications were documented. No strokes were observed within the study and
the ejection fraction was improving. The mean follow up duration was
12.3±5.5 months and survival rate was 100%.
Conclusion Percutaneous HM3 deactivation appears to be a safe alternative to surgical explanation as the survival after the procedure was 100%
and no events, especially thromboembolic ones, occurred.

Study: The optimal treatment of end stage heart failure for elderly
patients remains challenging. This study compares survival, complications
and readmissions after orthotopic heart transplant (OHT) versus left ventricular assist device (LVAD) implantation in patients 70 years and older.
Methods: In a high-volume single center, we retrospectively evaluated all
consecutive 70 years and older patients with end stage heart failure who
underwent OHT or LVAD between February 2010 to May 2020 (n=119).
In our study 88 patients (73.9%) underwent OHT, and 31 patients (26.1%)
underwent LVAD implantation. Our primary endpoint was survival over a
three-year period. Secondary end points included incidence of early (30
days) and late (>30 days) post-operative adverse events which included
gastrointestinal (GI) bleeding, stroke, right ventricular failure, infection,
renal failure, length of hospital stay and hospital readmissions.
Results: The LVAD group was significantly older, median age 74 years
(interquartile range (IQR) 72 - 77) compared to the OHT group, median
age 71 years (IQR 70 - 73), (p <0.0001). The OHT patients had shorter
length of hospital stay, 11 (IQR 9-16) vs 30 (IQR 23-50) days, (p<0.0001).
Early adverse events including infection, 5.7% (n=5) vs 13.3% (n=4);
stroke, 5.7% (n=5) vs 6.6% (n=2); and renal failure requiring permanent
dialysis 1.2% (n=1) vs 3.7% (n=1); were not significantly different between
OHT and LVAD groups, respectively. The OHT patients had lower incidence
of late infection, 12% (n=10) vs 42.3% (n=11); GI-bleeding, 3.6% (n=3)
vs 8.2% (n=9); RV failure, 0% vs 13.3% (n=4) and freedom from hospital
readmission (66% vs 42%), (p <0.05). Overall survival at 3 years was 83%
(95% CI (73.6- 90.2)) in the OHT group vs 60% (95% CI (40 -76.1)) in the
LVAD group, (p=0.01). Conclusion: As the population of patients 70 years
and older with heart failure continues to grow, age should not be the sole
criteria for exclusion for consideration of transplantation.
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Comparing Postoperative Outcomes Between The Heartware HVAD And
The HeartMate 3
Gardner Yost, MD, MS1, Laura Coyle, ARNP, MSN2,
Robin Paliga, ARNP, MSN2, Colleen Gallagher, BSN2,
Nicole Graney, ARNP, MSN2, Lisa Kukla, ARNP, MSN2,
Roxanne Siemeck, ARNP, MSN2, Muhyaldeen Dia, MD2,
Patroklos Pappas, MD2, Antone Tatooles, MD2; 1University of Michigan,
Ann Arbor, MI, USA, 2Advocate Christ Medical Center, Oak Lawn, IL, USA
Study: Postoperative complications including stroke remain a leading
cause of morbidity and mortality in patients supported with long term
left ventricular assist devices (LVADs). Though the HeartMate 3 (HM3)
and HeartWare HVAD (HVAD) are the most technologically advanced
LVADs currently available, there is relatively little data comparing clinical
outcomes for these devices. The present analysis seeks to describe clinical
outcomes in a contemporary, non-clinical trial cohort of HM3 and HVAD
patients.
Methods: This is a single center, non-randomized retrospective study
which includes patients implanted with either a HVAD (n= 41) or HM3
(n= 36) during 2019 with a minimum follow-up of 1 year, concluding
12/31/2020. The primary endpoints were postoperative stroke, infection,
arrhythmia, and hemolysis. The secondary endpoint was 1 year postoperative stroke-free survival.

Results: The rate of preoperative stroke or TIA was 24.4% in the HVAD
group and 22.2% in the HM3 group, p=.082. There were no significant
differences between preoperative clinical and demographic variables
between the groups, with select parameters provided in Table 1. 30-day
survival was 97% in the HVAD group and 100% in the HM3 group, p=1.0.
There were no hemolysis episodes in the HM3 patients, compared to
0.94 events per patient year (EPPY) in the HVAD patients, p=0.001. Stroke
occurred at a rate of 0.72 EPPY in the HVAD group and 0.32 EPPY in the
HM3 group, p<0.001. Infection occurred at a rate of 1.23 EPPY in the
HVAD group and 0.66 EPPY in the HM3, p<.001. Arrhythmia occurred at
a rate of 1.69 EPPY in the HVAD and 0.90 in the HM3 group, p=0.001.
Kaplan-Meier analysis indicated significantly improved stroke free survival
in the HM3 group, p<0.001 (Figure 1). Conclusions: Our study describes
a predominantly destination therapy cohort with excellent early survival.
There were higher rates of stroke, infection, arrhythmia, and hemolysis as
well as reduced 1-year stroke-free survival in the HVAD group compared
to HM3.
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Impact Of LVAD Outflow Cannula Configurations On Blood Flow
Characteristic - A Computational Study
Jonathan Grinstein, MD1, Ryo Torii, PhD2,
Pablo J. Blanco, PhD, DSc3, Pedro A. Lemos, MD, PhD4,
Christos V. Bourantas, MD, PhD5,
Hector M. Garcia-Garcia, MD, PhD6; 1University of Chicago, Chicago, IL,
USA, 2University College of London, London, United Kingdom, 3National
Laboratory for Scientific Computing, Petrópolis, Brazil, 4Heart Institute,
University of São Paulo Medical School, São Paulo, Brazil, 5Barts Heart
Centre, London, United Kingdom, 6MedStar Cardiovascular Research
Network, Washington, DC, USA

EVAHEART 2 Left Ventricular Assist System With The Double-cuff Tipless
Inflow Cannula Is Promising For Prevention Of Thromboembolic Events:
Case Report
Tomoki Ushijima, MD, PhD, Yoshihisa Tanoue, MD, PhD,
Hiromichi Sonoda, MD, PhD, Akira Shiose, MD, PhD; Cardiovascular
Surgery, Kyushu University Hospital, Fukuoka, Japan.
Study: A 34-year-old man with fulminant myocarditis leading to asystole
had received paracorporeal biventricular support for 4 months, and then
he had undergone implantation of an EVAHEART 2 left ventricular assist
system with the double-cuff tipless inflow cannula, not protruding into
the left ventricle, and concomitant total cavopulmonary connection as an
alternative right heart assist. His heart had remained in asystole during
the entire support. Approximately 2 years after EVAHEART 2 implantation,
he underwent heart transplantation. This is the first report of explanting
the EVAHEART 2 with the double-cuff tipless inflow cannula. The purpose
of this study is to verify the clinical efficacy of the double-cuff tipless
inflow cannula.
Methods: We reviewed his clinical course during the support, assessed
the inflow position by image examinations, and macroscopically investigated around the left ventricular inflow ostium of the excised heart during
heart transplantation.
Results: There was no thromboembolic and cardiac events and pump
malfunction. Computed tomography showed no malposition of the inflow
cannula and pump body. Left ventricular cavity of the excised heart
showed smooth inflow ostium with appropriate intimal formation and
neither pannus formation nor wedge thrombus formation. This finding,
which had been previously shown in animal study, suggested the validity
of the double-cuff tipless inflow cannula in a long-term clinical situation. This unique inflow cannula is promising for reduction of thromboembolic events and may contribute to more stable long-term patient
management.

Study: Our current understanding of flow through the circulatory system
in patients with left ventricular assist device (LVAD) remains incompletely
understood. Here we investigate the impact of outflow cannula configurations on the aortic flow with an LVAD using a computational fluid dynamics (CFD), which allow for analysis of flow in the cardiovascular system.
Methods: A 3D anatomical model of the aorta with outflow cannula was
reconstructed from multi-slice CT images in a patient supported by an
LVAD. Using a lumped-parameter computational model of the patient’s
circulatory system, including performance (HQ) curve of a HeartMate3, a
patient-specific LVAD outflow was estimated and applied as inflow condition of 3D CFD analysis with the anatomical model. In total, 12 variations
of the outflow cannula were included: 3 insertion points (original insertion point and its 2 cm proximal/distal locations), 2 cannula diameters
(14 mm and 10 mm), and 2 insertion angles (45 and 90 degrees). CFD
simulations were conducted to characterize the flow patterns.
Results: Maximum velocities in the aorta was 2.22±0.15 m/s (10 mm
cannula) vs 1.12±0.10 m/s (14 mm cannula). This resulted in 56% larger
blood volume exposed to abnormal shear rate (>1000 s-1) for 10 mm
cannula, compared to 14 mm cannula (0.97±0.38 ml vs 0.62±0.08 ml). The
location of the insertion point defines the flow patterns in the aorta, and
some combinations of the cannula configuration offers a unique benefit;
10 mm cannula inserted at low ascending aorta with 90-degree insertion
produced a healthier ESS in the aortic root (1.38 Pa vs 0.38±0.17 Pa for
all the other cases). The results suggests that a “sweet spot” of cannula
configuration is possible and CFD could identify the ideal configuration for
each individual patient.
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process of being cultivated and tested. It is planned that a working model
will completed before the final presentation.

Fractal Eyes V2.0 - Visual Natural Language Processing Of Medical
Images For Enhanced Value
Madellyn Brown, BS; College of Engineering, University of Arizona,
Tucson, AZ, USA
Study: Platelet activation (PA) is central in thrombosis which continues
to limit cardiovascular therapeutic devices. Understanding mechanisms
of PA, and the time course and natural history PA are vital in efforts
to modulate thrombosis. To assist this research effort we developed a
neural-network based platform for the qualitative analysis of platelets in
varying phases of PA.

Methods: The Fractal Eyes system extracts feature data from scanning EM
including: platelet area, perimeter, eccentricity, color density differences,
light intensity, and approximate pixel length and width as it maps to an
image. The system consists of four subsystems: Graphical User Interface
(image selection and summary of results), Image Pre-Processing (voxel
creation/image normalization), Image Classification (via pre-trained convolutional neural network model trained on non-activated platelets and
activated platelets), and Feature Extraction.

Results: Fractal Eyes effectively can calculate platelet center, pixel area
and perimeter, and determine and eccentricity with major and minor axis
lengths as seen in Fig. 1. Another example of what the feature extraction subsystem can calculate for a non-activated platelet and activated
platelets is in Fig. 2. This figure is displaying the data calculated from the
subsystem, which can be seen in Fig. 1 and is an example for how the
data will be displayed to the user in the Graphical User Interface. Current
development of the Image Classification subsystem has yielded acceptable model accuracy in terms of the validation process of the model training for binary classification of SEM images of non-activated platelets and
activated platelets. The results of the binary classification training can be
seen in Fig. 3. At the current moment of the writing of this abstract, the
image dataset for training a model on the different phases of PA are in the
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In Vitro Investigation Of The Effect Of Pulsatility Modes On Left
Ventricular Hemodynamics In Third Generation Lvads
Fanette Chassagne, PhD1, Venkat Keshav Chivukula, PhD2,
Jennifer A. Beckman, MSN, ARNP3, Song Li, MD3,
Claudius Mahr, DO3, Alberto Aliseda, PhD4; 1INSERM, UMR1059,
SAINBIOSE, CIS-EMSE, Mines-Saint Etienne, Saint-Etienne, France,
2
Department of Biomedical and Chemical Engineering and Sciences,
Florida Institute of Technology, Melbourne, FL, USA, 3Division of
Cardiology, University of Washington, Seattle, WA, USA, 4Department of
Mechanical Engineering, University of Washington, Seattle, WA, USA

A Higher Sensitivity Mini-loop Hemolysis Model For Ventricular Assist
Devices
James Dawson, BS, MS, Joel Graham, Master of Engineering,
Sinduja Thinamany, BS, MS, Kevin O’Brien, BS,
Randy Rose, None, Narendra K. Simha, PhD; Medtronic Inc., Mounds
View, MN, USA
Study: Pre-clinical hemolysis assessment of ventricular assist devices
(VAD) is a requirement to demonstrate safety before clinical studies.
Testing guidelines are standardized in ASTM-F1841, but for the latest
generation of VADs, like the HVAD, the ASTM method detects a low blood
trauma signal-to-noise ratio (SNR) which is insufficient to evaluate future
design changes and improvements. Hence, the goal of this study was to
develop a hemolysis test method with a higher signal sensitivity.
Methods: Mini-loop modifications from the ASTM model include removal
of blood reservoir (500 to 60mL volume reduction); decreased test time
and sampling (6 to 2 hrs); and more blood passes through the pump [4/5
to 8 liters per minute (LPM)]. Mini-loop test feasibility was evaluated with
ten HVAD devices in 68 tests using citrated bovine blood from 14 donors
for two use cases: nominal (4LPM, 100mmHg; n=26) and accelerated
(8LPM, 100mmHg; n=38). Delta plasma free hemoglobin (PfHb) was
the measured difference before pump start and at 2 hrs. Delta PfHb,
normalized index of hemolysis (NIH), and PfHb SNR (µ/σ) were compared
to previously collected HVAD ASTM data (5LPM, 100mmHg; n=47 in 12
heparinized bovine donors).
Results: Delta PfHb is similar between 4LPM mini-loop and 5LPM ASTM
(33 vs 35 mg/dl). A 7-fold increase was observed (220 vs 33 mg/dl)
between the 8LPM and 4LPM mini-loops (Figure 1). NIH results in the
4LPM mini-loop was reduced compared to 5LPM ASTM (0.0027 vs 0.0068)
though NIH was higher in the 8LPM mini-loop (0.0092). SNR of Delta PfHb
increased in the 8LPM mini-loop compared to 5LPM ASTM (4.3 vs 2.3).
Conclusion: This work shows the feasibility of evaluating hemolysis
of VADs using the mini-loop model. The mini-loop model has a higher
signal-to-noise ratio than the ASTM method, which is advantageous for
evaluating minor changes to the VAD system such as controller, algorithm,
or pump design improvements.

Study: The aim of this study is to investigate the effect of pulsatility
modes on the hemodynamics in the Left Ventricle (LV).
Methods: A patient-specific LV silicone model is implanted with a transparent cannula connected to a third generation LVAD. The LV/LVAD test rig
is connected to a flow loop, with accurate control of pre- and after load,
and peripheral resistance. An index of refraction-matched working fluid
is used, and its viscosity is matched to that of blood to achieve complete
dynamics similarity wth the clinical problem. We measure the intraventricular flow velocity via time-resolved stereo Particle Image Velocimetry
(PIV). The influence of the timing between the LVAD speed modulation
and the ventricle filling cycle (preload) is characterized to understand if
it contributes to the ventricular “wash out”. While keeping all conditions constant, measurements were repeated with the LVAD pulsatility
triggering at 4 phases related to the peak intraventricular pressure (IVP):
minimum/maximum IVP, and in the middle of the increasing and decreasing pressure stages.
Results: For every LVAD speed, the LV flow field shows stagnation and
recirculation areas, especially between the cannula and the apex, and
in the LVOT. Keeping the average LVAD flowrate constant (4.5L/min), the
timing between the oscillatory IVP (systole-diastole) and the onset of
LVAD pulsatility induces large variations in the instantaneous flowrate and
also strongly impacts flow patterns in the LV. This parametric study shows
that the effectiveness of LVAD speed modulation strongly depends on
physiological parameters, such as the native LV contractility (preload) and
the peripheral resistance (afterload), and that this dependency is sensitive
to the operating rpm of the pump. Optimization of LVAD pulsatility mode
(rpm lowering/raising values, duration and timing) needs to consider
these parameters globally to reduce thrombogenicity of LVAD therapy
and improve long-term outcomes for patients.
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Left Atrial Appendage Occlusion To Reduce Thromboembolic Risk With
Left Ventricular Assist Devices: A Simulation Study
Mojgan Ghodrati, MSc1, Thomas Schloeglhofer, MSc1,
Christoph Gross, PhD1, Daniel Zimpfer, MD, PhD2,
Dietrich Beitzke, MD3, Francesco Zonta, PhD4,
Francesco Moscato, PhD1, Heinrich Schima, PhD1,
Philipp Aigner, MSc1; 1Medical Physics and Biomedical Engineering,
Medical University of Vienna, Vienna, Austria, 2Department for Cardiac
Surgery, Medical University of Vienna, Vienna, Austria, 3Department of
Biomedical Imaging and Image guided Therapy, Medical University of
Vienna, Vienna, Austria, 4Institute of Fluid Dynamics and Heat Transfer,
Technical University of Vienna, Vienna, Austria.

Outcomes In Significant Mitral Regurgitation After Left Ventricular Assist
Device Implantation
Samat Kabani, MD, Maria M. Patarroyo Aponte, MD,
Sriram Nathan, MD, Biswajit Kar, MD, Igor D. Gregoric, MD; Advanced
Cardiopulmonary Therapies and Transplantation, The Univ. of Texas
Health Science Center-Houston, Houston, TX, USA
Study: Significant mitral regurgitation (MR) after the placement of a
continuous-flow left ventricular assist device (LVAD) is associated with
pulmonary hypertension, right ventricular failure, and mortality in small
studies. We completed a large cohort study to determine the impact of
MR on LVAD patients over an extended follow-up period (mean = 1.96
years).
Methods: A retrospective review of LVAD recipients from January 2012 to
March 2020 at a single tertiary institution was completed. Severity of MR
was determined by echocardiography report. Tiers of MR included moderate (mMR), moderate-to-severe (msMR), and severe (sMR). Echocardiographic parameters and survival status outcomes were collected.
Results: 413 patients received a LVAD; 55 were excluded from the final
analysis (15 received biventricular support and 40 had inadequate imaging). Of the patients analyzed, 86.3% (309/358) had less than mMR. In the
49 patients with significant MR, 22 patients (44.9%) had mMR, 16 (32.6%)
had msMR, and 11 (22.4%) had sMR. Compared with mMR and msMR,
the sMR group had a larger LVIDD (6.5 ± 1.5, 6.8 ± 1.1, 8.0 ± 1.9 cm,
respectively) and a higher RVSP (29 ± 9.4, 38 ± 9.5, 42 ± 19 mmHg, respectively); however, neither reached statistical significance (p= 0.09 and p =
0.14, respectively). There was no significant difference in mortality among
patients with msMR/sMR compared with the all cohort (HR 1.24±0.43, CI
0.62-2.4, p=0.18) even when patients who underwent heart transplant
were excluded (HR 1.21±0.43, CI 0.6-2.4, p=0.19) (Figure1). Conclusion:
Tiered, significant MR post-LVAD may be associated with a larger LVIDD &
increased RVSP, but there is no significant difference in mortality, regardless of MR severity.

Study: Thromboembolic events and consequently stroke are devastating complications of left ventricular assist devices (LVADs) therapy. Atrial
fibrillation (AF) is a common comorbidity in LVAD patients and has been
identified as a risk factor for stroke as blood stasis inside the left atrial
appendage (LAA) can be a major source of thrombosis. Previous clinical
studies suggest that LAA occlusion (LAAO) may prevent thromboembolism in LVAD patients, however its impact on blood flow dynamics has not
been established. Therefore, this study aims to investigate the effect of
LAA occlusion on thrombosis-related parameter using Computation Fluid
Dynamics (CFD) simulation.
Methods: Left ventricular and atrial models of an LVAD patient with AF
were obtained from computed tomography. Hemodynamic data were
generated by a lumped parameter model for full support condition with
a total cardiac output of 5 L/min (LVAD flow: 3.6-7.6 L/min) and stroke
volume of 35 mL. The hemodynamics then were applied for two pulsatile
CFD simulations with moving walls over 6 cardiac cycles (CC) comparing
LAAO to the LAA situation. Stagnation regions (mean velocity <5mm/s),
wall shear stress (WSS), and blood washout applying a virtual-ink technique were evaluated.
Results: The ventricular flow patterns were similar for both simulations,
however, LAAO leads to +8% higher mean velocity within the atrium. An
increase of +13% WSS at the atrial wall was observed with LAAO leading
to decrease of atrial stagnation volume by -35%. After 6 CC, 100% of
blood was cleared from the atrium with LAAO compared to only 91%
clearance for the atrium with LAA. In CFD simulations significant stagnation volumes in the LAA where identified in LVAD patients with AF. Blood
stagnation in the LAA and low WSS are potential sources for thrombus
formation which might be resolved by LAA occlusion. This significantly
reduced the thrombus-related flow parameters and might also lowers the
risk of thromboembolic events from the appendage.
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Hemodynamics Of Impella Support: A Computational Patient-specific
Model Of Therapy For Cardiogenic Shock
Farhad Rikhtegar Nezami, PhD, DSc1, Farhan Khodaee, MSc2,
Zhongwei Qi, MSc3, Scott Corbett, PhD3, Steven P. Keller, MD, PhD2,
Elazer R. Edelman, MD, PhD2; 1Cardiac Surgery Division, Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA, USA, 2MIT,
Cambridge, MA, USA, 3Abiomed, Danvers, MA, USA

Simultaneous Protek Duo RVAD And Impella LVAD For Hemodynamic
Support In Cardiogenic Shock
Jacob C. Richards, BA1, Jerome Crowley, MD2, Kamila Drezek, BS1,
Kenneth Shelton, MD3, Erin Coglianese, MD1,
Mauricio Villavicencio-Theoduloz, MD4,
David D’Alessandro, MD1, Van-Khue Ton, MD, PhD3; 1Cardiac Surgery,
Massachusetts General Hospital, Boston, MA, USA, 2Anesthesia, Critical
Care and Pain Medicine, Massachusetts General Hospital, Boston, MA,
USA, 3Cardiology, Massachusetts General Hospital, Boston, MA, USA,
4
Cardiac Surgery, Mayo Clinic, Rochester, MN, USA

Study: Though percutaneous ventricular assist devices (PVAD) such as the
Impella increasingly provide circulatory support, understanding of their
hemodynamic impact remains limited.
Methods: A patient-specific computational model of aorta flow with
Impella support was developed. Physiologically validated aortic waveforms were used for virtual implantation of catheter, impeller, and
surrounding cage. Total perfusion was set to 5 LPM while varying relative
heart failure with progressively reduced native flow including fraction
of Impella CP flow: 0 (baseline, without Impella), 30, and 70%. Dynamic
boundary conditions at aortic outlets were assigned considering lumpedparameter models. Hemodynamic patterns were captured solving for
the turbulent flow and quantifiable features including velocity, turbulent
kinetic energy, shear stress metrics, and vital organs perfusion.
Results: Aortic flow during Impella support demonstrated greater vorticity and turbulent energy with increasing PVAD support. End-organ perfusion was maintained in all scenarios even when flow became less pulsatile
with increasing Impella contribution. Impella-induced flow alterations
increased shear stress within the ascending aorta commensurate with
that reported for other circulatory support devices. Our results illuminate the unique potential of computational approaches for mechanistic
understanding and risk stratification of mechanical support therapies and
demonstrated flow and perfusion patterns with support under different
heart failure states.

Study: Mortality from cardiogenic shock (CS) remains high. Veno-arterial
extracorporeal membrane oxygenation (VA-ECMO) is commonly used for
biventricular support in CS, but is associated with increased complications. We reported our single center’s experience with simultaneous
Protek Duo RVAD and Impella LVAD (perc-BiVAD) to treat CS.
Methods: We performed a retrospective study of patients receiving
perc-BiVAD for CS in 4/20-12/20. Patients’ outcomes were reported.
Vasoactive-inotropic score (VIS) was the total dose of all vasoactive and
inotropic medications the patient received within the hour before, and
24 hours after perc-BiVAD implant. Comparison was made with Wilcoxon
signed-rank test. P < 0.05 was considered statistically significant.
Results: Five consecutive patients received perc-BiVAD. Mean age was
65 ± 7 years. Mean support duration was 15 ± 10 days. Mean VIS in four
patients decreased from 16 ± 9 at implant to 8 ± 8 mcg/kg/min postimplant (p = 0.06, Figure) (pre-implant VIS unavailable in one patient).
Etiologies of CS were: stress cardiomyopathy (n = 1), acute heart failure
(n = 2), and cardiac arrest (n = 2). One patient was on VA-ECMO then
converted to perc-BiVAD, while the rest received perc-biVAD as first-line
therapy. Four patients had axillary Impella 5.5 placement, allowing
early ambulation; one had Impella CP. In four patients, perc-BiVAD was
removed due to myocardial recovery. Survival to discharge was 80%. One
patient died of sepsis while on device support. There was no stroke or
device-related infection. One patient had gastrointestinal bleeding, and
another had insertion site hematoma. In conclusion, simultaneous Protek
Duo RVAD and Impella LVAD allows direct left ventricular unloading,
reduction of venous congestion from right heart failure, patient’s mobilization, and less inotrope use. This is a viable and safe option for timely
hemodynamic support to treat patients with CS.
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Conclusions: The J-MOVE cohort showed satisfactory long-term outcomes
of AVR+MVP.

Long-term Outcomes Of Porcine Bioprosthesis Replacement In The
Aortic Position With Concomitant Mitral Valve Repair
Haruhiko Sugimori, MD1, Tatsuya Nakao, MD1,
Yukikatsu Okada, MD, PhD2, Yutaka Okita, MD3, Hitoshi Yaku, MD4,
Junjiro Kobayashi, MD5, Hideyuk Uesugi, MD6,
Shuichiro Takanashi, MD7, Toshiaki Ito, MD8, Tadaak Koyama, MD9,
Taichi Sakaguchi, MD10, Kouji Yamamoto, MD11,
Yasush Yoshikawa, MD12, Yoshik Sawa, MD13; 1New Tokyo Hospital,
Matsudo city, Chiba, Japan, 2Midori Hospital, Kobe city, Hyogo, Japan,
3
Takatsuki General Hospital, Takatsuki city, Osaka, Japan, 4Kyoto
Prefectural University of Medicine, Kyoto city, Kyoto, Japan, 5National
Cerebral and Cardiovascular Center, Suita city, Osaka, Japan, 6Saiseikai
Kumamoto Hospital, Kumamoto city, Kumamoto, Japan, 7Kawasaki Saiwai
Hospital, Kawasaki city, Kanagawa, Japan, 8Japanese Red Cross Nagoya
Daiichi Hospital, Nagoya city, Aichi, Japan, 9Kobe City Medical Center
General Hospital, Kobe city, Hyogo, Japan, 10Hyogo College of Medicine,
Kobe city, Hyogo, Japan, 11Yokohama City University School of Medicine,
Yokohama city, Kanagawa, Japan, 12Tottori University, Tottori city, Tottori,
Japan, 13Osaka University Graduate School of Medicine, Suita city, Osaka,
Japan.
Study: Aortic valve disease with concomitant mitral regurgitation is clinically relevant, especially in the era of transcatheter interventions involving aortic and mitral valves. However, a lack of data regarding combined
or multiple-valvular disease has led to the absence of clear evidencebased recommendations.This study retrospectively evaluated long-term
outcomes after stented porcine aortic valve bioprosthesis (Mosaic,
Medtronic Inc.) replacement in the aortic position with concomitant
mitral valve repair/plasty (MVP).
Methods: We focused on the subgroup of patients at 10 centers in Japan
as part of the Mosaic valve long-term multicenter study (J-MOVE), which
constituted a large, retrospective, multicenter clinical study.
Results: From 1999 to 2014, 157 patients (median (interquartile range)
age, 75 (70-79) years; 47% women) underwent aortic valve replacement
using the Mosaic bioprosthesis with concomitant MVP (AVR+MVP) and
1,045 patients (median (interquartile range) age, 76 (70-80) years; 54%
women) underwent aortic valve replacement (AVR alone) using the
Mosaic bioprosthesis. Five-year overall survival rates were 81.5±4.1% for
AVR+MVP and 85.1±1.4% for AVR alone; 10-year overall survival rates
were 75.2±5.7% for AVR+MVP and 75.1±2.6% for AVR alone. Cox proportional hazards analysis showed no significant difference in survival rates
between AVR+MVP and AVR alone (hazard ratio: 0.87, 95% confidence
interval: 0.54-1.40, P=0.576), shown in Figure 1. Among female patients
with mild-to-moderate to mitral regurgitation who were not receiving
dialysis, those who underwent AVR+MVP, were aged >75 years (Figure
2A), and had preoperative left ventricular ejection fraction 30%-75% (Figure 2B) tended to have lower mortality risk than those who underwent
AVR alone.
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Surface Coatings For Rotary Ventricular Assist Devices: A Systematic
Review
Meili Zhang, PhD1, Matthew S. Dargusch, PhD2,
John F. Fraser, MD, PhD1, Jo P. Pauls, PhD1; 1Critical Care Research Group,
The Prince Charles Hospital, Brisbane, Australia, 2School of Mechanical
and Mining Engineering, University of Queensland, Brisbane, Australia.
Study: Rotary ventricular assist devices (VADs) are frequently used to
provide mechanical circulatory support to patients suffering from endstage heart failure. These devices (especially their pump impeller and
housing components) have stringent requirements on wear resistance
and haemocompatibility. Various surface coatings have been investigated
to improve the wear resistance and/or haemocompatibility of these
devices. Durability (retention ability on the substrate) of coatings is also of
great importance. The aim of the present systematic review was to build a
comprehensive understanding of surface coatings utilised in rotary VADs
and provide insights on potential future research directions.
Methods: A Boolean search for peer-reviewed studies was conducted
in databases Web of Science, Scopus, PubMed and ScienceDirect. A
preferred reporting items for systematic reviews and meta-analyses
(PRISMA) process was followed for selecting relevant papers for analysis.
Included articles were reviewed to identify the wear properties, durability
and haemocompatibility of coatings.
Results: A total of 45 out of 527 publications were included for analysis.
Eighteen coatings were reported to improve the wear resistance and/or
haemocompatibility of rotary VADs. Six ceramic coatings like diamond-like
carbon (DLC), BioMedFlex (BMF), titanium nitride (TiN) and ultrananocrystalline diamond (UNCD®) were both wear-resistant and haemocompatible
coatings. The other 12 coatings were haemocompatible (only) coatings
like heparin, methacryloyloxyethyl phosphorylcholine (MPC), sintered
titanium microspheres and endothelial cells. The most widely investigated coatings were MPC, heparin and DLC, accounting for 24.4%, 20%
and 17.8% of publications. Ninety-three percent of studies focused on
haemocompatibility, while only 4% of studies focused on wear properties
and 13% of studies investigated durability, indicating that investigation on
wear properties and durability is needed in future work.
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Survival Of Pregnant COVID-19 Patient After Prolonged Use Of VV ECMO
Kelli Hu, None, Rebecca Rose, Other, Viktoriya Kagan, ARNP, MSN,
Karen Meehan, Other, Justin Okray, PA-C,
Shana Creighton, MSN, ACNP-BC, Colleen LaBuhn, ARNP, MSN,
Valluvan Jeevanandam, MD, Tae Song, MD; Cardiac Surgery, University of
Chicago, Chicago, IL, USA

The Shortcomings Of Tocilizumab In COVID-19
Raghavendra Tirupathi, MD1, Kavya Bharathidasan, MD2,
Ali Rabaan, PhD3.; 1Penn State University School of Medicine, Hershey,
PA, USA, 2Vydehi Institute of Medical Sciences, Bangalore, India, 3Johns
Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Study: IL-6 blockers have gained the spotlight for their benefits in treating
coronavirus disease (COVID-19) induced cytokine release syndrome (CRS).
Tocilizumab, sarilumab, and siltuximab are being investigated in numerous clinical trials for their efficacy in preventing ICU admission, mechanical ventilation, and ultimately death. While several case series, and case
reports claim favorable outcomes with the drug, the first phase III clinical
trial results for tocilizumab (COVACTA) failed to meet primary and secondary target endpoints. We hypothesize some reasons that might have
contributed to this outcome.
Methods: A qualitative review was performed on PubMed to screen for
case reports, case series, and cross-sectional studies involving the offlabel use of tocilizumab to treat COVID-19 from March to October 2020.
We analyzed the study design and results described in each article to
hypothesize why more recent findings have been contradictory to earlier
statements.
Results: We found that an inadequate understanding of the pathophysiology behind COVID-19 cytokine storm, particularly with regards to IL-6,
inconsistencies in the time of administration and dosing, the use of
adjunctive therapies, and an element of reporting bias were plausible
reasons for tocilizumab’s failure in latest clinical trials. The NIH COVID-19
treatment guidelines and IDSA recommendations both discourage the offlabel use of tocilizumab outside of clinical trial settings. Although several
studies have reported remarkable results with tocilizumab, it would be
advisable to wait for further results from other clinical trials before reaching a verdict.

Study: The mortality rate in patients with coronavirus disease 2019
(COVID-19) requiring mechanical ventilation is high, however, venovenous extracorporeal membrane oxygenation (VV ECMO) may serve as
a successful rescue therapy for some patients. To date, there are limited
case series reporting the impact of COVID-19 on pregnant women who
require prolonged VV ECMO. Here we describe the survival of a pregnant
COVID-19 patient who had a successful C-section preterm delivery before
subsequent intubation and placement on VV ECMO.
Methods: The patient is a 42-year-old female who presented with a
history of dyspnea and fever at 27 weeks 3 days gestation. She tested
positive for COVID-19 and presented to the intensive care unit for hypoxic
respiratory failure. Due to fetal decompensation and persistent hypoxia,
the patient underwent a high-risk C-section at only 28 weeks. She continued to have respiratory failure requiring mechanical ventilation, paralysis,
and proning. The patient was ultimately placed on VV ECMO with inflow
cannulation to the left internal jugular vein and outflow to the right
internal jugular vein.
Results: The patient’s post ECMO course included sepsis, DVTs requiring
anticoagulation, and development of an acute bleed from the brachial
artery that led to hemorrhagic shock. She required blood transfusions,
medical management with pressers and antibiotics, and received a
tracheostomy while on ECMO. Following a total of 37 days on ECMO support, the patient was successfully decannulated and discharged home in
stable condition.
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Can Hb-based Oxygen Carriers (HBOC) Be Used In COVID-19 Treatment?
Jan Simoni, PhD1, Paula Simoni, PharMD2, Joe X. Castillo, III, MD3,
Donald E. Wesson, MD4.; 1Texas HemoBioTherapeutics & BioInnovation
Center, Lubbock, TX, USA, 2Texas Tech University Health Sciences Center
School of Pharmacy & Covenant Health System, Lubbock, TX, USA,
3
Hospital General de Zapopan & Universidad Autonoma de Guadalajara
School of Medicine, Zapopan, Mexico, 4Texas A&M University College of
Medicine & Donald E Wesson Consulting, LLC, Dallas, TX, USA

It’s Easy To Miss Mis-a: A Case Series Of Multi-inflammatory Syndrome
In Adults Associated With Sars-Cov-2 Infection And Cardiogenic Shock
Managed With Mechanical Circulatory Support
Maya Ignaszewski, MD1, Clare Phelps, APNP1, Faraz Ahmad, MD1,
Tarek Kabbany, MD1, Jane Wilcox, MD1, Yasmin Raza, MD1,
Jonathan Rich, MD1, Esther Vorovich, MD1, Ike Okwuosa, MD1,
Anjan Tibrewala, MD1, Clyde Yancy, MD1, Amit Pawale, MD2,
Duc Pham, MD2.; 1Cardiology, Northwestern Memorial Hospital, Chicago,
IL, USA, 2Cardiothoracic Surgery, Northwestern Memorial Hospital,
Chicago, IL, USA

Study: The main clinical manifestation of severe COVID-19 is hypoxemia
that fulfills the criteria of acute respiratory distress syndrome (ARDS). The
“cytokine storm” driven in large part by reactive oxygen species (ROS)
during an excessive immune response to SARS-CoV-2 infection leads to
ARDS aggravation and multi-organ failure (MOF). Other complications
include massive endothelial dysfunction and widespread coagulopathy.
Despite all efforts there is no effective therapy available yet. The efficacy
of vaccines could be threatened by viral mutations. Since HBOCs are
intended to reverse hypoxemia, this study examined their hypothetical
therapeutic potential for COVID-19.
Methods: There are several types of HBOCs under development: human,
bovine or worm Hb-based; cross-linked, conjugated, polymerized or
encapsulated; low or high oxygen affinity (P50); oxygenated or carbonylated (CO); pharmacologically modified. The most common conjugation
methods are PEGylation, nitroxylation or antioxidant enzymes. Glutaraldehyde is still being used as a polymerization agent. Pharmacologic
modification includes cross-linking with o-ATP, polymerization with
o-adenosine and conjugation with GSH. This analysis was based on HBOCs
published pre-clinical/clinical performance vis-à-vis severe COVID-19
pathophysiology.
Results: HBOCs with low P50 can yield insufficient oxygen delivery and
with high P50 will be unable to be properly oxygenated. CO-HBOCs can
deepen hypoxemia. HBOCs with uncontrolled redox potential will be a
source of ROS/ferryl Hb, thus augmenting “cytokine storm,” endothelial
injury and MOF. HBOCs not catabolized physiologically will lead to iron
overload, increasing susceptibility to bacterial infections.
Conclusions: It seems that only oxygenated HBOCs with moderate P50,
controlled redox chemistry and anti-inflammatory properties, without
procoagulant activity and catabolized physiologically could be considered
for future studies to establish their therapeutic value in COVID-19.

Study: Hyperinflammatory syndrome with multi-system organ involvement has been identified in adults diagnosed with COVID-19 infection.
Paralleling a disease in children similar to Kawasaki, it has been aptly
titled multi-inflammatory syndrome in adult (MIS-A). We present two
cases of MIS-A leading to profound inflammation and cardiogenic shock
successfully managed with mechanical circulatory support (MCS).
Methods: Patient 1 and 2 were admitted with elevated inflammatory
markers, severe left ventricular systolic dysfunction and vasoplegia. This
quickly progressed to mixed shock with a cardiogenic component leading
to multi-organ failure necessitating initiation of multiple vasopressors and
inotropes. Despite escalating doses of parenteral support, the patients
continued to decline from a hemodynamic and metabolic perspective.
Demographics, laboratory findings, imaging results, treatment and outcomes are summarized in Table 1.
Results: Patient 1 underwent intra-aortic balloon pump placement and
Patient 2 required VA-ECMO and axillary Impella placement. Both were
treated with high dose steroids with significant improvement in inflammatory markers and clinical status. MCS was eventually weaned and decannulated with recovery in left ventricular function and favorable outcomes
despite critical illness in both cases. MIS-A is characterized by elevated
inflammatory markers, multi-organ involvement, cardiac dysfunction and
shock. It remains a challenging entity to diagnose as little is understood
about this hyperinflammatory syndrome, which has precluded standardization of treatment. We present two cases of MIS-A associated with
cardiogenic shock successfully treated with MCS, confirming feasibility of
using MCS to support this patient cohort through severe illness.
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Mitigating Bleeding Risk In COVID-19 Infected Patients Undergoing
Extracorporeal Membranous Oxygenator Support. A Focus On
Fibrinogen
Richard H. Cosgrove, PharMD1, Robyn L. Basken, PharMD1,
Jacqueline R. Finger, PharMD1,
Richard G. Smith, Masters, Engineering1, Joshua Malo, MD2,
Kenneth A. Fox, MD3, Toshinobu Kazui, MD, PhD3,
Christopher D. Derby, MD3, Robyn J. Meyer, MD4,
Jarrod M. Mosier, MD2.; 1Banner UMC-Tucson, University of Arizona,
Tucson, AZ, USA, 2University of Arizona, Department of Medicine,
Tucson, AZ, USA, 3University of Arizona, Department of Surgery, Division
of Cardiothoracic Surgery, Tucson, AZ, USA, 4University of Arizona,
Department of Pediatrics, Tucson, AZ, USA

Results Of Responding To A Responsive LVAD Patient With A Prolonged
Pump-off Event: A Case Study
Chrystine L. Black, BSN, RN, CCRN, Christina Cheyne, MS,
Sara Dick, MS, Kirk Nelson, MS, Himabindu Vidula, MD, MS,
Beth Carlson, PA-C, Janine Rumora, CNP, Dana Shannon, CNP; Cardiology
- Advanced Heart Failure, UR Medicine, University of Rochester Medical
Center, Rochester, NY, USA
Study: We discuss the case of a HeartMate II patient whose LVAD was off
for 4.5 hours before being restarted.
Methods: Our elderly patient frequently admitted for concern for
dementia. Psychiatry, neurology, PT and OT were consulted regarding his
memory deficits (especially regarding power management of the LVAD.)
The patient’s caregiver often noted LVAD alarms due to power cable disconnections. Device interrogations yielded “no external power” alarms,
causing the VAD coordinators to counsel the caregiver about the need for
24/7 supervision, which could not be arranged. On the day of the event,
the caregiver found the patient drowsy, confused, and disconnected from
the LVAD’s external power. There were no visual or audible alarms. His
caregiver promptly reconnected the controller to power and noted the
green “pump running” symbol to illuminate, and the pump to restart. She
immediately called the LVAD clinic.
Results: The patient regained mentation when the LVAD restarted, and
he suffered no ill effects from his prolonged pump stoppage. Head CT
done at a local ER was unremarkable. Pump function remained normal
and free of alarms. Abbott logfiles were obtained, showing the controller utilized the emergency backup battery for 75 minutes until depletion.
The logfile timestamp and caregiver arrival time at the home, proved the
HMII pump to be off for 4.5 hours. This incident highlighted the need for
ongoing emergency response education. A formal algorithm was created
to address emergency situations with the intent to review the content
yearly. This caregiver remains actively engaged, checking in several times
per day via phone. She also installed a robust camera system which
allows for intercom communication 24/7. This case highlights a favorable
outcome, with little evidence supporting repeatability in subsequent or
similar cases. Beyond the need for robust emergency management education, the team gained valuable clinical experience, and ideas for aiding
in providing 24/7 care, even from afar.

Study: Different fibrinogen management approaches for COVID-19
patients on extracorporeal membranous oxygenation (ECMO) support are
compared in two patients. Observations of measured levels and blood
transfusion requirements are reported.
Methods: Case #1. A 25-year-old obese, asthmatic male progressed to
septic shock requiring two courses of ECMO support. The fibrinogen
replacement threshold for this patient was 100 mg/dL. The patient’s
fibrinogen level prior to ECMO cannulation was 808 mg/dL, and fell to
a low of 184 mg/dL by Day 7 of the first ECMO course. The patient’s
anticoagulation regimen consisted of heparin infusion at an average
rate of 17 units/kg/hr for a goal anti Xa level of 0.15-0.3 IU/mL until he
developed a large chest wall hematoma requiring multiple packed red
blood cell (pRBC) l transfusions. The patient was eventually extubated and
discharged. Case #2. A 25-year-old post-partum female also developed
septic shock requiring ECMO support. This patient’s fibrinogen replacement threshold was set at 250 mg/dL initially. Anticoagulation was
initiated with heparin infusion then was changed to bivalirudin with an
average rate of 0.2 mg/kg/hr and an aPTT goal range of 60-80 seconds.
This patient received multiple transfusions of cryoprecipitate. As concern
for fibrin accumulation in the patient’s oxygenator prompted a circuit
replacement, the fibrinogen threshold was reset to 100mg/dL. She then
experienced moderate oral bleeding. Her highest fibrinogen level was
840 mg/dL prior to cannulation, falling to 85 mg/dL after threshold/circuit
change. She was able to be discharged with respiratory support.
Results: Fibrinogen level management led to the following blood product
utilization. Patient #1 received 14 units of pRBC’s and was noted to have
had both an internal jugular vein thrombus and pulmonary embolism during his 13 days of ECMO. Patient #2 received 12 units of cryoprecipitate
and 3 units of pRBC’s through her 20-day ECMO course.
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Enhancing Communication To Prevent LVAD Early Readmissions Postacute Care
Britney Hurt, LSW, Vika Kagan, APRN-BC, Justin Okray, PA-C,
Karen Meehan, APRN-BC, Annalyse Chinco, BSN,
Shana Creighton, APRN-BC, Katie O’Halloran, APRN-BC,
Pamela Combs, PhD, Colleen Labuhn, APRN-BC,
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Implementation Of An LVAD Educator To Improve Quality Outcomes
Colleen LaBuhn, FNP-BC, Vika Kagan, APNP, Karen Meehan, APNP,
Justin Okray, PA-C, Shana Creighton, APNP,
Anna Chinco, RN, Katie O’Halloran, APNP, Sean Pinney, MD,
Valluvan Jeevanandam, MD; University of Chicago Medical Center,
Chicago, IL, USA
Study: Left Ventricular Assist Devices (LVAD) is a growing form of therapy
for patients with advanced heart failure. While LVAD patient volumes
grow, the need for additional education both for the patients and hospitals has grown. The implementation of dedicated LVAD educators into
LVAD programs can be beneficial for program quality indicators as well as
patient outcomes.
Methods: Left Ventricular Assist Devices (LVAD) is a growing form of
therapy for patients with advanced heart failure. While LVAD patient volumes grow, the need for additional education both for the patients and
hospitals has grown. The implementation of dedicated LVAD educators
into LVAD programs can be beneficial for program quality indicators as
well as patient outcomes.
Results: The implementation of a dedicated LVAD educator occurred
January of 2018. Outcome results were evaluated for 2017 prior to the
educator and 2018 after implantation of the educator. The volumes for
2017 and 2018 were similar at 47 and 63 respectively. Outcomes evaluated included median length of stay from implant of LVAD to discharge
from hospital which decreased from 20.5 days to 18.9 days. Driveline
infections rates decreased from 23.81% to 17.71%. Unplanned readmissions decreased from 3.53% to 2.91% and one year survival between
the two groups remained comparable at 93.74% and 92.81%. Acuity of
the patients was comparable in both groups and programmatic staffing
remained unchanged otherwise.

Study: Hospital readmissions remain a significant obstacle for patients
supported with durable left ventricular assist devices (LVADs). Our team
identified an increase in readmissions of LVAD patients discharged to
acute inpatient rehabilitation following hospitalization. We sought to
determine if an enhanced LVAD team communication plan with our acute
inpatient rehab quality partners would reduce unplanned 30 and 60 day
hospital readmissions.
Methods: A retrospective analysis of patients implanted with durable left
ventricular assist devices between January 1st 2019 and January 1st 2021
discharged to acute inpatient rehab was performed. Unplanned readmissions within 30 and 60 days of discharge were analyzed. The implementation of our enhanced communication plan began January 1st 2020. This
consisted of weekly emails from the acute inpatient rehab updating the
LVAD team on medication changes, lab results, LVAD related issues, and
updated discharge medication lists with plan when patients were discharged from the rehab to ensure timely follow up at the LVAD center.
Results: In 2019 and 2020, 14 and 12 patients were discharged to acute
inpatient rehab, respectively. Prior to the communication implementation
plan, the initial 30-day hospital readmission rate was 43% (n=6/14) and
two additional patients were admitted within 60 days, with a 60 day readmission rate of 57% (n=8/14). After the initiation of the communication
plan, hospital readmission rate decreased to 16% at 30 days (n=2) and
one patient was admitted within 60 days (n=3/12). Utilizing an enhanced
inter-center communication plan ensures safe and effective transition of
care and can potentially decrease unplanned hospital readmissions. Further investigation is required to explore reasons for unplanned readmissions in order to prevent them. Furthermore, a similar implementation
plan can be applied to non LVAD patients to reduce readmissions and
enhance transitions of care from acute hospitalizations.
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